CA2568221A1 - Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof - Google Patents
Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof Download PDFInfo
- Publication number
- CA2568221A1 CA2568221A1 CA002568221A CA2568221A CA2568221A1 CA 2568221 A1 CA2568221 A1 CA 2568221A1 CA 002568221 A CA002568221 A CA 002568221A CA 2568221 A CA2568221 A CA 2568221A CA 2568221 A1 CA2568221 A1 CA 2568221A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- benzyl
- chr
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OFPZNTXZCGKCMU-QUQSCIKMSA-N Dictyostatin 1 Natural products CC(C=C/C=C)C1OC(=O)C=C/C=C/C(C)C(O)CC(O)C=C/C(C)C(O)C(C)CC(C)CCC(O)C1C OFPZNTXZCGKCMU-QUQSCIKMSA-N 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims description 81
- OFPZNTXZCGKCMU-VXBOPZJTSA-N (3z,5e,7r,8s,10s,11z,13s,14r,15s,17s,20r,21s,22s)-22-[(2s,3z)-hexa-3,5-dien-2-yl]-8,10,14,20-tetrahydroxy-7,13,15,17,21-pentamethyl-1-oxacyclodocosa-3,5,11-trien-2-one Chemical compound C=C\C=C/[C@H](C)[C@@H]1OC(=O)\C=C/C=C/[C@@H](C)[C@@H](O)C[C@H](O)\C=C/[C@H](C)[C@H](O)[C@@H](C)C[C@@H](C)CC[C@@H](O)[C@@H]1C OFPZNTXZCGKCMU-VXBOPZJTSA-N 0.000 title abstract description 44
- 238000003786 synthesis reaction Methods 0.000 title abstract description 30
- 230000015572 biosynthetic process Effects 0.000 title abstract description 28
- 239000000543 intermediate Substances 0.000 title abstract description 17
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 342
- 125000003118 aryl group Chemical group 0.000 claims abstract description 276
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 225
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 162
- 125000006239 protecting group Chemical group 0.000 claims abstract description 123
- 150000001875 compounds Chemical class 0.000 claims abstract description 114
- 125000005843 halogen group Chemical group 0.000 claims abstract description 43
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims abstract description 34
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 31
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims abstract description 30
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 30
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 29
- OFPZNTXZCGKCMU-VXUABRCOSA-N (3z,5e,7r,8r,10r,11z,13r,14s,15s,21r,22r)-22-[(2r,3z)-hexa-3,5-dien-2-yl]-8,10,14,20-tetrahydroxy-7,13,15,17,21-pentamethyl-1-oxacyclodocosa-3,5,11-trien-2-one Chemical compound C=C\C=C/[C@@H](C)[C@H]1OC(=O)\C=C/C=C/[C@@H](C)[C@H](O)C[C@@H](O)\C=C/[C@@H](C)[C@@H](O)[C@@H](C)CC(C)CCC(O)[C@H]1C OFPZNTXZCGKCMU-VXUABRCOSA-N 0.000 claims abstract description 24
- 125000004171 alkoxy aryl group Chemical group 0.000 claims abstract description 24
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 20
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 51
- -1 CH2OR2c Chemical group 0.000 claims description 49
- 238000006243 chemical reaction Methods 0.000 claims description 45
- 238000006722 reduction reaction Methods 0.000 claims description 33
- 150000002576 ketones Chemical class 0.000 claims description 27
- 150000001345 alkine derivatives Chemical class 0.000 claims description 23
- 230000009467 reduction Effects 0.000 claims description 22
- 230000008569 process Effects 0.000 claims description 20
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 12
- 239000007858 starting material Substances 0.000 claims description 10
- 230000003647 oxidation Effects 0.000 claims description 7
- 238000007254 oxidation reaction Methods 0.000 claims description 7
- 238000006268 reductive amination reaction Methods 0.000 claims description 5
- 230000002194 synthesizing effect Effects 0.000 claims description 5
- CRWXTDHKQZZNHK-DIVQDLRVSA-N (3z,5e,7r,8s,10s,11z,13s,14r,15s,20r,21s,22s)-22-[(2s,3z)-hexa-3,5-dien-2-yl]-8,10,14,20-tetrahydroxy-7,13,15,21-tetramethyl-1-oxacyclodocosa-3,5,11-trien-2-one Chemical compound C=C\C=C/[C@H](C)[C@@H]1OC(=O)\C=C/C=C/[C@@H](C)[C@@H](O)C[C@H](O)\C=C/[C@H](C)[C@H](O)[C@@H](C)CCCC[C@@H](O)[C@@H]1C CRWXTDHKQZZNHK-DIVQDLRVSA-N 0.000 claims description 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 4
- 101150065749 Churc1 gene Proteins 0.000 claims description 4
- 102100038239 Protein Churchill Human genes 0.000 claims description 4
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims description 4
- 238000006263 metalation reaction Methods 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 229910052703 rhodium Inorganic materials 0.000 abstract description 19
- 239000002246 antineoplastic agent Substances 0.000 abstract description 7
- 238000010189 synthetic method Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 216
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 198
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 177
- 101150041968 CDC13 gene Proteins 0.000 description 175
- 239000011734 sodium Substances 0.000 description 165
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 122
- 239000000243 solution Substances 0.000 description 113
- 235000019439 ethyl acetate Nutrition 0.000 description 108
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 94
- 239000012230 colorless oil Substances 0.000 description 91
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 67
- 238000003818 flash chromatography Methods 0.000 description 66
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 63
- 235000019341 magnesium sulphate Nutrition 0.000 description 61
- 238000005160 1H NMR spectroscopy Methods 0.000 description 57
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 57
- 239000000203 mixture Substances 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 53
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 47
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 39
- 238000005481 NMR spectroscopy Methods 0.000 description 37
- 210000004027 cell Anatomy 0.000 description 37
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 230000002829 reductive effect Effects 0.000 description 34
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- 150000001299 aldehydes Chemical class 0.000 description 31
- 239000012267 brine Substances 0.000 description 31
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 31
- 229920006395 saturated elastomer Polymers 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 29
- 229960001592 paclitaxel Drugs 0.000 description 29
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 28
- 229930012538 Paclitaxel Natural products 0.000 description 28
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 28
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 27
- 238000000746 purification Methods 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 26
- 235000017557 sodium bicarbonate Nutrition 0.000 description 26
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 26
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 239000010410 layer Substances 0.000 description 24
- 201000003379 Townes-Brocks syndrome Diseases 0.000 description 23
- 102000004243 Tubulin Human genes 0.000 description 23
- 108090000704 Tubulin Proteins 0.000 description 23
- 150000001241 acetals Chemical group 0.000 description 23
- 238000007792 addition Methods 0.000 description 23
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 description 19
- 239000007983 Tris buffer Substances 0.000 description 19
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 239000000284 extract Substances 0.000 description 18
- 238000004587 chromatography analysis Methods 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 14
- 239000002253 acid Substances 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 11
- 150000001408 amides Chemical class 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 230000008020 evaporation Effects 0.000 description 11
- 239000012981 Hank's balanced salt solution Substances 0.000 description 10
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 9
- 150000007931 macrolactones Chemical class 0.000 description 9
- 101100495912 Arabidopsis thaliana CHR12 gene Proteins 0.000 description 8
- 230000001028 anti-proliverative effect Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000004688 microtubule Anatomy 0.000 description 8
- 235000013923 monosodium glutamate Nutrition 0.000 description 8
- 229930014626 natural product Natural products 0.000 description 8
- 239000012279 sodium borohydride Substances 0.000 description 8
- 229910000033 sodium borohydride Inorganic materials 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 102000029749 Microtubule Human genes 0.000 description 7
- 108091022875 Microtubule Proteins 0.000 description 7
- 150000001336 alkenes Chemical class 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 7
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 7
- 239000004223 monosodium glutamate Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- OZGSEIVTQLXWRO-UHFFFAOYSA-N 2,4,6-trichlorobenzoyl chloride Chemical compound ClC(=O)C1=C(Cl)C=C(Cl)C=C1Cl OZGSEIVTQLXWRO-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000036515 potency Effects 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 5
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 5
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 5
- 150000003951 lactams Chemical class 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 4
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- 101100328486 Caenorhabditis elegans cni-1 gene Proteins 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- QDWJUBJKEHXSMT-UHFFFAOYSA-N boranylidynenickel Chemical compound [Ni]#B QDWJUBJKEHXSMT-UHFFFAOYSA-N 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 150000002596 lactones Chemical class 0.000 description 4
- 239000011981 lindlar catalyst Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- YCXKIYDKOVQIAA-UHFFFAOYSA-N methyl 4,4,4-trifluoro-2-phosphonooxy-2-(2,2,2-trifluoroethyl)butanoate Chemical compound COC(=O)C(CC(F)(F)F)(CC(F)(F)F)OP(O)(O)=O YCXKIYDKOVQIAA-UHFFFAOYSA-N 0.000 description 4
- 238000009448 modified atmosphere packaging Methods 0.000 description 4
- 235000019837 monoammonium phosphate Nutrition 0.000 description 4
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 4
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 4
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- 235000019345 sodium thiosulphate Nutrition 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006463 Yamaguchi esterification reaction Methods 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 101150084411 crn1 gene Proteins 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000006841 macrolactonization reaction Methods 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000005055 short column chromatography Methods 0.000 description 3
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 3
- 229960005499 (+)-discodermolide Drugs 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 241001209177 Akis Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 238000005811 Corey-Fuchs synthesis reaction Methods 0.000 description 2
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 229910010199 LiAl Inorganic materials 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JQGGAELIYHNDQS-UHFFFAOYSA-N Nic 12 Natural products CC(C=CC(=O)C)c1ccc2C3C4OC4C5(O)CC=CC(=O)C5(C)C3CCc2c1 JQGGAELIYHNDQS-UHFFFAOYSA-N 0.000 description 2
- 238000003489 Nozaki-Hiyama reaction Methods 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- OURRXQUGYQRVML-AREMUKBSSA-N [4-[(2s)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate Chemical compound CC1=CC(C)=CC=C1C(=O)OCC1=CC=C([C@@H](CN)C(=O)NC=2C=C3C=CN=CC3=CC=2)C=C1 OURRXQUGYQRVML-AREMUKBSSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000000670 ligand binding assay Methods 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 229940074439 potassium sodium tartrate Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000003186 propargylic group Chemical group 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 2
- 239000001476 sodium potassium tartrate Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- LXOFIYNBYFRHSH-LQNDIRFKSA-N (2e,4r,5s,7s,8z,10s,11r,12s,14s,17r,18r,19s,20s,21z)-5,7,11,17-tetrakis[[tert-butyl(dimethyl)silyl]oxy]-19-[(4-methoxyphenyl)methoxy]-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraen-1-ol Chemical compound COC1=CC=C(CO[C@@H]([C@@H](C)\C=C/C=C)[C@@H](C)[C@@H](CC[C@H](C)C[C@H](C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)\C=C/[C@H](C[C@H](O[Si](C)(C)C(C)(C)C)[C@H](C)\C=C\CO)O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)C=C1 LXOFIYNBYFRHSH-LQNDIRFKSA-N 0.000 description 1
- XYLOXXJEGYWGGR-QTDGGUCWSA-N (2r,4s,5r,6s)-5-[tert-butyl(dimethyl)silyl]oxy-7-[(4-methoxyphenyl)methoxy]-2,4,6-trimethylheptan-1-ol Chemical compound COC1=CC=C(COC[C@H](C)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)C[C@@H](C)CO)C=C1 XYLOXXJEGYWGGR-QTDGGUCWSA-N 0.000 description 1
- CYGINQXHKHLSCL-HFDGUPOZSA-N (2r,4s,5r,6s)-5-[tert-butyl(dimethyl)silyl]oxy-n-[(1s,2s)-1-hydroxy-1-phenylpropan-2-yl]-7-[(4-methoxyphenyl)methoxy]-n,2,4,6-tetramethylheptanamide Chemical compound C1=CC(OC)=CC=C1COC[C@H](C)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)C[C@@H](C)C(=O)N(C)[C@@H](C)[C@@H](O)C1=CC=CC=C1 CYGINQXHKHLSCL-HFDGUPOZSA-N 0.000 description 1
- KDYDAOSTOLZLGF-LHHIYVIUSA-N (2r,4s,5r,6s,7z,9s,11s,12r,13e)-5,9,11-tris[[tert-butyl(dimethyl)silyl]oxy]-2,4,6,12-tetramethyl-15-trityloxypentadeca-7,13-dien-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC/C=C/[C@@H](C)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](\C=C/[C@H](C)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)C[C@H](CO)C)O[Si](C)(C)C(C)(C)C)C1=CC=CC=C1 KDYDAOSTOLZLGF-LHHIYVIUSA-N 0.000 description 1
- OIXOPVQHUWZJJH-GBESFXJTSA-N (2s,3r,4s)-3,7-bis[[tert-butyl(dimethyl)silyl]oxy]-2,4-dimethylheptan-1-ol Chemical compound CC(C)(C)[Si](C)(C)O[C@@H]([C@H](CO)C)[C@@H](C)CCCO[Si](C)(C)C(C)(C)C OIXOPVQHUWZJJH-GBESFXJTSA-N 0.000 description 1
- GSAMOXBBVYEPFS-ABSDTBQOSA-N (2s,3r,4s)-3-[tert-butyl(dimethyl)silyl]oxy-5-[(4-methoxyphenyl)methoxy]-2,4-dimethylpentan-1-ol Chemical compound COC1=CC=C(COC[C@H](C)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)CO)C=C1 GSAMOXBBVYEPFS-ABSDTBQOSA-N 0.000 description 1
- OEDPOQNNPOTAAP-FUMNGEBKSA-N (2s,3r,4s,6r)-3,7-bis[[tert-butyl(dimethyl)silyl]oxy]-2,4,6-trimethylheptan-1-ol Chemical compound CC(C)(C)[Si](C)(C)OC[C@H](C)C[C@H](C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)CO OEDPOQNNPOTAAP-FUMNGEBKSA-N 0.000 description 1
- ZYCHFPONKLNGHC-PJTXBUSSSA-N (4r)-4-benzyl-3-[(2r,4s,5r,6s)-5-[tert-butyl(dimethyl)silyl]oxy-7-[(4-methoxyphenyl)methoxy]-2,4,6-trimethylheptanoyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(OC)=CC=C1COC[C@H](C)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)C[C@@H](C)C(=O)N1C(=O)OC[C@H]1CC1=CC=CC=C1 ZYCHFPONKLNGHC-PJTXBUSSSA-N 0.000 description 1
- WXDSQYLISYHONW-SJVQGLCSSA-N (4r)-4-benzyl-3-[(4s,5r,6s)-5-[tert-butyl(dimethyl)silyl]oxy-7-[(4-methoxyphenyl)methoxy]-4,6-dimethylheptanoyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(OC)=CC=C1COC[C@H](C)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)CCC(=O)N1C(=O)OC[C@H]1CC1=CC=CC=C1 WXDSQYLISYHONW-SJVQGLCSSA-N 0.000 description 1
- YNHMJAWMYZLJAZ-NPPFBWRTSA-N (4s,5r,6s)-5-[tert-butyl(dimethyl)silyl]oxy-7-[(4-methoxyphenyl)methoxy]-4,6-dimethylheptanoic acid Chemical compound COC1=CC=C(COC[C@H](C)[C@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)CCC(O)=O)C=C1 YNHMJAWMYZLJAZ-NPPFBWRTSA-N 0.000 description 1
- ZAWXPOOJJSNHEF-BMNXYQLZSA-N (4s,5r,6s,7z,9s,11s,12r,13e)-5,9,11-tris[[tert-butyl(dimethyl)silyl]oxy]-4,6,12-trimethyl-15-trityloxypentadeca-7,13-dien-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC/C=C/[C@@H](C)[C@@H](O[Si](C)(C)C(C)(C)C)C[C@@H](\C=C/[C@H](C)[C@H](O[Si](C)(C)C(C)(C)C)[C@H](CCCO)C)O[Si](C)(C)C(C)(C)C)C1=CC=CC=C1 ZAWXPOOJJSNHEF-BMNXYQLZSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- XXFPHLNYAYZRCE-LPBQHKGWSA-N (e,3s,4r)-3-[tert-butyl(dimethyl)silyl]oxy-4-methyl-7-trityloxyhept-5-en-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC/C=C/[C@@H](C)[C@H](CCO)O[Si](C)(C)C(C)(C)C)C1=CC=CC=C1 XXFPHLNYAYZRCE-LPBQHKGWSA-N 0.000 description 1
- JGCFQKKUOVTVAN-LHKIOBMXSA-N (e,3s,4r)-3-[tert-butyl(dimethyl)silyl]oxy-n-methoxy-n,4-dimethyl-7-trityloxyhept-5-enamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC/C=C/[C@@H](C)[C@@H](O[Si](C)(C)C(C)(C)C)CC(=O)N(C)OC)C1=CC=CC=C1 JGCFQKKUOVTVAN-LHKIOBMXSA-N 0.000 description 1
- XXFPHLNYAYZRCE-AHBAYXCNSA-N (e,3s,4s)-3-[tert-butyl(dimethyl)silyl]oxy-4-methyl-7-trityloxyhept-5-en-1-ol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(OC/C=C/[C@H](C)[C@H](CCO)O[Si](C)(C)C(C)(C)C)C1=CC=CC=C1 XXFPHLNYAYZRCE-AHBAYXCNSA-N 0.000 description 1
- QXALONDOJZQWLF-QJPGBWLHSA-N (e,4r,5s)-5,7-bis[[tert-butyl(dimethyl)silyl]oxy]-4-methylhept-2-en-1-ol Chemical compound OC/C=C/[C@@H](C)[C@@H](O[Si](C)(C)C(C)(C)C)CCO[Si](C)(C)C(C)(C)C QXALONDOJZQWLF-QJPGBWLHSA-N 0.000 description 1
- 150000000185 1,3-diols Chemical class 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- YLUMOTIQYNIXLO-UHFFFAOYSA-N 1-morpholin-4-ylethanesulfonic acid Chemical compound OS(=O)(=O)C(C)N1CCOCC1 YLUMOTIQYNIXLO-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 238000006130 Horner-Wadsworth-Emmons olefination reaction Methods 0.000 description 1
- 238000006546 Horner-Wadsworth-Emmons reaction Methods 0.000 description 1
- 108091077621 MAPRE family Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 238000006804 Parikh-Doering oxidation reaction Methods 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 244000180577 Sambucus australis Species 0.000 description 1
- 235000018734 Sambucus australis Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
- XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 101150113676 chr1 gene Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000005828 desilylation reaction Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 238000005906 dihydroxylation reaction Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- VITHGYBTVNARLC-VPHMPFFRSA-N ethyl (e,4r,5s)-5,7-bis[[tert-butyl(dimethyl)silyl]oxy]-4-methylhept-2-enoate Chemical compound CCOC(=O)\C=C\[C@@H](C)[C@@H](O[Si](C)(C)C(C)(C)C)CCO[Si](C)(C)C(C)(C)C VITHGYBTVNARLC-VPHMPFFRSA-N 0.000 description 1
- DUHNXEDXVGGRAP-ZXQGIGGESA-N ethyl (e,4s,5r,6s)-5-[tert-butyl(dimethyl)silyl]oxy-7-[(4-methoxyphenyl)methoxy]-4,6-dimethylhept-2-enoate Chemical compound CCOC(=O)\C=C\[C@H](C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)COCC1=CC=C(OC)C=C1 DUHNXEDXVGGRAP-ZXQGIGGESA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- KDZMEZRLDMNVMZ-UHFFFAOYSA-N hept-5-enamide Chemical compound CC=CCCCC(N)=O KDZMEZRLDMNVMZ-UHFFFAOYSA-N 0.000 description 1
- 238000009904 heterogeneous catalytic hydrogenation reaction Methods 0.000 description 1
- 238000003929 heteronuclear multiple quantum coherence Methods 0.000 description 1
- 238000009905 homogeneous catalytic hydrogenation reaction Methods 0.000 description 1
- 238000011905 homologation Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- USZLCYNVCCDPLQ-UHFFFAOYSA-N hydron;n-methoxymethanamine;chloride Chemical compound Cl.CNOC USZLCYNVCCDPLQ-UHFFFAOYSA-N 0.000 description 1
- 150000007928 imidazolide derivatives Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
- ATCCIZURPPEVIZ-BYPYZUCNSA-N methyl (2s)-3-hydroxy-2-methylpropanoate Chemical compound COC(=O)[C@@H](C)CO ATCCIZURPPEVIZ-BYPYZUCNSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical group CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- NOUIRZGGWSLLAJ-GXFFZTMASA-N n-[(1s,2s)-1-hydroxy-1-phenylpropan-2-yl]-n-methylpropanamide Chemical compound CCC(=O)N(C)[C@@H](C)[C@@H](O)C1=CC=CC=C1 NOUIRZGGWSLLAJ-GXFFZTMASA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- AYPPPHYHITUTBD-ANULTFPQSA-N tert-butyl-[(2r,4s,5r,6s)-5-[tert-butyl(dimethyl)silyl]oxy-2,4,6-trimethyloct-7-ynoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OC[C@H](C)C[C@H](C)[C@@H](O[Si](C)(C)C(C)(C)C)[C@@H](C)C#C AYPPPHYHITUTBD-ANULTFPQSA-N 0.000 description 1
- AHESXNGICPESFS-UFYCRDLUSA-N tert-butyl-[(4s,5r,6s)-5-[tert-butyl(dimethyl)silyl]oxy-4,6-dimethyloct-7-ynoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[C@@H]([C@@H](C)C#C)[C@@H](C)CCCO[Si](C)(C)C(C)(C)C AHESXNGICPESFS-UFYCRDLUSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Abstract
Dictyostatin and its analogs show great promise as new anticancer agents. The present invention provides dictyostatin analogs, synthetic intermediates for the synthesis of dictyostatin analogs, and synthetic methods for the synthesis of such analogs and intermediates. Dictyostatin analogs can have the following structure or its enantiomer (I) wherein R1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom; R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbRc, CH2ORd, or CORe; Ra, Rb and Rc are independently an alkyl group or an aryl group; Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -RiSiRaRbRc or a benzyl group, wherein Ri is an alkylene group; Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group; R3 is (CH2)n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C.ident.C-; R4 is (II) wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbRc, CH2ORd, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbRc, CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtRu; Rt and Ru are independently H, an alkyl group, an aryl group or an alkoxyaryl group; and R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbRc, CH2ORd, or CORe; provided that the compound is not dictyostatin 1.
Description
ANALOGS OF DICTYOSTATIN, INTERMEDIATES THEREFOR AND
METHODS OF SYNTHESIS THEREOF
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application, which claims benefit of U.S. Provisional Patent Application No. 60/574,858 filed May 27, 2004, the disclosure of which is incorporated herein by reference, is a continuation in part of U.S. Patent Application Serial No.
10/655,916, the disclosure of which is incorporated herein by reference, which claims the benefit of U.S.
Provisional Patent Application Serial No. 60/408,503, filed September 6, 2002 and U.S.
Provisional Patent Application Serial No. 60/437,736 filed January 2, 2003, the disclosures of which are incorporated herein by reference.
GOVERNMENT INTEREST
METHODS OF SYNTHESIS THEREOF
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application, which claims benefit of U.S. Provisional Patent Application No. 60/574,858 filed May 27, 2004, the disclosure of which is incorporated herein by reference, is a continuation in part of U.S. Patent Application Serial No.
10/655,916, the disclosure of which is incorporated herein by reference, which claims the benefit of U.S.
Provisional Patent Application Serial No. 60/408,503, filed September 6, 2002 and U.S.
Provisional Patent Application Serial No. 60/437,736 filed January 2, 2003, the disclosures of which are incorporated herein by reference.
GOVERNMENT INTEREST
[0002] This invention was made with government support under grant CA 78039 awarded by the National Institutes of Health. The government has certain rights in this invention.
BACKGROUND OF THE INVENTION
BACKGROUND OF THE INVENTION
[0003] The present invention relates to analogs of dictyostatin, intermediates for the synthesis of such analogs and methods of synthesis of such intermediates and a.nalogs.
[0004] References set forth herein may facilitate understanding of the present invention or the background of the present invention. Inclusion of a reference herein, however, is not intended to and does not constitute an admission that the reference is available as prior art with respect to the present invention.
[0005] The discovery and development of new chemotherapeutic agents for the treatment of cancer is currently of high importance. Some of the best currently available chemotherapeutic agents are natural products or natural product analogs. For example, Taxol (paclitaxel) is a natural product that is currently being used to treat patients with breast and ovarian cancer among others. A number of analogs of Taxol, including Taxotere (docetaxel), are also powerful aa.lticancer agents.
[0006] Recently, the natural product (+)-discodermolide and its analogs have shown great promise as anticancer agents. Discodermolide has been shown to have a mechanisin of action similar to Taxol, but it is active against Taxol-resistant cell lines and it is more water soluble than Taxol. Accordingly, it may have a different and/or broader spectrum of action than Taxol and be easier to formulate and administer. Analogs of discodermolide have been made and tested for activity. For example, see Myles, D. C. Emerging microtubule stabilizing agents for cancer chemotherapy, Annual Reports In Medicinal Chem;
Academic Press: San Diego, CA, 2002; pp 125-132. An interesting feature of discodermolide is that both enantiomers are biologically active.
AcO O OH OH - -PhCONH O 14 16 = ; 24 \\H 1 .=,, OH = OH O
HO O Ac0 OH H2N 0 O
OH PhCO
(-)-taxol (+)-discodermolide [0007] Recently, an unusual macrolactone natural product dictyostatin 1(sometimes called simply "dictyostatin") was isolated from two different sponges and a partial structure was assigned as shown. below. See Pettit, G. R.; Cichacz, Z. A. Isolation and structure of dictyostatin 1. In US 5,430,053; 1995; Pettit, G. R.; Cichacz, Z. A.; Gao, F.;
Boyd, M. R.;
Schmidt, J. M. Isolation and structure of the cancer cell growth inhibitor dictyostatin 1. J.
Chem. Soc., Chem. Comm.un. 1994, 1111-1112. The configurations at C16 and C19 were not yet assigned in the natural product and the absolute configuration was not known.
Dictyostatin shows extremely high potencies against and array of cancer cell lines.
y OH16 HO HO,, or O O OH OH OH OH
originally suggested structures dictyostatin 1 absolute configuration unknown, configurations at C16 and C19 unassigned [0008] Dictyostatin was also shown to stabilize microtubules, like discodermolide and Taxol. See Wright, A. E.; Cummins, J. L.; Pomponi, S. A.; Longley, R. E.;
Isbrucker, R. A.
Dictyostatin compounds for stabilization of microtubules. In PCT Int. Appl.;
W062239, 2001. Accordingly, dictyostatin and its analogs show great promise as new anticancer agents.
In U.S. Patent Application Serial No. 10/655,916, it was shown that novel analogs of dictyostatin are promising anti-cancer agents with potential advantages over Taxol and discodermolide, and taught the syntheses of these analogs.
Academic Press: San Diego, CA, 2002; pp 125-132. An interesting feature of discodermolide is that both enantiomers are biologically active.
AcO O OH OH - -PhCONH O 14 16 = ; 24 \\H 1 .=,, OH = OH O
HO O Ac0 OH H2N 0 O
OH PhCO
(-)-taxol (+)-discodermolide [0007] Recently, an unusual macrolactone natural product dictyostatin 1(sometimes called simply "dictyostatin") was isolated from two different sponges and a partial structure was assigned as shown. below. See Pettit, G. R.; Cichacz, Z. A. Isolation and structure of dictyostatin 1. In US 5,430,053; 1995; Pettit, G. R.; Cichacz, Z. A.; Gao, F.;
Boyd, M. R.;
Schmidt, J. M. Isolation and structure of the cancer cell growth inhibitor dictyostatin 1. J.
Chem. Soc., Chem. Comm.un. 1994, 1111-1112. The configurations at C16 and C19 were not yet assigned in the natural product and the absolute configuration was not known.
Dictyostatin shows extremely high potencies against and array of cancer cell lines.
y OH16 HO HO,, or O O OH OH OH OH
originally suggested structures dictyostatin 1 absolute configuration unknown, configurations at C16 and C19 unassigned [0008] Dictyostatin was also shown to stabilize microtubules, like discodermolide and Taxol. See Wright, A. E.; Cummins, J. L.; Pomponi, S. A.; Longley, R. E.;
Isbrucker, R. A.
Dictyostatin compounds for stabilization of microtubules. In PCT Int. Appl.;
W062239, 2001. Accordingly, dictyostatin and its analogs show great promise as new anticancer agents.
In U.S. Patent Application Serial No. 10/655,916, it was shown that novel analogs of dictyostatin are promising anti-cancer agents with potential advantages over Taxol and discodermolide, and taught the syntheses of these analogs.
[0009] It remains desirable to further develop analogs of dictyostatin as well at to develop methods of synthesis of dictyostatin analogs and intermediates for use in such methods.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0010] The inventors of the present invention have shown that the proposed structures of (-)-dictyostatin set forth above are incorrect and that the correct structure is as shown below.
OH/
HO,, O O
I = 1 OH OH
dictyostatin, 1, corrected structure In several aspects of the present invention, new and improved methods and new intermediates for the synthesis of dictyostatin and analogs are provided. In several other.aspects of the present invention, analogs of dictyostatin as well as methods and intermediates for the synthesis of these analogs are provided.
OH/
HO,, O O
I = 1 OH OH
dictyostatin, 1, corrected structure In several aspects of the present invention, new and improved methods and new intermediates for the synthesis of dictyostatin and analogs are provided. In several other.aspects of the present invention, analogs of dictyostatin as well as methods and intermediates for the synthesis of these analogs are provided.
[0011] The present inventors have shown that of the dictyostatin analogs set forth in the specification and claims of U.S. Patent Application Serial No. 10/655,916, those analogs having a stereostructure similar to that of dictyostatin are relatively hightly biologically active. In that regard, compounds having the following structure were found to be relatively highly active:
R3 R5 ~CHR' O
R4---~ O
wherein Rl is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
RZ is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R' are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an allcoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 ls R23a0 OR23b 3 wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, R23b is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtR;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group; and R5 is H or ORZb, wherein R 2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRRbR , CH2ORd, or CORe; provided that the compound is not dictyostatin 1.
R3 R5 ~CHR' O
R4---~ O
wherein Rl is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
RZ is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R' are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an allcoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 ls R23a0 OR23b 3 wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, R23b is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtR;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group; and R5 is H or ORZb, wherein R 2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRRbR , CH2ORd, or CORe; provided that the compound is not dictyostatin 1.
[0012] When groups including, but not limited to, -SiRaRbR , CHZORd, and/or CORe are set forth as a substituent for more than one group in compounds of the claims and the specification of the present invention (for example, as a substituent of R2 and R23a above), it is to be understood that the groups of those substituents (Ra, Rb, W,Ra, and Re in this example), are independently, the same of different within each group and amoung the groups.
[0013] In one embodiment, the compound has the followings stereostructure or its enantiomer:
H
RI
., ., R20., O
R4-"~ O
wherein Rl is allcenyl; RZ is H; R3 is -CH2CH(CH3), CH2CH2, -CH=CH, or -CH=C(CH3). In one such compound (16-desmethyldictyostatin), R3 is CH2CH2, RS is OH, R' is CH=CH2 and R23a, R23b are H. In another embodiment, R5 is OH or OSiRaRbR . In several embodiments, C2-C3 E-sterioisomers of the compounds or their enantiomers are provided.
H
RI
., ., R20., O
R4-"~ O
wherein Rl is allcenyl; RZ is H; R3 is -CH2CH(CH3), CH2CH2, -CH=CH, or -CH=C(CH3). In one such compound (16-desmethyldictyostatin), R3 is CH2CH2, RS is OH, R' is CH=CH2 and R23a, R23b are H. In another embodiment, R5 is OH or OSiRaRbR . In several embodiments, C2-C3 E-sterioisomers of the compounds or their enantiomers are provided.
[0014] Several intermediates are useful in synthesizing such compounds. For example, one such intermediate is a compound of the following structure or its enantiomer.
OR2d R4=CO2R'0 wherein R' is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
RZ and R2d are independently H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRRbR, CHaORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Ra is an allcyl group, an aryl group, an allcoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is R23a0 OR23b wherein Rz3a is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b together form a portion of six-meinbered acetal ring incorporating CRtR ;
Rt and R" are independently H, an allcyl group, an aryl group or an alkoxyaryl group;
R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R10isHoralkyl.
OR2d R4=CO2R'0 wherein R' is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
RZ and R2d are independently H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRRbR, CHaORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Ra is an allcyl group, an aryl group, an allcoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is R23a0 OR23b wherein Rz3a is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b together form a portion of six-meinbered acetal ring incorporating CRtR ;
Rt and R" are independently H, an allcyl group, an aryl group or an alkoxyaryl group;
R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R10isHoralkyl.
[0015] In one embodiment, the compound has the following stereostructure, or its enantiomer:
H
R20,, ==,,, ==,,, O R2d R4=CO2R1 wherein Rl is allcenyl; R2 is H; RZd is H, OC(O)CH3 or OC(O)NRgRh wherein Rg and Rl' are independently H, an alkyl group or an aryl group; R3 is CH2CH(CH3), CH2CH2, CH=CH or CH=C(CH3); and RS is OH or OSiRaRbR ; and R10 is H or alkyl. In one embodiment, Rl is -CH=CH2, and R2d is H, C(O)CH3 or C(O)NH2.
H
R20,, ==,,, ==,,, O R2d R4=CO2R1 wherein Rl is allcenyl; R2 is H; RZd is H, OC(O)CH3 or OC(O)NRgRh wherein Rg and Rl' are independently H, an alkyl group or an aryl group; R3 is CH2CH(CH3), CH2CH2, CH=CH or CH=C(CH3); and RS is OH or OSiRaRbR ; and R10 is H or alkyl. In one embodiment, Rl is -CH=CH2, and R2d is H, C(O)CH3 or C(O)NH2.
[0016] In another aspect, a compound of the following structure or its enantiomer is provided:
OR2d I ~CHR12 R11a0 OR11b wherein Ri is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 and R2d are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, or CORe;
Ra, Rb and W are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an allcoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CHZ)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R5 is H or OR 2b, wherein RZb is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Rila and Rllb are independently H, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, CORe, or Rila and Rllb togetlier form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an allcoxyaryl group; and R12 is a halogen atom, CH2ORac, CHO, C02R10, CH=CHCH2OR2o, CH=CHCHO, wherein R2o is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or alkyl.
OR2d I ~CHR12 R11a0 OR11b wherein Ri is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 and R2d are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, or CORe;
Ra, Rb and W are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an allcoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CHZ)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R5 is H or OR 2b, wherein RZb is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Rila and Rllb are independently H, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, CORe, or Rila and Rllb togetlier form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an allcoxyaryl group; and R12 is a halogen atom, CH2ORac, CHO, C02R10, CH=CHCH2OR2o, CH=CHCHO, wherein R2o is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or alkyl.
[0017] In one embodiment, the compound has the following stereostructure or its enantiomer:
R20,, '='=, _ OR2d I ~CHR12 R11aO OR11b wherein R' is alkenyl; R2 and RZd are independently, H, OC(O)CH3 or OC(O)NRgRh wherein Rg and Rh are independently H, an alkyl group or an aryl group; R3 is CH2CH(CH3)CH2CH2, CH=CH or CH=C(CH3); Rlla and Rllb are H or together form a portion of a six-membered acetal ring containing C(H)(p-C6H4OCH3) or C(CH3)2; R12 is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2ORzc, CH=CHCHO, wherein R2o is H, an alkyl group, a benzyl group, a trityl group, -SiRaRUR , CH2ORd, or CORe, and R10 is H or alkyl. In one embodiment, R' is -CH=CH2, R2d is H, -C(O)CH3 or -O (O)NH2, and R12 is -CH2OH, -CHO
or -C02R10.
R20,, '='=, _ OR2d I ~CHR12 R11aO OR11b wherein R' is alkenyl; R2 and RZd are independently, H, OC(O)CH3 or OC(O)NRgRh wherein Rg and Rh are independently H, an alkyl group or an aryl group; R3 is CH2CH(CH3)CH2CH2, CH=CH or CH=C(CH3); Rlla and Rllb are H or together form a portion of a six-membered acetal ring containing C(H)(p-C6H4OCH3) or C(CH3)2; R12 is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2ORzc, CH=CHCHO, wherein R2o is H, an alkyl group, a benzyl group, a trityl group, -SiRaRUR , CH2ORd, or CORe, and R10 is H or alkyl. In one embodiment, R' is -CH=CH2, R2d is H, -C(O)CH3 or -O (O)NH2, and R12 is -CH2OH, -CHO
or -C02R10.
[0018] In another aspect, a compound having the following stereostructure or its enantiomer is provided:
R14aO OR14b RIIaO OR11b wherein RZ is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRI', wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
RS is H or OR2b, wherein RZb is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Rlla and Rllb are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRRbR , CH2ORd, CORe, or Riia and Rllb together form a portion of six-membered acetal ring containing CRtR ;
Rt and R are independently H, an allcyl group, an aryl group or an allcoxyaryl group;
RlZ is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2OR2o or CH=CHCHO, CH=CHCO2R10, wherein Rz is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, or CORe, and R10 is H or allcyl; and R14a and R14b are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or R14a and R14b together form a six-membered ring containing CR'"RW, wherein R and R' are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
R14aO OR14b RIIaO OR11b wherein RZ is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRI', wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
RS is H or OR2b, wherein RZb is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Rlla and Rllb are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRRbR , CH2ORd, CORe, or Riia and Rllb together form a portion of six-membered acetal ring containing CRtR ;
Rt and R are independently H, an allcyl group, an aryl group or an allcoxyaryl group;
RlZ is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2OR2o or CH=CHCHO, CH=CHCO2R10, wherein Rz is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, or CORe, and R10 is H or allcyl; and R14a and R14b are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or R14a and R14b together form a six-membered ring containing CR'"RW, wherein R and R' are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
[0019] In one embodiment, the compound has the following stereostructure or its enantiomer:
R20,, R14a0 OR14b R11a0 OR11b wherein R2 is H; R3 is CH2CH(CH3) or CH=C(CH3); Rlla and Rllb are H or together fonn a portion of a six-membered acetal ring containing C(H)(p-C6H4OCH3) or C(CH3)2;
R" is a halogen atom, CH2OR2o, CHO, C02R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein RZ is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or alkyl.
R20,, R14a0 OR14b R11a0 OR11b wherein R2 is H; R3 is CH2CH(CH3) or CH=C(CH3); Rlla and Rllb are H or together fonn a portion of a six-membered acetal ring containing C(H)(p-C6H4OCH3) or C(CH3)2;
R" is a halogen atom, CH2OR2o, CHO, C02R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein RZ is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or alkyl.
[0020] In another aspect, a compound having the follwing formula, or its enantiomer is provided:
C
R14aO OR14b R11aO OR11b R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R', Rb and R are independently an allcyl group or an aryl group;
Rd is an allcyl group, an aryl group, an allcoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an allcoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CHZ)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=-C-;
Rlla and Rllb are independently H, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or Rlla and Rllb together form a portion of six-membered acetal ring containing CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an allcoxyaryl group;
R12 is a halogen atom, CH20R2o, CHO, C02R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein R2o is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbW, CH2ORa, or CORe, and R10 is H or alkyl; and R14a and R14U are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbW, CH2ORd, CORe, or R14a and R14b together form a six-meinbered ring containing CR R', wherein R and RW are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
C
R14aO OR14b R11aO OR11b R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R', Rb and R are independently an allcyl group or an aryl group;
Rd is an allcyl group, an aryl group, an allcoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an allcoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CHZ)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=-C-;
Rlla and Rllb are independently H, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or Rlla and Rllb together form a portion of six-membered acetal ring containing CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an allcoxyaryl group;
R12 is a halogen atom, CH20R2o, CHO, C02R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein R2o is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbW, CH2ORa, or CORe, and R10 is H or alkyl; and R14a and R14U are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbW, CH2ORd, CORe, or R14a and R14b together form a six-meinbered ring containing CR R', wherein R and RW are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
[0021] In one embodiment, the compound has the following stereostructure or its enantiomer:
'0 R20t, R14aO OR14b I).CHR12 wherein R3 is CH2CH2, CH=CH, CH2CH(CH3) or CH=C(CH3); Rla is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein R2c is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or alkyl.
'0 R20t, R14aO OR14b I).CHR12 wherein R3 is CH2CH2, CH=CH, CH2CH(CH3) or CH=C(CH3); Rla is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein R2c is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or alkyl.
[0022] In a further aspect, a compound having the following formula or its enantiomer is provided:
R24 =
R11aO OR11b wherein R~ is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRRbR , CH2ORd, or CORe;
Ra, Rb and Rc are independently an allcyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR' or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and R1i are independently H, an alkyl group or an aryl group;
R11a and R11b are independently H, an allcyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or R11a and R11b together form a portion of six-membered acetal ring containing CRtR ;
Rt and R are independently H, an allcyl group or an aryl group;
R12 is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein R2o is H, aprotecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORa, or CORe, and R10 is H or alkyl;
R16 is H or alkyl; and R17 is CHZORZ ; CHO, CO2R10, wherein RZf is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R24 is C=C, cis or trans CH=CH, or CH2CH2.
R24 =
R11aO OR11b wherein R~ is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRRbR , CH2ORd, or CORe;
Ra, Rb and Rc are independently an allcyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR' or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and R1i are independently H, an alkyl group or an aryl group;
R11a and R11b are independently H, an allcyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or R11a and R11b together form a portion of six-membered acetal ring containing CRtR ;
Rt and R are independently H, an allcyl group or an aryl group;
R12 is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein R2o is H, aprotecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORa, or CORe, and R10 is H or alkyl;
R16 is H or alkyl; and R17 is CHZORZ ; CHO, CO2R10, wherein RZf is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R24 is C=C, cis or trans CH=CH, or CH2CH2.
[0023] In one einbodiment, the compound has the following stereostructure or its enantiomer:
R2O,, R11aO OR11b wherein RZ is H, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, or CORe, and R24 is C=C or cis CH=CH.
R2O,, R11aO OR11b wherein RZ is H, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, or CORe, and R24 is C=C or cis CH=CH.
[0024] In one embodiment, a process for synthesizing dictyostatin analogs includes a process for conversion of a first compound having the following formula or its enantiomer:
R4=CO2R10 wherein R' is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R2d is H;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR' or a benzyl group, wherein R' is an alkylene group;
Re is an allcyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CHZ)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is R23a0 OR23b wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR~, CH20Rd, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b togetller form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group; and R10 is H;
to a second compound with the formula R3 R5 ~CHR1 O
R4---~ O
comprising the step of reacting the first compound under conditions suitable to effect macrolactonization.
R4=CO2R10 wherein R' is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R2d is H;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR' or a benzyl group, wherein R' is an alkylene group;
Re is an allcyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CHZ)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is R23a0 OR23b wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR~, CH20Rd, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b togetller form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group; and R10 is H;
to a second compound with the formula R3 R5 ~CHR1 O
R4---~ O
comprising the step of reacting the first compound under conditions suitable to effect macrolactonization.
[0025] In one embodiment, the first compound has the following stereostructure or its enantiomer:
H
,,R~
.,, .
R20,, OR2d R4.C02R1o wherein Rl is H, an alkyl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R2d is H;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an allcyl group, an allyl group, a benzyl group, an aryl group, an allcoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-; and Rlo is H;
and the second compound has the following fonnula or its enantiomer H
R20,, .,s O
R4 --'~ O
In one embodiment, Rl is alkenyl; R3 is CH2CH2, CH=CH, CH2CH(CH3) or CH=C(CH3);
and R5 is OR2b. In one embodiment of the process, the first compound is reacted with 2,4,6-trichlorobenzoylchloride.
H
,,R~
.,, .
R20,, OR2d R4.C02R1o wherein Rl is H, an alkyl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R2d is H;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an allcyl group, an allyl group, a benzyl group, an aryl group, an allcoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-; and Rlo is H;
and the second compound has the following fonnula or its enantiomer H
R20,, .,s O
R4 --'~ O
In one embodiment, Rl is alkenyl; R3 is CH2CH2, CH=CH, CH2CH(CH3) or CH=C(CH3);
and R5 is OR2b. In one embodiment of the process, the first compound is reacted with 2,4,6-trichlorobenzoylchloride.
[0026] In another aspect, the present invention provides a compound having the following formula, or its enantiomer R3~~ O
R14a0 OR14b "CHR12 R11aO OR11b Rz is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
Rlla and Rllb are independently H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or R11a and Rllb together form a portion of six-membered acetal ring containing CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R12 is a halogen atom, CH2OR2o, CHO, COZRlO, CH=CHCH2OR2c, CH=CHCHO or CH=CHCO2R10, wherein R2o is H, a protecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or allcyl; and R14a and R14b are independently H, an alkyl group, a berizyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or R14a and R14b together form a six-membered ring containing CR
R', wherein R" and RW are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
R14a0 OR14b "CHR12 R11aO OR11b Rz is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
Rlla and Rllb are independently H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or R11a and Rllb together form a portion of six-membered acetal ring containing CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R12 is a halogen atom, CH2OR2o, CHO, COZRlO, CH=CHCH2OR2c, CH=CHCHO or CH=CHCO2R10, wherein R2o is H, a protecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or allcyl; and R14a and R14b are independently H, an alkyl group, a berizyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or R14a and R14b together form a six-membered ring containing CR
R', wherein R" and RW are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
[0027] In one embodiment, the coinpound has the following stereostructure, or its enantiomer O
R20,, R14ao-OR14b R11a0 OR11b wherein R3 is CH2CH(CH3)CH2CH2, CH=CH, or CH=C(CH3); and Rlla and Rllb are H
or together form a portion of a six-membered acetal ring containing C(H)(p-C6H4OCH3) or C(CH3)2.
R20,, R14ao-OR14b R11a0 OR11b wherein R3 is CH2CH(CH3)CH2CH2, CH=CH, or CH=C(CH3); and Rlla and Rllb are H
or together form a portion of a six-membered acetal ring containing C(H)(p-C6H4OCH3) or C(CH3)2.
[0028] In another aspect, the present invention provides a coinpound having the following formula, or its enantiomer R ~CHR12 wherein R2 is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an allcyl group, an aryl group, an allcoxylalkyl group, -R'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an allcoxy group, or -NRgRh, wherein Rg and Rl' are independently H, an allcyl group or an aryl group;
Rll is a protecting group, an allcyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R12 is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein R2o is H, a protecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, or CORe, and R10 is H or alkyl;
R16 is H or allcyl;
R17 is CH2OR2 ; CHO, C02R10, wherein R2f is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R24 is C=C, cis or trans CH=CH, or CH2CH2.
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an allcyl group, an aryl group, an allcoxylalkyl group, -R'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an allcoxy group, or -NRgRh, wherein Rg and Rl' are independently H, an allcyl group or an aryl group;
Rll is a protecting group, an allcyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R12 is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein R2o is H, a protecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, or CORe, and R10 is H or alkyl;
R16 is H or allcyl;
R17 is CH2OR2 ; CHO, C02R10, wherein R2f is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R24 is C=C, cis or trans CH=CH, or CH2CH2.
[0029] In one embodiment, the compound has the following stereostructure, or its enantiomer R2O,, ,R24 wherein R2 is H, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
and R24 is C=C or cis CH=CH.
and R24 is C=C or cis CH=CH.
[0030] In another aspect, the present invention provides a compound having the following formula, or its enantiomer wherein X is H, NCH3(OCH3), or a leaving group;
Rll is H, a protecting group, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, Rt and R are independently H, an allcyl group or an aryl group;
R12 is a halogen atom, CH2OR2o, CHO, C02R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein R2o is H, a protecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or allcyl.
Rll is H, a protecting group, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, Rt and R are independently H, an allcyl group or an aryl group;
R12 is a halogen atom, CH2OR2o, CHO, C02R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein R2o is H, a protecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or allcyl.
[0031] In a further aspect, the present invention provides a compound having the following formula, or its enantiomer ~CHR12 R11aO OR11b wherein Rila and Rllb are independently H, a protecting group, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, CORe, or Rlia and Rllb together form a portion of six-membered acetal ring containing CRtR";
Rt and R' are independently H, an allcyl group, an aryl group or an allcoxyaryl group;
RlZ is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein Ra is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORa, or CORe, and R10 is H or alkyl;
[00321 In another aspect, the present invention provides a process of conversion of a compound with the following formula, or its enantiomer R24 =
O OR11b' wherein R2 a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRUR , CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRI', wherein Rg and Rh are independently H, an alkyl group or an aryl group;
Rllb' is an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, CORe;
R12 is a halogen atom, CH2OR2o, COzRlO, CH=CHCH2OR2o, or CH=CHCO2R10, wherein R2o is a protecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR, CH2ORa, or CORe, and R10 is H or alkyl;
R16 is H or alkyl; and R17 is CH2OR2 ; CO2R10, wherein RZf is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, or CORe; and R24 is C=C to a compound of the following formula, or its enantiomer R2~ _ R11a0 OR11b wherein Rlla is H, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR~, CH2ORa, CORe and Rllb is an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or Rlla and Rl lb together form a portion of six-membered acetal ring containing CRtR ;
Rt and R are independently H, an alkyl group or an aryl group; and RM is cis CH=CH, including at least the steps of semi-reduction of the alleyne and asymmetric reduction of the ketone, or asymmetric reduction of the ketone and semihydrogentation of the allcyne.
[0033] In one embodiment, the process includes at least the steps of semi-reduction of the allcyne, asymmetric reduction of the ketone and protection of a resulting alcohol, or asymmetric reduction of the ketone, protection of a resulting alcohol and semihydrogentation of the alkyne, or asymmetric reduction of the ketone, semi-hydrogentation of the alkyne and protection of a resulting alcohol.
[0034] In a further aspect, the present invention provides a compound of the following formula, or its enantiomer R20,, wherein R2 is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and Rc are independently an alkyl group or an aryl group;
Ra is an alkyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an allcoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R16 is H or alkyl; and R17 is CH20R2 ; CHO, CONHCH(CH3)CH(OH)Ph, COZRiO, wherein R2f is H, a protecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, or CORe;
R25 is C02R10, CHO, CH=CBr2, C=CH, or C=C SiRaRbR ; and R10 is H or an allcyl group.
[0035] In another aspect the present invention provides a process for reacting a first compound of the following formula, or its enantiomer R20,, wherein R2 a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbW, CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Ra is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R16 is H or alkyl; and R17 is CH2OR2 ; CHO, C02R , wherein RZf is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R25 CH=CX2, C=CH or C=CSiRaRbR;
X is Cl, Br or I with a second compound of the following formula, or its ena.ntioiner wherein X is NCH3(OCH3), or a leaving group;
Rl l an allcyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR~, CH2ORd, CORe;
R12 is a halogen atom, CH20R2o, C02R , CH=CHCH2ORz or CH=CHC02R , wherein RZ0 is an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R is alkyl, including the steps of metalation of the first compound and addition of the second compound to produce a compound of the following formula, or its enantiomer R2O,, ~CHR12 rc"11 wherein R24 is C=C.
[0036] In another aspect, the present invention provides a process for reacting a first compound of the following formula, or its enantiomer ., R20r, wherein RZ a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an allcyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an allcyl group, an allyl group, a benzyl group, an aryl group, an allcoxy group, or -NRgRh, wherein Rg and Rh are independently H, an allcyl group or an aryl group;
R16 is H or alkyl;
Rl7 is CH20R2f, CHO, COZR10, wherein R2f is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R25 CH=CX2, C=CH or C=CSiRaRbR;
with a second compound of the following formula, or its enantiomer X -~CHR12 wherein X is H;
R11 an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe;
R12 is a halogen atom, CH20R2o, C02R10, CH=CHCH2OR2o or CH=CHCO2R10, wherein R2o is an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is allcyl, including the steps of metalation of the first compou.nd and addition of the second compound to produce a compound of the following formula, or its enantiomer R20,, ,, wherein R24 is C=C.
[0037] In another aspect, the present invention provides a compound of the following structure R4.C02RI0 wherein Rl is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CHZ)p where p is an integer in the range of 4 to 12, -(CHRkl)yl (CHRI'2)yZ(CHRI'3)y3(CHRk4)y4(CHRkS)y5C(Rsl)=C(Rs2)C(Rs3)=C(Rs4)-, -(CHRk)yl (CHRk2)y2(CHe)y3(CHRk4)y4(CHRk5)y5CH(Rs1)CH(Rs2)C(Rs3)=C(Rs4)-, -(CHRkl)yl (CHe)y2(CHR~3)y3(CHRk4)y4(CHRks)y5C(RSl)=C(Rs2)CH(Rs3)CH(Rs4)-, -(CHRkl)yl (CHRI'2)y2(CHe)y3(CHRk4)y4(CHRks)y5CH(Rsl)CH(Rs2)CH(Rs3)CH(Rs4)-, wherein yl and y2 are 1 and y3, y4 and y5 are independently 0 or 1, Rl'l, Rl2, Rl'3, Rl'4 and Rks are independently H, CH3, or OR2a, and RSI, RS2, Rs3, and Rs4 are independently H or CH3, wherein RZa is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, or CORe; and R5 is H or ORZb, wherein RZb is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, or CORe; and R26 is H, a protecting group, an allcyl group, an aryl group, -SiRaRbR , or CORe;
[0038] In one embodiment, the compound of has the following stereostructure, or its enantiomer R3 R5 CHR' R20,, R4.CO2R'o wherein Rl is alkenyl; R3 is - CH2CH2, -CH=CH, -CH2CH(CH3) or -CH=C(CH3); and R4 is CHg R23a0 OR23b wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtR;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
[0039] In another apsect, the present invention provides a compound of the following structure R3 R5 ~CHRI
R4-'-~ O
wherein R' is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an allcyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an allkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2)p where p is an integer in the range of 4 to 12, -(CHRkI)Yl (CHR~2)Y2(CHRk3)y3(CHRk4)y4(CHRk5 )y5C(RSl)=C(Rs2)C(Rs3)~c(Rs4)-, -(CHRkI)Yl (CHRk2)Y2(CHe)Y3(CHRk4)y4(CHRkS)y5CH(R.sl)CH(Rs2)C(R53)=C(RS4)-, -(CHRkl )Yl (CHR~2)Y2(CHe)Y3(CHk4)Y4(CIMk5)Y5C(Rs1)=C(Rs2)CH(Rs3)CH(Rs4)-, -(CHRkI)yl (CHRI'z)y2(CHR~')y3(CHRk4)y4(CHRks)ySCH(RSl)CH(Rs2)CH(Rs3)CH(Rs4)-, wherein yl and y2 are 1 and y3, y4 and y5 are independently 0 or 1, Rkl, R~2 , e , Rk4 and Rk5 are independently H, CH3, or OR2a, and RSI, Rs2, Rs3, and Rs4 are independently H or CH3, wherein R2a is H, an alkyl group, a benzyl group, a trityl group, -SiRRbR , CHZORd, or CORe; and R 5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R26 is H, a protecting group, an alkyl group, an aryl group, -SiRRbR , or CORe;
[0040] In one embodiment, the compound has the following stereostructure, or its enantiomer H
Rl R20,, R4'1-~ O
wherein Rl is alkenyl; R3 is -CH2CH2, -CH=CH, -CH2CH(CH3) or -CH=C(CH3); and R4 is R23a0 OR23b wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CHaORa, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R" are independently H, an alkyl group, an aryl group or an alkoxyaryl group [0041] In another aspect, the present invention provides a process for synthesizing a compound having the following structure R3 R5 CHR' R4-'-~ O
wherein Rl is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
RZ is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an allcoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is a.nd integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2)p where p is an integer in the range of 4 to 12, -(CHRkl)yl (CHR~2)y2(CHRk3)y3(CHRk4)y4(CHRkS)y5C(RSl)=C(Rs2)C(Rss)=C(Rs4)-, -(CHRkl)yl (CHRIO)y2(CHe)y3(CHe)y4(ClIlits)ySCH(RSl)CH(Rsz)C(Rs3)=C(Rs4)-, -(CHRkI)yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRks)y5C(RSl)=C(Rs2)CH(Rs3)CH(Rs4)-, -(CHRkl)yi (CHRO)y2(CHRIc3)y3(CHRk4)y4(CHRks)ySCH(RSl)CH(Rs2)CH(Rs3)CH(Rs4)-, wllerein yl and y2 are 1 and y3, y4 and y5 are independently 0 or 1, Rkl, R~2 , e, Rk4 and Rk5 are independently H, CH3, or OR2a, and Rsl, RS2, Rs3, and Rs4 are independently H or CH3, wherein R2a is H, an allcyl group, a benzyl group, a trityl group, -SiRaRR , CH2ORa, or CORe; and R5 is H or ORZV, wherein R2b is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRRUR , CH2ORd, or CORe; and R26 is H, a protecting group, an allcyl group, a aryl group, -SiRaRbR , or CORe;
including the step of reacting a starting compound having the formula:
R4.C02RI0 wherein R10 is H, under conditions suitable to form the macrolactam ring.
[0042] In one embodiment of the process, the starting compound has the following structure, or its enantiomer R20,, R4.C02R10 wherein Rl is alkenyl; R3 is -CH2CH(CH3) or -CH=C(CH3); and R4 is R23aO OR23b wherein R23a is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtR";
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group and the product compound has the following structure, or its enantiomer H
R20s, ', '=-, R4---~
[0043] In a further aspect, the present invention provides a process for converting a starting compound of the following structure OH
R4.C02R10 wherein R' is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 and R2d are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an allcyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rl' are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2)p where p is an integer in the range of 4 to 12, -(CHRkl)yl (CHRI'2)y2(CHR~3)y3(CHk4)y4(CHlks)y5C(Rs1)=C(Rs2)C(Rs3)=C(Rs4)-, -(CHRkI)yl (CHR!')y2(CHRk3)y3(CHRk4)y4(CHRks)ySCH(Rs1)CH(Rs2)C(Rs3)=C(Rs4)-, -(CHRkl)yl (CHe)y2(CHe)y3(CHRk4)y4(CHRks)y5C(RSl)=C(Rs2)CH(Rs3)CH(Rs4)-, -(CHRkl)yl (CHRk2)y2(CHe)y3(CHRk4)y4(CHRks)y5CH(RSl)CH(Rs2)CH(Rs3)CH(Rs4)-, wherein yl and y2 are 1 and y3, y4 and y5 are independently 0 or 1, Rkl, e , Rk3' Rk4 alld Rk5 are independently H, -CH3, or OR2a, and Rsl, RS2, Rs3, and Rs4 are independently H or CH3, wherein R2a is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R5 is H or OR2b, wherein R2b is H, a protecting groupan alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R10 is H or alkyl to a compound of the following structure R4.C02R10 where R26 is H, a protecting group, an alkyl group, a aryl group, -SiRaRbR , or CORe, including at least the steps of alcohol oxidation and reductive amination.
[0044] In one embodiment of the process, the starting compound has the following structure, or its enantiomer R3 R5 ~CHR' R2O,, OH
R4.C02R'o wherein Rl is alkenyl; R3 is -CH2CH(CH3) or -CH=C(CH3); and R4 is CH3 , R23aO OR23b wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbW, CH2ORd, or CORe, R23b is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRRbR , CH2ORd, or CORe, or R 23a and R23b togetller form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group and the product compound has the following structure, or its enantiomer R2O,, R4=CO2R10 [0045] In a further aspect, the present invention provides a compound of the following structure or its enantiomer OR2d R4=CO2R'o wherein Rl is H, a protecting group, an allcyl group, an aryl group, an all<:enyl group, an alkynyl group, or a halogen atom;
RZ and Rad are independently H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R~ is R23a0 OR23b wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, Rz3b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRRbR , CHzORd, or CORe;
R10 is H or alkyl; and R27 is CH=CHC(O), CH=CHCH(OH), or CH2CH2C(O).
[0046] In still a further aspect, the present invention provides a compound of the following structure or its enantiomer OR2d R11aO OR11b wherein Rl is H, a protecting group, an allcyl group, an aryl group, an alkenyl group, an allcynyl group, or a halogen atom;
RZ and RZd are independently H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CHzORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR' or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CHZ)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
RS is H or OR2b, wherein RZb is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Rila and Rllb are independently H, a portecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CHzORd, CORe, or Rlla and Rllb together form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R are independently H, an allcyl group, an aryl group or an alkoxyaryl group;
R12 is a halogen atom, CH2OR2o, CHO, C02R10, CH=CHCH2OR2o, CH=CHCHO, wherein R2o is H, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or alkyl; and R27 is CH=CHC(O), CH=CHCH(OH), or CH2CH2C(O).
[0047] The above general structures for the compounds of the present invention include all stereoisomers thereof (other than the natural compound dictyostatin 1). Moreover, the structures of the compounds of the present invention include the compounds in racemic form, enantiomerically enriched form or enantiomerically pure form. Wherein double bonds (for example, with the groups -CH=CH- or -CH=C(CH3)-) a present in R3, a preferred stereoisomer is Z.
[0048] The terms "alkyl", "aryl" and other groups refer generally to both unsubstituted and substituted groups unless specified to the contrary. In that regard, the groups set forth above can be substituted with a wide variety of substituents to synthesize analogs retaining biological activity. Unless otherwise specified, alkyl groups are hydrocarbon groups and are preferably C1-C15 (that is, having 1 to 15 carbon atoms) alkyl groups, and more preferably C1-C10 alkyl groups, and can be branched or unbranched, acyclic or cyclic. The above definition of an alkyl group and other definitions apply also when the group is a substituent on another group (for exainple, an alkyl group as a substituent of an alkylamino group or a dialkylamino group). The term "aryl" refers to phenyl or naphthyl. As used herein, the terms "halogen" or "halo" refer to fluoro, chloro, bromo and iodo.
[0049] The term "alkoxy" refers to -OR, wherein R is an alkyl group. The term "alkenyl" refers to a straight or branched chain hydrocarbon group with at least one double bond, preferably with 2-15 carbon atoms, and more preferably with 2-10 carbon atoms (for example, -CH=CHR or -CH2CH=CHR; wherein R can be a group including, but not limited to, an alkyl group, an alkoxyalkyl group, an amino alkyl group, an aryl group, or a benzyl group). The term "alkynyl" refers to a straight or branched chain hydrocarbon group with at least one triple bond, preferably with 2-15 carbon atoms, and more preferably with 2-10 carbon atoms (for example, -C=CR or -CH2-C=CR; wherein R can be a group including, but not limited to, an alkyl group, an alkoxyalkyl group, an amino alkyl group, an aryl group, or a benzyl group). The terms "alkylene," "alkenylene" and "alkynylene" refer to bivalent forms of alkyl, alkenyl and alkynyl groups, respectively.
[0050] The term "trityl" refers to a triphenyl methyl group or -C(Ph)3.
[0051] Certain groups such as amino and hydroxy groups may include protective groups as known in the art. Preferred protective groups for amino groups include tert-butyloxycarbonyl, formyl, acetyl, benzyl, p-methoxybenzyloxycarbonyl, trityl.
Preferred protecting groups for alcohol include trialkylsilyl (for example, trietllylsilyl, triisopropylsilyl and tributyldimethylsilyl), p-methoxybenzyl, trityl, and (in the case of 1,3-diols) p-methoxyphenyl acetals. Other suitable protecting groups as known to those skilled in the art are disclosed in Greene, T., Wuts, P. G. M., Protective Groups in rganic Synthesis, Wiley (1991), the disclosure of which is incorporated herein by reference.
[0052] Other aspects of the present invention include the synthesis of the compounds of the present invention as well as the biological assaying of such compounds and the biological activity of such compounds against, for example, cancer (such as breast, prostate cancer and ovarian cancer). For example, in another aspect, the present invention provides a method of treating a patient for cancer, including the step of administering a pharmaceutically effective amount of a biologically active compound of the present invention or a pharmaceutically acceptable salt thereof.
[0053] The present invention, along with the attributes and attendant advantages thereof, will best be appreciated and understood in view of the following detailed description talcen in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1 illustrates two embodiments of the synthesis of dictyostatin bottom fragment 15.
[0055] Figure 2 illustrates two embodiments of the syntheses of dictyostatin middle fragment 29.
[0056] Figure 3 illustrates one embodiment of the coupling of bottom and middle fragments of dictyostatin and elaboration to build the upper fragment.
[0057] Figure 4 illustrates one embodiment of the construction of dictyostatin 1 and representative analogs 50 and 59.
[0058] Figure 5 illustrates an einbodiment of the synthesis of representative analog C 16-desmethyldictyostatin 79.
[0059] Figure 6 illustrates an embodiment of the synthesis representative C6-epi,C14-epi intermediate 95.
[0060] Figure 7 illustrates an embodiment of the synthesis of representative analog C2-E,C6-epi,C14-epi dictyostatin 100 and its C2-C3 Z-isomer.
[0061] Figure 8 illustrates an embodiment of the synthesis of representative analog C6-epi,C14-ep,Cl9-epi dictyostatin 108 and its C2-C3 E-isomer.
[0062] Figure 9 illustrates representative examples and methods of synthesis of lactam analogs of the present invention.
[0063] Figure 10 illustrates representative turbidity profiles of 16-desmethyldictyostatin in comparison to that of dictyostatin 1 in a tubulin-only (no MAPs, no GTP, assembly supported by monosodium glutamate) assay.
DETAILED DESCRIPTION OF THE INVENTION
[0064] Figures 1-9 show exemplary synthetic pathways and intermediates for the synthesis of dictyostatin analogs.
[0065] The synthesis of an exemplary "bottom fragment" 15 for making dictyostatin and analogs is shown in Figure 1. 1,3-Propanediol 3 was elaborated via Evans chiral auxiliary-based methods to the known, bis-TBS-protected Horner-Wadsworth-Emmons product 10 in nine steps. See, Phukan, P.; Sasmal, S.; Maier, M. E. Eur. J.
Org. Chena. 2003, 1733, and Andrus, M. B.; Argade, A. B. Tetrahedron Lett. 1996, 37, 5049. This unsaturated ester was reduced to the allylic alcohol 11, which was protected with a trityl group and its primary TBS group removed with HF-pyridine to give alcoho113, which was oxidized in two steps to the carboxylic acid and coupled with the Weinreb reagent to give amide 15. The fifteen-step process from 3 to 15 yielded this intermediate in 9.5% overall yield.
[0066] A shorter route to 10, also illustrated in Figure 1, was also deployed.
Brown crotylmetalation of TBS-protected 3-hydroxypropanal 16 (prepared quantitatively in two steps from 3), was followed by protection of the resulting alcohol 17, Os04-catalyzed dihydroxylation and diol cleavage with periodate, and finally Homer-Wadsworth-Emmons homologation. This second generation route improved the overall yield of 15 from 3 to 27%.
[0067] The synthesis of an exemplary "middle fragment" 29 for making dictyostatin and analogs is shown in Figure 2. The secondary alcohol of known compound 19 (see, Sinitll, A. B.; Beauchamp, T. J.; LaMarche, M. J.; Kaufrnan, M. D.; Qiu, Y.
P.; Arimoto, H.;
Jones, D. R.; Kobayashi, K. J Am. Chem. Soc. 2000, 122, 8654-8664.), prepared in four steps from the (S)-Roche ester, was protected with a TBS group and the Evans auxiliary was removed with LiBH4 to give alcohol 21. Oxidation to the aldehyde and Homer-Emmons reaction gave the ester 22. Alkene reduction with nickel boride, saponification with LiOH
and coupling with the Evans auxiliary gave amide 25. Asymmetric methylation provided one diastereomer 26 very predominantly. Removal of the chiral auxiliary, TBS
protection, and PMB deprotection with DDQ gave the primary alcohol 28. Corey-Fuchs reaction gave the desired alkyne 29. This route from 19 to 29 proceeded in 16% overall yield.
[0068] Another route to 29, also illustrated in Figure 2, involved conversion of 21 to its iodide and asymmetric alkylation with Myers' auxiliary 30 to give amide 31.. See, Myers, A.; Yang, B. Y.; Chen, H.; McKinstry, L.; Kopecky, D. J.; Gleason, J. J. Am.
Chem. Soc.
1997, 119, 6496-6511. Removal of the auxiliary gave 27 in high yield, which was converted to 29 by the steps described above. This second generation approach to 29 doubled the overall yield from 19 to 31%. By using the enantiomer of Myers' auxiliary 30, the epimer of 29 at C16 (dictyostatin numbering) is prepared.
[0069] The bottom and middle fragments were then coupled and the synthesis of dictyostatin was completed as summarized in Figures 3 and 4. The route is flexible and generally allows access to many analogs. The Weinreb amide 15 was reacted with two equivalents of the anion from allcyne 29 to give the coupling product 32 in high yield.
Reduction with the (S,S)-Noyori catalyst gave predominantly one isomer of the alcohol 33 (see, Matsumura, K.; Hashiguchi, S.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc.
1997, 119, 8738-8739), whose alkyne group was reduced by Lindlar hydrogenation to alkene 34.
Rt and R' are independently H, an allcyl group, an aryl group or an allcoxyaryl group;
RlZ is a halogen atom, CH2OR2o, CHO, CO2R10, CH=CHCH2OR2o, CH=CHCHO or CH=CHCO2R10, wherein Ra is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORa, or CORe, and R10 is H or alkyl;
[00321 In another aspect, the present invention provides a process of conversion of a compound with the following formula, or its enantiomer R24 =
O OR11b' wherein R2 a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRUR , CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRI', wherein Rg and Rh are independently H, an alkyl group or an aryl group;
Rllb' is an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, CORe;
R12 is a halogen atom, CH2OR2o, COzRlO, CH=CHCH2OR2o, or CH=CHCO2R10, wherein R2o is a protecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR, CH2ORa, or CORe, and R10 is H or alkyl;
R16 is H or alkyl; and R17 is CH2OR2 ; CO2R10, wherein RZf is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, or CORe; and R24 is C=C to a compound of the following formula, or its enantiomer R2~ _ R11a0 OR11b wherein Rlla is H, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR~, CH2ORa, CORe and Rllb is an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe, or Rlla and Rl lb together form a portion of six-membered acetal ring containing CRtR ;
Rt and R are independently H, an alkyl group or an aryl group; and RM is cis CH=CH, including at least the steps of semi-reduction of the alleyne and asymmetric reduction of the ketone, or asymmetric reduction of the ketone and semihydrogentation of the allcyne.
[0033] In one embodiment, the process includes at least the steps of semi-reduction of the allcyne, asymmetric reduction of the ketone and protection of a resulting alcohol, or asymmetric reduction of the ketone, protection of a resulting alcohol and semihydrogentation of the alkyne, or asymmetric reduction of the ketone, semi-hydrogentation of the alkyne and protection of a resulting alcohol.
[0034] In a further aspect, the present invention provides a compound of the following formula, or its enantiomer R20,, wherein R2 is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and Rc are independently an alkyl group or an aryl group;
Ra is an alkyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an allcoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R16 is H or alkyl; and R17 is CH20R2 ; CHO, CONHCH(CH3)CH(OH)Ph, COZRiO, wherein R2f is H, a protecting group, an allcyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, or CORe;
R25 is C02R10, CHO, CH=CBr2, C=CH, or C=C SiRaRbR ; and R10 is H or an allcyl group.
[0035] In another aspect the present invention provides a process for reacting a first compound of the following formula, or its enantiomer R20,, wherein R2 a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbW, CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Ra is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R16 is H or alkyl; and R17 is CH2OR2 ; CHO, C02R , wherein RZf is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R25 CH=CX2, C=CH or C=CSiRaRbR;
X is Cl, Br or I with a second compound of the following formula, or its ena.ntioiner wherein X is NCH3(OCH3), or a leaving group;
Rl l an allcyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR~, CH2ORd, CORe;
R12 is a halogen atom, CH20R2o, C02R , CH=CHCH2ORz or CH=CHC02R , wherein RZ0 is an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R is alkyl, including the steps of metalation of the first compound and addition of the second compound to produce a compound of the following formula, or its enantiomer R2O,, ~CHR12 rc"11 wherein R24 is C=C.
[0036] In another aspect, the present invention provides a process for reacting a first compound of the following formula, or its enantiomer ., R20r, wherein RZ a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an allcyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an allcyl group, an allyl group, a benzyl group, an aryl group, an allcoxy group, or -NRgRh, wherein Rg and Rh are independently H, an allcyl group or an aryl group;
R16 is H or alkyl;
Rl7 is CH20R2f, CHO, COZR10, wherein R2f is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
R25 CH=CX2, C=CH or C=CSiRaRbR;
with a second compound of the following formula, or its enantiomer X -~CHR12 wherein X is H;
R11 an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, CORe;
R12 is a halogen atom, CH20R2o, C02R10, CH=CHCH2OR2o or CH=CHCO2R10, wherein R2o is an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is allcyl, including the steps of metalation of the first compou.nd and addition of the second compound to produce a compound of the following formula, or its enantiomer R20,, ,, wherein R24 is C=C.
[0037] In another aspect, the present invention provides a compound of the following structure R4.C02RI0 wherein Rl is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CHZ)p where p is an integer in the range of 4 to 12, -(CHRkl)yl (CHRI'2)yZ(CHRI'3)y3(CHRk4)y4(CHRkS)y5C(Rsl)=C(Rs2)C(Rs3)=C(Rs4)-, -(CHRk)yl (CHRk2)y2(CHe)y3(CHRk4)y4(CHRk5)y5CH(Rs1)CH(Rs2)C(Rs3)=C(Rs4)-, -(CHRkl)yl (CHe)y2(CHR~3)y3(CHRk4)y4(CHRks)y5C(RSl)=C(Rs2)CH(Rs3)CH(Rs4)-, -(CHRkl)yl (CHRI'2)y2(CHe)y3(CHRk4)y4(CHRks)y5CH(Rsl)CH(Rs2)CH(Rs3)CH(Rs4)-, wherein yl and y2 are 1 and y3, y4 and y5 are independently 0 or 1, Rl'l, Rl2, Rl'3, Rl'4 and Rks are independently H, CH3, or OR2a, and RSI, RS2, Rs3, and Rs4 are independently H or CH3, wherein RZa is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, or CORe; and R5 is H or ORZb, wherein RZb is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CHZORd, or CORe; and R26 is H, a protecting group, an allcyl group, an aryl group, -SiRaRbR , or CORe;
[0038] In one embodiment, the compound of has the following stereostructure, or its enantiomer R3 R5 CHR' R20,, R4.CO2R'o wherein Rl is alkenyl; R3 is - CH2CH2, -CH=CH, -CH2CH(CH3) or -CH=C(CH3); and R4 is CHg R23a0 OR23b wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtR;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
[0039] In another apsect, the present invention provides a compound of the following structure R3 R5 ~CHRI
R4-'-~ O
wherein R' is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an allcyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an allkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2)p where p is an integer in the range of 4 to 12, -(CHRkI)Yl (CHR~2)Y2(CHRk3)y3(CHRk4)y4(CHRk5 )y5C(RSl)=C(Rs2)C(Rs3)~c(Rs4)-, -(CHRkI)Yl (CHRk2)Y2(CHe)Y3(CHRk4)y4(CHRkS)y5CH(R.sl)CH(Rs2)C(R53)=C(RS4)-, -(CHRkl )Yl (CHR~2)Y2(CHe)Y3(CHk4)Y4(CIMk5)Y5C(Rs1)=C(Rs2)CH(Rs3)CH(Rs4)-, -(CHRkI)yl (CHRI'z)y2(CHR~')y3(CHRk4)y4(CHRks)ySCH(RSl)CH(Rs2)CH(Rs3)CH(Rs4)-, wherein yl and y2 are 1 and y3, y4 and y5 are independently 0 or 1, Rkl, R~2 , e , Rk4 and Rk5 are independently H, CH3, or OR2a, and RSI, Rs2, Rs3, and Rs4 are independently H or CH3, wherein R2a is H, an alkyl group, a benzyl group, a trityl group, -SiRRbR , CHZORd, or CORe; and R 5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R26 is H, a protecting group, an alkyl group, an aryl group, -SiRRbR , or CORe;
[0040] In one embodiment, the compound has the following stereostructure, or its enantiomer H
Rl R20,, R4'1-~ O
wherein Rl is alkenyl; R3 is -CH2CH2, -CH=CH, -CH2CH(CH3) or -CH=C(CH3); and R4 is R23a0 OR23b wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CHaORa, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORa, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R" are independently H, an alkyl group, an aryl group or an alkoxyaryl group [0041] In another aspect, the present invention provides a process for synthesizing a compound having the following structure R3 R5 CHR' R4-'-~ O
wherein Rl is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
RZ is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an allcoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is a.nd integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2)p where p is an integer in the range of 4 to 12, -(CHRkl)yl (CHR~2)y2(CHRk3)y3(CHRk4)y4(CHRkS)y5C(RSl)=C(Rs2)C(Rss)=C(Rs4)-, -(CHRkl)yl (CHRIO)y2(CHe)y3(CHe)y4(ClIlits)ySCH(RSl)CH(Rsz)C(Rs3)=C(Rs4)-, -(CHRkI)yl (CHRk2)y2(CHRk3)y3(CHRk4)y4(CHRks)y5C(RSl)=C(Rs2)CH(Rs3)CH(Rs4)-, -(CHRkl)yi (CHRO)y2(CHRIc3)y3(CHRk4)y4(CHRks)ySCH(RSl)CH(Rs2)CH(Rs3)CH(Rs4)-, wllerein yl and y2 are 1 and y3, y4 and y5 are independently 0 or 1, Rkl, R~2 , e, Rk4 and Rk5 are independently H, CH3, or OR2a, and Rsl, RS2, Rs3, and Rs4 are independently H or CH3, wherein R2a is H, an allcyl group, a benzyl group, a trityl group, -SiRaRR , CH2ORa, or CORe; and R5 is H or ORZV, wherein R2b is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRRUR , CH2ORd, or CORe; and R26 is H, a protecting group, an allcyl group, a aryl group, -SiRaRbR , or CORe;
including the step of reacting a starting compound having the formula:
R4.C02RI0 wherein R10 is H, under conditions suitable to form the macrolactam ring.
[0042] In one embodiment of the process, the starting compound has the following structure, or its enantiomer R20,, R4.C02R10 wherein Rl is alkenyl; R3 is -CH2CH(CH3) or -CH=C(CH3); and R4 is R23aO OR23b wherein R23a is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtR";
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group and the product compound has the following structure, or its enantiomer H
R20s, ', '=-, R4---~
[0043] In a further aspect, the present invention provides a process for converting a starting compound of the following structure OH
R4.C02R10 wherein R' is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 and R2d are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an allcylene group;
Re is an allcyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rl' are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2)p where p is an integer in the range of 4 to 12, -(CHRkl)yl (CHRI'2)y2(CHR~3)y3(CHk4)y4(CHlks)y5C(Rs1)=C(Rs2)C(Rs3)=C(Rs4)-, -(CHRkI)yl (CHR!')y2(CHRk3)y3(CHRk4)y4(CHRks)ySCH(Rs1)CH(Rs2)C(Rs3)=C(Rs4)-, -(CHRkl)yl (CHe)y2(CHe)y3(CHRk4)y4(CHRks)y5C(RSl)=C(Rs2)CH(Rs3)CH(Rs4)-, -(CHRkl)yl (CHRk2)y2(CHe)y3(CHRk4)y4(CHRks)y5CH(RSl)CH(Rs2)CH(Rs3)CH(Rs4)-, wherein yl and y2 are 1 and y3, y4 and y5 are independently 0 or 1, Rkl, e , Rk3' Rk4 alld Rk5 are independently H, -CH3, or OR2a, and Rsl, RS2, Rs3, and Rs4 are independently H or CH3, wherein R2a is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R5 is H or OR2b, wherein R2b is H, a protecting groupan alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe; and R10 is H or alkyl to a compound of the following structure R4.C02R10 where R26 is H, a protecting group, an alkyl group, a aryl group, -SiRaRbR , or CORe, including at least the steps of alcohol oxidation and reductive amination.
[0044] In one embodiment of the process, the starting compound has the following structure, or its enantiomer R3 R5 ~CHR' R2O,, OH
R4.C02R'o wherein Rl is alkenyl; R3 is -CH2CH(CH3) or -CH=C(CH3); and R4 is CH3 , R23aO OR23b wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbW, CH2ORd, or CORe, R23b is H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRRbR , CH2ORd, or CORe, or R 23a and R23b togetller form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group and the product compound has the following structure, or its enantiomer R2O,, R4=CO2R10 [0045] In a further aspect, the present invention provides a compound of the following structure or its enantiomer OR2d R4=CO2R'o wherein Rl is H, a protecting group, an allcyl group, an aryl group, an all<:enyl group, an alkynyl group, or a halogen atom;
RZ and Rad are independently H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Ra, Rb and R are independently an alkyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -4'SiRaRbR or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R~ is R23a0 OR23b wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, Rz3b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, or R23a and R23b together form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRRbR , CHzORd, or CORe;
R10 is H or alkyl; and R27 is CH=CHC(O), CH=CHCH(OH), or CH2CH2C(O).
[0046] In still a further aspect, the present invention provides a compound of the following structure or its enantiomer OR2d R11aO OR11b wherein Rl is H, a protecting group, an allcyl group, an aryl group, an alkenyl group, an allcynyl group, or a halogen atom;
RZ and RZd are independently H, a protecting group, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CHzORd, or CORe;
Ra, Rb and R are independently an allcyl group or an aryl group;
Rd is an alkyl group, an aryl group, an alkoxylalkyl group, -R'SiRaRbR' or a benzyl group, wherein R' is an alkylene group;
Re is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein Rg and Rh are independently H, an alkyl group or an aryl group;
R3 is (CHZ)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
RS is H or OR2b, wherein RZb is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe;
Rila and Rllb are independently H, a portecting group, an alkyl group, a benzyl group, a trityl group, -SiRaRbR , CHzORd, CORe, or Rlla and Rllb together form a portion of six-membered acetal ring incorporating CRtR ;
Rt and R are independently H, an allcyl group, an aryl group or an alkoxyaryl group;
R12 is a halogen atom, CH2OR2o, CHO, C02R10, CH=CHCH2OR2o, CH=CHCHO, wherein R2o is H, an allcyl group, a benzyl group, a trityl group, -SiRaRbR , CH2ORd, or CORe, and R10 is H or alkyl; and R27 is CH=CHC(O), CH=CHCH(OH), or CH2CH2C(O).
[0047] The above general structures for the compounds of the present invention include all stereoisomers thereof (other than the natural compound dictyostatin 1). Moreover, the structures of the compounds of the present invention include the compounds in racemic form, enantiomerically enriched form or enantiomerically pure form. Wherein double bonds (for example, with the groups -CH=CH- or -CH=C(CH3)-) a present in R3, a preferred stereoisomer is Z.
[0048] The terms "alkyl", "aryl" and other groups refer generally to both unsubstituted and substituted groups unless specified to the contrary. In that regard, the groups set forth above can be substituted with a wide variety of substituents to synthesize analogs retaining biological activity. Unless otherwise specified, alkyl groups are hydrocarbon groups and are preferably C1-C15 (that is, having 1 to 15 carbon atoms) alkyl groups, and more preferably C1-C10 alkyl groups, and can be branched or unbranched, acyclic or cyclic. The above definition of an alkyl group and other definitions apply also when the group is a substituent on another group (for exainple, an alkyl group as a substituent of an alkylamino group or a dialkylamino group). The term "aryl" refers to phenyl or naphthyl. As used herein, the terms "halogen" or "halo" refer to fluoro, chloro, bromo and iodo.
[0049] The term "alkoxy" refers to -OR, wherein R is an alkyl group. The term "alkenyl" refers to a straight or branched chain hydrocarbon group with at least one double bond, preferably with 2-15 carbon atoms, and more preferably with 2-10 carbon atoms (for example, -CH=CHR or -CH2CH=CHR; wherein R can be a group including, but not limited to, an alkyl group, an alkoxyalkyl group, an amino alkyl group, an aryl group, or a benzyl group). The term "alkynyl" refers to a straight or branched chain hydrocarbon group with at least one triple bond, preferably with 2-15 carbon atoms, and more preferably with 2-10 carbon atoms (for example, -C=CR or -CH2-C=CR; wherein R can be a group including, but not limited to, an alkyl group, an alkoxyalkyl group, an amino alkyl group, an aryl group, or a benzyl group). The terms "alkylene," "alkenylene" and "alkynylene" refer to bivalent forms of alkyl, alkenyl and alkynyl groups, respectively.
[0050] The term "trityl" refers to a triphenyl methyl group or -C(Ph)3.
[0051] Certain groups such as amino and hydroxy groups may include protective groups as known in the art. Preferred protective groups for amino groups include tert-butyloxycarbonyl, formyl, acetyl, benzyl, p-methoxybenzyloxycarbonyl, trityl.
Preferred protecting groups for alcohol include trialkylsilyl (for example, trietllylsilyl, triisopropylsilyl and tributyldimethylsilyl), p-methoxybenzyl, trityl, and (in the case of 1,3-diols) p-methoxyphenyl acetals. Other suitable protecting groups as known to those skilled in the art are disclosed in Greene, T., Wuts, P. G. M., Protective Groups in rganic Synthesis, Wiley (1991), the disclosure of which is incorporated herein by reference.
[0052] Other aspects of the present invention include the synthesis of the compounds of the present invention as well as the biological assaying of such compounds and the biological activity of such compounds against, for example, cancer (such as breast, prostate cancer and ovarian cancer). For example, in another aspect, the present invention provides a method of treating a patient for cancer, including the step of administering a pharmaceutically effective amount of a biologically active compound of the present invention or a pharmaceutically acceptable salt thereof.
[0053] The present invention, along with the attributes and attendant advantages thereof, will best be appreciated and understood in view of the following detailed description talcen in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1 illustrates two embodiments of the synthesis of dictyostatin bottom fragment 15.
[0055] Figure 2 illustrates two embodiments of the syntheses of dictyostatin middle fragment 29.
[0056] Figure 3 illustrates one embodiment of the coupling of bottom and middle fragments of dictyostatin and elaboration to build the upper fragment.
[0057] Figure 4 illustrates one embodiment of the construction of dictyostatin 1 and representative analogs 50 and 59.
[0058] Figure 5 illustrates an einbodiment of the synthesis of representative analog C 16-desmethyldictyostatin 79.
[0059] Figure 6 illustrates an embodiment of the synthesis representative C6-epi,C14-epi intermediate 95.
[0060] Figure 7 illustrates an embodiment of the synthesis of representative analog C2-E,C6-epi,C14-epi dictyostatin 100 and its C2-C3 Z-isomer.
[0061] Figure 8 illustrates an embodiment of the synthesis of representative analog C6-epi,C14-ep,Cl9-epi dictyostatin 108 and its C2-C3 E-isomer.
[0062] Figure 9 illustrates representative examples and methods of synthesis of lactam analogs of the present invention.
[0063] Figure 10 illustrates representative turbidity profiles of 16-desmethyldictyostatin in comparison to that of dictyostatin 1 in a tubulin-only (no MAPs, no GTP, assembly supported by monosodium glutamate) assay.
DETAILED DESCRIPTION OF THE INVENTION
[0064] Figures 1-9 show exemplary synthetic pathways and intermediates for the synthesis of dictyostatin analogs.
[0065] The synthesis of an exemplary "bottom fragment" 15 for making dictyostatin and analogs is shown in Figure 1. 1,3-Propanediol 3 was elaborated via Evans chiral auxiliary-based methods to the known, bis-TBS-protected Horner-Wadsworth-Emmons product 10 in nine steps. See, Phukan, P.; Sasmal, S.; Maier, M. E. Eur. J.
Org. Chena. 2003, 1733, and Andrus, M. B.; Argade, A. B. Tetrahedron Lett. 1996, 37, 5049. This unsaturated ester was reduced to the allylic alcohol 11, which was protected with a trityl group and its primary TBS group removed with HF-pyridine to give alcoho113, which was oxidized in two steps to the carboxylic acid and coupled with the Weinreb reagent to give amide 15. The fifteen-step process from 3 to 15 yielded this intermediate in 9.5% overall yield.
[0066] A shorter route to 10, also illustrated in Figure 1, was also deployed.
Brown crotylmetalation of TBS-protected 3-hydroxypropanal 16 (prepared quantitatively in two steps from 3), was followed by protection of the resulting alcohol 17, Os04-catalyzed dihydroxylation and diol cleavage with periodate, and finally Homer-Wadsworth-Emmons homologation. This second generation route improved the overall yield of 15 from 3 to 27%.
[0067] The synthesis of an exemplary "middle fragment" 29 for making dictyostatin and analogs is shown in Figure 2. The secondary alcohol of known compound 19 (see, Sinitll, A. B.; Beauchamp, T. J.; LaMarche, M. J.; Kaufrnan, M. D.; Qiu, Y.
P.; Arimoto, H.;
Jones, D. R.; Kobayashi, K. J Am. Chem. Soc. 2000, 122, 8654-8664.), prepared in four steps from the (S)-Roche ester, was protected with a TBS group and the Evans auxiliary was removed with LiBH4 to give alcohol 21. Oxidation to the aldehyde and Homer-Emmons reaction gave the ester 22. Alkene reduction with nickel boride, saponification with LiOH
and coupling with the Evans auxiliary gave amide 25. Asymmetric methylation provided one diastereomer 26 very predominantly. Removal of the chiral auxiliary, TBS
protection, and PMB deprotection with DDQ gave the primary alcohol 28. Corey-Fuchs reaction gave the desired alkyne 29. This route from 19 to 29 proceeded in 16% overall yield.
[0068] Another route to 29, also illustrated in Figure 2, involved conversion of 21 to its iodide and asymmetric alkylation with Myers' auxiliary 30 to give amide 31.. See, Myers, A.; Yang, B. Y.; Chen, H.; McKinstry, L.; Kopecky, D. J.; Gleason, J. J. Am.
Chem. Soc.
1997, 119, 6496-6511. Removal of the auxiliary gave 27 in high yield, which was converted to 29 by the steps described above. This second generation approach to 29 doubled the overall yield from 19 to 31%. By using the enantiomer of Myers' auxiliary 30, the epimer of 29 at C16 (dictyostatin numbering) is prepared.
[0069] The bottom and middle fragments were then coupled and the synthesis of dictyostatin was completed as summarized in Figures 3 and 4. The route is flexible and generally allows access to many analogs. The Weinreb amide 15 was reacted with two equivalents of the anion from allcyne 29 to give the coupling product 32 in high yield.
Reduction with the (S,S)-Noyori catalyst gave predominantly one isomer of the alcohol 33 (see, Matsumura, K.; Hashiguchi, S.; Ikariya, T.; Noyori, R. J. Am. Chem. Soc.
1997, 119, 8738-8739), whose alkyne group was reduced by Lindlar hydrogenation to alkene 34.
[0070] The newly generated secondary hydroxy group was protected with a TBS
group to give 35. Selective deprotection of the primary TBS group with HF-pyridine in buffered pyridine at 0 C gave 36. The aldehyde formed by Dess-Martin oxidation was reacted with the phosphonate 38 (prepared from 37) under Horner-Wadsworth-Enunons conditions to give the conjugated alkene 39 in good yield. Selective reduction with nickel boride gave the ketone 40, which was reduced in a purposefully unselective manner with NaBH4 to give a 2.4:1 mixture of C19 epimers of 41, with the (3 isomer, necessary for preparation of (-)-dictyostatin, predominating. The isomers of 41 were readily separated by silica gel chromatography. A ratio favoring 41(3 (5:1) was obtained by use of the bulkier reducing agent LiAl(O-t-Bu)3H, whereas a 1:1 ratio of the a and (3 isomers was obtained when L-Selectride was employed.
[0071] Alcohol 410 was protected with a TBS group to give 42, whose PMP acetal was cleaved with DIBAL-H to give alcohol 43 (Figure 4). Oxidation to the aldehyde followed by Nozaki-Hiyama addition and Peterson-type elimination installed the (E,Z)-diene to give 44 in high yield. The allylic trityl group was removed with ZnBr2 to give alcoho145.
Dess-Martin oxidation to the aldehyde and Still-Gennari reaction gave the (E,Z)-conjugated ester 46. The PMB group was removed with DDQ to give 47 and saponification with aqueous KOH in EtOH-THF to give acid 48. Yamaguchi macrolactonization gave 49 in good yield. Global deprotection with 3N HC1 in MeOH-THF gave (-)-dictyostatin 1. The sample exhibited spectral data identical to the natural product and the optical rotation matched well. Thus, the previously proposed structures of dictyostatin are incorrect.
[0072] Also shown in Figure 4 are the synthetic steps leading to two representative analogs, the open-chain methyl ester 50 and C19-epi-dictyostatin 59. Ester 50 was prepared by global removal of the TBS groups from 48 in 36% yield. The C19-epi analog 59 was prepared from alcoho141a, as made in Figure 3, by the same methods used for preparation of 1.
[0073] Synthesis of C16-desmethyl dictyostatin 79, another exemplary analog, is shown in Figure 5. The synthesis proceeded from ester 23 in a mamler similar to the existing route to 1, but with omission of the C16-methyl group. Thus, a considerably simpler-to-make middle fragment 64 lacking the awkward C16 stereocenter was used for construction of 79.
Intermediate 23 was elongated to ester 60 by Homer-Wadsorth-Emmons reaction.
Nickel boride then DIBAL-H reduction of the ester gave alcohol 61 in 76% yield. The primary hydroxy group was protected with TBSCI to give 62 quantitatively, then the PMB
group was removed to give alcohol 63 in 90% yield. Oxidation of 63 to the aldehyde by using Parikh-Doering conditions, followed by Corey-Fuchs reaction, afforded the middle fragment alkyne 64.
[0074] The remainder of the synthesis from 64 to C16-desmethyldictyostatin 79 was then completed by using the same synthetic pathway described above for 1.
Interestingly, reduction of ketone 70 (not shown, the desmethyl homologue of 40) with 3 equivalents of LiAl(O-t-Bu)3H gave the desired 71(3 in 95% yield, with only 5% of the a-isomer.
[0075] The synthesis of yet other representative analogs are shown in Figure 6-8.
These are epimers of dictyostatin at C6, C14 and/or C19. The alkyne 80 was added to bottom fragment 81 to give alkyne 82 in 98% yield (Figure 8). When this alkynyl ketone was subjected to Noyori reduction conditions, one major isomer 83 was formed in 87% yield.
Also in this case, about 20 mol% of the (S,S)-Noyori catalyst was preferred.
The Noyori product 83 was reduced by using Lindlar catalyst to give the cis-alkene 84 in 90% yield.
When the reaction time was extended (- 1 day), partial over-reduction of other multiple bonds occurred.
[0076] In order to assign the configuration of the newly generated stereocenter at C9, 84 was treated with TBAF to remove both TBS groups. The resulting triol was reacted with excess 2,2-dimethoxypropane (3.0 equiv) to form the acetal, whose HMQC (500 MHz) NMR
spectrum showed the two methyl groups of the acetonide at similar chemical shifts (24.5 ppm and 25.1 ppm) and the tertiary carbon at 100.4 ppm. These data show an anti-relationship between the C7 and C9 hydroxy groups based on the Rychnovsky method. The C9 hydroxy group in 84 was protected with a TBS group to give 85 in quantitative yield.
The PMB group was then removed with DDQ to give 86 in 84% yield. The resulting secondary hydroxy group was protected again by a TBS group, giving 87 in 94% yield. Selective deprotection of the primary TBS group was accomplished in 66% yield by treatment with HF-pyridine complex in buffered pyridine at 0 C for 2 days to give 88 along with other deprotected byproducts. After the successful coupling of the middle and bottom fragments, 88 was oxidized to the aldehyde, which then was subjected to Horner-Emmons reaction with the phosphonate 38, yielding 89 in 78% yield.
[0077] The alkene in a,(3-unsaturated ketone 89 was reduced with nickel boride giving 90 in 76% yield. As a side reaction, some over-reduction of the C4-C5 alkene in the bottom fragment was also observed. The C19 ketone was reduced by NaBH4 yielding a 1.7:1 ratio of diastereomers of 91, with the (3 isomer as the major (62%), less polar product and the a isomer as the minor (36%), more polar product. These two diastereomers could be separated by silica gel column chromatography. The newly generated C19 hydroxy group in 910 was protected by a TBS group to give 92 in 86% yield, then the PMB acetal was cleaved with DIBAL-H to give the primary alcohol 93 in 97% yield. Oxidation to the aldehyde and subsequent Nozaki-Hiyama and Peterson syn-elimination reactions gave the diene 94 in 85%
yield.
[0078] Removal of the trityl group in 94 with ZnBr2 in CH2C12-MeOH gave 95 in 83% yield. This was oxidized to the aldehyde and the (E,Z)-diene was installed by Still-Gennari reaction in 90% yield (Figure 7). The PMB group in 96 was removed by DDQ to give 97 in 90% yield, and the resulting methyl ester was hydrolyzed with 1N
aqueous KOH
in EtOH-THF. Macrolactonization by the Yamaguchi method gave, surprisingly, mainly the C2E,C4E macrolactone 99 in 78% yield. Final global TBS deprotection yielded 100 in 25%
yield.
[0079] The C19 epimer of 100 was prepared from 91a using similar reaction pathways (Figure 8). After Yamaguchi lactonization, and global TBS
deprotection, the (E,Z)-isomer 108 (less polar, 45%) could be isolated along with the isomerized (E,E)-isoiner 109 (more polar, 15%) in a 3:1 ratio.
[0080] The methods outlined in Figures 1-8 are only exemplary of many possible variants. For example, analogs containing a C15-C16 Z-alkene can be prepared by the methods outlined in US Patent Application Serial No. 10/655,916. Analogs lacking the C9 oxygen atom (C9-deoxy analogs) can likewise be prepared by methods shown in that application. See, for example, Figures 8 and 11, among others.
[0081] The preferred method for forming the macrolactones (often called macrocyclic lactones or macrolides) is the Yainaguchi lactonization. See, for example, Inanaga, J.;
Kuniko, H.; Hiroko, S.; Katsuki, T.; Yamaguchi, M. Bull. Cheyn. Soc. Jpn.
1979, 52, 1989.
An example of the Yamaguchi lactonization is the conversion of hydroxy acid 48 to lactone 49 in Figure 4. Many other commons conditions suitable to effect macrolactone formation from hydroxy acids are well laiown to those skilled in the art, and these can also be used.
See, for example, Kirst, H. A. Macrolides. Large Ring Molecules; Wiley: NY;
1996; pp 345-375, and Boeclcman, R. K., Jr; Goldstein, S. W. The Total Synthesis of Macrocyclic Lactones. The Total Synthesis ofNatural Products; Wiley: New York, 1988; p 1.
[0082] The steps of semi-reduction of the C 10-C 11 alkyne, asymmetric reduction of the C9 ketone and (optionally) protection of the resulting alcohol can be conducted under and assortment of different reaction conditions. For one example, see the conversion of alkynyl ketone 32 to alkynyl alcohol 33, to alkenyl alcohol 34, to silyl ether 35 in Figure 3. The preferred conditions for reduction of the ketone involve use of the Noyori reagent, see K.
Matsumura, S. Hashiguchi, T. Ikariya, R. Noyori, J. Am. Chem. Soc. 1997, 119, 8738-39.
However, many other common ketone reducing agents, both chiral and achiral, can also be used. See, for example, Itsuno, S. Enantioselective Reduction of Ketones. Org.
React. (N..Y.) 1998, 52, 395-576. In cases were two epimers of the alcohol are formed, chromatographic separation is used to isolate the individual epimers (see, for example, separation of 41 in Figure 3). The Lindlar reduction is the preferred method of semi-reduction of the alkyne to the Z-alkene, but other methods can also be used. See for example, Siegel, S.
Heterogeneous Catalytic Hydrogenation of C=C and Alkynes. Comprehensive Organic Synthesis;
Pergamon Press: Oxford, 1991; pp 417, and Takaya, H. Homogeneous Catalytic Hydrogenation of C=C
and Alkynes. Coinprehensive Organic Synthesis; Pergamon Press: Oxford, 1991;
pp 443.
[0083] The reactions in this sequence of steps can also be conducted in several orders.
The preferred order is semi-reduction of the C10-C11 alkyne, followed by asymmetric reduction of the C9 ketone followed by (optionally) protection of the resulting alcohol.
Other orders of reactions are asymmetric reduction of the ketone, protection of the alcohol and semi-reduction of the alkyne, or asymmetric reductiori of the ketone, semi-reduction of the alkyne and protection of the alcohol.
[0084] The preceding steps of coupling of an alkynyl anion with an activated carboxylic acid, see for example conversion of 15 and 29 to 32 in Figure 3, also can be conducted under different sets of conditions. A preferred method is the deprotonation of the alkyne with a strong base, for example BuLi, followed by addition of a carboxylic acid derivative that is activated with a suitable leaving group. Preferred activated carboxylic acids for acylation (acylating agents) are Weinreb amides where the leaving group is the N-methoxy-N-methyl amide group. Many other agents such as esters, acid halides, acid imidazolides, etc. can also be used. These have standard leaving groups such as alkoxide, imidazole and halide. The alkynyl anion can also be generated in situ from a silylalkyne by desilylation or from a geminal-haloalkene by treatment with two or more equivalents of a lithiating agent like BuLi.
[0085] In an alternative route, the alkynyl anion can be reacted with an aldehyde instead of an activated carboxylic acid to produce a C9 alcohol directly after workup. This route is more direct, but mixtures of epimers at C9 may result and chromatographic separation of the epimers may be required. One epimer of a C9 (or other) alcohol can be converted to the other by a Mitsu.nobu reaction.
[0086] Lactam analogs of dictyostatin are important as anticancer agents because of their increased hydrolytic stability compared to the lactones, both in vivo and in vitro. These analogs are readily made by starting with intermediates of the current invention, as exemplified in Figure 9. Standard oxidation of the free C21 alcohol of 110 to a ketone followed by reductive amination provides 111. If desired, the C21 amine stereoisomers can be separated by chromatography. Hydrolysis of the ester to the acid followed by macrolactamization provides lactam 112. The specific example of dictyostatin macrolactam 115, made for example by the sequence 113 -> 114 -> 115, is exemplary of a lactam analog of this invention.
[0087] The steps in the sequence can be conducted in different orders and also on different intermediates. When the C21 nitrogen atom is installed earlier in the synthesis, it is optionally protected with a standard nitrogen protecting group for the subsequent steps prior to macrolactamization. In another approach, this iiitrogen can be installed by a Mitsunobu reaction of a suitably acidic nitrogen nucleophile (for example, azide) with a C21 alcohol.
This reaction occurs with inversion, so the configuration of C23 is chosen accordingly.
[0088] For exemplary methods and conditions of reductive amination, see Baxter, E.
W.; Reitz, A. B. Reductive aminations of carbonyl compounds with borohydride and borane reducing agents. Org. React. (N.Y.) 2002, 59, 1-714. Methods of synthesizing macrolactams (macrocyclic lactams) are related to those for macrolactones. For exemplary methods and conditions, see Nubbemeyer, U. Top. Curr. Chein. 2001, 216, 125-196. For exemplary methods and conditions for Mitsunobu reactions, see Hughes, D. L. Org. Prep.
Proced. Int.
1996, 28, 127-164:
Biology [0089] Tubulin polymerization. The abilities of the new compounds to cause tubulin polymerization were determined under reaction conditions consisting of purified bovine brain tubulin (1 mg/mL) in the presence or absence of microtubule-associated proteins (MAPs, 0.75 mg/mL) and GTP (100 M). Test agents were initially screened at 10 and 40 M. In these experiments, test agent-induced assembly of soluble tubulin into polymer, with respect to the presence and absence of cofactors and at different temperatures, was monitored in a multi-cuvette, temperature-controlled spectrophotometer via development of turbidity in the solution. The initial temperature was closely controlled at 0 C, then rapidly raised to 10 C, to 20 C, then finally to 30 C to determine both the temperature at which a test agent induced assembly as well as the extent of agent-induced assembly. The temperature increases were followed by a rapid decrease in temperature back to 0 C to determine the cold-stability of polymer formed. The effects of dictyostatin 1 and discodermolide 2 were similar and far more potent than those of paclitaxel.
[0090] The C16-desmethyl compound 79 is especially potent among the analogs.
Figure 10 shows the simplest of its turbidity profiles in comparison to that of dictyostatin 1 in a tubulin-only (no MAPs, no GTP, asseinbly supported by monosodium glutamate) assay wherein initial temperature was 0 C for 2 min, followed by rapid rise in temperature to 30 C
for 20 min, then rapid decrease to 0 C. Turbidity profiles showed that analogs 50 and 59 also caused tubulin assembly at temperatures lower than 30 C. The results showed that all of the compounds had effects on the isolated target, tubulin, but with a range of potencies.
[0091] Antiproliferative activity. Representative analogs were examined for their antiproliferative activities against human ovarian carcinoma 1A9 cells and their paclitaxel-resistant mutants, lA9/Ptx10 and 1A9/Ptx22. Each of these resistant lines contains single inutations in the major [3-tubulin gene that confer to the cells, which do not express drug efflux pumps, appreciable tolerance to paclitaxel. Paclitaxel had subnanomolar potency against the parental 1A9 cells, but the mutant cells showed ca. 90- and 70-fold resistance to the drug (Table 1). Analogs 50 and 59 gave G150 values in the mid-nanomolar range. C6-epi,C14-epi-Cl9-epi-dictyostatin 108 and its C2E-diene derivative 109 were antiproliferative agents, giving mid micromolar GI50 values. Even though 100 also had three stereo/geometric alterations (C2E,C6-epi,C14-epi), it was a more potent antiproliferative agent than 108 and 109, showing high nanomolar G150 values. WitlZ one notable exception (vide infra), the fold-resistance values for 1 and its analogs against 1A9/Ptx10 and lA9/Ptx22 cell lines were much lower than that observed for paclitaxel. The one exception was compound 79, which appeared to be essentially equipotent to 1 against the parental 1A9 cells and the A1a364->Thr (3-tubulin mutant lA9/Ptx22 cells, but experienced resistance from the Phe270->Val (3-tubulin mutant lA9/PtxlO cells. Because these mutant cells are not clinically relevant, the result of reduced potency is primarily of mechanistic importance.
Table 1. Antiproliferative potencies of dictyostatin (1) and analogs as compared to discodermolide (2) and paclitaxel against human ovarian carcinoma cells (lA9) and their paclitaxel-resistant, (3-tubulin mutant clones (lA9/Ptx10 and lA9/Ptx22).
G150 S.D., nM (fold-resistance) Compound 1A9 lA9/Ptx10 1A9/Ptx22 (Phe270->Val) (A1a364->Thr) dictyostatin-1 (1) 0.69 :L 0.80 3.2 2.4 (4.6) 1.3 1.0 (1.9) discodermolide (2) 1.7 1.2 6.2 3.6 (3.6) 7.0 8.4 (4.1) paclitaxel 0.71 0.11 64 8 (90) 51 9 (72) 50 56 + 16 79 zL 13 (1.4) 85 2(1.5) 59 21 14 120 + 60 (5.7) 43 12 (2.0) 79 0.41 ::L 0.52 470 70 (1146) 5.6 4.7 (14) 107 >500 >500 (-) >500 (-) 100 310 +_ 40 780 + 200 (2.5) 790 + 560 (2.5) 108 28 :L 1 M 26 O M (0.9) 30 1 M (1.1) 109 25 + 2 M 25 1 M (1) 30 + 1 M (1.2) [0092] Pelleting Assay (EC50 determination). Dictyostatin and representative analogs were evaluated in a quantitative assay for their ability to promote tubulin polymerization. The EC50 value (defined as test agent concentration required to polyinerize 50% of tubulin compared to control) observed for dictyostatin 1 under these conditions was 3.1 0.2 M, similar to that obtained for discodermolide 2(3.6+0.4 M). Both were far superior to paclitaxel, wliich gave an EC50 value of 25+3 M. The C16-desmethyl analog 79 yielded an EC50 of 14+7 M. When the percent polymer formed was determined in the reactions, a comparison of the activities of all the analogs could be made.
Compounds 50 and 59 showed moderate activity. These EC50 data correlated well with the relative antiproliferative potencies of the analogs.
Table 2. Tubulin Assembly EC50 determinations.a Compound EC50 ( M) SD (1V) % Tubulin polymerized by 50 gM test agent dictyostatin (1) 3.1 + 0.2 (3) 99 + 4 discodermolide (2) 3.6 + 0.4 (3) 98 + 5 paclitaxel 25 3 (3) 89 + 6 50 > 50 (2) 39 7 59 > 50 (2) 30 2 79 14 7(3) 91 6 100 >50(2) 1 1 108 >50(2) 5 1 109 > 50 (2) 5 4 aBovine brain tubulin (10 M) in 0.2 M MSG, 15 min at 20 oC, centrifugation and Lowry determination of remaining soluble tubulin [0093] Radiolabeled Ligand Binding Assays. The abilities of test agents to inhibit the binding of radiolabeled forms of the microtubule stabilizers paclitaxel, discodermolide and epothilone B from tubulin polymer were determined. Dictyostatin 1 was equipotent to discodermolide in inhibition of the binding of radiolabeled paclitaxel and epothilone B to microtubules. These two compounds were the most potent of all agents tested.
The open chain methyl ester 50 and the 16-desmethyl analog 79 were ca. 60% as potent as 1 in inhibiting the binding of radiolabeled paclitaxel to microtubules.
Table 4. Percent inhibition of radiolabel from microtubules ( SD (N, number of independent determinations)).
Test Agent (4 pM) [3H]Paclitaxel [3H]Discodermolide [14C]Epothilone B
dictyostatin (1) 75 + 5(3) 40 + 3(3) 88 + 1(3) discodermolide (2) 76 6 (4) nd 90 1 (3) paclitaxel nd 6+ 5(3) 26 + 1(3) 50 42 1(3) nd nd 59 7 2(3) nd nd 79 48 3(3) nd nd 100 0 1 nd nd 108 0 1 nd nd 109 0 1 nd nd epothilone B nd 14 + 3 nd docetaxel 63 8(4) 8+ 6(3) 36 + 1(3) epothilone A 53 + 4(4) 6+ 6(3) 25 + 3 (3) [0094] Multiparameter Fluorescence Analysis of Cellular Effects. HeLa cells were plated on collagen-coated 384-well microtiter plates, allowed to attach, then treated for 24 h with test agents. Test agent concentrations began at 1 M, and two-fold dilutions were made to levels below 1 nM. After the treatment period, the cells were fixed with formalin and their chromatin stained with Hoechst 33342. Cells were permeablilized and treated with primary antibodies for a-tubulin and phosphohistone H3, and then with fluorophore-labeled secondary antibodies. The three fluorescent channels were then examined on an ArrayScan II, wliich gives quantitative pixel distribution and density information in each channel on a per cell basis. Dictyostatin 1 was the most potent of all compounds tested, followed by paclitaxel, discodermolide and the 16-desmethyl analog 79.
Table 5. Minimum detectable cellular changes determined by multiparameter fluorescence high information content analysis.
Compound Nuclear Phosphohistone Tubulin polymer intensity condensation H3 dictyostatin (1) 32.7 11.7 (3) 9.6 ~ 2.4 (4) 7.4 ~ 2.5 (4) 50 479 182 (4) 149 ~ 23.6 (4) 219 ~ 36 (4) 59 363 146 (2) 261 ~ 91 (4) 284 +108 (4) 79 71.5 18.0 (4) 34.4 ~ 10.5 (4) 26.9 2.9 (4) 100 > 5000 (4) > 5000 (4) > 5000 (4) 108 > 5000 (4) > 5000 (4) > 5000 (4) 109 > 5000 (4) > 5000 (4) > 5000 (4) discodermolide (2) 62.5 (1) 38.4 ~ 21.9 (2) 64.6 ~ 0.0 (2) Paclitaxel 40.2 13.9 (4) 17.5 ~ 6.8 (4) 8.0 ~ 2.9 (4) EXAMPLES
Chemistry [0095] Ethyl (4R,5S,2E)-5,7-bis(tert-butyldimethylsilyloxy)-4-methylhept-2-enoate (10). A solution of triethyl phosphonoacetate (3.5 inL, 17.6 mmol) was added to a cooled (0 C) stirred suspension of NaH (0.43 g, 17.0 rnmol, 95% dispersion in inineral oil) in THF (46 mL) dropwise over a 10 min period. The mixture was brought to room temperature with a water bath (30 min) and then cooled back to -78 C and the aldehyde (2.73 g, 7.58 mmol) in THF (5 mL) was added. The resulting mixture was stirred for 1 h at 0 C then pH7 phosphate buffer solution (10 mL) and Et20 (50 mL) were added. The mixture was allowed to warm to room temperature and the phases were separated. The organic phase was washed with sat'd NH4Cl solution (30 mL) and brine (30 mL), dried with MgSO4, filtered and concentrated to give oily crude product. Purification by flash chromatography (EtOAc/hexane 1:9) afforded pure ester 10 (2.92 g, 59% for 2 steps) as a colorless oil: IR
(CHC13) 2956, 2930, 2857, 1724, 1651, 1472, 1463, 1367, 1256, 1180, 1098, 1036, 836, 775 cm 1; 'H NMR (300 MHz, CDCl3) b6.88 (dd, J= 15.8, 7.6 Hz, 1H), 5.74 (d, J=
15.8 Hz, 1H), 4.19 (q, J= 7.IHz, 2H), 3.79 (ddd, J= 6.7, 4.7, 4.4 Hz, 1H), 3.59 (m, 2H), 2.43 (m, 1H), 1.53 (m, 3H), 1.22 (t, J= 7.1 Hz, 3H), 1.01 (d, J= 6.8 Hz, 3H), 0.83 (s, 18H), 0.02 (m, 12H);
13C NMR (75 MHz, CDC13) 8 166.4, 150.9, 121.3, 71.8, 59.9, 59.5, 42.0, 36.8, 25.82, 25.78, 26.1, 18.1, 18.0, 14.4, 14.2, -4.6, -4.7, -5.4; LRMS (El) 415 (M - CH3), 373, 303, 147;
HRMS (EI) calcd for C21H43O4Si 415.2710 (M - CH3), found 415.2712; [a]20D +3.8 (c 0.21, CHC13).
[0096] (4R,5S,2E)-5,7-bis(tert-Butyldimethylsilyloxy)-4-methylhept-2-en-l-ol (11). DIBAL-H (26.5 mL, 26.5 mmol, 1.0 M solution in hexane) was added to the ester 10 (3.14 g. 7.30 mol) in CH2C12 (35 mL) at -78 C dropwise and stirred for 1 h.
The reaction mixture was quenched by EtOAc (5 mL) and sat'd sodium potassium tartrate solution (20 mL) followed by vigorous stirring for 4 h. The aqueous phase was extracted with CHZCIZ (3 x 30 mL) and the combined organic layers were washed with brine (10 mL). After drying over MgSO4 and evaporation under vacuum, flash column chromatography (hexane/EtOAc 4:1) provided 2.75 g of alcohol 11 (97%) as a colorless oil: IR (CHC13) 3349, 2956, 2928, 2857, 1471, 1462, 1255, 1099, 836, 774 cm 1; 'H NMR (300 MHz, CDC13) b5.57 (m, 2H), 4.03 (m, 2H), 3.70 (ddd, J= 9.7, 6.0, 3.8 Hz, 1H), 3.59 (m, 2H), 2.27 (m, 1H), 2.00 (s, 1H), 1.53 (q, J
= 6.5 Hz, 2H), 0.96 (d, J= 6.9 Hz, 3H), 0.85 (s, 9H), 0.84 (s, 9H), 0.00 (m, 12H);13C NMR
(75 MHz, CDC13) S 134.7, 129.2, 72.4, 63.6, 60.1, 41.8, 36.3, 25.9, 18.2, 18.0, 15.1, 10.7, -4.6, -5.4; LRMS (EI) 370 (M - H20), 303, 171, 147; HRMS (EI) calcd for C20H42O2Si2 370.2723 (M - H20), found 370.2725; [a]20D -3.0 (c 0.57, CHC13).
[0097] ((4R,5S,2E)-5,7-bis(tert-Butyldimethylsilyloxy)-4-methylhept-2-enyloxy)triphenylmethane (12). Trityl chloride (4.1 g, 14.7 inmol) and DMAP
(1.8 g, 14.7 mmol) were added to a solution of alcohol 11 (2.75 g, 7.1 mmol) in pyridine (71 mL). The mixture was heated to reflux for 18 h, cooled to ambient temperature and added to a solution of sat'd CuSO4 (200 mL). The mixture was extracted with Et20 (2 x 20 mL) and the combined organic extracts were washed sat'd CuSO4 (2 x 20 mL). The organic layer was separated, dried (MgS04), filtered, and concentrated in vacuo. Flash column chromatography (EtOAc/hexane 1:19) provided 12 (4.46 g, quantitative) as a pale yellow oil:
IR (CHC13) 2954, 2856, 1471, 1448, 1254, 1095, 835, 773, 705 cm 1;111 NMR (300 MHz, CDC13) b7.56 (m, 6H), 7.32 (m, 9H), 5.79 (dd, J= 15.6, 6.7 Hz, 1H), 5.65 (dd, J= 15.7, 5.0 Hz, 1H), 3.85 (m, 1H), 3.74 (m, 1H), 3.66 (d, J= 4.9 Hz, IH), 2.43 (m, 1H), 1.70 (q, J= 6.5 Hz, 2H), 1.21 (d, J= 6.9 Hz, 3H), 0.99 (s, 9H), 0.97 (s, 9H), 0.154 (s, 3H), 0.150 (s, 3H), 0.13 (s, 3H), 0.12 (s, 3H); 13C NMR (75 MHz, CDC13) 8 144.4, 134.2, 128.7, 127.7, 126.9, 126.8, 86.8, 72.6, 65.1, 60.2, 42.1, 36.6, 26.0, 18.3, 18.1, 15.3, -4.4, -5.3; LRMS (ESI) 653.3 [M+Na]+, 422.4, 243.2; HRMS (ESI) calcd for C39H58O3Si2Na 653.3822 [M+Na]+, found 653.3851;
[a]20D -1.9 (c 0.42, CHC13).
[0098] (3S,4R,5E)-3-(tert-Butyldimethylsilyloxy)-4-methyl-7-(trityloxy)hept-5-en-1-ol (13). HF-pyridine in pyridine (40 mL, prepared by slow addition of 12 mL
pyridine to 3 mL HF-pyridine complex followed by dilution with 25 mL THF) was added to a solution of TBS ether 12 (4.46 g, 7.07 mmol) in THF (10 mL). The mixture was stirred overnight at room temperature and quenched with sat'd NaHCO3 (100 mL). The aqueous layer was separated and extracted with Et20 (3 x 50 mL). The combined organic layers were washed with sat'd CuSO4 (3 x 50 mL), dried over MgSO4, and concentrated. Flash colunui chromatography (EtOAc/hexane 1:4) afforded 3.26 g (89%) of alcohol 13 as a colorless oil:
IR (CHC13) 3407, 2955, 2928, 2856, 1490, 1471, 1448, 1254, 1058, 1031, 836, 773, 705 cm 1; 'H NMR (300 MHz, CDC13) b7.57 (m, 6H), 7.37 (m, 9H), 5.78 (dd, J= 15.6, 6.5 Hz, 1H), 5.73 (dt, J= 15.5, 4.8 Hz, 1H), 3.91 (m, 1H), 3.82 (d, J= 5.9 Hz, 2H), 3.69 (d, J= 4.4 Hz, 2H), 2.51 (m, 1H), 2.22 (br, 1H), 1.77 (m, 2H), 1.13 (d, J= 6.8 Hz, 3H), 1.03 (s, 9H), 0.21 (s, 3H), 0.19 (s, 3H); 13C NMR (75 MHz, CDC13) S 144.2, 134.1, 128.6, 127.7, 127.1, 126.9, 86.8, 74.3, 64.9, 60.4, 42.0, 34.8, 25.9, 18.0, 14.5, -4.4, -4.6; LRMS (ESI) 539.2 [M+Na]+, 243.2; HRMS (ESI) calcd for C33H44O3Si1Na 539.2957 [M+Na]+, found 539.2976;
[a]20D -2.8 (c 2.0, CHC13).
[0099] (3S,4R,5E)-3-(tert-Butyldimethylsilyloxy)-N-methoxy-N,4-dimethyl-7-(trityloxy)hept-5-enamide (15). Sulfur trioxide pyridine coinplex (3.02 g, 19.1 mmol) was added to a stirred solution of alcohol 13 (3.26 g, 6.31 mmol) and triethylamine (2.6 mL, 19.1 mmol) in anhydrous CH2C12 (6 mL) and DMSO (12 mL) at 0 C. The reaction mixture was stirred at the ambient temperature for 1 h. The mixture was diluted with Et20(100 mL) and washed with aqueous 0.5 N HCl (50 mL) and brine (10 mL). The separated organic layer was dried over MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 4:1) provided the crude aldehyde as a colorless oil, which was used without further purification. A solution of the aldehyde in THF (25 mL) and H20 (12 mL) was treated with 2-methyl-2-butene in THF (2M, 18 mL, 9.0 mmol), NaH2PO4=H20 (2.6 g, 18.8 mmol) and NaC1O2 (2.1 g, 18.6 mmol). The reaction mixture was stirred for 2 h, diluted with 1N HCl (20 mL) and extracted with CHaC12 (2 x 40 mL). The combined organic layers were dried over MgSO4, concentrated in vacuo and the crude acid was used for the next reaction without further purification. N, O-Dimethylhydroxylamine hydrochloride (0.62 g, 6.36 mmol), Et3N (0.88 mL, 6.31 mmol), DMAP (0.63 mmol) were successively added to a solution of the crude acid in CHZCIZ (10 mL). The reaction mixture was cooled to 0 C, and DCC (1.30 g, 6.30 mmol) was added. The mixture was stirred at ambient temperature for 15 h and filtered. The filtrate was washed with 0.5 N HCI, saturated aqueous NaHCO3, and brine, dried over anhydrous MgSO4 and concentrated. Purification by column chromatography over silica gel (hexane/EtOAc 4:1) gave the Weinreb amide 15 (2.65 g, 73%
for 3 steps) as a colorless oil: IR (CHC13) 2956, 2929, 2855, 1663, 1448, 1252, 1083, 1032, 836 cm'1; 'H NMR (300 MHz, CDC13) b7.58, m, 6H), 7.37 (m, 9H), 5.89 (dd, J=
15.6, 7.6 Hz, 1H), 5.72 (dt, J= 15.6, 5.2 Hz, 1H), 4.38 (ddd, J= 8.0, 5.0, 3.0 Hz, 1H), 3.74 (s, 3H), 3.70 (d, J= 5.1 Hz, 2H), 3.27 (s, 3H), 2.79 (dd, J= 15.1, 7.4 Hz, 1H), 2.52 (m, 2H), 1.20 (d, J
= 6.9 Hz, 3H), 1.02 (s, 9H), 0.22 (s, 3H), 0.16 (s, 3H);13C NMR (75 MHz, CDC13) b 172.6, 144.2, 133.3, 128.5, 127.7, 127.5, 126.8, 86.7, 72.4, 64.8, 61.2, 42.4, 36.3, 31.9, 25.8, 18.0, 15.7, -4.6, -5.0; LRMS (ESI) 596.2 [M+Na]+, 449.2, 243.0; HRMS (ESI) calcd for C35H47O4NSiNa 596.3172 [M+Na]+, found 596.3165; [a]20D -14.7 (c 0.65, CHC13).
[00100] (R)-3-((2R,3S,4S)-5-(4-Methoxybenzyloxy)-3-(tert-butyldimethylsilyloxy)-2,4-dimethylpentanoyl)-4-benzyloxazolidin-2=one (20). 2,6-Lutidine (5.14 mL, 44.2 mmol) and TBSOTf (9.36 mL, 40.8 mmol) were added to a solution of 19 (15.0 g, 33.9 mmol) in CHZCl2 (340 mL) stirred at 0 C. The mixture was stirred at 0 C for 2 h and then quenched by the addition of saturated aqueous NaHCO3. The phases were separated and the aqueous layer was extracted with CHZCl2. The combined organic phases were washed with 0.5 M
aqueous NaHSO4. The organic phase was dried over NaZSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (hexane/EtOAc 4:1) to give 20 (17.9 g, 95%) as a colorless oil: IR (film) 1781, 1696, 1513, 1383, 1248, 1209, 1110, 1042 cm'1; 'H NMR (300 MHz, CDC13) 57.35-7.28 (m, 7H), 6.85 (d, J= 8,7 Hz, 1H), 4.49 (m, 1H), 4.38 (d, J= 11.7 Hz, 1H), 4.34 (d, J= 11.7 Hz), 4.03 (m, 3H), 3.81 (m, 3H), 3.77 (s, 3H), 3.54 (dd, J= 9.2, 5.6 Hz, 1H), 3.22 (dd, J= 13.3, 3.1 Hz, 1H), 3.17 (dd, J= 9.1, 5.9 Hz, 1H), 2.72 (dd, J= 13.3, 9.6 Hz, 1H), 1.97 (m, 1H), 1.25 (d, J= 6.5 Hz, 3H), 1.02 (d, J= 7.0 Hz, 3H), 0.91 (s, 9H), 0.07 (s, 6H);13C NMR (75 MHz, CDC13) 8 176.4, 159.4, 153.1, 135.8, 131.1, 129.8, 129.3, 129.2, 127.6, 75.6, 72.9, 72.0, 66.1, 55.8, 55.6, 41.9, 39.3, 38.0, 26.4, 18.7, 15.3, 15.2, -3.5, -3.6; HRMS (ESI) calcd for C31H45NO6SiNa 578.2914 [M+Na]+, found 578.2923; [a]20D -8.1 (c 7.6, CHC13).
[00101] (2S,3R,4S)-5-(4-Methoxybenzyloxy)-3-(tert-butyldimethylsilyloxy)-2,4-dimethylpentan-l-ol (21). Dry MeOH (1.05 mL, 26.0 mmol) then LiBH4 (13 mL, 2.0 M
solution in THF, 26 mmol) were added to a stirred solution of 20 (4.79 g, 8.62 mmol) in THF
(75 mL) at 0 C. The resulting mixture was stirred at 0 C for 45 min and at room temperature for 1 h. The solution was cooled to 0 C and treated carefully with a 1.0 M
aqueous NaOH (50 mL). The phases were separated and the aqueous phase was extracted with CHZC12. The combined organic phases were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (hexane/EtOAc 7:3) to give the alcoho121 (2.98 g, 90%) as a colorless oil:
IR (film) 3425, 1613, 1513, 1463, 1249, 1091, 1037 cm 1; 1H NMR (300 MHz, CDC13) 8 7.26 (d, J= 8.5 Hz, 2H), 6.88 (d, J= 8.5 Hz, 2H), 4.47 (d, J= 11.7 Hz, 1H), 4.40 (d, J= 11.7 Hz, 1H), 3.84 (s, 3H), 3.75 (dd, J= 5.7, 2.9 Hz, 1H), 3.52 (m, 3H), 3.28 (dd, J=
9.1, 7.1 Hz, 1H), 2.10 (br, 1H), 2.05 (m, 1H), 1.93-1.81 (m, 1H), 0.97 (d, J= 7.0 Hz, 3H), 0.90 (s, 9H), 0.87 (d, J= 7.1 Hz, 3H), 0.07 (s, 3H), 0.05 (s, 3H);13C NMR (75 MHz, CDC13) 8 159.2, 130.7, 129.3, 113.8, 74.8, 72.8, 72.7, 66.3, 55.4, 39.0, 37.7, 26.2, 18.4, 15.2, 12.0, -4.1;
HRMS (ESI) calcd for C18H31O3SiNa 323.2042 [M+Na]+, found 323.2035; [a]20D -0.76 (c 2.9, CHC13).
[00102] (4S,5R,6S,2E)-Ethyl-7-(4-methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-4,6-dimethylhept-2-enoate (22). The procedure for 10 was used with the aldehyde from 21 (17.5 g, 31.6 mmol), Py-S03 (15.2 g, 95.5 mmol) and Et3N (13.3 mL, 95.5 mmol), NaH (0.90 g, 39.7 mmol) and triethylphosphonoacetate (7.2 mL, 40.3 mmol) to yield 8.96 g (63% for 3 steps) of the ester 22 by flash coluinn chromatography (EtOAc/Hexane 1:9) as a colorless oil: IR (CHC13) 2957, 2931, 2856, 1720, 1651, 1613, 1513, 1463, 1366, 1250, 1180, 1093, 1077, 837 cm"1 ; 1H NMR (300 MHz, CDC13) 57.31-7.27 (m, 2H), 7.03 (dd, J= 15.8, 7.8 Hz, 1H), 6.93-6.91 (m, 2H), 5.83 (dd, J= 15.8, 1.3 Hz, 1H), 4.48-4.40 (m, 2H), 4.23 (q, J= 7.1 Hz, 2H), 3.84 (s, 3H), 3.67 (m, 1H), 3.52 (m, 1H), 3.30 (dd, J= 9.1, 7.2 Hz, 1H), 2.59 (m, 1H), 2.00 (m, 1H), 1.33 (t, J= 7.1 Hz, 3H), 1.09 (d, J= 6.8 Hz, 3H), 1.01 (d, J= 7.0 Hz, 3H), 0.94 (s, 9H), 0.08 (m, 6H); 13C NMR (75 MHz, CDC13) 8 166.5, 159.0, 152.7, 130.6, 129.0, 120.4, 113.6, 76.8, 72.5, 71.8, 60.0, 55.1, 40.2, 38.0, 26.0, 18.2, 14.8, 14.3, 14.2, -4.0, -4.2; LRMS (ESI) 473.2 [M+Na]+; HRMS (ESI) calcd for C25H42O5SiNa 473.2699 [M+Na]+, found 473.2716; [a]20o -28.3 (c 0.41, CHC13).
[00103] (4S,5R,6S)-Ethyl-7-(4-methoxy)benzyloxy)-5-(tert-butyldimethylsilyloxy)-4,6-dimethylheptanoate (23). NiC12=6H20 (2.4 g, 10.1 mmol) then portionwise NaBH4 (1.50 g, 39.7 mmol) were added to a stirred solution of unsaturated ketone 22 (8.96 g, 19.9 mol) in MeOH (66 mL), THF (20 mL) at 0 C. After 1 h, the solvent was evaporated and filtered with Celite using Et20 as an eluent (60 mL). The organic phase was concentrated and the residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 8.76 g of 23 (97%) as a colorless oil: IR (CHC13) 2957, 2856, 1737, 1613, 1513, 1463, 1374, 1249, 1172, 1091, 1038, 836, 773 cm 1; 'H NMR (300 MHz, CDC13) 57.40-7.37 (m, 2H), 7.02-6.99 (m, 2H), 4.59-4.50 (m, 2H), 4.25 (q, J= 7.1 Hz, 2H), 3.91 (s, 3H), 3.66-3.62 (m, 2H), 3.40 (dd, J
= 8.8, 7.3 Hz, 1H), 2.52-2.33 (m, 2H), 2.13-2.02 (m, 1H), 1.90-1.82 (m, 111), 1.78-1.57 (m, 2H), 1.38 (t, J= 7.1 Hz, 3H), 1.09 (d, J= 6.9 Hz, 3H), 1.03 (s, 9H), 1.00 (d, J= 6.5 Hz, 3H), 0.19 (s, 3H), 0.18 (s, 3H); 13C NMR (75 MHz, CDC13) 8 173.6, 158.9, 130.7, 129.0, 113.5, 76.8, 72.5, 60.0, 55.0, 38.0, 35.6, 32.5, 29.9, 26.0, 18.3, 14.9, 14.1, 13.7, -3.9, -4.2; LRMS
(ESI) 475.3 [M+Na]+; HRMS (ESI) calcd for C25H44O5SiNa 475.2856 [M+Na]+, found 473.2877; [a]20D -6.0 (c 1.9, CHC13).
[00104] (4S,5R,6S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-4,6-dimethylheptanoic acid (24). Aqueous LiOH (1N, 193 mL, 0.19 mol) was added to.
a THF-H20 solution of 23 (8.76 g, 19.4 mmol). The resulting solution was warmed tQ
60 oC and stirred with heating for 6 h. Aqueous 1N HCl was added to give a neutral pH
and the mixture was extracted with CH2C12 , dried over MgSO4, filtered and evaporated to yield 8.22 g of crude acid 24, which was used without further purification: 1H NMR (300 MHz, CDC13) 6 7.24-7.22 (m, 2H), 6.86-6.83 (m, 2H), 4.39 (m, 2H), 3.77 (s, 3H), 3.69 (q, J=
7.0 Hz, 1H), 3.52 (m, 1 H), 3.47 (q, J= 7.0 Hz, 1H), 3.19 (t, J= 8.5 Hz, 114), 2.16 (m, 1H), 1.90 (m, 114), 1.65-1.51 (m, 2H), 1.21 (t, J= 7.0 Hz, 2H), 0.92-0.85 (m, 12H), 0.81 (d, J=
6.3 Hz, 3H), 0.00 (m, 6H); 13C NMR (75 MHz, CDC13) S 181.0, 158.9, 130.6, 129.1, 113.6, 72.5, 65.8, 58.0, 55.1, 37.8, 30.6, 26.1, 18.3, 18.1, 15.2, 14.0, -3.5, -4.1.
[00105] (R)-3-((4S,5R,6S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-4,6-dimethylheptanoyl)-4-benzyloxazolidin-2-one (25). A solution of the acid 24 (8.22 g, 19.4 nunol) and Et3N (5.40 mL, 38.8 mmol) in 100 mL of dry THF was cooled to -78 C and treated dropwise with pivaloyl chloride (2.86 g, 23.3 mmol), stirred in the cold for 2 h and warmed to 0 C prior to the addition of the oxazolidinone (3.5 g, 19.8 mmol) and LiCl (2.46 g, 58.8 mmol). This mixture was stirred overnight at room temperature and diluted with water (200 mL). The separated aqueous phase was extracted with ether (100 mL) and the combined organic layers were dried and evaporated to give a residue that was chromatographed to yield 7.91 g (70% for 2 steps) of imide 25 by flash colunm chromatography (EtOAc/hexane 1:4) as a colorless oil: 1H NMR (300 MHz, CDC13) S 7.41-7.23 (m, 7H), 6.94-6.91 (m, 2H), 4.71 (m, 1H), 4.51 (d, J= 11.6 Hz, 1H), 4.46 (d, J= 11.6 Hz, 1H), 4.25-4.16 (m, 2H), 3.84 (s, 3H), 3.63-3.58 (m, 2H), 3.37-3.31 (m, 2H), 3.14-3.04 (m, 1H), 2.94-2.86 (m, 1H), 2.79 (dd, J=
13.3, 9.7 Hz, 1H), 2.04 (m, 1H), 1.87-1.60 (m, 3H), 1.03 (d, J= 6.9 Hz, 3H), 0.99-0.97 (m, 12H), 0.14 (s, 3H), 0.12 (s, 3H); 13C NMR (75 MHz, CDC13) S 173.1, 158.8, 153.3, 135.2, 130.7, 129.3, 129.0, 128.8, 127.1, 113.5, 77.1, 72.5, 72.4, 65.9, 55.1, 54.9, 37.9, 37.7, 35.6, 33.7, 29.2, 26.0, 18.3, 14.9, 13.9, -3.8, -4.2.
[00106] (R)-3-((2R,4S,5R,6S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-2,4,6-trimethylheptanoyl)-4-benzyloxazolidin-2-one (26).
NaHMDS (1 M in THF, 14.9 mL, 14.9 mmol) was added dropwise over a 30 min period to a cooled (-78 C) suspension of the imide 25 (7.91 g, 13.6 mmol) in THF (45 mL).
After 15 min of stirring, the resulting cold solution was treated with Mel (2.53 mL, 40.8 mmol) and allowed to stir at -78 C for 3 h before being warmed to 25 C overnight (12 h) The reaction was quenched with H20 (100 mL), and the aqueous layer was extracted with Et20 (3 x 150 mL). The combined organic extracts were dried (MgSO4), concentrated in vacuo and chromatographed (EtOAc/hexane 1:9) to provide 5.97 g (74%) of 26 as a colorless oil: 1H
NMR (300 MHz, CDC13) 8 7.42-7.26 (m, 7H), 6.95-6.92 (m, 2H), 4.71 (m, 1H), 4.51 (m, 2H), 4.18 (m, 2H), 3.95 (m, 1H), 3.84 (s, 3H), 3.63 (dd, J= 8.9, 3.8 Hz, 1H), 3.57 (dd, J=
6.4, 2.7 Hz, 1H), 3.35 (t, J= 8.5 Hz, 1H), 3.28 (dd, J= 13.3, 3.1 Hz, 1H), 2.83 (dd, J= 13.3, 9.4 Hz, 1H), 2.10-1.95 (m, 2H), 1.68 (m, 1H), 1.38 (ddd, J= 14.1, 9.8, 4.9 Hz, 1H), 1.31 (d, J
= 6.8 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 0.98 (s, 9H), 0.95 (d, J= 6.7 Hz, 3H), 0.14 (s, 3H), 0.13 (s, 3H); 13C NMR (75 MHz, CDC13) S 176.8, 158.8, 152.8, 135.1, 130.8, 129.3, 128.9, 128.7, 127.1, 113.5, 77.6, 72.6, 72.4, 65.7, 55.0, 38.9, 38.0, 37.6, 35.3, 33.8, 26.0, 18.8, 18.3, 14.9, 13.8, -3.8, --4.2.
[00107] (2R,4S,5R,6S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-2,4,6-trimethylheptan-1-ol (27). n-BuLi (2.5 M in hexane, 17.6 mL, 44 mmol) was added to a solution of diisopropylamine (6.65 mL, 47.4 mmol) in THF (48 mL) stirred at -78 C. The solution was stirred at -78 C for 5 min and warmed to 0 C for 15 min. Borane-ammonia complex (90%, 1.55 g, 45.2 mmol) was added and the resulting mixture was stirred at 0 C
for 15 min, warmed to room temperature for 15 min and then cooled to 0 C. A
solution of amide 26 (6.62 g, 11.3 minol) in THF (35 mL) was added dropwise and the reaction was stirred at 0 C for 1 h and then at room temperature for 2 h. The mixture was cooled to 0 C
and quenched carefully with saturated aqueous NH4C1. The mixture was extracted with Et20 and the combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (step gradient of 4:1 to 7:3 hexane/EtOAc) to afford the alcohol 27 (4.57 g, 96%) as a colorless oil:
IR (film) 3410, 1612, 1513, 1249, 1067, 1038 cm 1; 'H NMR (300 MHz, CDC13) 8 7.26 (d, J
= 8.6 Hz, 2H), 6.88 (d, J= 8.6 Hz, 2H), 4.44 (d, J= 11.7 Hz, 1H), 4.39 (d, J=
11.7 Hz, 1H), 3.81 (s, 3H), 3.51 (m, 2H), 3.44 (dd, J = 5.6, 3.4 Hz, 1H), 3.37 (dd, J =
10.6, 6.5 Hz, 1H), 3.22 (dd, J= 9.0, 7.0 Hz, 1H), 2.03-1.95 (m, 1H), 1.78-1.62 (m, 2H), 1.53 (br, 1H), 1.41 (ddd, J= 13.5, 7.5, 5.8 Hz, 1H), 0.95 (d, J= 6.9 Hz, 3H), 0.94 (d, J= 6.7 Hz, 3H), 0.88 (s, 9H), 0.87 (d, J = 6.9 Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (75 MHz, CDC13) S 159.2, 130.9, 129.4, 113.9, 77.5, 72.8, 67.7, 55.4, 38.3, 38.0, 33.6, 33.2, 26.3, 18.6, 18.0, 15.6, 15.5, -3.5, -3.8; [a]20D -6.3 (c 1.7, CHC13).
[00108] (2S,3R,4S,6R)-3,7-bis(tert-Butyldimethylsilyloxy)-2,4,6-trimethylheptan-l-ol (28). TBSCI (4.16 g, 27.6 mmol) was added to a solution of alcohol 27 (5.86 g, 13.8 mmol), imidazole (2.89 g, 41.4 mmol), and DMAP (169 mg, 1.38 mmol) in CH2C12 (55 mL).
The resulting white suspension was stirred at room temperature for 2 h and the volatiles were removed under reduced pressure. The residue was dissolved in hexane and brine.
The phases were separated and the organic layer was washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (hexane/EtOAc 19:1) to afford the TBS protected alcohol (7.04 g, 95%) as a colorless oil: IR
(film) 1513, 1471, 1463, 1249, 1091, 1039 crri 1; 1H NMR (300 MHz, CDC13) b 7.30 (d, J=
8.6 Hz, 2H), 6.91 (d, J= 8.6 Hz, 2H), 4.48 (d, J= 11.9 Hz, 1H), 4.44 (d, J=
11.9 Hz, 1H), 3.82 (s, 3H), 3.60-3.49 (m, 3H), 3.39-3.28 (m, 3H), 2.05-1.95 (m, 1H), 1.80-1.66 (m, 2H), 1.49-1.40 (m, 2H), 1.02 (d, J= 6.9 Hz, 3H), 1.0-0.91 (m, 24 H), 0.10 (s, 3H), 0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (75 MHz, CDC13) 8 159.2, 131.1, 129.3, 127.9, 77.3, 73.1, 72.8, 68.4, 55.3, 38.9, 38.5, 33.5, 26.4, 26.2, 18.7, 18.6, 18.1, 15.3, 15.1, -3.4, =3.8, -5.2; [a]20o -15.9 (c 0.47, CHC13). A solution of above TBS protected alcohol (5.28 g, 9.8 mmol) in CH2C12 (332 mL) and pH 7 phosphate buffer solution (33 mL) was treated with DDQ (3.34 g, 14.7 mmol).
The reaction was stirred at room temperature for 1 h and was quenched with saturated aqueous NaHCO3 solution. The phases were separated and the aqueous layer was extracted with CH2C12. The combined organic extracts were washed with water, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography (hexane/EtOAc 97:3 to 93:7) to afford 28 (4.01 g, 98%) as a colorless oil: IlZ
(film) 3353, 1472, 1463, 1388, 1360, 1255, 1091, 1030, 1005 cm 1; 1H NMR (300 MHz, CDC13) 8 3.60 (d, J= 5.3 Hz, 2H), 3.55-3.45 (m, 2H), 3.32 (dd, J= 9.7, 6.7 Hz, 1H), 2.49 (br, 1H), 1.45 (ddd, J= 13.5, 7.5, 5.3 Hz, 1H), 0.95 (d, J= 7.1 Hz, 3H), 0.92 (s, 9H), 0.89 (s, 9H), 0.93-0.87 (m, 6H), 0.11 (s, 3H), 0.09 (s, 3H), 0.04 (s, 6H); 13C NMR (75 MHz, CDC13) b 80.9, 68.0, 66.2, 38.4, 37.8, 35.4, 33.5, 26.3, 26.1, 18.5, 18.3, 16.2, 15.7, -3.6, -3.9, -5.3;
[a]20D -16.1 (c 4.4, CHC13).
[00109] (3S,4R,5S,7R)-4-(tert-Butyldimethylsilyloxy)-7-((tert-butyldimethylsilyloxy)methyl)-3,5-dimethyloct-1-yne (29). Sulfur trioxide pyridine complex (5.44 g, 34.2 mmol) was added to a solution of 28 (4.78 g, 11.4 rnmol) and triethylamine (4.77 mL, 34.2 mmol) in CH2C12 (23 mL) and DMSO (46 mL) at 0 C.
The mixture was stirred at 0 C for 1 h and then diluted with Et20. The organic phase was washed with cold 0.5 M aqueous NaHSO4 and then with brine. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by short flash chromatography (hexane/EtOAc 9:1) to afford the crude aldehyde as a golden oil which was used directly in the next reaction without further purification. Carbon tetrabromide (7.56 g, 22.8 mmol) was added to a solution of triphenylphosphine (12.3 g, 45.6 mmol) in CH2Cl2 (56 mL) at 0 C. The resulting dark-red mixture was stirred at 0 C for 10 min.
A solution of the crude aldehyde and 2,6-lutidine (2.66 mL, 22.8 mmol) in CH2C12 (45 mL) was added dropwise. The dark-brown mixture was stirred at 0 C for 1 h and then quenched with a saturated aqueous NH4C1. The layers were separated and the aqueous phase was extracted with CHZC12. The combined organic extracts were washed with HZO, dried over MgS04, filtered and concentrated under reduced pressure. The residue was purified by short flash chromatography (hexane 100%) to afford the dibromoolefin (4.76 g, 73% yield from the alcohol) as a colorless oil that was used without further purification. A
solution of the dibromoolefin (4.76 g, 8.2 nunol) in THF (40 mL) stirred at -78 C was treated with n-BuLi (1.6 M in hexane, 15.4 mL, 24.6 mmol). The solution was stirred at -78 C for 2 h and then quenched with saturated aqueous NH4C1. The mixture was allowed to reach room temperature and was diluted with Et20. The aqueous layer was extracted with Et20. The combined organic extracts were washed with brine, dried over MgS0~, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (hexane:EtOAc 97:3) to afford the pure alkyne 29 (3.26 g, 95%) as a colorless oil: IR (film) 3313, 2100, 1472, 1463, 1252, 1088, 1005 cm 1; 'H NMR (300 MHz, CDC13) 8 3.53-3.48 (m, 2H), 3.33 (d, J= 9.7, 6.8 Hz, 1H), 2.62 (ddddd, J= 7.2, 7.2, 7.2, 5.1, 2.5 Hz, 1H) 2.03 (d, J=
2.5 Hz, 1H), 1.97-1.80 (m, 1H), 1.73-1.6 (m, 1H), 1.47 (m, 1H), 1.21 (d, J=
7.1 Hz, 3H), 0.99-0.91 (m, 6H), 0.95 (s, 9H), 0.93 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H), 0.08 (s, 6H); 13C
NMR (75 MHz, CDC13) S 87.9, 77.8, 70.2, 68.5, 39.2, 33.9, 33.7, 32.3, 26.4, 26.3, 18.6, 17.9, 17.5, 15.7, -3.6, -5.1; HRMS (ESI) calcd for C22H45O2Si2Na 397.2958 [M+Na]}, found 397.2950; [a]20D -8.2 (c 3.1, CHC13).
[00110] (2R,4S,5R,6S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-N-((1S,2S)-1-hydroxy-l-phenylpropan-2-yl)N,2,4,6-tetramethylheptanamide (31).
PPh3 (7.05 g, 26.2 mmol), imidazole (1.78 g, 26.2 mmol), diisopropylethylamine (4.6 mL, 26.2 mmol) in benzene (80 mL), diethyl ether (165 mL) and acetonitrile (33 mL) were stirred at room temperature and treated with iodine (6.65 g, 26.2 mmol). The resulting mixture was vigorously stirred until the formation of a beige suspension. A solution of the alcoho121 (5.0 g, 13.1 mmol) in Et20 (20 mL) was added dropwise to the suspension and the resulting mixture was stirred at room temperature for 30 min. The reaction was quenched with saturated aqueous NaHCO3 and diluted with Et20. The aqueous phase was extracted with Et20 and the combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was triturated with hexane and the triturate was concentrated under reduced pressure. This procedure was repeated two more times to afford the iodide as a colorless oil that was used directly in the next reaction. A
solution of n-BuLi in hexane (2.5 M, 21 mL, 52.4 mmol) was added to a suspension of LiCl (7.05 g, 166.4 nunol) and diisopropylamine (7.85 mL, 56.3 mmol) in THF (40 mL) at -78 C.
The suspension was stirred at -78 C for 5 min, 0 C for 15 min and then cooled to -78 C. A
solution of (S,S)-pseudoephedrine propionamide (Meyer's auxiliary, 30) (6.09 g, 27.5 mmol) in THF (70 mL) was added dropwise. The resulting mixture was stirred at -78 C
for 1 h, at 0 C for 15 min and at room temperature for 5 min. The suspension was cooled to 0 C and the iodide was added as a solution in THF (6 mL followed by a 6 mL rinse). The reaction mixture was stirred at room temperature for 24 h and quenched with half-saturated aqueous NH4C1. The aqueous layer was extracted with EtOAc and the combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash chromatography (hexane/EtOAc 1:1) to afford the amide 31 (6.69 g, 87%) as a colorless oil: IR (film) 3387, 1616, 1513, 1463, 1248, 1087, 1037 cm 1; HRMS
(ESI) calcd for C34H56NO5Si 586.3928, found 586.3940; [a]20D +23.2 (c 1.26, CHC13).
[00111] (4R,5S,10S,11R,12S,14R,2E)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12,14-tetramethyl-l-(trityloxy)pentadec-2-en-8-yn-7-one (32). Alkyne 29 (4.12 g, 10.0 mmol) was dissolved in THF (100 mL) and cooled to -78 C. n-BuLi (6.25 mL, 1.6 M
hexane solution) was added slowly. After 5 min, the mixture was warmed to 0 C
and stirred for 30 min. The mixture was then cooled to -78 C and amide 15 (6.47 g, 11.3 mmol) in THF
(5 mL) was added slowly. After 5 min, the solution was warmed to 0 C and stirred for 30 min. The reaction was quenched with saturated aqueous NH4C1 and the mixture was partitioned in a separatory fu.nnel. The aqueous phase was extracted with Et20 (3 x 20 mL).
The combined organic extracts were washed with brine and dried over MgSO4.
Filtration and concentration under reduced pressure, followed by flash chromatography on silica gel (hexane/EtOAc 19:1), afforded the ynone 32 (9.70 g, 93%) as a pale yellow oil:
IR (CHC13) 2955, 2928, 2856, 2209, 1676, 1471, 1462, 1252, 1085, 836, 774 cm"1; 'H NMR
(300 MHz, CDC13) 57.56, m, 6H), 7.36 (m, 9H), 5.80 (dd, J= 15.6, 7.1 Hz, 1H), 5.69 (dt, J= 15.7, 4.8 Hz, 1H), 4.37 (m, 1H), 3.69 (d, J= 4.7 Hz, 2H), 3.61 (m, 1H), 3.58 (dd, J=
9.7, 5.0 Hz, 1H), 3.43 (dd, J= 9.7, 6.5 Hz, 1H), 2.87 (m, 1H), 2.73 (m, 1H), 2.46 (m, 1H), 1.88 (m, 1H), 1.76 (m, 1 H), 1.59 (m, 1 H), 1.31 (d, J= 7.1 Hz, 3H), 1.15 (d, J= 6.8 Hz, 3H), 1.05 (m, 111), 1.00 (m, 34H), 0.194 (s, 3H), 0.190 (s, 3H), 0.17 (s, 3H), 0.15 (s, 3H), 0.14 (s, 6H);13C NMR (75 MHz, CDC13) 6 186.1, 144.2, 132.9, 128.6, 127.7, 126.9, 96.8, 86.8, 83.1, 71.5, 68.0, 64.9, 50.0, 42.3, 38.1, 34.4, 33.2, 32.1, 26.01, 25.96, 25.85, 18.3, 18.0, 17.9, 17.2, 15.5, 15.4, -3.8, -4.1, -4.6, -4.7, -5.4; LRMS (ESI) 947.5 [M+Na]+, 562:3, 243.1; HRMS (ESI) calcd for C56H$$O5Si3Na 947.5837 [M+Na]+, found 947.5875; [a]20D -12.0 (c 0.54, CHC13).
[00112] (4R,5S,7S,10S,11R,12S,14R,2E)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12,14-tetramethyl-l-(trityloxy)pentadec-2-en-8-yn-7-ol (33). Ynone 32 (5.28 g, 5.71 mmol) was taken up in i-PrOH (58 mL). The (S, S)-Noyori catalyst (0.77 g, 1.15 mmol, 20 mol%) was added in one portion and the solution was stirred overnight. The solvent was removed under vacuuin, and the crude residue was purified by flash chromatography on silica gel (hexane/EtOAc 97:3), affording propargylic alcoho133 (4.18 g, 79%) as a pale yellow oil:
IR (CHC13) 3469, 2955, 2856, 1471, 1448, 1252, 1084, 836, 774 cm"1; 1H NMR
(300 MHz, CDC13) 8 7.55 (m, 6H), 7.36 (m, 9H), 5.71 (m, 2H), 4.59 (m, 1H), 4.03 (quint, J= 3.9 Hz, 1 H), 3.65 (d, J= 3.9 Hz, 2H), 3.5 8(dd, J= 4.6, 3.2 Hz, 111), 3.55 (dd, J=
10.1, 5.1 Hz, 111), 3.38 (dd, J= 9.7, 6.8 Hz, 1H), 2.71 (m, 1H), 2.50 (m, 1H), 2.32 (d, J= 5.4 Hz, 1H), 1.88 (m, 1H), 1.80 (m, 2H), 1.55 (m, 1H), 1.23 (d, J= 7.1 Hz, 3H), 1.11 (d, J= 6.8 Hz, 3H), 0.98 (m, 34H), 0.20 (s, 3H), 0.17 (s, 3H), 0.16 (s, 3H), 0.14 (s, 3H), 0.12 (s, 6H);
13C NMR (75 MHz, CDC13) 6 144.3, 134.0, 128.6, 127.8, 127.1, 126.9, 88.1, 86.8, 83.0, 72.6, 68.3, 65.8, 65.1, 59.5, 41.9, 40.3, 38.7, 33.5, 33.2, 32.1, 26.0, 25.9, 18.4, 18.1, 17.7, 17.4, 15.7, 15.3, 14.2, -3.9, -4.0, -4.4, -4.5, -5.3; LRMS (ESI) 949.7 [M+Na]+, 413.3, 243.1; FIRMS
(ESI) calcd for C56H9oO5Si3Na 949.5994 [M+Na]+, found 949.6018; [a]20D -10.0 (c 1.2, CHC13).
[00113] (2E,4R,5S,7S,8Z,lOS,11R,12S,14R)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12,14-tetramethyl-l-(trityloxy)pentadeca-2,8-dien-7-ol (34).
A catalytic amount of Lindlar catalyst (ca. 200 mg) was added to a solution of alcohol 33 (4.18 g, 4.51 mmol) in toluene (100 mL). The flask was flushed with H2 via a balloon several times, then stirred under an atmosphere of H2 until starting material was consumed (usually 1 h) as indicated by TLC analysis. The mixture was filtered through a pad of Celite and concentrated under reduced pressure to afford the alkene 34 as a colorless oil (3.82 g, 91%):
IR (CHC13) 3436, 2954, 2926, 2855, 1461, 1378, 1252, 1061, 836, 773 cm"1; 1H
NMR (300 MHz, CDC13) S 7.56 (m, 6H), 7.34 (m, 9H), 5.73 (m, 2H), 5.60 (t, J= 10.3 Hz, 1H), 5.43 (dd, J= 10.9, 8.4 Hz, 1H), 4.73 (m, 1H), 3.98 (q, J= 5.0 Hz, 1H), 3.68 (d, J= 4.1 Hz, 1H), 3.59 (dd, J= 9.7, 4.7 Hz, 1H), 3.48 (m, 1H), 3.36 (dd, J= 9.0, 7.3 Hz, 1H), 2.79 (m, 1H), 2.58 (m, 1H), 2.23 (br, 1H), 1.78 (m, 1H), 1.71 (m, 1H), 1.66 (m, 2H), 1.50 (m, 1H), 1.11 (d, J= 6.8 Hz, 3H), 1.07 (d, J= 6.8 Hz, 3H), 1.00 (m, 34H), 0.22 (s, 3H), 0.18 (s, 3H), 0.14 (s, 6H), 0.13 (s, 6H); 13C NMR (75 MHz, CDC13) 8 144.3, 135.3, 134.6, 131.5, 128.7, 127.7, 127.0, 126.8, 86.8, 79.6, 73.0, 68.2, 65.0, 64.7, 42.0, 39.6, 38.0, 36.4, 34.9, 33.4, 26.2, 26.0, 25.9, 19.9, 18.4, 18.3, 18.1, 18.0, 15.2, 14.5, =3.4, -3.7, -4.2, -4.4, -4.5, -5.4; LRMS
(ESI) 951.7 [M+Na]+, 413.3, 243.1; HRMS (ESI) calcd for C56H92O5Si3Na 951.6150 [M+Na]+, found 951.6172; [a]20o 1.0 (c 0.62, CHC13).
[00114] ((2E,4R,5S,7S,8Z,lOS,11R,12S,14R)-5,7,11,15-tetrakis(tert-Butyldimethylsilyloxy)-4,10,12,14-tetramethylpentadeca-2,8-dienyloxy)triphenylmethane (35). TBSOTf (2.08 mL, 9.07 mmol) was added to a stirred solution of the alcohol 34 (3.82 g, 4.11 mmol) and 2,6-lutidine (1.14 mL, 9.85 mmol) in CHZC12 (14 mL) at 0 C. The reaction mixture was stirred for 1 h at 0 C. The reaction mixture was quenched by the addition of H20 (25 mL). The reaction mixture was extracted with CHZCIa wliich was dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by short colunm chromatography (hexane/EtOAc 19:1) to obtain 35 (4.27 g, 99%) as a colorless oil: IR (CHC13) 2956, 2929, 2856, 1471, 1462, 1449, 1255, 1089, 1005, 836, 773, 705 cm"1; 'H NMR (300 MHz, CDC13) S 7.60 (m, 6H), 7.39 (m, 9H), 5.77 (m, 2H), 5.56 (t, J= 10.8 Hz, 1H), 5.42 (dd, J= 11.0, 8.2 Hz, 1H), 4.69 (m, 1 H), 4.07 (m, 1 H), 3.71 (d, J= 3.8 Hz, 2H), 3.64 (dd, J= 9.8, 4.8 Hz, 1 H), 3.5 3(m, 1 H), 3.40 (dd, J= 9.6, 7.5 Hz, 1H), 2.74 (m, 1H), 2.55 (m, 1H), 1.89 (m, 3H), 1.59 (m, 3H), 1.12 (d, J= 6.2 Hz, 6H), 1.04 (m, 42H), 0.26 (s, 3H), 0.24 (s, 3H), 0.19 (s, 6H), 0.18 (s, 3H), 0.17 (s, 6H), 0.16 (s, 3H); 13C NMR (75 MHz, CDC13) 8 144.4, 134.5, 132.9, 132.6, 128.7, 127.7, 126.8, 86.8, 79.9, 72.3, 68.3, 66.5, 65.1, 64.1, 42.4, 41.6, 37.9, 36.0, 35.3, 33.6, 26.3, 26.02, 25.97, 25.7, 19.4, 18.5, 18.4, 18.20, 18.15, 18.1, 15.5, 13.3, -2.9, -3.5, -3.7, -4.1, -4.2, -4.3, -5.3; LRMS (ESI) 1065.9 [M+Na]+, 413.3, 359.3, 328.3, 243.1; HRMS (ESI) calcd for C62H106O5Si4Na 1065.7015 [M+Na]+, found 1065.7026; [a]20D -10.4 (c 0.53, CHC13).
[00115] (2R,4S,5R,6S,7Z,9S,11S,12R,13E)-5,9,11-tris(tert-Butyldimethylsilyloxy)-2,4,6,12-tetramethyl-15-(trityloxy)pentadeca-7,13-dien-l-ol (36). HF-pyridine in pyridine (40 mL, prepared by slow addition of 12 mL pyridine to 3 mL HF-pyridine complex followed by dilution with 25 mL THF) was slowly added to a solution of TBS ether 35 (4.27 g, 4.10 mmol) in THF (5 mL) at 0 C. The mixture was stirred for 21 h at 0 C and quenched with saturated aqueous NaHCO3 (100 mL). The aqueous layer was separated and extracted with Et20 (3 x 50 mL). The combined organic layers were washed with saturated aqueous CuSO4 (3 x 50 mL), dried over MgSO4, filtered and concentrated. Flash column chromatography (EtOAc/hexane 1:4) afforded 2.55 g (67%) of the alcohol 36 as a colorless oil:
IR (CHC13) 3350, 2956, 2928, 2856, 1471, 1448, 1254, 1086, 836, 773, 705 cm"1; 'H NMR
(300 MHz, CDC13) S 7.52 (m, 6H), 7.32 (m, 9H), 5.68 (m, 2H), 5.50 (t, J = 10.6 Hz, 1H), 5.35 (dd, J=
10.9, 8.5 Hz, 1H), 4.61 (t, J= 8.5 Hz, 1H), 4.00 (t, J= 8.1 Hz, 1H), 3.62 (d, J= 3.2 Hz, 2H), 3.58 (dd, J= 10.6, 4.3 Hz, 1H), 3.45 (m, 1H), 3.36 (dd, J= 9.9, 7.3 Hz, 1H), 2.66 (m, 1H), 2.48 (m, 1H), 1.70 (m, 3H), 1.49 (m, 3H), 1.04 (d, J= 6.6 Hz, 6H), 0.97 (s, 18H), 0.93 (m, 6H), 0.87 (s, 9H), 0.18 (s, 3H), 0.16 (s, 3H), 0.11 (s, 6H), 0.10 (s, 3H), 0.08 (s, 3H); 13C NMR
(75 MHz, CDC13) b 144.3, 134.4, 133.0, 132.1, 128.7, 127.7, 126.8, 86.7, 79.8, 72.3, 67.7, 66.5, 65.1, 42.4, 41.5, 37.3, 35.7, 35.5, 33.3, 26.2, 26.0, 25.9, 19.6, 18.4, 18.14, 18.06, 17.98, 15.7, 13.2, -2.9, -3.6, -3.7, -4.1, -4.2, -4.3; LRMS (ESI) 951.8 [M+Na]+, 771.6, 328.3;
HRMS (ESI) calcd for C56H92O5Si3Na 951.6150 [M+Na]+, found 951.6162; [a]20D -12.0 (c 0.71, CHC13).
[00116] (2R,4E,6R,8S,9R,10S,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-4,11,17-trien-3-one (39). The alcohol 36 (2.55 g, 2.75 mol) in CH2C12 (30 mL) was treated with Dess-Martin periodinane (1.74 g, 4.10 mol). After 1 h, the mixture was quenched with saturated aqueous NaHCO3 (30 mL) and Na2SzO3 (30 mL). The aqueous layer was extracted with Et20 (2 x 30 mL) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 4:1) provided the crude aldehyde as a colorless oil, which was used without further purification. A mixture of ketophosphonate 38 (1.06 g, 2.75 mmol) and Ba(OH)2 (0.38 g, activated by heating to 100 C for 1-2 h before use) in THF (40 mL) was stirred at room temperature for 30 min. A solution of the above aldehyde in wet THF (4 x 1 mL washings, 40:1 THF/H20) was then added. After stirring for 12 h, the reaction mixture was diluted with Et20 (30 mL) and washed with saturated aqueous NaHCO3 (50 mL) and brine (50 mL). The organic solution was dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was chromatographed (hexane/EtOAc 9:1) to yield 39 (2.60 g, 80% for 2 steps) as a colorless oil: IR (CHC13) 2956, 2928, 2855, 1688, 1618, 1518, 1471, 1461, 1338, 1251, 1080, 1038, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) S 7.50 (m, 6H), 7.40 (m, 2H), 7.30 (m, 9H), 6.89 (m, 2H), 6.73 (dd, J= 15.6, 8.5 Hz, 1H), 6.29 (d, J= 15.6 Hz, 1H), 5.66 (m, 2H), 5.46 (t, J= 10.4 Hz, 1H), 5.46 (s, 1 H), 5.31 (dd, J=
11.0, 8.4 Hz, 1H), 4.58 (t, J= 8.1 Hz, 1H), 4.12 (dd, J= 11.3, 4.6 Hz, 1H), 3.96 (m, 1H), 3.92 (dd, J= 10.0, 4.2 Hz, 1H), 3.80 (s, 3H), 3.60 (d, J= 2.8 Hz, 2H), 3.56 (m, 1H), 3.39 (t, J=
3.3 Hz, 1H), 2.93 (m, 1H), 2.64 (m, 1H), 2.45 (m, 1H), 2.37 (m, 1H), 2.01 (m, 1H), 1.61 (m, 111), 1.54 (m, 2H), 1.50 (m, 1H), 1.44 (m, 1H), 1.27 (d, J= 7.0 Hz, 3H), 1.06 (d, J= 6.6 Hz, 3H), 1.02 (d, J= 6.5 Hz, 3H), 0.99 (d, J= 6.6 Hz, 3H), 0.95 (s, 9H), 0.94 (s, 9H), 0.88 (d, J=
6.6 Hz, 3H), 0.84 (s, 9H), 0.79 (d, J= 6.7 Hz, 3H), 0.15 (s, 3H), 0.14 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H), 0.03 (s, 3H); 13C NMR (75 MHz, CDC13) 8 200.7, 159.8, 152.3, 144.3, 134.3, 132.8, 132.1, 131.0, 128.6, 127.7, 127.1, 126.8, 126.6, 113.4, 100.8, 86.7, 82.7, 80.0, 72.8, 72.1, 66.4, 65.0, 55.2, 47.1, 42.4, 41.4, 39.3, 35.8, 34.7, 34.6, 32.2, 26.1, 25.92, 25.86, 20.8, 19.7, 18.3, 18.1, 18.0, 15.0, 13.0, 12.4, 10.8, -2.9, -3.7, -3.8, -4.18, -4.25, -4.35; LRMS (ESI) 1209.6 [M+Na]+, 828.4, 715.3, 449.2, 243.1; HRMS (ESI) calcd for C72H110O8Si3Na 1209.7406 [M+Na]+, found 1209.7474; [a]20D -6.7 (c 0.11;
CHC13).
[00117] (2R,6S,8S,9R,lOS,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-3-one (40). NiC12=6H20 (0.26 g, 1.09 mmol) then portionwise NaBH4 (0.17 g, 4.49 mmol) were added to a stirred solution of unsaturated ketone 39 (2.60 g, 2.19 mol) in 80 mL of 3:2 MeOH/THF at 0 C.
After 1 h, the reaction mixture was evaporated and filtered through Celite using Et20 (30 mL) as an eluent.
The organic phase was concentrated and the residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 1.98 g of 40 (76%) as a colorless oil: IR (CHC13) 2955, 2927, 2855, 1711, 1614, 1518, 1461, 1251, 1076, 835, 773 cni 1; 1H NMR (300 MHz, CDC13) 8 7.46 (m, 6H), 7.27 (m, 11H), 6.85 (m, 2H), 5.60 (m, 2H), 5.43 (s, 1H), 5.40 (m, 1H), 5.27 (m, 1H), 4.52 (m, 1H), 4.11 (dd, J= 11.1, 4.7 Hz, 1H), 3.91 (m, 2H), 3.78 (s, 3H), 3.55 (m 2H), 3.50 (m, 1H), 3.35 (m, 1H), 2.67 (m, 1H), 2.58 (m, 1H), 2.51 (m, 1H), 2.41 (m, 1H), 2.01 (m, 1H), 1.68 (in, 3H), 1.41 (m, 5H), 1.23 (d, J= 7.1 Hz, 3H), 0.96 (d, J= 6.7 Hz, 3H), 0.90 (s, 9H), 0.89 (s, 9H), 0.88 (m, 1H), 0.87 (m, 3H), 0.80 (s, 9H), 0.78 (m, 6H), 0.10 (s, 3H), 0.08 (s, 3H), 0.04 (s, 3H), 0.03 (s, 6H), 0.01 (s, 3H); 13C NMR (75 MHz, CDC13) b 211.9, 159.8, 144.5, 144.3, 134.4, 132.9, 132.4, 130.9, 128.6, 127.9, 127.8, 127.7, 127.1, 126.8, 113.4, 100.8, 86.7, 83.1, 79.9, 72.8, 72.2, 66.4, 65.1, 55.1, 48.3, 42.3, 41.5, 41.2, 38.1, 35.7, 35.0, 31.2, 29.8, 29.7, 26.2, 25.92, 25.87, 20.2, 19.4, 18.4, 18.1, 18.0, 15.2, 13.2, 12.1, 9.6, -3.0, -3.5, -3.7, -4.2, -4.28, -4.34; LRMS (ESI) 1211.9 (30 mL), 1031.8, 870.4, 684.3, 366.4, 243.1; HRMS (ESI) calcd for C72H112O8Si3Na 1211.7563 (30 mL), found 1211.7616;
[a]20D
+1.6 (c 0.50, CHC13).
[00118] (2S,3R,6S,8S,9R,lOS,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-3-ol (41(3). NaBH4 (0.095 g, 2.51 mmol) was added to a solution of ketone 40 (1.98 g, 1.67 mrnol) in MeOH (28 mL) at 0 C.
After stirring for 2 h at 0 C, the reaction mixture was evaporated and water (30 mL) was added. The reaction mixture was extracted with ether (2 x 40 mL) and washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield major product the title compound 410 (1.39 g, 70%, less polar) and minor product 41a (0.58 g, 28%, more polar) as a colorless oil. 41(3: IR
(CHC13) 3398, 2954, 2926, 2854, 1517, 1460, 1251, 1072, 835 cm 1; 1H NMR (300 MHz, CDC13) 8 7.50 (m, 6H), 7.39 (m, 2H), 7.33 (m, 9H), 6.89 (in, 2H), 5.66 (m, 2H), 5.54 (s, 1H), 5.46 (m, 1H), 5.32 (m, 1 H), 4. 5 8(m, 1H), 4.14 (dd, J= 11.3, 4.6 Hz, 1H), 3.95 (m, 1H), 3.87 (m, 1H), 3.80 (s, 3H), 3.72 (d, J= 9.8 Hz, 1H), 3.61 (m, 2H), 3.55 (m, 1H), 3.41 (m, 1H), 3.24 (br, 1H), 2.64 (m, 1H), 2.46 (m,1 H), 2.16 (m, 1H), 1.82 (m, 1H), 1.71 (m, 2H), 1.53 (m, 5H), 1.35 (m, 2H), 1.06 (d, J= 7.2 Hz, 3H), 1.01 (d, J= 6.6 Hz, 3H), 0.95 (s, 9H), 0.93 (s, 9H), 0.90 (m, 9H), 0.85 (s, 9H), 0.78 (d, J= 6.6 Hz, 3H), 0.14 (m, 6H), 0.09 (m, 12H); 13C
NMR (75 MHz, CDC13) 8 160.0, 144.5, 144.3, 134.4, 132.9, 132.4, 130.7, 128.7, 127.9, 127.8, 127.7, 127.6, 127.2, 127.1, 126.8, 113.6, 101.2, 89.1, 86.7, 80.0, 76.9, 73.1, 72.2, 66.5, 65.1, 42.3, 41.5, 41.4, 37.0, 36.7, 35.1, 32.5, 32.1, 30.4, 30.3, 26.2, 25.93, 25.87, 20.4, 19.4, 18.4, 18.1, 18.0, 15.4, 13.2, 11.8, 5.4, -3.0, -3.5, -3.7, -4.2, -4.27, -4.33;
LRMS (ESI) 1213.7 [M+Na]+, 1033.6, 570.9, 364.3, 243.1; HRMS (ESI) calcd for C7aH114O$Si3Na 1213.7719 [M+Na]+, found 1213.7861; [a]20D +6.5 (c 0.31, CHC13). 41a: IR
(CHC13) 3540, 2956, 2929, 2855, 1615, 1518, 1461, 1383, 1251, 1074, 835, 773 cm 1; 'H NMR
(300 MHz, CDC13) b 7.61 (m, 6H), 7.51 (m, 2H), 7.44-7.32 (m, 9H), 7.00 (m, 2H), 5.77 (m, 2H), 5.61 (s, 1H), 5.55 (m, 1H), 5.45 (m, 1H), 4.71 (m, 1H), 4.24 (dd, J= 11.1, 4.5 Hz, 1H), 4.07 (m, 111), 4.01 (m, 1H), 3.88 (s, 3H), 3.73-3.60 (m, 4H), 3.54 (m, 1H), 2.76 (m, 1H), 2.56 (m, 1H), 2.49 (m,1 H), 2.24 (m, 1H), 1.94-1.78 (m, 4H), 1.72-1.46 (m, 6H), 1.42-1.31 (m, 2H), 1.22 (d, J=
7.0 Hz, 3H), 1.13 (d, J= 5.9 Hz, 3H), 1.06 (s, 18H), 1.03 (m, 6H), 0.96 (s, 9H), 0.86 (d, J=
6.6 Hz, 3H), 0.27-0.18 (m, 18H); 13C NMR (75 MHz, CDC13) 8 159.9, 144.4, 144.3, 134.3, 132.9, 132.4, 131.0, 128.6, 127.6, 127.2, 126.8, 113.5, 101.0, 86.7, 82.8, 79.8, 74.8, 73.2, 72.2, 66.4, 65.0, 55.1, 42.3, 41.5, 37.8, 35.9, 34.9, 33.2, 32.4, 30.3, 30.2, 26.2, 25.92, 25.87, 20.4, 19.3, 18.4, 18.1, 18.0, 15.3, 13.2, 11.8, 11.0, -3.0, -3.4, -3.7, -3.9, -4.2, -4.28, -4.34;
LRMS (ESI) 1213.9 [M+Na]+, 987.7, 659.3, 437.2, 243.1; HRMS (ESI) calcd for CnH114OgSi3Na 1213.7719 [M+Na]+, found 1213.7760; [a]20D +2.3 (c 0.75, CHC13).
[00119] (4S,5S)-4-((2R,3R,6S,8S,9R,10S,11Z,13S,15S,16R,17E)-3,9,13,15-tetrakis(tert-Butyldimethylsilyloxy)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-2-yl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxane (42). TBSOTf (0.40 mL, 1.74 mmol) was added to a stirred solution of alcohol 410 (1.39 g, 1.17 mmol) and 2,6-lutidine (0.27 mL, 2.33 mmol) in CH2CI2 (23 mL) at 0 C. After stirring for 1 h at ambient temperature, the reaction mixture was quenched by the addition of water (50 mL) and extracted by CH2Cl2. After drying over MgSO4, followed by the evaporation of the solution under reduced pressure, the residue was purified by short column chromatography (hexane/EtOAc 9:1) to yield 42 (1.51 g, 99%) as a colorless oil: IR (CHC13) 2955, 2928, 2855, 1615, 1517, 1461, 1250, 1074, 1039, 835, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.59 (m, 6H), 7.52 (m, 2H), 7.41 (m, 9H), 7.01 (m, 2H), 5.74 (m, 2H), 5.57 (s, 1H), 5.50 (m, 1H), 5.43 (in, 1H), 4.67 (m, 1H), 4.25 (dd, J= 11.3, 4.6 Hz, 1H), 4.04 (m, 1H), 3.94 (s, 3H), 3.78 (m, 1H), 3.70 (m, 3H), 3.49 (m, 1H), 3.16 (m, 1H), 2.72 (m 1H), 2.54 (m, 1H), 2.18 (m, 1H), 2.01 (m, 1H), 1.82 (m, 3H), 1.54 (m, 6H), 1.14 (d, J= 6.9 Hz, 3H), 1.11 (d, J= 6.8 Hz, 3H), 1.10 (d, J= 6.5 Hz, 311), 1.05 (s, 9H), 1.03 (s, 9H), 1.02 (s, 12H), 0.98 (d, J= 6.3 Hz, 3H), 0.94 (s, 9H), 0.87 (d, J= 6.7 Hz, 3H), 0.24 (s, 3H), 0.22 (s, 3H), 0.17 (in, 18H); 13C
NMR (75 MHz, CDC13) 8 159.6, 144.5, 144.3, 134.4, 133.1, 132.6, 131.5, 128.6, 127.7, 127.6, 127.1, 126.8, 126.7, 113.3, 100.4, 86.7, 81.9, 79.8, 74.9, 73.3, 72.2, 66.4, 65.1, 55.1, 42.3, 41.5, 38.8, 35.9, 34.5, 31.3, 31.2, 30.8, 30.7, 26.3, 25.99, 25.97, 25.91, 22.6, 20.3, 19.2, 18.5, 18.10, 18.05, 15.1, 14.1, 13.1, 12.4, 10.6, ,-3.0, -3.2, -3.6, -4.2, -4.25, -4.30; LRMS
(ESI) 1327.8 [M+Na]+, 1147.7, 833.3, 631.3, 429.2, 364.3,.301.1; HRMS (ESI) calcd for C78HlZ$O8Si4Na 1327.8584 [M+Na]+, found 1327.8693; [a]20D +7.6 (c 0.17, CHC13).
[00120] (2S,3S,4R,5R,8S,l OS,11R,12S,13Z,15S,17S,18R,19E)-3-(4-Niethoxyb enzyloxy)-5,11,15,17-tets=akis(tert-butyldimethylsilyloxy)-2,4,8,10,12,18-hexamethyl-21-(trityloxy)henicosa-13,19-dien-l-ol (43). DIBAL-H (1.0 M in hexane, 11.7 mL, 11.7 mmol) was added dropwise to a stirred solution of TBS protected acetal 42 (1.53 g, 1.17 mmol) in anhydrous CHZC12 (2.3 mL) under an atmosphere of N2 at 0 C.
After stirring for additional 30 min at 0 C the reaction mixture was quenched by the careful addition of aqueous saturated aqueous potassium sodium tartrate (30 mL). The resulting mixture was stirred for 3 h at room temperature. The organic layer was separated, and the aqueous layer was extracted by CH2Cl2 (20 mL). The combined organic layers were washed with brine and dried over MgSO4 followed by the evaporation of the organic solution under reduced pressure. The residue was purified by column chromatography (EtOAc/hexane 1:9) to obtain pure 43 (1.35 g, 88%) as a colorless oil: IR (CHC13) 3464, 2956, 2929, 2856, 1613, 1514, 1471, 1252, 1087, 836, 773 cm"1; 'H NMR (300 MHz, CDC13) 8 7.46 (m, 6H), 7.28 (m, 1 1H), 6.88 (m, 2H), 5.61 (in, 2H), 5.39 (m, 1H), 5.28 (m, 1H), 4.57 (m, 1H), 4.53 (s, 2H), 3.92 (m, 2H), 3.83 (m, 1H), 3.80 (s, 3H), 3.60 (m, 2H), 3.56 (m, 2H), 3.46 (dd, J= 6.2, 4.5 Hz, 1H), 3.37 (m, 1H), 3.03 (m, 1H), 2.86 (m 1H), 2.59 (m, 1H), 2.41 (m, 1H), 1.93 (m, 1H), 1.88 (m, 1H), 1.66 (m, 3H), 1.35 (m, 5H), 1.11 (d, J= 7.0 Hz, 3H), 1.01 (d, J= 6.8 Hz, 3H), 0.97 (d, J
= 6.8 Hz, 3H), 0.92 (m, 27H), 0.85 (m, 10H), 0.81 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H), 0.07 (s, 3H), 0.06 (s, 6H), 0.05 (s, 6H), 0.04 (s, 3H); 13C NMR (75 MHz, CDC13) 6 159.2, 144.4, 144.3, 134.3, 133.0, 132.4, 130.5, 129.1, 128.6, 127.6, 126.7, 113.8, 86.7, 85.4, 79.8, 75.1, 73.8, 72.2, 66.4, 65.0, 55.0, 42.3, 41.6, 41.5, 40.5, 37.1, 35.8, 34.8, 32.0, 31.9, 30.7, 26.2, 25.94, 25.86, 20.3, 19.2, 18.4, 18.1, 18.0, 15.6, 15.2, 13.2, 10.0, -3.0, -3.4, -3.8, -3.9, --4.2, -4.28, -4.34, -4.4; LRMS (ESI) 1329.8 [M+Na]+, 707.3, 413.2, 243.1; HRMS (ESI) calcd for C78H130O8Si4Na 1329.8741 [M+Na]+, found 1329.8779; [a]20D -8.9 (c 0.46, CHC13).
[00121] ((2E,4R,5S,7S,82,1 OS,11R,12S,14S,17R,18R,19S,20S,21z)-19-(4-Methoxyb enzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraenyloxy)triphenylmethane (44). The alcoho143 (1.35 g, 1.03 mol) in CHZC12 (20 mL) was treated with Dess-Martin periodinane (0.66 g, 1.56 mol). After 1 h, the mixture was quenched with saturated aqueous NaHCO3 (20 mL) and Na2SaO3 (20 mL). The aqueous layer was extracted with EtzO (2 x 20 mL) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 9:1) provided the crude aldehyde as a colorless oil, which was used without further purification. CrC12 (1.06 g, 8.62 mmol) was added to a stirred solution of the crude aldehyde and 1-bromoallyl trimethylsilane (1.28 g, 5.20 mmol) in anhydrous THF (26 mL) under an atmosphere of N2 at room temperature and the mixture was stirred for additional 14 h at ambient temperature. The reaction mixture was diluted with hexane followed by filtration through celite. After the evaporation of the solvent under reduced pressure, the residue was purified by short silica gel column chromatography using EtOAc/hexane (1:9) as eluent. The foregoing product in THF (40 mL) was cooled to 0 C and NaH (95% w/w, 0.52 g, 20.6 mmol) was added in one portion. The ice bath was removed after 15 min and the mixture was stirred for 2 h at ambient temperature. The reaction mixture was cooled to 0 C, quenched with H20 (5 mL) and extracted with Et20 (2 x 20 mL). The coinbined organic layers were washed with brine, dried over MgSO4, filtered and the solvent removed under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 49:1) to obtain 44 (1.17 g, 85% for 3 steps) as a colorless oil:
IR (CHC13) 2956, 2928, 2856, 1614, 1514, 1471, 1462, 1249, 1088, 836, 772 cm 1; 1H NMR
(300 MHz, CDC13) S 7.46 (m, 6H), 7.27 (m, 11H), 6.86 (m, 2H), 6.58 (ddd, J= 17.0, 10.6, 10.5 Hz, 1H), 6.00 (t, J= 11.0 Hz, 1 H), 5.60 (m, 3H), 5.31 (m, 2H), 5.17 (d, J= 16.9 Hz, 1 H), 5.09 (d, J=
10.4 Hz, 1H), 4.51 (m, 3H), 3.90 (in, 2H), 3.80 (s, 3H), 3.61 (m, 1H), 3.56 (d, J= 3.7 Hz, 1H), 3.33 (m, 2H), 3.00 (m, 1H), 2.56 (m, 1H), 2.40 (m, 1H), 2.21 (m, 1H), 1.63 (m, 3H), 1.38 (m, 2H), 1.27 (m, 3H), 1.21 (m, 2H), 1.10 (d, J= 6.7 Hz, 3H), 0.96 (m, 3H), 0.93 (s, 9H), 0.91 (s, 9H), 0.89 (s, 9H), 0.86 (m, 6H), 0.82 (m, 6H), 0.80 (s, 9H), 0.79 (m, 3H), 0.08 (m, 6H), 0.05 (n1, 6H), 0.04 (m, 6H), 0.01 (m, 6H); 13C NMR (75 MHz, CDC13) S
159.0, 146.2, 144.5, 144.4, 134.6, 134.5, 133.1, 132.7, 132.3, 131.4, 129.0, 128.9, 128.7, 127.7, 126.8, 117.1, 113.7, 86.8, 84.4, 79.9, 75.0, 72.9, 72.3, 66.5, 65.1, 55.2, 42.4, 41.9, 41.6, 40.6, 36.0, 35.6, 35.3, 34.5, 32.5, 31.7, 30.5, 26.3, 26.0, 25.9, 20.2, 19.2, 18.8, 18.5, 18.2, 18.1, 15.1, 13.3, 9.3, -2.9, -3.0, -3.3, -3.6, -3.7, -4.2, -4.3, -4.4; LRMS (ESI) 1351.8 [M+Na]+, 1171.7, 1043.7, 889.6, 707.3, 536.1, 453.3, 413.2, 359.2; HRMS (ESI) calcd for C81H132O7Si4Na 1351.8948 [M+Na]+, found 1351.9012; [a]20o +1.1 (c 1.7, CHC13).
[00122] (2E,4R,5S,7S,8Z,10S,11R,12S,14S,17R,18R,19S,20S,21Z)-19-(4-Methoxybenzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraen-l-ol (45). ZnBr2 (0.41 g) in 1.2 mL of 5:1 CH2C12/MeOH was added dropwise for 30 min to a stirred solution of trityl compound 44 (0.24 g, 0.18 mol) in 1.4 mL of 6:1 CH2Cla/MeOH at 0 C. After 4 h, the reaction mixture was quenched with saturated aqueous NaHCO3 (20 mL) and extracted with Et20 (2 x 10 mL).
The organic phase were separated, dried with MgSO4, filtered and concentrated.
The residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 45 (0.15 g, 77%) as a colorless oil: IR (CHC13) 3432, 2956, 2856, 1613, 1514, 1471, 1462, 1360, 1250, 1082, 835, 773 cm 1; 1H NMR (300 MHz, CDC13) S 7.29 (m, 2H), 6.88 (m, 2H), 6.58 (ddd, J=
16.9, 10.6, 10.6 Hz, 1H), 6.00 (t, J= 11.0 Hz, 1H), 5.63 (m, 3H), 5.38 (t, J= 11.0 Hz, 1H), 5.27 (dd, J= 11.2, 8.3 Hz, 1 H), 5.17 (d, J= 16.8 Hz, 1 H), 5.10 (d, J= 10.3 Hz, 1 H), 4. 5 3(m, 3H), 4.08 (d, J= 4.4 Hz, 2H), 3.90 (m, 1H), 3.81 (s, 3H), 3.62 (m, 1H), 3.33 (m, 2H), 2.99 (ddd, J
= 10.0, 6.8, 3.2 Hz, 1H), 2.57 (m, 1H), 2.39 (m, 1H), 1.63 (m, 3H), 1.42 (m, 3H), 1.28 (m, 5H), 1.11 (d, J= 6.8 Hz, 3H), 0.97 (d, J= 6.8 Hz, 3H), 0.96 (d, J= 6.9 Hz, 3H), 0.93 (s, 9H), 0.91 (s, 18H), 0.89 (m, 3H), 0.88 (s, 9H), 0.81 (d, J= 6.7 Hz, 3H), 0.80 (d, J= 6.2 Hz, 3H), 0.10 (s, 3H), 0.09 (s, 3H), 0.08 (s, 6H), 0.06 (s, 3H), 0.05 (s, 6H), 0.03 (s, 3H); 13C NMR (75 MHz, CDC13) 8 159.0, 146.9, 135.2, 134.6, 133.0, 132.7, 132.3, 131.4, 129.2, 129.1, 128.9, 127.93, 127.90, 127.2, 84.4, 80.0, 75.0, 72.8, 72.2, 66.6, 63.9, 55.2, 42.4, 41.8, 41.7, 40.5, 35.9, 35.2, 34.6, 32.6, 31.6, 30.5, 26.3, 25.99, 25.96, 25.93, 20.2, 19.2, 18.8, 18.5, 18.2, 18.1, 15.1, 13.2, 9.2, -3.0, -3.3, -3.6, -3.7, -4.2, -4.4, -4.5; LRMS (ESI) 1109.8 [M+Na]+, 823.6, 691.5, 559.4; HRMS (ESI) calcd for C62H118O7Si4Na 1109.7852 [M+Na]+, found 1109.7897;
[a]20D +1.6 (c 0.94, CHC13).
[00123] (2Z,4E,6R;7S,9S,10Z,12S,13R,14S,16S,19R,20R,21S,22S,23Z)-Methy1-21-(4-methoxy-b enzyloxy)-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (46). The alcoho145 (127 mg, 0.117 mol) in CH2C12 (4 mL) was treated with Dess-Martin periodinane (75 mg, 0.18 mol).
After 1 h, the mixture was quenched with saturated aqueous NaHCO3 (5 mL) and Na2S2O3 (5 mL). The aqueous layer was extracted with Et20 (2 x 10 mL) and the coinbined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash colunm chromatography (hexane/EtOAc 9:1) provided the crude aldehyde as a colorless oil, which was used for the next reaction without further purification. KHIVIDS (0.28 mL, 0.14 mol, 0.5M solution in toluene) was added dropwise to a stirred solution of bis(2,2,2-trifluoroethyl)-(inethoxycarbonylmethyl) phosphate (0.030 mL, 0.14 mol) and 18-crown-6 (0.15 g, 0.57 mmol) in THF (2.3 mL) at -78 C. Thereafter, the aldehyde in THF
(0.5 mL) was added and the solution was stirred for 4 h at -78 C. The reaction mixture was quenched by addition of a saturated aqueous NH4Cl (5 mL) and diluted with EtaO (20 mL).
The organic phase was washed with brine (30 mL), dried with MgSO4, filtered and concentrated. The residue was purified by flash chromatography (EtOAc/hexane 1:19) yielding (E,Z)-doubly unsaturated ester 46 (0.12 g, 86% for 2 steps) as a colorless oil: IR (CHC13) 2955, 2929, 2856, 1722, 1514, 1471, 1462, 1250, 1174, 1085, 1041, 836, 773 cm 1; 'H NMR
(300 MHz, CDC13) 6 7.39 (dd, J= 15.4, 11.3 Hz, 1H), 7.29 (m, 2H), 6.88 (m, 2H), 6.59 (ddd, J= 16.9, 10. 8, 10. 6 Hz, 1 H), 6. 5 5(t, J= 11.3 Hz, 1 H), 6.01 (t, J= 11.0 Hz, 1H), 6.00 (dd, J= 15 . 7, 7. 0 Hz, 1H), 5.60 (d, J= 11.3 Hz, 1H), 5.59 (t, J= 10.4 Hz, 1H), 5.39 (t, J= 10.4 Hz, 1H), 5.27 (dd, J= 11.0, 8.3 Hz, 1H), 5.18 (d, J= 16.8 Hz, 1H), 5.11 (d, J= 10.3 Hz, 1H), 4.54 (m, 3H), 3.96 (m, 1H), 3.81 (s, 3H), 3.74 (s, 3H), 3.63 (m, 1H), 3.34 (m, 2H), 3.00 (m, 1H), 2.57 (in, 2H), 1.64 (m, 3H), 1.55 (m, 1H), 1.46 (t, J= 5.9 Hz, 2H), 1.26 (m, 5H), 1.11 (d, J= 6.8 Hz, 3H), 1.05 (d, J= 6.7 Hz, 3H), 0.97 (d, J= 6.9 Hz, 3H), 0.96 (d, J= 7.1 Hz, 3H), 0.94 (s, 9H), 0.92 (s, 9H), 0.91 (s, 9H), 0.87 (s, 9H), 0.83 (d, J= 6.4 Hz, 3H), 0.82 (d, J=
6.0 Hz, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H), 0.06 (s, 3H), 0.05 (s, 6H), 0.04 (s, 3H);
13C NMR (75 MHz, CDC13) S 166.8, 159.0, 147.3, 145.5, 134.6, 132.9, 132.8, 132.4, 131.4, 129.0, 128.9, 126.9, 117.1, 115.5, 113.7, 84.4, 80.0, 75.0, 72.9, 72.1, 66.5, 55.2, 50.9, 43.5, 42.5, 41.8, 40.5, 36.0, 35.3, 34.5, 32.5, 31.6, 30.5, 26.3, 25.99, 25.96, 25.91, 20.2, 19.2, 18.8, 18.5, 18.2, 18.1, 15.0, 13.4, 9.2, -3.0, -3.2, -3.3, -3.6, -3.7, -4.1, -4.4, -4.5; LRMS (EST) 1163.9 [M+Na]+, 1009.8, 684.3, 610.2, 513.4; HRMS (ESI) calcd for C65H12oO8Si4Na 1163.7958 [M+Na]+, found 1163.7985; [oc]20D -9.3 (c 1.2, CHC13).
[00124] (2Z,4E,6R,7S,9S,l OZ,12S,13R,14S,16S,19R,20R,21S,22S,23Z)-Methyl-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (47). The ester 46 (81 mg, 71 mol) was added to CH2C12 (2 mL) and Ha0 (0.1 mL) and DDQ (20 mg, 88 mol) was added at 0 C.
After 1 h of stirring at 0 C, the reaction mixture was quenched by adding saturated aqueous NaHCO3 (5 mL). The organic phase was washed with saturated aqueous NaHCO3 (3 x mL) and brine, dried over MgSO4, filtered and concentrated. Purification by flash column chromatography (EtOAc/hexane 1:9) furnished 47 (64 mg, 88%) as a colorless oil: IR
(CHC13) 3541, 2956, 2929, 2856, 1722, 1639, 1471, 1462, 1377, 1360, 1254, 1175, 1086, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 6 7.34 (dd, J= 15.4, 11.2 Hz, 1H), 6.61 (ddd, J=
16.8, 10.7, 10.6 Hz, 1H), 6.51 (t, J= 11.3 Hz, 1H), 6.06 (t, J= 11.0 Hz, 1H), 5.96 (dd, J=
15.4, 7.1 Hz, 1 H), 5. 5 6(d, J= 11.3 Hz, 1 H), 5.3 9(t, J= 10.1 Hz, 1H), 5. 3 8(t, J= 10.3 Hz, 1H), 5.22 (dd, J= 11.0, 8.5 Hz, 1H), 5.17 (d, J= 18.7 Hz, 1H), 5.09 (d, J=
10.1 Hz, 1H), 4.50 (m, 1H), 3.92 (m, 1H), 3.71 (m, 1H), 3.70 (s, 3H), 3.44 (m, 1H), 3.32 (m, 1H), 2.74 (m, 1H), 2.52 (m, 2H), 2.31 (br, 1H), 1.61 (m, 4H), 1.39 (m, 2H), 1.31 (m, 2H), 1.26 (m, 3H), 1.00 (d, J= 6.7 Hz, 3H), 0.93 (d, J= 6.9 Hz, 3H), 0.92 (d, J= 6.7 Hz, 3H), 0.86 (m, 27H), 0.84 (m, 6H), 0.82 (m, 12H), 0.05 (s, 9H), 0.02 (s, 3H), 0.01 (s, 6H), 0.00 (s, 6H); 13C NMR
(75 MHz, CDC13) b 166.8, 147.3, 145.5, 135.3, 132.7, 132.6, 132.3, 129.9, 126.8, 117.7, 115.5, 79.9, 77.6, 76.6, 72.1, 66.5, 51.0, 43.5, 42.4, 41.5, 37.7, 36.1, 35.7, 35.0, 32.1, 31.5, 30.6, 26.3, 25.9, 25.9, 20.4, 19.4, 18.5, 18.1, 17.9, 17.7, 15.3, 13.3, 6.9, -3.0, -3.4, -3.7, -4.1, -4.2, -4.4; LRMS (ESI) 1043.6 [M+Na]}, 889.6, 757.5, 625.4, 393.3; HRMS (ESI) calcd for C57H112O7Si4Na 1043.7383 [M+Na]+, found 1043.7417; [a]20D -25.3 (c 0.61, CHC13).
[00125] (2Z,4E,6R,7S,9S,I OZ,12S,13R,14S,16S,19R,20R,21S,22S,23Z)-7,9,13,19-tetrakis(tert-Butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoic acid (48). A stirried solution of alcohol 47 (25 mg, 24 mol) in 3.4 mL of 12:5 EtOH/THF was treated with 1N aqueous KOH (0.24 mL) and the mixture was refluxed gently for 3 h. The ethanolic solution was concentrated and then diluted with Et20 (4 mL). After the solution was acidified to pH3 with 1N aqueous HC1, the organic phase was separated and aqueous phase was extracted with Et20 (2 x 5 mL). The combined organic phase was dried with MgSO4, filtered, concentrated and the residue was used without further purification: IR (CHC13) 2956, 2929, 2857, 1693, 1635, 1600, 1471, 1462, 1254, 1088, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.33 (dd, J= 15.2, 11.3 Hz, 1H), 6.61 (t, J= 11.4 Hz, 1 H), 6.61 (m, 1 H), 6.07 (t, J= 11.0 Hz, 1 H), 6.02 (dd, J= 15 . 8, 7.2 Hz, 1 H), 5.5 8 (d, J=
11.3 Hz, 1 H), 5.3 9(m, 2H), 5.23 (dd, J= 11.0, 8.2 Hz, 1 H), 5.18 (d, J= 16.8 Hz, 1 H), 5.09 (d, J= 10.2 Hz, 1H), 4.50 (m, 1H), 3.92 (m, 1H), 3.73 (m, 1H), 3.46 (dd, J=
7.3, 2.6 Hz, 1H), 3.34 (m, 1H), 2.78 (m, 1H), 2.54 (m, 2H), 1.66 (m, 4H), 1.42 (m, 4H), 1.24 (m, 3H), 1.01 (d, J= 6.8 Hz, 3H), 0.95 (d, J= 6.7 Hz, 3H), 0.94 (d, J= 6.7 Hz, 3H), 0.88 (m, 30H), 0.84 (m, 15H), 0.09 (s, 3H), 0.07 (s, 3H), 0.06 (s, 6H), 0.02 (s, 6H), 0.01 (s, 6H); 13C NMR
(75 MHz, CDC13) 8 171.2, 148.2, 147.3, 135.2, 133.2, 132.7, 132.3, 123.0, 127.0, 117.7, 115.2, 79.9, 77.6, 76.5, 72.1, 66.4, 43.5, 42.6, 41.6, 37.8, 36.0, 35.8, 34.9, 32.1, 31.5, 30.6, 26.2, 25.93, 25.87, 20.3, 19.4, 18.4, 18.10, 18.05, 17.7, 15.3, 13.6, 6.9 -3.0, -3.4, -3.7, -4.1, -4.19, -4.24, -4.4; LRMS (ES1) 1029.7 [M+Na]+, 875.6, 743.6, 611.4, 593.4, 393.3; HRMS
(ESI) calcd for C56H11oO7Si4Na 1029.7226 [M+Na]+, found 1029.7274; [a]20D -25.7 (c 0.54, CHC13).
[00126] (8S,10S,14R,20R)-tetrakis(tert-Butyldimethylsilyloxy)-(7R,13S,15S,17S,21S)-pentamethyl-(22S)-((1S)-methylpenta-2,4-dienyl)oxacyclodocosa-3,5,11-trien-2-one (49). A solution of 48 in THF (2 mL) was treated at 0 C
with Et3N (0.020 mL, 147 mol) and 2,4,6-trichlorobenzoyl chloride (0.019 mL, 122 mol). The reaction mixture was stirred at 0 C for 30 min and then added to 4-DMAP (12 mL, 0.02 M
solution in toluene) at 25 C. After stirring for 12 h, the reaction mixture was concentrated, Et20 (10 mL) was added and the crude was washed with 1N HC1 (2 x 5 mL) and dried over MgSO4.
Purification by flash colunui cliromatography (EtOAc/hexane 1:49) furnished the macrolactone (19 mg, 78% for 2 steps) as a colorless oil: IR (CHC13) 2955, 2929, 2857, 1716, 1642, 1474, 1225, 1043, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) S 6.98 (dd, J=
14.8, 11.3 Hz, 111), 6.55 (m, 1H), 6.52 (t, J= 11.2 Hz, 1H), 6.04 (t, J= 10.5 Hz, 1H), 6.01 (dd, J=
15.4, 6.4 Hz, 1H), 5.59 (d, J= 11.2 Hz, 1H), 5.58 (m, 1H), 5.38 (t, J= 10.6 Hz, 1H), 5.33 (dd, J= 11.3, 8.1 Hz, 1 H), 5.19 (d, J= 16.6 Hz, 1H), 5.11 (d, J= 10.5 Hz, 1 H), 5.06 (dd, J=
7. 6, 3.7 Hz, 1H), 4.52 (m, 1 H), 4.01 (m, 1H), 3.63 (m, 1H), 3.19 (d, J= 6.2 Hz, 1H), 3.03 (m, 1H), 2.58 (m, 1H), 2.52 (m, 2H), 1.81 (m, 4H), 1.45 (m, 3H), 1.25 (m, 3H), 1.09 (m, 3H), 1.02 (d, J= 6.8 Hz, 3H), 1.01 (d, J= 7.0 Hz, 3H), 0.97 (d, J= 6.6 Hz, 3H), 0.95 (d, J= 6.4 Hz, 3H), 0.91 (s, 9H), 0.89 (s, 9H), 0.88 (s, 9H), 0.86 (s, 9H), 0.77 (d, J=
6.4 Hz, 3H), 0.75 (d, J= 6.5 Hz, 3H), 0.10 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H), 0.04 (s, 3H), 0.033 (s, 6H), 0.026 (s, 6H); 13C NMR (75 MHz, CDC13) S 166.5, 143.1, 141.8, 133.9, 132.7, 131.8, 130.2, 129.8, 128.0, 118.4, 118.1, 81.0, 78.0, 70.4, 66.5, 62.5, 43.1, 42.3, 41.4, 39.1, 35.2, 34.8, 34.5, 31.6, 30.3, 29.7, 29.3, 26.2, 26.0, 25.94, 25.85, 20.2, 19.7, 18.5, 18.24, 18.16, 18.08, 16.2, 14.0, 9.9, -2.7, -3.4, -3.5, -3.8, -3.9, -4.2, -4.3; [a]20D -18.1 (c 0.24, CHC13).
[00127] (8S,10S,14R,20R)-Tetrahydroxy-(7R,13S,15S,17S,21S)-pentamethyl-(22S)-((1S)-methylpenta-2,4-dienyl)oxacyclodocosa-3,5,11-trien-2-one (Dictyostatin, 1). A
stirred solution of macrolactone 49 (18 mg, 18 mol) in THF (3 mL) at 0 C was treated with 3N HCl (10 mL, prepared by adding 2.5 inL of conc. HCl to 7.5 mL MeOH). After 24 h at room temperature, the reaction mixture was diluted with EtOAc (4 mL) and H20 (4 mL). The organic phase was saved and the aqueous phase was extracted with EtOAc (2 x 4 mL). The combined organic phase was washed with saturated aqueous NaHCO3 (10 mL), dried with MgSO4, filtered and concentrated. The residue was purified by flash chromatography (EtOAc/hexane 3:2) to yield 1 as a white solid (5.3 mg, 55%): IR (CHC13) 3406, 2960, 2924, 2872, 1693, 1637, 1461, 1378, 1274, 1181, 1069, 998, 738 cni 1; 1H NMR (600 MHz, CD3OD) S 7.21 (dd, J= 15.6, 11.1 Hz, 1H), 6.71 (ddd, J= 16.9, 11.0, 10.6 Hz, 1H), 6.65 (dd, J=11.3, 11.3 Hz, 111), 6.17 (dd, J= 15.6, 6.7 Hz, 1H), 6.06 (dd, J= 11.1, 11.1 Hz, 1H), 5.56 (d, J= 11.3 Hz, 1H), 5.55 (dd, J= 11.0, 11.0 Hz, 1H), 5.41 (dd, J= 11.1, 8.8 Hz, 1H), 5.34 (dd, J= 10.7, 10.6 Hz, 1 H), 5.25 (dd, J= 16.8, 1.8 Hz, 1H), 5.15 (d, J= 10.1 Hz, 1H), 5.14 (dd, J= 7.0, 5.0 Hz, 1H), 4.65 (ddd, J= 9.5, 9.5, 3.3 Hz, 1H), 4.05 (ddd, J=
10.6, 3.7, 2.8 Hz, 1H), 3.17 (ddq, J= 10.1, 6.8, 6.6 Hz, 1H), 3.10 (dd, J= 8.1, 2.9 Hz, 1H), 2.76 (m, 1H), 2.60 (m, 1H), 1.89 (m, 1H), 1.84 (dddd, J= 12.9, 11.2, 6.4, 5.4 Hz, 1H), 1.60 (m, 1H), 1.58 (m, 1H), 1.54 (m, 1H), 1.50 (ddd, J= 14.1, 10.7, 3.5 Hz, 1H), 1.42 (ddd, J=
14.0, 10.0, 2.7 Hz, 1H), 1.25 (ddd, J= 13.7, 10.6, 3.6 Hz, 1H), 1.15 (d, J= 6.9 Hz, 3H), 1.12 (d, J= 7.0 Hz, 3H), 1.10 (m, 1H), 1.07 (d, J= 6.9 Hz, 3H), 1.01 (d, J= 6.8 Hz, 3H), 0.95 (d, J= 6.5 Hz, 3H), 0.93 (d, J= 6.5 Hz, 3H). 0.90 (m, 1H), 0.71 (dddd, J= 12.9, 12.8, 8.7, 4.9 Hz, 1H); 13C
NMR (150 MHz, CD3OD) 6 168.10, 146.42, 144.90, 134.87, 134.54, 133.43, 131.32, 131.27, 128.60, 118.58, 118.04, 80.37, 78.64, 73.73, 70.41, 65.53, 44.07, 42.28, 40.84, 40.65, 35.84, 35.78, 35.33, 32.75, 32.51, 31.23, 21.81, 19.36, 18.08, 15.98, 13.80, 10.41;
LRMS (ESI) 555.3 [M+Na]+, 449.2, 243.1; HRMS (ESI) calcd for C32H52O6Na 555.3662 [M+Na]+, found 555.3665; [a]20D -22.6 (c 0.27, MeOH).
[00128] (2Z,4E,6R,7S,9S,l OZ,12S,13R,14S,16S,19R,20S,21S,22S,23Z)-Methyl-7,9,13,19,21-penta-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (50). 3N HCl (10 mL, prepared by adding 2.5 mL of conc. HCl to 7.5 mL
MeOH) was added to a stirred solution of the macrolactonization precursor 48 (23 mg, 23 mol) in THF (3 mL) at 0 C. After 24 h at room temperature, the reaction mixture was diluted with EtOAc (4 mL) and H20 (4 mL). The organic phase was retained and aqueous phase was extracted with EtOAc (2 x 4 mL). The combined organic phase was washed with saturated aqueous NaHCO3 (10 mL), dried with MgSO4, filtered and concentrated.
The residue was purified by flash chromatography (EtOAc/hexane 3:2) to yield the product 50 (4.5 mg, 36%) as a colorless oil: IR (CHC13) 3399, 2917, 2849, 1713, 1635, 1600, 1461, 1439, 1197, 1178, 970, 757 cm 1;1H NMR (600 MHz, CD3OD) S 7.36 (dd, J= 15.3, 11.2 Hz, 1H), 6.67 (ddd, J= 16.9, 11.1, 10.6 Hz, 1H), 6.63 (dd, J= 11.3, 11.3 Hz, 1H), 6.14 (dd, J=
15.4, 8.3 Hz, 1H), 6.03 (dd, J= 11.0, 11.0 Hz, 1H), 5.59 (d, J= 11.4 Hz, 1H), 5.43 (dd, J=
10.7, 10.7 Hz, 1H), 5.42 (dd, J= 10.8, 9.2 Hz, 1H), 5.32 (dd, J= 10.4, 10.4 Hz, 1H), 5.17 (dd, J= 16.8, 2.0 Hz, 1H), 5.08 (d, J= 10.2 Hz, 1H), 4.61 (ddd, J= 12.9, 8.5, 4.6 Hz, 1H), 3.80 (ddd, J= 8.9, 4.4, 4.4 Hz, 1H), 3.69 (s, 3H), 3.63 (m, 1H), 3.46 (t, J=
5.8 Hz, 1H), 3.13 (dd, J= 8.0, 3.2 Hz, 1H), 2.93 (m, 1H), 2.71 (m, 1H), 2.38 (m, 1H), 1.73 (m, 1H), 1.56-1.53 (m, 3H), 1.52-1.46 (m, 2H), 1.44-1.36 (m, 3H), 1.09 (d, J= 6.9 Hz, 3H), 0.98 (d, J= 6.8 Hz, 3H), 0.96 (d, J= 6.6 Hz, 3H), 0.95 (m, 2H), 0.94 (d, J= 6.9 Hz, 3H), 0.87 (d, J= 6.6 Hz, 3H), 0.86 (d, J= 6.8 Hz, 3H); 13C NMR (150 MHz, CD3OD) 6 168.4, 148.5, 146.9, 135.7, 135.4, 133.85, 133.82, 130.6, 128.2, 117.7, 116.2, 79.2, 78.5, 74.8, 72.4, 65.8, 51.5, 45.1, 43.2, 43.0, 41.0, 37.2, 36.5, 34.0, 33.3, 33.1, 31.0, 20.7, 18.6, 18.4, 16.7, 13.8, 7.8; LRMS
(ESI) 587.5 [M+Na]+, 559.2, 485.2, 413.3, 355.1, 212.1; HRMS (ESI) calcd for C33H5607Na 587.3924 [M+Na]+, found 587.3953; [a]20D +8.7 (c 0.30, CDC13).
(4S,5S)-4-((2R,3S,6S,8S,9R,lOS,11Z,13S,15S,16R,17E)-3,9,13,15-tetrakis(tert-Butyldimethylsilyloxy)-6,8,10,16-tetramethyl-19-trityloxynonadeca-11,17-dien-2-yl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxane (51).
[00129] The procedure for 42 was used with 41a (0.58 g, 0.49 mmol), TBSOTf (0.17 mL, 0.74 mmol) and 2,6-lutidine (0.11 mL, 0.97 mmol) to yield 0.62 g (97%) of the product by flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR
(CHC13) 2955, 2856, 1615, 1518, 1462, 1385, 1251, 1082, 835, 773, 705 cm 1; iH NMR (300 MHz, CDC13) 6 7.55 (m, 6H), 7.49 (m, 2H), 7.40-7.27 (m, 9H), 6.96 (m, 2H), 5.72 (m, 2H), 5.53 (m, 1H), 5.52 (s, 1H), 5.38 (m, 1H), 4.65 (m, 1H), 4.19 (dd, J= 11.0, 4.4 Hz, 1H), 4.03 (m, 1H), 3.95 (d, J= 8.7 Hz, 1H), 3.86 (m, 1H), 3.84 (s, 3H), 3.66 (d, J= 3.7 Hz, 2H), 3.56 (t, J= 11.1 Hz, 1H), 3.50 (m 1H), 2.71 (m, 1H), 2.52 (m, 1H), 2.12 (m, 1H), 1.90-1.79 (m, 2H), 1.75-1.68 (in, 3H), 1.61-1.37 (m, 6H), 1.08 (d, J= 6.6 Hz, 6H), 1.02-0.91 (m, 36H), 0.81 (d, J= 6.5 Hz, 3H), 0.22-0.13 (in, 24H); 13C NMR (75 MHz, CDC13) 6 159.7, 144.5, 134.4, 132.8, 132.6, 131.7, 128.7, 127.7, 127.3, 126.8, 113.4, 100.9, 86.7, 81.4, 80.1, 73.4, 72.3, 71.5, 66.5, 65.1, 55.1, 42.4, 41.5, 37.9, 35.5, 35.1, 31.3, 30.8, 30.2, 27.9, 26.3, 26.01, 25.99, 25.93, 25.7, 20.6, 19.5, 18.4, 18.11, 18.07, 15.4, 13.4, 13.3, 12.2, 9.2, -2.9, -3.5, -3.7, -3.9, -4.1, -4.2, -4.3, -4.9; LRMS (ESI) 1328.0 [M+Na]+, 782.5, 659.3, 437.2; HRMS (ESI) calcd for C78H128O8Si.4Na 1327.8584 [M+Na]+, found 1327.8624; [a]20D +6.1 (c 0.93, CHC13).
[00130] (2S,3S,4R,5S,8S,lOS,1-1R,12S,13Z,15S,17S,18R,19E)-3-(4-Methoxyb enzyloxy))-5,11,15,17-tetrakis(tert-butyldimethylsilyloxy)-2,4,8,10,12,18-hexamethyl-21-trityloxyhenicosa-13,19-dien-l-ol (52). The procedure for 43 was used with 51 (0.62 g, 0.47 mmol) and DIBAL-H (1.0 M in hexane, 4.7 mL, 4.7 mmol) to yield 0.54 g (87%) of the product after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 3479, 2955, 2928, 2856, 1613, 1514, 1471, 1251, 1084, 835, 773 cni 1; 1H
NMR (300 MHz, CDC13) 6 7.56-7.52 (in, 6H), 7.38-7.33 (m, 9H), 7.30 (m, 2H), 6.94 (m, 2H), 5.72 (m, 2H), 5.52 (m, 1H), 5.38 (m, 1H), 4.67 (d, J= 10.3 Hz, 1H), 4.65 (m, 1H), 4.60 (d, J= 10.4 Hz, 1H), 4.03 (m, 1H), 3.83 (s, 3H), 3.70 (m, 3H), 3.65 (d, J= 3.7 Hz, 2H), 3.49 (m, 1H), 3.02 (m, 1H), 2.71 (m 1H), 2.52 (m, 1H), 1.91 (m, 2H), 1.80-1.64 (m, 3H), 1.60-1.34 (m, 8H), 1.09-0.90 (m, 54H), 0.21-0.12 (m, 24H); 13C NMR (75 MHz, CDC13) S 159.2, 144.5, 144.3, 134.4, 132.8, 132.4, 130.6, 129.0, 128.6, 127.7, 126.8, 113.8, 86.7, 84.7, 80.0, 74.8, 74.5, 72.2, 66.5, 66.2, 65.1, 55.1, 42.3, 41.4, 38.7, 35.5, 35.2, 35.0, 31.5, 30.9, 30.7, 29.8, 26.2, 26.00, 25.95, 25.89, 20.5, 19.4, 18.4, 18.13, 18.08, 18.02, 15.4, 15.2, 13.2, 10.4, -3.0, -3.6, -3.7, -3.8, -4.18, -4.24, -4.3, -4.4; LRMS (ESI) 1329.8 [M+Na]+, 782.4, 413.2;
HRMS (ESI) calcd for C78H130O8Si4Na 1329.8741 [M+Na]+, found 1329.8782; [a]20D
-6.8 (c 0.66, CHC13).
[00131] ((2E,4R,5S,7S,8Z,l OS,11R,12S,14S,17S,18R,19S,20S,21Z)-19-(4-Methoxybenzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraenyloxy)triphenylmethane (53). The procedure for 44 was used with 52 (0.54 g, 0.41 mol) and Dess-Martin periodinane (0.26 g, 0.61 mol), 1-bromoallyl trimethylsilane (0.50 g, 2.60 mmol) and CrC12 (0.42 g, 3.42 mmol), NaH (95%
w/w, 0.21 g, 8.31 mmol) to yield 0.46 g (83% for 3 steps) of the product by flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 2955, 2928, 2856, 1613, 1514, 1462, 1250, 1069, 835, 773, 705 cm 1; 'H NMR (300 MHz, CDC13) S 7.58-7.54 (m, 6H), 7.40-7.35 (m, 9H), 7.33-7.30 (m, 2H), 6.96-6.93 (m, 2H), 6.69 (ddd, J=
16.8, 10.6, 10.5 Hz, 1H), 6.12 (t, J= 11.0 Hz, 1H), 5.80-5.67 (m, 3H), 5.52 (t, J= 10.4 Hz, 1H), 5.40 (m, 1H), 5.28 (d, J= 16.8 Hz, 1H), 5.19 (d, J=10.2 Hz, 1H), 4.63 (m, 3H), 4.03 (m, 1H), 3.85 (s, 3H), 3.67 (m, 2H), 3.51 (m, 1H), 3.38 (m, 1H), 2.96 (m, 1H), 2.72 (m, 1H), 2.53 (m, 1H), 1.93-1.74 (m, 2H), 1.66-1.37 (m, 7H), 1.31-1.23 (m, 3H), 1.18 (d, J= 6.8 Hz, 3H), 1.09 (m, 6H), 1.03-0.92 (m, 45H), 0.23-0.10 (m, 24H); 13C NMR (75 MHz, CDC13) 6 159.1, 144.5, 144.4, 134.7, 134.5, 133.0, 132.6, 132.2, 131.4, 129.1, 129.0, 128.7, 127.7, 126.8, 117.5, 113.7, 86.8, 84.6, 79.9, 74.7, 73.6, 72.3, 66.5, 65.1, 55.2, 42.5, 42.4, 41.6, 36.1, 35.9, 34.8, 32.0, 30.8, 29.8, 26.3, 26.02, 25.96, 20.5, 19.3, 18.6, 18.5, 18.2, 18.1, 15.4, 13.3, 10.5, -2.9, -3.4, -3.7, -4.1, -4.2, -4.3; LRMS (ESI) 1352.0 [M+Na]+, 782.5, 647.6, 619.6, 437.2;
HRMS (ESI) calcd for C81H132O7Si4Na 1351.8948 [M+Na]+, found 1351.8987; [a]20D -8.6 (c 1.6, CHC13).
[00132] (2E,4R,5S,7S,8Z,l OS,11R,12S,14S,17S,18R,19S,20S,21Z)-19-(4-Methoxyb enzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraen-l-ol (54). The procedure for 45 was used with 53 (0.46 g, 0.35 mol) and ZnBr2 (0.41 g in 5.8 mL of 24:5 CH2C12/MeOH) to yield 0.21 g (55%) of the product after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 3410, 2956, 2929, 2856, 1614, 1514, 1471, 1462, 1251, 1075, 836, 773 cm 1;
'H NMR (300 MHz, CDC13) S 7.28 (m, 2H), 6.87 (m, 2H), 6.60 (ddd, J= 16.8, 10.7, 10.6 Hz, 1H), 6.03 (t, J= 11.0 Hz, 1H), 5.67-5.57 (m, 3H), 5.41 (m, 1H), 5.29 (m, 1H), 5.20 (d, J=
18.2 Hz, 1H), 5.11 (d, J= 10.2 Hz, 1H), 4.56 (m, 3H), 4.10 (d, J= 4.4 Hz, 1H), 3.93 (m, 1H), 3.81 (s, 3H), 3.66-3.57 (m, 2H), 3.40 (dd, J= 4.6, 2.6 Hz, 1H), 3.28 (dd, J
6.2, 4.2 Hz, 1H), 2.85 (m, 1H), 2.60 (m, 1H), 2.39 (m, 1H), 1.79 (m, 1H), 1.70 (m, 1H), 1.66-1.56 (m, 2H), 1.51-1.19 (m, 8H), 1.09 (d, J= 6.8 Hz, 3H), 0.98 (d, J= 6.8 Hz, 3H), 0.97 (d, J= 6.9 Hz, 3H), 0.92-0.86 (m, 45H), 0.11-0.00 (m, 24H); 13C NMR (75 MHz, CDC13) 8 159.0, 135.2, 134.7, 132.8, 132.7, 132.3, 131.4, 129.2, 129.1, 129.0, 117.4, 113.7, 84.6, 80.0, 74.7, 73.6, 72.2, 66.6, 63.9, 63.3, 55.3, 42.4, 41.7, 36.1, 35.8, 34.8, 31.9, 30.8, 29.8, 26.3, 26.0, 25.9, 20.5, 19.4, 19.3, 18.6, 18.5, 18.1, 15.3, 13.3, 10.5, -3.0, -3.4, -3.7, -4.2, -4.3, -4.5; LRMS
(ESI) 1109.9 [M+Na]+, 947.8, 782.5, 689.2, 615.2, 541.1, 413.3, 306.3; HRMS
(ESI) calcd for C62H118O7Si4Na 1109.7856 [M+Na]+, found 1109.7902; [a]20D -12.0 (c 1.7, CHC13).
[00133] (2Z,4E,6R,7S,9S,10Z,12S,13R,14S,16S,19S,20R,21S,22S,23Z)-Methyl-21-(4-methoxyb enzyloxy)-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (55). The procedure for 46 was used with 54 (117 mg, 0.108 mol) and Dess-Martin periodinane (69 mg, 0.16 mol), bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl) phosphate (0.027 mL, 0.13 mol), 18-crown-6 (0.14 g, 0.53 mmol) and KHMDS (0.26 mL, 0.13 mol, 0.5 M solution in toluene) to yield 69 mg (56% for 2 steps) of the product after flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2956, 2929, 2856, 1722, 1640, 1514, 1471, 1462, 1250, 1174, 1080, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.44 (dd, J= 15.2, 11.3 Hz, 1H), 7.28 (m, 2H), 6.88 (m, 2H), 6.60 (ddd, J= 16.7, 10.6, 10.5 Hz, 1H), 6.56 (t, J=11.3 Hz, 1H), 6.04 (dd, J= 15.5, 7.1 Hz, 1H), 6.00 (t, J= 11.0 Hz, 1H), 5.62 (m, 2H), 5.42 (m, 1H), 5.27 (m, 1H), 5.21 (d, J=16.8 Hz, 1H), 5.11 (d, J=10.3 Hz, 1H), 4.54 (m, 3H), 3.97 (m, 1H), 3.81 (s, 3H), 3.74 (s, 3H), 3.60 (m, 111), 3.40 (m, 1H), 3.29 (m, 1H), 2.86 (m, 1H), 2.57 (m, 211), 1.80-1.67 (m, 3H), 1.55-1.41 (in, 4H), 1.40-1.20 (m, 4H), 1.09 (d, J= 6.8 Hz, 3H), 1.06 (d, J
= 6.8 Hz, 3H), 0.99 (d, J= 6.6 Hz, 3H), 0.98 (d, J= 6.7 Hz, 3H), 0.95-0.85 (m, 42H), 0.13-0.00 (m, 24H); 13C NMR (75 MHz, CDC13) S 166.8, 159.0, 147.3, 145.5, 134.7, 132.9, 132.7, 132.3, 131.4, 129.1, 129.0, 126.9, 117.4, 115.5, 113.7, 84.6, 80.0, 74.7, 73.6, 72.1, 66.5, 55.3, 51.0, 43.5, 42.4, 41.6, 36.1, 35.8, 34.8, 31.9, 30.7, 29.8, 26.3, 26.0, 25.9, 20.5, 19.3, 18.6, 18.5, 18.1, 15.3, 13.4, 10.5, -3.0, -3.3, -3.7, -4.10, -4.15, -4.19, -4.3, -4.4; LRMS (ESI) 1163.8 [M+Na]+, 1057.7, 782.4, 541.1; HRMS (ESI) calcd for C65H12oO$Si4Na 1163.7958 [M+Na]+, found 1163.8000; [a]20D -16.7 (c 0.33, CHC13).
[00134] (2Z,4E,6R,7S,9S,10Z,12S,13R,14S,16S,19S,20R,21S,22S,23Z)-Methyl-7,9,13,19-tetf=akis(tert-butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (56). The procedure for 47 was used with 55 (68 mg, 60 mol) and DDQ (15 mg, 66 mol) to yield 56 mg (92%) of the product after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 3499, 2956, 2929, 2856, 1723, 1641, 1471, 1462, 1255, 1175, 1081, 836, 773 cm 1; 1H NMR
(300 MHz, CDC13) 8 7.35 (dd, J= 15.2, 11.3 Hz, 1H), 6.64 (ddd, J= 16.9, 10.6, 10.5 Hz, 1H), 6.52 (t, J
= 11.3 Hz, 1H), 6.07 (t, J= 11.0 Hz, 1H), 5.96 (dd, J= 15.5, 7.1 Hz, 1H), 5.56 (d, J= 11.3 Hz, 1H), 5.44-5.33 (m, 2H), 5.26-5.21 (m, 1H), 5.17 (d, J= 16.7 Hz, 1H), 5.07 (d, J= 10.1 Hz, 1H), 4.49 (m, 1H), 3.92 (m, 1H), 3.73-3.67 (m, 5H), 3.34 (m, 1H), 3.25 (br, 1H), 2.73 (m, 1H), 2.52 (m, 2H), 1.82-1.50 (m, 4H), 1.44-1.16 (m, 7H), 1.01 (d, J= 6.8 Hz, 3H), 0.97 (d, J
= 7.1 Hz, 3H), 0.93 (d, J= 6.9 Hz, 3H), 0.90 (d, J= 6.9 Hz, 3H), 0.88-0.81 (m, 42H), 0.08-0.00 (m, 24H); 13C NMR (75 MHz, CDC13) 6 166.8, 147.3, 145.5, 136.5, 132.8, 132.7, 132.6, 129.6, 126.8, 117.3, 115.5, 79.8, 78.4, 74.2, 72.1, 66.5, 51.0, 43.5, 42.5, 41.4, 36.0, 35.9, 35.8, 35.0, 32.4, 31.9, 30.7, 26.3, 26.0, 25.9, 20.4, 19.4, 18.5, 18.12, 18.08, 17.98, 17.4, 15.3, 13.4, 10.8, -3.0, -3.4, -3.7, -4.1, -4.2, -4.3, -4.4, -4.8; LRMS (ESI) 1043.7 [M+Na]+, 889.6, 758.2, 684.2, 610.1; HRMS (ESI) calcd for C57H112O7Si4Na 1043.7383 [M+Na]+, found 1043.7435; [a]20D -9.4 (c 0.62, CHC13).
[00135] (2Z,4E,6R,7S,9S,10Z,12S,13R,14S,16S,19S,20R,21S,22S,23Z)-7,9,13,19-tetrakis(tert-Butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoic acid (57). The procedure for 48 was used with 56 (56 mg, 55 mol) and 1N aqueous KOH (0.54 mL) to yield 57, which was used without further purification: IR
(CHC13) 2956, 2929, 2857, 1693, 1634, 1471, 1462, 1254, 1082, 836, 773 cm 1;
'H NMR
(300 MHz, CDC13) 8 7.34 (dd, J= 15.1, 11.4 Hz, 1H), 6.64 (ddd, J= 16.5, 10.6, 10.5 Hz, 1H), 6.61 (t, J= 11.2 Hz, 1H), 6.07 (t, J= 11.0 Hz, 1H), 6.01 (dd, J= 15.5, 7.2 Hz, 1 H), 5.58 (d, J= 11.3 Hz, 1H), 5.44-5.34 (m, 2H), 5.23 (dd, J= 11.0, 8.2 Hz, 1H), 5.17 (d, J= 18.0 Hz, 1H), 5.08 (d, J= 10.1 Hz, 1H), 4.50 (m, 1H), 3.92 (m, 1H), 3.69 (m, 1H), 3.35 (m, 1H), 2.75 (m, 1H), 2.54 (m, 2H), 1.74-1.56 (m, 4H), 1.49-1.20 (m, 7H), 1.02 (d, J= 6.8 Hz, 3H), 0.98 (d, J= 7.2 Hz, 3H), 0.94 (d, J= 7.0 Hz, 3H), 0.90-0.82 (m, 45H), 0.09-0.01 (m, 24H); 13C
NMR (75 MHz, CDC13) 8 171.1, 148.2, 147.4, 136.4, 132.7, 132.6, 129.6, 127.0, 117.4, 115.1, 79.8, 78.4, 74.2, 72.1, 66.5, 43.5, 42.6, 41.5, 36.0, 35.9, 35.8, 35.0, 31.9, 30.8, 29.7, 26.3, 26.0, 25.9, 20.4, 19.3, 18.5, 18.13, 18.08, 17.97, 17.4, 15.4, 13.7, 10.8, -3.0, -3.4, -3.7, -4.1, -4.2, -4.3, -4.4, -4.8; LRMS (ESI) 1029.8 [M+Na]+, 832.3, 758.3, 684.3, 610.2, 541.2;
HRMS (ESI) calcd for C56H11oO7Si4Na 1029.7226 [M+Na]+, found 1029.7255; [a]20D
-6.5 (c 0.17, CHC13).
[00136] (8S,10S,14R,20S)-tetrakis(tert-Butyldimethylsilyloxy)-(7R,13S,15S,17S,21S)-pentamethyl-(22S)-((1S)-methylpenta-2,4-dienyl)-oxacyclodocosa-3,5,11-trien-2-one (58). The procedure for 49 was used with 57, Et3N (0.046 mL, 33 mol), 2,4,6-trichlorobenzoyl chloride (0.043 mL, 28 mol) and 4-DMAP (27 mL, 0.02 M
solution in toluene) to yield 42 mg (78% for 2 steps) of 58 after flash column chromatography (EtOAc/hexane 1:49) as a colorless oil: IR (CHC13) 2956, 2929, 2856, 1704, 1638, 1471, 1462, 1378, 1361, 1255, 1086, 1044, 1004, 835, 773 cm 1; 1H NMR (300 MHz, CDC13) 6 6.98 (dd, J= 15.3, 11.3 Hz, 1H), 6.58 (ddd, J= 16.9, 10.6, 10.5 Hz, 1H), 6.42 (t, J= 11.4 Hz, 1H), 5.94 (t, J= 9.2 Hz, 1H), 5.92 (dd, J= 9.5, 5.2 Hz, 1H), 5.55 (m, 1H), 5.42 (d, J= 11.6 Hz, 1H), 5.33-5.21 (in, 3H), 5.12 (d, J= 15.1 Hz, 1H), 4.99 (d, J= 9.7 Hz, 1H), 4.54 (m, 1H), 3.99 (m, 1H), 3.44 (m, 1H), 3.17 (m, 1H), 2.99 (m, 1H), 2.54 (m, 1H), 2.19 (m, 114), 1.99 (m, 1H), 1.61-1.42 (m, 7H), 1.37-1.18 (m, 3H), 1.10 (d, J= 6.9 Hz, 3H), 1.05 (d, J= 7.1 Hz, 3H), 1.00 (d, J= 6.3 Hz, 3H), 0.98 (d, J= 6.4 Hz, 3H), 0.98-0.82 (m, 36H), 0.79 (d, J= 6.6 Hz, 3H), 0.66 (d, J= 6.7 Hz, 3H), 0.11-0.01 (m, 24H); 13C NMR (75 MHz, CDC13) 8 166.4, 146.5, 143.9, 134.3, 132.7, 132.2, 130.8, 129.8, 127.9, 117.4, 117.1, 81.6, 78.0, 77.1, 73.0, 66.7, 46.9, 45.7, 41.2, 37.5, 35.8, 35.1, 34.5, 31.1, 29.7, 26.2, 26.1, 26.0, 25.9, 20.5, 19.5, 19.1, 18.5, 18.4, 18.2, 17.9, 17.3, 16.9, 7.9, -2.6, -3.4, -3.5, -4.3, -4.4, -4.6; LRMS (ESI) 1011.7 [M+Na]+, 803.5, 633.1, 544.2, 413.2; HRMS (ESI) calcd for C56H10sO6Si4Na 1011.7121 [M+Na]+, found 1011.7164; [a]20D -61.6 (c 2.8, CHC13).
[00137] (8S,1 OS,14R,20S)-Tetrahydroxy-(7R,13S,15S,17S,21S)-pentamethyl-(22S)-((1S)-methylpenta-2,4-dienyl)-oxacyclodocosa-3,5,11-trien-2-one (59). 3N HCl (10 mL, prepared by adding 2.5 mL of conc. HCl to 7.5 mL MeOH) was added to a stirred solution of macrolactone 58 (42 ing, 42 mol) in THF (3 mL) at 0 C. After 24 h at room temperature, the reaction mixture was diluted with EtOAc (4 mL) and H20 (4 mL). The organic phase was retained and the aqueous phase was extracted with EtOAc (2 x 4 mL). The combined organic phase was washed with saturated aqueous NaHCO3 (10 mL), dried with MgSO4, filtered and concentrated. The residue was purified by flash chromatography (EtOAc/hexane 3:2) to yield 59 (7.9 mg, 35%) as a colorless oil: IR (CHC13) 3415, 2961, 2917, 2849, 1681, 1637, 1461, 1279, 1067, 965, 758 cm 1;1H NMR (600 MHz, CD3OD) 6 7.05 (dd, J= 15.3, 11.3 Hz, 1H), 6.65 (ddd, J= 16.9, 10.2, 10.1 Hz, 1H), 6.53 (dd, J= 11.5, 11.5 Hz, 1H), 5.97 (dd, J= 15.3, 9.5 Hz, 1H), 5.94 (dd, J= 11.0, 11.0 Hz, 1H), 5.60 (dd, J= 10.8, 9.6 Hz, 1H), 5.41 (d, J=
11.5 Hz, 1H), 5.20 (dd, J= 10.5, 10.3 Hz, 1H), 5.11 (dd, J= 16.9, 2.0 Hz, 1H), 5.10 (dd, J=
9.7, 2.1 Hz, 1H), 5.01 (d, J= 10.1 Hz, 1H), 4.60 (ddd, J=10.1, 9.7, 2.7 Hz, 1H), 3.94 (ddd, J
= 11.0, 2.1, 2.0 Hz, 1 H), 3.3 8(ddd, J= 9. 8, 3.0, 2.0 Hz, 1 H), 3.09 (ddq, J= 13 .0, 7.0, 4.9 Hz, 1H), 3.01 (dd, J= 8.3, 2.7 Hz, 1H), 2.70 (m, 1H), 2.23(ddd, J= 9.3, 7.0, 2.4 Hz, 1H), 2.07 (ddd, J= 7.0, 2. 6, 2.5 Hz, 1 H), 1.67 (m, 2H), 1. 5 6(ddd, J= 14. 0, 10. 9, 2.9 Hz, 1H), 1.51 (m, 1H), 1.47 (ddd, J= 14.1, 10.5, 1.9 Hz, 1H), 1.17 (d, J= 6.9 Hz, 3H), 1.13 (m, 1H), 1.11 (d, J
= 7.1 Hz, 3H), 1.09 (d, J= 7.0 Hz, 3H), 1.02 (d, J= 6.7 Hz, 3H), 1.00 (m, 1H), 0.93 (d, J=
6.4 Hz, 311), 0.92 (m, 1H), 0.78 (m, 1H), 0.76 (d, J= 6.7 Hz, 3H). 0.74 (m, 1H); 13C NMR
(150 MHz, CD3OD) 8 168.3, 147.6, 145.3, 135.4, 134.3, 133.5, 131.3, 131.0, 130.1, 118.1, 81.2, 79.9, 77.6, 72.0, 65.1, 45.9, 44.8, 42.4, 38.7, 36.0, 35.6, 31.8, 29.8, 27.8, 22.2, 19.8, 18.4, 17.6, 16.4, 9.1; LRMS (ESI) 555.3 [M+Na]+, 443.2; HRMS (ESI) calcd for 555.3662 [M+Na]+, found 555.3655; [a]20D -76.2 (c 0.45, MeOH).
[00138] (4S,5R,6,S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-4,6-dimethylheptan-l-ol (61). DIBAL-H (19.8 mL, 19.8 mmol, 1.0 M solution in hexane) was added at -78 C dropwise to ester 60 (3.59 g. 7.94 mol) in CHaC12 (40 mL).
After stirring for 1 h, the reaction mixture was quenched by addition of EtOAc (5 mL) and saturated aqueous sodium potassium tartrate (80 mL), followed by vigorous stirring for 4 h. The aqueous phase was extracted with CHZCIz (3 x 20 mL) and the combined organic layers were washed with brine (40 mL). After drying over MgSO4, filtration and evaporation under vacuum, flash column chromatography (hexane/EtOAc 3:7) provided 60 (2.51 g, 77%) as a colorless oil: IR (CHC13) 3387, 2934, 2856, 1612, 1513, 1472, 1462, 1360, 1302, 1249, 1172, 1039, 836, 773 crri 1; 'H NMR (300 MHz, CDC13) b7.42-7.38 (m, 2H), 7.03-6.98 (m, 2H), 4.58 (d, J= 11.6 Hz, 1H), 4.53 (d, J= 11.6 Hz, 1H), 3.92 (s, 3H), 3.70 (d, J=
6.6 Hz, 2H), 3.64 (m, 2H), 3.38 (dd, J= 8.8, 7.6 Hz, 1H), 2.31 (br, 1H), 2.16-2.03 (m, 1H), 1.78-1.66 (m, 2H), 1.65-1.50 (m, 2H), 1.38-1.28 (m, 1H), 1.09 (d, J= 6.9 Hz, 3H), 1.03 (s, 9H), 1.01 (d, J=
6.9 Hz, 3H), 0.18 (s, 3H), 0.17 (s, 3H); 13C NMR (75 MHz, CDC13) b 159.0, 130.7, 129.0, 113.6, 77.4, 72.6, 72.5, 62.8, 55.1, 37.8, 36.1, 30.8, 30.4, 26.0, 18.3, 15.2, 14.5, -3.8, -4.2;
LRMS (ESI) 433.3 [M+Na]+; HRMS (ESI) calcd for C23H42O4SiNa 433.2750 [M+Na]+, found 433.2765; [a]20D -10.2 (c 1.0, CHC13).
[00139] 1-(((2S,3R,4S')-3,7-bis(tert-Butyldimethylsilyloxy)-2,4-dimethylheptyloxy)methyl)-4-methoxybenzene (62). TBSC1 (0.92 g, 6.11 mmol) was added to a solution of above alcohol 61 (2.51 g, 6.11 mmol) and imidazole (0.46 g, 6.76 mmol) in CH2C12 (20 niL). The resulting slurry was stirred for 1 h at room temperature. The organic phase was washed with water (100 mL) and brine (2 x 100 mL). After drying over MgSO4, filtration and evaporation under vacuum, the residue was used directly in next step:
IR (CHC13) 2930, 2856, 1613, 1513, 1471, 1360, 1250, 1098, 1040, 835, 773 cm"1; 1H NMR
(300 MHz, CDC13) S 7.29-7.26 (m, 2H), 6.90-6.88 (m, 2H), 4.46 (d, J= 11.6 Hz, 1H), 4.42 (d, J= 11.6 Hz, 1H), 3.81 (s, 3H), 3.62 (t, J= 6.3 Hz, 2H), 3.58-3.52 (m, 2H), 3.28 (dd, J=
8.8, 7.7 Hz, 1H), 2.02-1.94 (m, 1H), 1.66-1.54 (m, 2H), 1.52-1.39 (m, 2H), 1.28-1.18 (m, 1H), 0.99 (d, J= 6.9 Hz, 3H), 0.94 (s, 9H), 0.92 (s, 9H), 0.89 (d, J= 6.8 Hz, 3H), 0.09 (s, 6H), 0.07 (s, 3H), 0.06 (3H);13C NMR (75 MHz, CDC13) S 159.0, 130.9, 129.0, 113.6, 77.5, 72.8, 72.6, 63.4, 55.1, 38.0, 36.3, 31.1, 30.8, 26.1, 25.9, 18.4, 18.3, 15.2, 14.4, -3.8, -4.1, -5.3; LRMS (ESI) 547.4 [M+Na]+ 413.3, 212.1; HRMS (ESI) calcd for C29H56O4Si2Na 547.3615 [M+Na]+, found 547.3638; [a]20D -9.9 (c 2.5, CHC13).
[001401 (2S,3R,4S)-3,7-bis(tert-Butyldimethylsilyloxy)-2,4-dimethylheptan-l-ol (63). The PMB alcohol 62 (6.11 mmol) was added to CH2C1Z (19 mL) then H20 (1 mL) and DDQ (1.80 g, 7.93 mol) were added. After 1 h of stirring, the reaction was quenched by adding saturated aqueous NaHCO3 (100 mL). The organic phase was washed with saturated aqueous NaHCO3 (3 x 100 mL) and brine, dried over MgSO4 filtered and concentrated.
Purification by flash colunm cliromatography (EtOAc/hexane 1:9) fiuliished 63 (2.23 g, 90%) as a colorless oil: IR (CHC13) 3403, 2928, 2856, 1472, 1463, 1388, 1256, 1100, 836, 773 cm"
1; 'H NMR (300 MHz, CDC13) b3.59-3.50 (m, 4H), 3.46 (dd, J= 5.5, 3.7 Hz, 1H), 1.83-1.75 (m, 1H), 1.62-1.52 (m, 2H), 1.49-1.35 (m, 2H), 1.18-1.05 (m, 1H), 0.91 (d, J=
7.0 Hz, 3H), 0.87-0.84 (m, 21H), 0.05 (s, 3H), 0.03 (s, 3H), 0.00 (s, 6H); 13C NMR (75 MHz, CDC13) b 80.4, 65.8, 63.3, 38.1, 37.8, 31.1, 29.6, 26.0, 25.9, 18.2, 15.9, 14.9, -4.0, -4.2, -5.4; LRMS
(ESI) 427.3 [M+Na]+, 256.8, 212.1; HRMS (ESI) calcd for C21H48O3SiaNa 427.3040 [M+Na]+, found 427.3050; [a]20D -14.0 (c 0.6, CHC13).
[001411 (3S,4R,5S)-4,8-bis(tert-Butyldimethylsilyloxy)-3,5-dimethyloct-1-yne (64).
Sulfur trioxide pyridine complex (2.63 g, 16.5 mmol) was added to a stirred solution of alcoho163 (2.23 g, 5.51 mmol) and triethylamine (2.25 mL, 16.5 mmol) in anhydrous CH2C12 (12 mL) and DMSO (22 mL) at 0 C. The reaction mixture was stirred at ambient temperature for 1 h. The mixture was diluted with EtaO (100 niL) and washed with 0.5N
aqueous HC1(50 mL) and brine (10 mL). The separated organic layer was dried over MgSO4.
Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 4:1) provided the crude aldehyde as a colorless oil, which was used without further purification. A mixture of carbon tetrabromide (3.65 g, 11.0 mmol) and triphenylphosphine (5.78 g, 22.0 mmol) in CH2Cla (50 mL) was stirred at 0 C for 10 min. A
solution of the crude aldehyde and 2,6-lutidine (1.27 mL, 11.0 mmol) in CH2C12 (5 mL) was transferred via cannula to the reaction mixture. The reaction was stirred for an additional 2 h at 0 C, then quenched with a saturated aqueous NH4C1 (20 mL). The layers were separated and the aqueous layer was extracted with CH2C12 (2 x 20 mL). The combined layers were dried over MgSO4, filtered and concentrated irz vacuo. Flash column chromatography over silica gel (EtOAc/hexane 1:19) afforded the vinyl dibromide as a colorless oil. The vinyl dibromide in THF (18 mL) was cooled to -78 C and treated with n-BuLi (8.6 mL, 13.8 mmol, 1.6 M
solution in hexane). The reaction was stirred for 1 h at -78 C, warmed to 20 C and stirred an additional 1 h. Saturated aqueous NH4C1(5 mL) was added, the layers were separated and the aqueous layer was extracted with Et20. The combined organic layer was dried over MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (EtOAc/hexane 1:9) furnished 64 (1.20 g, 55% for 3 steps) as a colorless oil:
IR (CHC13) 3313, 2930, 2857, 1472, 1463, 1387, 1361, 1254, 1099, 835, 774, 627 cm 1; 1H
NMR (300 MHz, CDC13) b3.74 (m, 2H), 3.66 (dd, J= 4.7, 3.8 Hz, 1H), 2.74 (m, 1H), 2.14 (d, J= 2.5 Hz, 1H), 1.85 (m, 111), 1.74-1.56 (m, 4H), 1.31 (d, J= 7.1 Hz, 3H), 1.05-1.01 (m, 18H), 0.23 (s, 3H), 0.20 (s, 3H), 0.18 (s, 6H);13C NMR (75 MHz, CDC13) b 87.4, 77.9, 69.9, 63.4, 36.5, 31.5, 31.0, 30.7, 26.1, 26.0, 18.4, 18.3, 17.5, 15.0, -3.9, -5.3; LRMS (ESI) 421.3 [M+Na]+, 372.8, 359.3, 256.8, 212.1; HRMS (ESI) calcd for C2aH46O2Si2Na 421.2934 [M+Na]+, found 421.2942; [a]20D -5.3 (c 1.3, CHC13).
[00142] (4R,5S,10S,11R,12S,E)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12-trimethyl-l-trityloxypentadec-2-en-8-yn-7-one. The procedure for 32 was used with 15 (1.31 g, 2.28 mol), 64 (1.20 g, 3.01 mmol) and n-BuLi (1.88 mL, 1.20 mmol) to yield the ynone (1.79 g, 86%) after flash colunm chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2929, 2856, 2209, 1675, 1471, 1462, 1385, 1254, 1093, 836, 775, 705 cm 1;
1H NMR (300 MHz, CDC13) 57.56-7.53 (m, 6H), 7.38-7.25 (m, 9H), 5.79 (dd, J=
15.6, 7.2 Hz, 111), 5.67 (dt, J= 15.6, 4.9 Hz, 111), 4.3 6(m, 1 H), 3.69-3.66 (m, 4H), 3.63 (t, J= 4.1 Hz, 111), 2.86 (m, 1H), 2.72 (m, 1H), 2.45 (m, 1H), 1.76 (m, 111), 1.67-1.51 (m, 311), 1.34 (m, 1H), 1.29 (d, J= 7.1 Hz, 3H), 1.14 (d, J= 6.8 Hz, 3H), 1.00-0.97 (m, 28H), 0.18-0.13 (m, 18H); 13C NMR (75 MHz, CDC13) S 186.0, 144.2, 132.8, 128.6, 127.9, 127.7, 126.8, 96.7, 86.8, 83.1, 77.8, 71.6, 64.8, 63.2, 50.1, 42.3, 37.2, 31.7, 30.9, 30.2, 26.0, 25.9, 25.8, 18.3, 18.2, 18.0, 17.3, 15.4, 14.8, -3.9, -4.1, -4.6, -4.7, -5.3; LRMS (ESI) 933.6 [M+Na]+, 795.5, 665.2, 496.1, 413.2, 243.1; HRMS (ESI) calcd for C55H86O5Si3Na 933.5681 [M+Na]+, found 933.5692; [a]20o -9.5 (c 0.55, CHC13).
[00143] (4R,5S,7S,10S,11R,12S,2E)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12-trimethyl-l-trityloxypentadec-2-en-8-yn-7-ol (65). The procedure for 33 was used with the above ynone (1.77 g, 1.94 mol), (S,S)-Noyori catalyst (0.26 g, 20 mol%) and i-PrOH (19 mL) to yield 65 (1.69 g, 95%) after flash column chromatography (EtOAc/hexane 1:19) as a pale yellow oil: IR (CHC13) 3464, 2929, 2856, 1471, 1448, 1386, 1254, 1090, 836, 774, 705 cm 1; 'H NMR (300 MHz, CDC13) 8 7.56-7.54 (m, 6H), 7.39-7.26 (m, 9H), 5.78 (dd, J= 15.7, 6.4 Hz, 1H), 5.68 (dt, J= 15.6, 4.9 Hz, 1H), 4.57 (m, 1H), 4.06 (m, 1H), 3.71-3.67 (m, 4H), 3.62 (t, J= 4.0 Hz, 1H), 2.74 (m, 1H), 2.50 (m, 1H), 2.46 (d, J= 5.4 Hz, 1H), 1.82 (m, 3H), 1.72-1.54 (m, 3H), 1.36 (m, 1H), 1.24 (d, J= 7.1 Hz, 3H), 1.13 (d, J=
6.8 Hz, 3H), 1.04-0.94 (m, 27H), 0.21-0.14 (m, 18H); 13C NMR (75 MHz, CDC13) S 144.3, 133.8, 128.6, 127.7, 127.2, 126.8, 87.8, 86.8, 83.1, 77.7, 72.5, 65.0, 63.5, 59.4, 41.9, 40.6, 36.4, 31.7, 30.7, 26.01, 25.96, 25.9, 18.3, 18.0, 17.4, 15.2, 14.5, -4.0, -4.1, -4.4, -4.5, -5.3; LRMS (ESI) 935.4 [M+Na]+; HRMS (ESI) calcd for C55H88O5Si3Na 935.5837 [M+Na]+, found 935.5851;
[a]20D -10.5 (c 0.86, CHC13).
[00144] (2E,4R,5S,7S,8Z,l OS,11R,12S)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12-trimethyl-l-(trityloxy)pentadeca-2,8-dien-7-ol (66). The procedure for 34 was used with alkyne 65 (1.69 g, 1.85 mol) and Lindlar catalyst (ca. 200 mg) to yield 66 (1.70 g, quantitative) as a pale yellow oil: IR (CHC13) 3477, 2955, 2856, 1471, 1448, 1386, 1254, 1057, 835, 773, 705 cm"1; 1H NMR (300 MHz, CDC13) 6 7.63-7.60 (m, 6H), 7.43-7.27 (m, 9H), 5.88-5.77 (m, 2H), 5.70 (t, J= 10.1 Hz, 1H), 5.49 (dd, J= 10.6, 8.4 Hz, 1H), 4.78 (m, 1H), 4.06 (m, 1H), 3.76-3.72 (m, 4H), 3.58 (t, J= 3.6 Hz, 1H), 2.89 (m, 1H), 2.63 (m, 1H), 2.20 (d, J= 2.8 Hz, 1H), 1.73-1.48 (m, 7H), 1.18 (d, J= 6.9 Hz, 3H), 1.15 (d, J= 7.0 Hz, 3H), 1.08-1.02 (m, 27H), 0.29-0.20 (m, 18H); 13C NMR (75 MHz, CDC13) 6 144.3, 134.9, 134.4, 131.5, 128.6, 127.7, 127.0, 126.8, 86.7, 79.8, 72.8, 65.0, 64.7, 63.5, 42.1, 39.7, 37.9, 35.9, 31.4, 29.9, 26.2, 26.0, 25.9, 20.1, 18.4, 18.3, 18.0, 14.9, 14.5, -3.6, -3.8, -4.5, -4.6, -5.3; LRMS (ESI) 937.5 [M+Na]+; HRMS (ESI) calcd for C55H9oO5Si3Na 937.5994 [M+Na]+, found 937.6016; [a]ZOD +2.1 (c 0.92, CHC13).
[00145] ((2E,4R,5S,7S,8Z,10S,11R,12S)-5,7,11,15-tetrakis(tert-Butyldimethylsilyloxy)-4,10,12-trimethylpentadeca-2,8-dienyloxy)triphenylmethane (67). The procedure for 35 was used with alcoho166 (1.70 g, 1.85 mol), TBSOTf (0.94 mL, 4.07 mmol) and 2,6-lutidine (0.51 mL, 4.44 mmol) to yield 67 (1.82 g, 96%) by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2956, 2856, 1471, 1448, 1254, 1092, 1004, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.77-7.75 (m, 6H), 7.57-7.47 (m, 9H), 6.02-5.87 (m, 2H), 5.76 (t, J= 10.8 Hz, 1H), 5.61 (dd, J= 10.8, 8.5 Hz, 1H), 4.88 (m, 1H), 4.24 (m, 1H), 3. 8 8(m, 4H), 3.75 (m, 1H), 2.94 (m, 1H), 2.73 (m, 1H), 1.83 (m, 2H), 1.75 (m, 2H), 1.57 (m, 1H), 1.46-1.41 (m, 2H), 1.31 (d, J = 6.8 Hz, 3H), 1.30 (d, J= 6.3 Hz, 3H), 1.24-1.13 (m, 39H), 0.44-0.34 (m, 24H); 13C NMR (75 MHz, CDC13) S 144.4, 134.4, 132.9, 132.2, 128.7, 127.7, 126.8, 86.8, 80.2, 72.3, 66.6, 65.1, 63.6, 42.4, 41.6, 38.4, 35.7, 31.6, 29.9, 26.3, 26.0, 19.6, 18.5, 18.4, 18.2, 15.1, 13.2, -2.9, -3.6, -3.7, -4.2, -5.2; LRMS
(ESI) 1051.6 [M+Na]+, 918.6, 769.5, 637.4, 413.2; HRMS (ESI) calcd for C61H1o4O5Si4Na 1051.6859 [M+Na]+, found 1051.6848 [a]20j, -8.3 (c 2.4, CHC13).
[00146] (4S,5R,6S,7Z,9S,11S,12R,13E)-5,9,11-tris(tert-Butyldimethylsilyloxy)-4,6,12-trimethyl-15-(trityloxy)pentadeca-7,13-dien-l-ol (68). The procedure for 36 was used with 67 (1.82 g, 1.77 mol) and HF-pyridine in pyridine (100 mL) to yield 68 (1.15 g, 71%) by flash column chromatography (EtOAc/Hexane 1:9) as a colorless oil: IR
(CHC13) 3349, 2956, 2929, 2856, 1471, 1448, 1254, 1060, 836, 773, 705 cm 1; 1H NMR
(300 MHz, CDC13) S 7.58-7.55 (m, 6H), 7.39-7.27 (m, 9H), 5.81-5.65 (m, 2H), 5.56 (t, J=
10.7 Hz, 1H), 5.41 (dd, J= 11.0, 8.4 Hz, 1H), 4.67 (m, 1H), 4.05 (m, 1H), 3.69-3.63 (m, 4H), 3.53 (m, 1H), 2.73 (m, 1H), 2.52 (m, 1H), 1.64 (m, 3H), 1.58-1.48 (m, 2H), 1.30-1.20 (m, 2H), 1.11 (d, J=
6.8 Hz, 3H), 1.10 (d, J= 6.6 Hz, 3H), 1.03-0.92 (m, 30H), 0.23-0.14 (m, 18H);
13C NMR (75 MHz, CDC13) 8 144.3, 134.3, 132.9, 132.0, 128.6, 127.7, 126.8, 86.7, 80.1, 72.3, 66.4, 65.0, 63.1, 42.4, 41.7, 38.2, 35.5, 31.2, 29.5, 26.2, 25.95, 25.89, 19.6, 18.4, 18.1, 18.0, 15.1, 13.3, -2.9, -3.7, -3.8, -4.17, -4.24, -4.3; LRMS (ESI) 937.6 [M+Na]+; HRMS (ESI) calcd for C55H9oO5Si3Na 937.5994 [M+Na]+, found 937.6035; [a]20D -10.8 (c 0.84, CHC13).
[00147] (2R,4E,8S,9R,10S,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-8,10,16-trimethyl-19-(trityloxy)nonadeca-4,11,17-trien-3-one (69). The procedure for 39 was used with alcohol 68 (1.15 g, 1.26 mol), Dess-Martin reagent (0.80 g, 1.89 mmol) and Ba(OH)2 (0.17 g, 1.01 mmol) and 38 (0.49 g, 1.27 mmol) to yield 69 (1.22 g, 83%) after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 2956, 2929, 2856, 1693, 1618, 1518, 1461, 1388, 1251, 1080, 836, 773 cm"1; 1H NMR (300 MHz, CDC13) S 7.70-7.68 (m, 6H), 7.60-7.57 (m, 2H), 7.52-7.39 (m, 9H), 7.11 (m, 1H), 7.07-7.04 (m, 2H), 6.54 (d, J= 15.6, Hz, 1H), 5.94-5.78 (m, 2H), 5.67 (t, J= 10.9 Hz, 1H), 5.64 (s, 1H), 5.54 (dd, J= 11.0, 8.2 Hz, 1 H), 4.80 (m, 1H), 4.28 (dd, J= 11.3, 4.6 Hz, 1H), 4.18 (m, 1H), 4.11 (dd, J= 9.8, 3.9 Hz, 1H), 3.94 (s, 3H), 3.81 (m, 2H), 3.71 (m, 1H), 3.66 (m, 1H), 3.12 (m, 1H), 2.87 (m, 1H), 2.66 (m, 1H), 2.47 (m, 1H), 2.34 (m, 1H), 2.19 (m, 1H), 1.90-1.73 (m, 3H), 1.67-1.51 (m, 2H), 1.45 (d, J= 7.0 Hz, 3H), 1.23 (d, J= 6.6 Hz, 3H), 1.22 (d, J= 6.8 Hz, 3H), 1.16-1.05 (m, 30H), 0.96 (d, J= 6.7 Hz, 3H), 0.36-0.26 (m, 18H); 13C
NMR (75 MHz, CDC13) S 200.4, 159.6, 147.2, 144.2, 134.1, 133.0, 131.9, 130.9, 128.5, 127.8, 127.6, 127.1, 126.7, 113.3, 100.6, 86.6, 82.7, 79.8, 72.7, 72.1, 66.3, 64.9, 55.0, 46.8, 42.3, 41.5, 37.9, 35.3, 32.0, 31.7, 30.8, 26.1, 25.9, 19.5, 18.3, 18.0, 17.9, 14.7, 13.1, 12.3, 10.4, -3.0, -3.7, -3.9, -4.3, -4.4; LRMS (ESI) 1195.7 [M+Na]+, 1051.8; HRMS (ESI) calcd for C71H108O8Si3Na 1195.7250 [M+Na]+ found 1195.7297; [a]20D +9.1 (c 1.2, CHC13).
[00148] (2R,8S,9R,lOS,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-8,10,16-trimethyl-19-trityloxynonadeca-11,17-dien-3-one (70). The procedure for 40 was used with 69 (1.22 g, 1.04 mol), NiC12-6H20 (0.12 g, 0.52 mmol) and NaBH4 (0.079 g, 2.08 mmol) to yield 70 (0.80 g, 65%) after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 2956, 2929, 2855, 1713, 1615, 1518, 1461, 1388, 1251, 1077, 1037, 836, 773 cm"1; 1H NMR (300 MHz, CDC13) 8 7.70-7.66 (m, 6H), 7.57-7.40 (m, 11H), 7.07-7.04 (m, 2H), 5.92-5.77 (m, 2H), 5.65 (m, 1H), 5.64 (s, 1H), 5.52 (m, 1H), 4.78 (m, 1H), 4.30 (dd, J= 11.2, 4.6 Hz, 1H), 4.14 (m, 2H), 3.94 (s, 3H), 3.79 (d, J= 3.9 Hz, 2H), 3.73 (t, J=
11.1 Hz, 1H), 3.61 (m, 1H), 2.92-2.79 (m, 2H), 2.72 (t, J= 7.4 Hz, 2H), 2.65 (m, 1H), 2.22 (m, 1H), 1.91-1.71 (m, 4H), 1.65-1.56 (m, 3H), 1.51 (m, 1H), 1.43 (d, J= 7.1 Hz, 3H), 1.35 (m, 1H), 1.20 (d, J= 6.7 Hz, 3H), 1.14-1.12 (m, 21H), 1.08 (d, J= 6.2 Hz, 3H), 1.05-1.03 (m, 9H), 0.96 (d, J = 6.7 Hz, 3H), 0.34-0.25 (m, 18H); 13C NMR (75 MHz, CDC13) S
211.5, 159.8, 144.4, 144.3, 134.3, 132.9, 132.2, 130.9, 128.6, 127.6, 127.1, 126.8, 113.4, 100.8, 86.7, 83.0, 80.1, 72.8, 72.2, 66.4, 65.0, 55.0, 48.2, 42.3, 41.6, 40.6, 38.0, 35.7, 33.5, 31.2, 27.6, 26.2, 25.91, 25.87, 23.9, 19.4, 18.4, 18.05, 17.99, 14.8, 13.2, 12.0, 9.5, -3.0, -3.6, -3.8, -4.2, -4.3, -4.4; LRMS (ESI) 1197.7 [M+Na]+, 684.2, 541.1; HRMS (ESI) calcd for C71H110O8Si3Na 1197.7406 [M+Na]+, foundll97.7411; [a]20D +4.6 (c 1.1, CHC13).
[00149] (2S,3R,8S,9R,lOS,11 Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-8,10,16-trimethyl-19-(trityloxy)nonadeca-11,17-dien-3-ol (71). LiAI(O-t-Bu)3H
(2.0 mL, 1.0 M solution in THF) was added to a solution of 70 (0.80 g, 0.68 mmol) in THF (7 mL).
After 30 min of stirring at room temperature, the reaction was quenched with saturated aqueous NH4C1 (1 mL), stirring for 1 h, dried over MgSO4, filtered, concentrated iya vacuo, and chromatographed (EtOAc/hexane 3:17) to provide the (3 isomer of 71 (0.76 g, 95%) as a colorless oil: IR (CHC13) 3538, 2929, 2855, 1615, 1518, 1461, 1385, 1251, 1072, 835, 773, 734 cm 1; 1H NMR (300 MHz, CDC13) 8 7.70-7.66 (m, 6H), 7.59-7.56 (m, 2H), 7.52-7.39 (m, 9H), 7.08-7.05 (m, 2H), 5.93-5.77 (m, 2H), 5.71 (s, 1H), 5.67 (t, J= 10.2 Hz, 1H), 5.55-5.48 (m, 1H), 4.78 (m, 1H), 4.30 (dd, J= 11.4, 4.8 Hz, 1H), 4.15 (m, 1H), 4.09 (m, 1H), 3.94 (s, 3H), 3.88 (dd, J= 10.0, 1.5 Hz, 1H), 3.79 (d, J= 3.9 Hz, 2H), 3.70 (t, J= 11.1 Hz, 1H), 3.64 (m, 1H), 3.38 (br, 1H), 2.84 (m, 1H), 2.65 (m,1H), 2.33 (m, 1H), 2.22-1.91 (m, 2H), 1.86-1.71 (m, 3H), 1.66-1.54 (m, 4H), 1.49-1.34 (m, 3H), 1.24 (d, J= 7.0 Hz, 3H), 1.21 (d, J= 6.6 Hz, 3H), 1.15-1.08 (m, 21H), 1.09 (d, J = 6.9 Hz, 3H), 1.04 (m, 9H), 0.94 (d, J= 6.7 Hz, 3H), 0.34-0.25 (m, 18H); 13C NMR (75 MHz, CDC13) b 160.0, 144.4, 144.3, 134.3, 132.8, 132.2, 130.6, 128.6, 127.6, 127.1, 126.7, 113.6, 101.1, 88.9, 86.7, 80.1, 76.2, 73.0, 72.2, 66.4, 65.0, 55.1, 42.3, 41.6, 38.2, 37.4, 35.7, 35.0, 33.6, 30.3, 28.0, 26.5, 26.1, 25.91, 25.87, 19.5, 18.4, 18.05, 17.99, 15.0, 13.2, 11.8, 5.6, -3.0, -3.7, -3.8, -4.2, -4.3; LRMS
(ESI) 1199.7 [M+Na]+, 937.6, 782.4, 413.2; HRMS (EST) calcd for C71H112O8Si3Na 1199.7563 [M+Na]+, found 1199.7538; [a]20D +8.9 (c 0.46, CHCl3).
[00150] (2S,3R,8S,9R,lOS,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-8,10,16-trimethyl-19-(trityloxy)nonadeca-11,17-dien-3-ol (72). The procedure for 42 was used with 71 (0.76 g, 0.65 mol), TBSOTf (0.22 mL, 0.98 mmol) and 2,6-lutidine (0.15 mL, 1.30 mmol) to yield 72 (0.76 g, 92%) after flash colunm chromatography (EtOAc/Hexane 1:9) as a colorless oil: IR (CHC13) 2955, 2929, 2856, 1615, 1518, 1471, 1388, 1251, 1074, 836, 773 cm l; 'H NMR (300 MHz, CDC13) S 7.60-7.57 (m, 6H), 7.52-7.49 (m, 211), 7.41-7.27 (m, 9H), 6.99-6.96 (in, 2H), 5.83-5.67 (m, 2H), 5.56 (t, J= 9.2 Hz, 1H), 5.55 (s, 1H), 5.43 (dd, J= 10.9, 8.4 Hz, 1H), 4.69 (m, 1H), 4.21 (m, 1H), 4.06 (m, 1H), 3.84 (s, 3H), 3.81 (m, 1H), 3.76-3.70 (m, 3H), 3.60 (t, J= 11.1 Hz, 1H), 3.54 (m, 1H), 2.74 (m 1H), 2.54 (m, 111), 2.14 (m, 1H), 2.00 (t, J= 6.7 Hz, 1H), 1.68 (m, 3H), 1.58-1.40 (m, 5H), 1.34-1.20 (m, 3H), 1.13 (d, J= 6.8 Hz, 3H), 1.10 (m, 3H), 1.05-0.95 (m, 42H), 0.84 (d, J=
6.4 Hz, 3H), 0.25-0.17 (m, 24H); 13C NMR (75 MHz, CDC13) b 159.7, 144.5, 144.3, 134.3, 132.9, 132.4, 131.6, 128.7, 127.7, 127.1, 126.8, 113.4, 100.5, 86.7, 81.9, 80.2, 74.7, 73.3, 72.3, 66.5, 65.0, 55.1, 42.3, 41.6, 38.9, 38.2, 35.9, 34.0, 33.7, 30.7, 28.4, 26.2, 26.0, 25.96, 25.9, 25.7, 19.4, 18.4, 18.1, 14.8, 13.2, 12.3, 10.6, -3.0, -3.5, -3.8, -4.2, -4.3; LRMS (ESn 1313.8 [M+Na]+, 782.4, 413.2; HRMS (ESI) calcd for C77H126O$Si4Na 1313.8428 [M+Na]+, found 1313.8402;
[a]20D +9.5 (c 0.38, CHC13).
[00151] (2S,3S,4R,5R,l OS,11R,12S,13Z,15S,17S,18R,19E)-3-(4-Methoxybenzyloxy)-5,11,15,17-tetrakis(tert-butyldimethylsilyloxy)-2,4,10,12,18-pentamethyl-21-trityloxyhenicosa-13,19-dien-l-ol (73). The procedure for 43 was used with 72 (0.76 g, 0.59 mol) and DIBAL-H (5.9 mL, 5.9 mmol) to yield 73 (0.69 g, 90%) after flash column chromatography (EtOAc/Hexane 3:17) as a colorless oil: IR
(CHC13) 3484, 2928, 2856, 1613, 1514, 1471, 1360, 1251, 1037, 835, 773 crn 1; 1H NMR
(300 MHz, CDC13) S 7.62-7.58 (m, 6H), 7.47-7.34 (m, 11H), 7.02-7.00 (m, 2H), 5.82-5.68 (m, 2H), 5.55 (t, J= 10.0 Hz, 1 H), 5.46-5.41 (m, 1 H), 4.70 (m, 1 H), 4.66 (s, 2H), 4.04 (m, 1 H), 3.97 (m, 1H), 3.94 (s, 3H), 3.77 (m, 1H), 3.70 (d, J= 3.3 Hz, 2H), 3.59 (dd, J= 6.6, 4.3 Hz, 1H), 3.53 (m, 1 H), 3.00 (dd, J= 5.8, 4.4 Hz, 1H), 2.72 (m 1 H), 2. 5 5(m, 1 H), 2.10 (m, 1 H), 2.02 (m, 1H), 1.77-1.61 (m, 5H), 1.55-1.47 (m, 3H), 1.41-1.33 (m, 5H), 1.25 (d, J= 7.0 Hz, 3H), 1.14 (d, J= 6.9 Hz, 3H), 1.11 (d, J= 6.8 Hz, 3H), 1.05-0.94 (m, 42H), 0.25-0.16 (m, 24H); 13C
NMR (75 MHz, CDC13) 6 159.2, 144.3, 144.2, 134.3, 132.9, 132.2, 130.5, 129.2, 128.6, 127.6, 126.8, 113.8, 86.7, 85.6, 80.1, 75.1, 73.4, 72.2, 66.4, 65.0, 55.0, 42.3, 41.5, 40.5, 38.2, 37.0, 35.7, 34.7, 33.7, 28.3, 26.2, 25.9, 19.4, 18.4, 18.1, 15.7, 14.8, 13.1, 10.1, -3.0, -3.6, -3.8, -3.9, -4.3, -4.4; LRMS (ESI) 1315.8 [M+Na]+, 937.6; HRMS (ESI) calcd for C77H128O8Si4Na 1315.8584 [M+Na]+, found 1315.8534; [a]20D -4.2 (c 1.5, CHC13).
[00152] ((2E,4R,5S,7S,8Z,l OS,11R,12S,17R,18R,19S,20S,21Z)-19-(4-Methoxybenzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,18,20-pentamethyltetracosa-2,8,21,23-tetraenyloxy)triphenylmethane (74). The procedure for 44 was used wit11 73 (0.69 g, 0.53 mol), Dess-Martin reagent (0.34 g, 0.80 mmol) and 1-bromoallyltrimethylsilane (0.66 g, 2.65 inmol), CrC12 (0.54 g, 4.39 nimol) and NaH (0.27 g, 10.7 mmol) to yield 74 (0.58 g, 82% for 3 steps) after flash colunm chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2955, 2929, 2856, 1613, 1514, 1471, 1250, 1063, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.63-7.60 (m, 6H), 7.43-7.31 (m, 11H), 6.99-6.97 (m, 2H), 6.74 (ddd, J= 16.8, 10.6, 1055 Hz, 1H), 6.16 (t, J=
11.0 Hz, 1H), 5.86-5.71 (m, 3H), 5.58 (t, J= 9.8 Hz, 1H), 5.46 (dd, J= 11.0, 8.3 Hz, 1H), 5.31 (d, J= 16.8 Hz, 1H), 5.23 (d, J= 10.2 Hz, 1H), 4.75-4.63 (m, 3H), 4.09 (m, 1H), 3.86 (s, 3H), 3.81 (m, 1H), 3.73 (d, J= 4.0 Hz, 1H), 3.55 (m, 1H), 3.49 (m, 1H), 3.18 (m, 1H), 2.77 (m, 1H), 2.57 (m, 1H), 1.91-1.78 (m, 2H), 1.73-1.50 (m, 6H), 1.49-1.35 (m, 3H), 1.26 (d, J=
6.6 Hz, 3H), 1.15 (d, J= 6.3 Hz, 3H), 1.13 (d, J= 5.9 Hz, 3H), 1.10-0.97 (m, 42H), 0.28-0.19 (m, 24H);
13C NMR (75 MHz, CDC13) 8 159.2, 144.5, 144.4, 134.6, 134.4, 133.0, 132.5, 132.4, 131.3, 129.1, 129.0, 128.7, 127.7, 126.8, 117.2, 113.7, 86.8, 84.3, 80.3, 75.0, 72.6, 72.3, 66.5, 65.1, 55.1, 42.4, 41.6, 40.7, 38.0, 36.0, 35.3, 35.2, 34.0, 28.2, 26.3, 26.03, 26.00, 25.97, 25.7, 19.4, 18.8, 18.5, 18.2, 18.14, 18.09, 14.8, 13.3, 9.4, -2.9, -3.5, -3.6, -3.8, -4.1, -4.2, -4.3, -4.4;
LRMS (ESI) 1337.8 [M+Na]+, 537.4, 243.1; HRMS (ESI) calcd for C80H130O7Si4Na 1337.8791 [M+Na]+, found 1337.8785; [a]20D +5.1 (c 0.37, CHC13).
[00153] (2E,4R,5S,7S,8Z,l OS,11R,12S,17R,18R,19S,20S,21Z)-19-(4-Methoxybenzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,18,20-pentamethyltetracosa-2,8,21,23-tetraen-l-ol (75). The procedure for 45 was used with 74 (0.58 g, 0.22 mol), ZnBr (0.25 g, 1.11 mmol) to yield 75 (0.42 g, 89%) after flash colunm chromatography (EtOAc/hexane 3:17) as a colorless oil: IR (CHC13) 3402, 2956, 2929, 2856, 1614, 1514, 1471, 1251, 1085, 836, 773 cm 1; 'H NMR (300 MHz, CDC13) S 7.47-7.44 (m, 2H), 7.04-7.01 (m, 2H), 6.76 (ddd, J= 16.8, 10.6, 10.5 Hz, 1H), 6.19 (t, J=
11.0 Hz, 1H), 5.87-5.72 (m, 3H), 5.59 (t, J= 10.0 Hz, 1H), 5.45 (dd, J= 10.9, 8.3 Hz, 1H), 5.35 (d, J= 16.8 Hz, 1H), 5.27 (d, J= 10.2 Hz, 1H), 4.75-4.65 (m, 3H), 4.22 (d, J= 4.5 Hz, 2H), 4.09 (m, 1H), 3.94 (s, 3H), 3.83 (m, 1H), 3.56 (in, 1H), 3.51 (m, 1H), 3.17 (m, 1H), 2.77 (m, 1H), 2.57 (m, 1H), 1.95 (m, 1H), 1.85 (m, 1H), 1.78-1.55 (m, 8H), 1.53-1.40 (m, 3H), 1.29 (d, J= 6.7 Hz, 3H), 1.56-1.06 (m, 45H), 1.01 (d, J= 6.7 Hz, 3H), 0.29-0.22 (m, 24H); 13C NMR
(75 MHz, CDC13) 6 158.9, 134.8, 134.5, 132.8, 132.4, 132.3, 131.2, 129.2, 129.1, 128.9, 117.1, 113.6, 84.3, 80.2, 75.0, 72.4, 72.2, 66.5, 63.6, 55.1, 42.3, 41.5, 40.5, 37.9, 35.7, 35.2, 33.8, 28.1, 26.2, 25.9, 25.6, 19.3, 18.8, 18.4, 18.2, 18.0, 14.6, 13.0, 9.2, -3.0, -3.5, -3.7, -3.9, -4.3, -4.4, -4.5; LRMS (ESI) 1095.7 [M+Na]+, 809.6, 677.5, 537.4, 413.2; HRMS (ESI) calcd for C61H116O7Si4Na 1095.7696 [M+Na]+, found 1095.7712; [a]20D +4.8 (c 1.7, CHC13).
[00154] (2Z,4E,6R,7S,9S,10Z,12S,13R,14S,19R,20R,21S,22S,23Z)-Methyl-21-(4-methoxybenzyloxy)-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-6,12,14,20,22-pentamethylhexacosa-2,4,10,23,25-pentaenoate (76). The procedure for 46 was used with 75 (0.42 g, 0.39 mol), Dess-Martin reagent (0.25 g, 0.59 mmol) and bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl) phosphate (0.10 mL, 0.47 mol), 18-crown-6 (0.52 g, 1.97 mmol) and KHMDS (0.94 mL, 0.47 mmol) to yield 76 (0.38 g, 86% for 2 steps) by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2955, 2856, 1722, 1640, 1514, 1462, 1250, 1174, 1084, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.44 (dd, J=15.3, 11.3 Hz, 1H), 7.31-7.29 (m, 2H), 6.90-6.87 (m, 2H), 6.04 (t, J= 11.0 Hz, 1H), 6.02 (m, 1H), 5.66-5.60 (m, 2H), 5.44 (t, J= 10.0 Hz, 1H), 5.30 (dd, J=
11.1, 8.3 Hz, 1H), 5.20 (d, J= 16.8 Hz, 1H), 5.12 (d, J= 10.2 Hz, 1H), 4.61-4.51 (m, 3H), 3.98 (m, 1H), 3.80 (s, 3H), 3.73 (s, 3H), 3.68 (m, 1H), 3.42 (m, 1H), 3.37 (dd, J= 7.6, 3.1 Hz, 1H), 3.03 (m, 1H), 2.60 (m, 2H), 1.72 (m, 2H), 1.61-1.41 (m, 1H), 1.38-1.27 (m, 3H), 1.20-1.15 (m, 2H), 1.14 (d, J= 6.7 Hz, 3H), 1.08 (d, J= 6.8 Hz, 3H), 1.01 (d, J= 6.6 Hz, 3H), 1.00 (d, J= 6.7 Hz, 3H), 0.99-0.87 (m, 39H), 0.16-0.07 (m, 24H); 13C NMR (75 MHz, CDC13) S
166.7, 159.0, 147.1, 145.4, 134.5, 132.6, 132.3, 131.3, 129.0, 128.9, 126.8, 117.1, 115.4, 113.6, 84.3, 80.2, 75.0, 72.5, 72.1, 66.4, 55.1, 50.8, 43.4, 42.4, 40.6, 37.9, 35.9, 35.2, 33.9, 28.1, 26.2, 26.0, 25.90, 25.87, 25.6, 19.3, 18.8, 18.4, 18.1, 18.05, 18.04, 14.6, 13.3, 9.3, -3.0, -3.5, -3.7, -3.8, -4.2, -4.3, -4.4, -4.5; LRMS (ESI) 1149.7 [M+Na]+, 995.7, 436.2;
HRMS (ESI) calcd for C64H118O$Si4Na 1149.7802 [M+Na]+, found 1149.7813; [a]20D -3.8 (c 0.85, CHC13).
[00155] (2Z,4E,6R,7S,9S,102,12S,13R,14S,19R,20R,21S,22S,232)-Methyl-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-21-hydroxy-6,12,14,20,22-pentamethylhexacosa-2,4,10,23,25-pentaenoate (77). The procedure for 47 was used with 76 (0.38 g, 0.34 mol) and DDQ (0.084 g, 0.37 mmol) to yield 77 (0.28 g, 82%) after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 3542, 2956, 2856, 1722, 1640, 1462, 1254, 1175, 1086, 1004, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.39 (dd, J= 15.2, 11.2 Hz, 1H), 6.63 (ddd, J= 16.9, 10.5, 10.4 Hz, 1H), 6.53 (t, J= 11.3 Hz, 1H), 6.09 (t, J= 11.0 Hz, 1H), 5.98 (dd, J= 8.3, 7.1 Hz, 1H), 5.58 (d, J=
11.3 Hz, 1H), 5.45-5.39 (m, 2H), 5.26 (dd, J= 10.8, 8.4 Hz, 1H), 5.20 (d, J= 16.9 Hz, 1H), 5.11 (d, J=
10.1 Hz, 1H), 4.53 (m, 1H), 3.95 (m, 1H), 3.76 (m, 111), 3.71 (s, 3H), 3.47 (m, 1H), 3.40 (m, 1H), 2.82 (m, 1H), 2.55 (m, 1H), 2.20 (br, 111), 1.72 (m, 2H), 1.60-1.35 (m, 5H), 1.32-1.10 (m, 5H), 1.04 (d, J= 6.8 Hz, 3H), 0.99-0.83 (m, 48H), 0.12-0.03 (m, 24H); 13C
NMR (75 MHz, CDC13) 8 166.7, 147.1, 145.4, 135.2, 132.6, 132.5, 132.3, 130.0, 126.8, 117.7, 115.5, 80.2, 77.3, 76.2, 72.1, 66.5, 50.9, 43.4, 42.5, 38.3, 38.1, 36.1, 35.8, 34.7, 33.7, 28.3, 26.2, 25.94, 25.89, 25.5, 19.5, 18.4, 18.1, 17.7, 14.9, 13.3, 7.2, -3.0, -3.6, -3.8, -4.18, -4.20, -4.37, -4.41; LRMS (ESI) 1029.7 [M+Na]+, 875.6, 379.3; HRMS (ESI) calcd for C56H11oO7Si4Na 1029.7226 [M+Na]+, found 1029.7244; [a]20D -18.7 (c 0.62, CHC13).
[00156] (8S,lOS,14R,20R)-tetrakis(tert-Butyldimethylsilyloxy)-(7R,13S,15S,21S)-tetramethyl-(22S)-((1S)-methylpenta-2,4-dienyl)-oxacyclodocosa-3,5,11-trien-2-one (78).
The procedure for 48 was used with 77 (0.28 g, 0.28 mol) and 1N KOH (2.8 mL, 2.8 mmol) to yield the acid (0.27 g, quantitative) as a pale yellow oil, which was used directly in next step: IR (CHC13) 2930, 1693, 1635, 1462, 1387, 1255, 1089, 838, 773 cm 1; 1H
NMR (300 MHz, CDC13) S 7.36 (dd, J= 15.0, 11.4 Hz, 1H), 6.6-6.57 (m, 2H), 6.08 (t, J=
10.9 Hz, 1H), 6.02 (dd, J= 15.7, 7.0 Hz, 1H), 5.59 (d, J= 11.3 Hz, 1H), 5.45-5.39 (m, 2H), 5.26 (m, 1H), 5.20 (d, J= 17.8 Hz, 1H), 5.11 (d, J= 10.2 Hz, 1H), 4.55 (in, 111), 3.95 (m, 1H), 3.76 (m, 1H), 3.49 (m, 1H), 3.41 (m, 1H), 2.82 (m, 1H), 2.57 (m, 2H), 1.70 (m, 2H), 1.57-1.41 (m, 5H), 1.31-1.12 (m, 5H), 1.04 (d, J= 6.7 Hz, 3H), 0.99-0.84 (m, 48H), 0.12-0.04 (m, 24H);
13C NMR (75 MHz, CDC13) S 170.9, 147.7, 146.8, 134.9, 132.5, 132.4, 132.2, 130.0, 126.9, 117.6, 115.5, 80.1, 75.7, 72.0, 66.4, 58.1, 43.4, 42.5, 38.3, 38.1, 35.9, 35.6, 34.7, 33.5, 28.3, 26.2, 25.90, 25.85, 25.5, 25.1, 19.5, 18.4, 18.1, 18.0, 17.7, 14.9, 13.3, 7.3, -3.1, -3.7, -3.8, -3.9, -4.2, -4.3, -4.4, -4.5; LRMS (ESI) 1015.7 [M+Na]+, 861.6, 729.5, 651.4;
HRMS (ESI) calcd for CssHi0sO7Si4Na 1015.7070 [M+Na]+, found 1015.7091; [a]20p -14.6 (c 1.4, CHC13). The procedure for 49 was used with the acid (0.26 g, 0.26 mol), 2,4,6-trichlorobenzoyl chloride (0.21 mL, 1.30 mmol), Et3N (0.22 mL, 1.56 inmol) and (130 mL, 2.6 mmol) to yield 78 (0.19 g, 76% for 2 steps) by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2956, 2929, 2856, 1714, 1640, 1471, 1255, 1088, 836, 773 cm 1; iH NMR (300 MHz, CDC13) 8 7.16 (dd, J= 15.6, 11.2 Hz, 1H), 6.61 (ddd, J= 16.8, 10.6, 10.5 Hz, 1H), 6.52 (t, J= 11.3 Hz, 1H), 6.03 (d, J=
9.6, 5.9 Hz, I H), 6.00 (t, J= 10.6 Hz, I H), 5.62 (t, J= 10.5 Hz, 1 H), 5.5 6(d, J= 11.3 Hz, 1 H), 5.3 9(t, J
= 10.5 Hz, 1H), 5.28 (dd, J= 11.2, 8.0 Hz, 1H), 5.20-5.14 (m, 2H), 5.09 (d, J=10.3 Hz, 1H), 4.59 (m, 1H), 4.01 (m, IH), 3.53 (in, 1H), 3.43 (m, IH), 3.06 (m, 1H), 2.56 (m, 1H), 2.45 (m, 1H), 1.90 (m, 1H), 1.55-1.35 (m, 6H), 1.28 (m, 1H), 1.24-1.12 (m, 4H), 1.08 (d, J= 6.7 Hz, 3H), 1.02 (d, J= 5.9 Hz, 3H), 1.01 (d, J= 6.0 Hz, 3H), 0.93-0.88 (m, 39H), 0.81 (d, J= 6.9 Hz, 3H), 0.14-0.05 (m, 24H); 13C NMR (75 MHz, CDCI,) b 166.2, 144.1, 142.6, 133.9, 132.1, 131.5, 129.7, 128.0, 127.5, 117.8, 117.6, 80.3, 74.0, 71.2, 66.5, 62.4, 43.7, 39.8, 39.3, 34.9, 34.0, 33.0, 31.8, 27.8, 26.1, 26.05, 25.98, 20.1, 18.33, 18.28, 18.14, 18.11, 17.8, 16.1, 14.0, 10.7, -2.7, -3.8, -4.0, -4.1, -4.2, -4.3; LRMS (ESI) 997.7 [M+Na]+, 843.6, 711.5, 579.4; HRMS (ESI) calcd for C5sH106O6Si4Na 997.6964 [M+Na]+, found 997.6989;
[a]20D -26.4 (c 0.59, CHC13).
[00157] (8S,10S,14R,20R)-Tetrahydroxy-(7R,13S,15S,21S)-tetramethyl-(22S)-((LS)-methylpenta-2,4-dienyl)-oxacyclodocosa-3,5,11-trien-2-one (79). The procedure for 1 was used with 78 (0.19 g, 0.19 mol), 3N HCl in 15 ml of 2:1 MeOH/THF to yield 79 (25 mg, 24%) after flash coluinn chromatography (EtOAc/hexane 3:7) as a colorless oil: IR
(CHC13) 3414, 2965, 2930, 1708, 1637, 1454, 1375, 1273, 1182, 1046, 968 cnf 1;
(600 MHz, CD3OD) S 7.22 (dd, J= 15.4, 11.2 Hz, 1H), 6.67 (ddd, J= 17.3, 11.0, 10.5 Hz, 1H), 6.64 (dd, J= 11.4, 11.4 Hz, 1 H), 6.07 (dd, J= 15.4, 7.7 Hz, 1H), 6.02 (dd, J= 10.9, 10.9 Hz, 1H), 5.55 (t, J= 10.6 Hz, 1H), 5.52 (d, J=11.4 Hz, 1H), 5.43 (dd, J= 10.9, 9.0 Hz, 1H), 5.3 5(dd, J= 10.7, 10.6 Hz, 1 H), 5.20 (d, J= 16.7 Hz, 1 H), 5.12 (d, J= 10.2 Hz, 1 H), 5.08 (dd, J= 5.9, 5.9 Hz, 1H), 4.64 (m, 1H), 3.86 (ddd, J= 8.4, 4.7, 4.5 Hz, 1H), 3.43 (m, 1H), 3.16 (m, 1H), 3.14 (dd, J= 8.1, 2.6 Hz, 1H), 2.73 (m, 1H), 2.37 (m, 1H), 1.84 (m, 1H), 1.68 (m, 1H), 1.51-1.45 (m, 3H), 1.31 (m, 1H), 1.20 (m, 1H), 1.14-1.11 (m, 1H), 1.08 (d, J= 6.9 Hz, 6H), 1.07-1.01 (in, 2H), 0.99 (d, J= 6.8 Hz, 3H), 0.98 (d, J= 6.7 Hz, 3H), 0.95 (m, 1H), 0.92 (d, J= 6.6 Hz, 3H); 13C NMR (150 MHz, CD3OD) 8 168.2, 146.6, 144.8, 134.3, 133.8, 133.4, 132.2, 131.3, 129.1, 118.5, 118.0, 79.9, 79.3, 72.4, 71.0, 65.5, 44.9, 41.7, 40.7, 37.9, 36.0, 35.4, 35.2, 33.9, 27.4, 27.2, 19.5, 18.3, 16.4, 15.1, 10.1; LRMS (ES1) 541.3 [M+Na]}, 483.3; HRMS (ESI) calcd for C31H50O6Na 541.3505 [M+Na]+, found 541.3521;
[a]20D -34.4 (c 0.18, MeOH).
[00158] (3S,4S,E)-3-(tert-Butyldimethylsilyloxy)-N-methoxy 1V,4-dimethyl-7-(trityloxy)hept-5-enamide (81). (3S,4S,E)-3-(tert-Butyldimethylsilyloxy)-4-methyl-7-trityloxyhept-5-en-l-ol (0.34 g, 0.66 mmol) in CHZC12 (10 mL) was treated with Dess-Martin periodinane (0.41 g, 0.99 mmol). After 1 h, the mixture was quenched with saturated NaHCO3 (10 mL). The aqueous layer was extracted with ethyl ether (10 mL x 2) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 8:2) to remove the Dess-Martin residue provided the aldehyde as a colorless oil, which was used for the next reaction without further purification. A solution of the above aldehyde in THF (10 mL) and H20 (5 mL) was treated with a 2 M solution of 2-methyl-2-butene (1.9 mL, 0.95 mmol) in THF, NaHZPO4=H20 (0.27 g, 1.96 mmol) and NaC1O2 (0.22 g, 1.96 mmol). The reaction mixture was stirred for 2 h, diluted with 1N HCI (20 mL) and extracted with CH2C12 (2 x 40 mL). The combined organic layers were dried over MgSO4, concentrated in vacuo and the crude was used for the next reaction without further purification. To a solution of acid in CH2C12, N, 0-dimethylhydroxylamine hydrochloride (0.064 g, 0.65 mmol), Et3N (0.09 mL, 0.65 mmol), DMAP (8 mg, 0.065 mmol) were successively added. The reaction mixture was cooled to 0 C, DCC (0.14 g, 0.65 mmol) was added. The mixture was stirred at ambient temperature for 15 h and filtered. The filtrate was washed with 0.5 N HCI, saturated aqueous NaHCO3, and brine, dried over anllydrous MgSO4 and concentrated. Purification by column chromatography over silica gel (hexane/EtOAc 4:1) gave the Weinreb amide 81 (0.37 g, 81 % for 3 steps) as a colorless oil: IR (CHC13) 2956, 2929, 2855, 1661, 1448, 1385, 1251, 1089, 1054, 1003, 836, 775, 706 cm 1; 1H NMR (300 MHz, CDC13) 57.64-7.61, m, 6H), 7.45-7.33 (m, 9H), 6.09 (dd, J= 15.7, 6.6 Hz, 1H), 5.75 (dt, J= 15.7, 5.2 Hz, 1H), 4.42 (m, 1H), 3.76 (s, 3H), 3.70 (m, 2H), 3.29 (s, 3H), 2.88 (m, 1H), 2.55 (m, 2H), 1.18 (d, J=
6.8 Hz, 3H), 1.06 (s, 9H), 0.27 (s, 3H), 0.20 (s, 3H) ; 13C NMR (75 MHz, CDC13) S 172.5, 144.2, 133.5, 128.5, 127.6, 126.8, 86.5, 72.8, 64.6, 61.1, 42.2, 36.0, 31.9, 25.8, 18.0, 14.8, -4.7, -4.8; LRMS (EI) 573, 558, 516, 246, 165; HRMS (EI) calcd for C35H47O4N1Si1 573.3290, found 573.3290;
[a]20D -40.1 (c 1.2, CHC13).
[00159] (4S,5S,10S,11R,12R,14R,E)-11-(4-Methoxybenzyloxy)-5,15-bis(tert-butyldimethylsilyloxy)-4,10,12,14-tetramethyl-l-(trityloxy)pentadec-2-en-8-yn-7-one (82).
Alkyne 80 (7.75 g, 18.5 mmol) was taken up in THF (185 mL) and cooled to -78 C. n-BuLi (11.6 mL, 1.6 M solution in hexane) was added slowly. After 5 min, the mixture was warmed to 0 C and stirred for 30 min. The mixture was then cooled to -78 C and amide 81 (5.31 g, 9.26 mmol) in THF (15 mL) was added slowly. After 5 min the solution was warmed to 0 C
and stirred for 1 h. The reaction was quenched with aq NH4Cl and the mixture was partitioned in a separatory funnel. The aqueous phase was extracted with ether (50 mL x 3) and combined organic extracts were washed with brine and dried over MgSO4.
Filtration and concentration under reduced pressure, followed by flash chromatography on silica gel (hexane/EtOAc 95:5) afforded ynone (8.45 g, 98 %) as a pale yellow oil: IR
(CHC13) 2955, 2929, 2856, 2208, 1674, 1514, 1470, 1249, 1092, 836, 775, 706 cm 1; 1H NMR
(300 MHz, CDC13) 57.50-7.47, m, 6H), 7.35-7.22 (m, 11H), 6.88-6.84 (m, 2H), 5.81 (dd, J=
15.6, 6.7 Hz, 1H), 5. 5 8(dt, .I = 15.6, 5.2 Hz, 1H), 4.64 (d, J= 10.8 Hz, 1 H), 4.54 (d, J= 10.8 Hz, 1H), 4.27 (m, 1H), 3.80 (s, 3H), 3.59 (d, J= 5.2 Hz, 2H), 3.44-3.34 (m, 2H), 3.18 (t, J= 5.4 Hz, 1H), 2.94 (m, 1H), 2.62 (m, 1H), 2.38 (m, 1H), 1.89 (m, 1H), 1.68 (m, 1H), 1.26 (d, J= 7.0 Hz, 3H), 1.24 (m, 1 H), 0.99 (d, J= 6.9 Hz, 3H), 0.97 (d, J= 6.9 Hz, 3H), 0.92 (s, 9H), 0.91 (m, 1H), 0.89 (s, 9H), 0.84 (d, J = 6.7 Hz, 3H), 0.09-0.05 (m, 12H); 13C NMR
(75 MHz, CDC13) S 186.4, 159.1, 144.3, 133.5, 130.7, 129.2, 128.7, 127.7, 127.3, 126.9, 113.7, 96.8, 86.8, 86.2, 82.6, 74.0, 72.3, 69.2, 64.9, 55.2, 50.5, 42.3, 34.9, 33.2, 33.0, 29.5, 26.0, 25.9, 18.3, 18.1, 17.2, 16.3, 15.9, 14.8, -4.50, -4.55, -5.3; LRMS (ESI) 953.6 [M+Na]+, 855.4, 797.4, 577.5, 413.4, 359.3, 328.4; HRMS (ESI) calcd for C58H82O6Si2Na 953.5548 [M+Na]+, found 953.5552; [a]20D -9.5 (c 2.8, CHC13).
[00160] (4S,5S,7.S,10S,11R,12R,14R,E)-11-(4-Methoxybenzyloxy)-5,15-bis(tert-butyldimethylsilyloxy)-4,10,12,14-tetramethyl-l-(trityloxy)pentadec-2-en-8-yn-7-ol (83).
Ynone 82 (7.06 g, 7.59 mmol) was taken up in i-PrOH (100 mL). Noyori catalyst (1.02 g, 1.52 mmol, 20 mol%) was added in one portion and the solution was stirred for 12 h. The solvent was removed under vacuum, and the crude residue was purified by flash chromatography on silica gel (hexane/EtOAc 9:1), affording propargylic alcohol 83 (6.16 g, 87 %) as a pale yellow oil: IR (CHC13) 3434, 2955, 2928, 2855, 1613, 1513, 1462, 1250, 1091, 836, 775 cm 1; 'H NMR (300 MHz, CDC13) S 7.59-7.57 (m, 6H), 7.42-7.30 (m, 11H), 6.96-6.93 (m, 2H), 5.96 (dd, J= 15.7, 6.4 Hz, 1H), 5.68 (dt, J= 15.2, 5.3 Hz, 1H), 4.79 (d, J
= 10.8 Hz, 1H), 4.67 (m, 1H), 4.63 (d, J= 10.9 Hz, 1H), 4.07 (m, 1H), 3.86 (s, 3H), 3.69 (d, J
= 4.7 Hz, 2H), 3.49 (m, 2H), 3.22 (t, J= 5.5 Hz, 1H), 2.91 (m, 1 H), 2.67 (d, J= 5.3 Hz, 1 H), 2.56 (m, 1H), 1.98 (m, 1H), 1.86 (m, 2H), 1.77 (m, 1H), 1.36 (m, 1H), 1.31 (d, J= 7.0 Hz, 3H), 1.09 (d, J= 7.1 Hz, 3H), 1.06 (d, J= 7.1 Hz, 3H), 1.03 (s, 9H), 1.02 (s, 9H), 0.94 (d, J=
6.6 Hz, 3H), 0.24 (s, 3H), 0.22 (s, 3H), 0.15 (s, 6H); 13C NMR (75 1VIHz, CDC13) S 158.9, 144.3, 133.2, 131.0, 129.1, 128.6, 127.7, 127.0, 126.8, 113.5, 87.5, 86.79, 86.74, 82.6, 74.0, 73.3, 69.3, 65.0, 59.6, 55.1, 41.4, 40.2, 34.5, 33.1, 32.7, 29.1, 25.9, 18.3, 18.0, 17.9, 16.6, 15.8, 15.3, -4.3, -4.5, -5.4; LRMS (ESI) 955.6 [M+Na]+, 707.3, 633.3, 559.2, 413.3; HRMS
(ESI) calcd for C58H84O6Si2Na 955.5704 [M+Na]+, found 955.5734; [a]20D -8.5 (c 1.5, CHC13).
[00161] (2E,4S,5S,7S,8Z,10S,11R,12R,14R)-11-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-15-(tert-butyldimethylsilyloxy))-4,10,12,14-tetramethyl-(trityloxy)pentadeca-2,8-dien-7-ol (84). A catalytic amount of Lindlar catalyst (ca. 200 mg) was added to a solution of alcoho183 (3.11 g, 3.33 mmol) in toluene (100 mL).
The flask was fitted with a Ha balloon, and stirred under an atmosphere of H2 until starting material was consumed (usually 1 h), as indicated by TLC analysis. The mixture was filtered through a pad of celite and concentrated under reduced pressure to afford the olefin 84 as a colorless oil (2.81 g, 90 %): IR (CHC13) 3434, 2956, 2928, 2856, 1613, 1514, 1471, 1249, 1062, 836, 774 cm i; 1H NMR (300 MHz, CDC13) 6 7.58-7.55 (m, 6H), 7.4-7.29 (m, 1H), 6.93 (m, 2H), 5.90 (dd, J= 15.6, 6.6 Hz, 1H), 5.68 (dt, J= 15.7, 5.4 Hz, 1H), 5.60 (dd, J= 11.1, 8.9 Hz, 1H), 5.51 (dd, J= 11.2, 7.3 Hz, 1H), 4.66 (m, 1H), 4.58 (d, J= 10.9 Hz, 1H), 4.55 (d, J= 10.9 Hz, 1H), 3.95 (m, 1H), 3.86 (s, 3H), 3.66 (dd, J= 4.9 Hz, 1H), 3.52-3.38 (m, 2H), 3.01 (m, 2H), 2.89 (br, 1H), 2.55 (m, 1H), 1.79 (m, 1H), 1.70 (m, 1H), 1.62 (m, 2H), 1.33-1.29 (m, 2H), 1.12 (d, J= 5.8 Hz, 3H), 1.10 (d, J= 6.7 Hz, 3H), 1.02 (s, 9H), 1.01 (s, 9H), 0.89 (d, J= 6.1 Hz, 314), 0.87 (d, J= 6.3 Hz, 3H), 0.19 (s, 6H), 0.14 (s, 6H); 13C NMR (75 MHz, CDC13) 8 158.9, 144.3, 134.1, 133.5, 132.6, 131.0, 129.0, 128.6, 127.7, 126.8, 126.7, 113.5, 88.4, 86.7, 74.9, 73.5, 69.4, 65.2, 65.1, 55.1, 41.8, 40.2, 35.0, 34.6, 33.1, 25.9, 19.1, 18.3, 18.0, 16.6, 15.8, 15.6, -4.4, -4.5, -5.3; LRMS (ESI) 957.6 [M+Na]+, 781.4, 707.3, 559.3, 485.2, 413.4;
HRMS (ESI) calcd for C58H86O6SiaNa 957.5861 [M+Na]+, found 957.5900; [a]20D
+2.0 (c 1.2, CHC13).
[00162] ((2E,4S,5S,7S,8Z,10S,11R,12R,14R)-11-(4-Methoxybenzyloxy)-5,7,15-tf=is(tert-butyldimethylsilyloxy)-4,10,12,14-tetramethylpentadeca-2,8-dienyloxy)triphenylmethane (85). TBSOTf (1.05 mL, 4.57 mmol) was added to a stirred solution of the alcohol 84 (3.89 g, 4.16 mmol) and 2,6-lutidine (0.58 mL, 5.01 mmol) in CH2C12 (14 mL) at 0 C. After stirring for 1 h at 0 C, the reaction mixture was quenched by the addition of water (25 mL), and extracted by CHZC12 and dried over MgSO4, followed by the evaporation of the solvent under reduced pressure. The residue was purified by short column chromatography (hexane/EtOAc 9:1) to obtain the product 85 (4.36 g, quantitative) as a colorless oil: IR (CHC13) 2956, 2928, 2856, 1613, 1514, 1471, 1462, 1250, 1088, 836, 773, 705 cm 1; 1H NMR (300 MHz, CDC13) S 7.61-7.58 (m, 6H), 7.43-7.31 (m, 11H), 6.97-6.94 (m, 2H), 5.95 (dd, J= 15.7, 6.0 Hz, 1H), 5.67 (dt, J= 15.7, 5.6 Hz, 1H), 5.62-5.46 (m, 2H), 4.71 (m, 1H), 4.62 (m, 2H), 4.05 (m, 1H), 3.87 (s, 3H), 3.69 (d, J= 5.3 Hz, 2H), 3.53-3.40 (m, 2H), 3.08 (m, 1H), 2.91 (m, 1H), 2.51 (m, 1H), 1.76 (m, 1H), 1.66 (m, 2H), 1.50-1.40 (m, 2H), 1.32 (m, 1H), 1.22 (d, J= 6.8 Hz, 6H), 1.09 (d, J= 6.9 Hz, 3H), 1.06-0.96 (m, 27H), 0.91 (d, J= 6.6 Hz, 3H), 0.83 (d, J= 6.5 Hz, 3H), 0.25-0.17 (m, 18H);
13C NMR (75 MHz, CDC13) 6 158.9, 144.4, 134.3, 133.7, 131.4, 129.4, 129.0, 128.6, 127.7, 126.8, 126.4, 113.5, 88.8, 86.7, 74.8, 72.8, 69.5, 66.3, 65.1, 55.1, 43.0, 42.3, 35.4, 35.1, 33.4, 33.1, 26.1, 26.0, 18.8, 18.3, 18.1, 16.7, 15.7, 14.6, -2.8, -3.9, -4.1, -4.2, -5.3; LRMS
(ESI) 1071.9 [M+Na]+, 413.4, 359.3, 243.2; HRMS (ESl) calcd for C64H100O6Si3Na 1071.6725 [M+Na]+, found 1071.6779; [a]20D -9.5 (c 3.0, CHC13).
[00163] (2R,4R,5R,6S,7Z,9S,11S,12S,13E)-1,9,11-tris(tert-Butyldimethylsilyloxy)-2,4,6,12-tetramethy1-15-(trityloxy)pentadeca-7,13-dien-5-ol (86). The above PMB alcohol 85 (2.90 g, 2.77 mmol) was added to CH2C12 (25 mL) and H20 (1 mL), and DDQ
(0.94 g, 4.15 mol) was added. After 1 h of stirring, the reaction mixture was quenched by adding sat'd NaHCO3 (200 mL). The organic phase was washed by sat'd NaHCO3 solution (3 x 100 mL) and brine, dried over MgSO4 and concentrated. Purification by flash column chromatography (EtOAc/hexane 5:95) furnished 86 (2.16 g, 84 %) as a colorless oil: IR
(CHC13) 3477, 2956, 2928, 2856, 1471, 1386, 1254, 1088, 836, 774 cm 1; 1H NMR
(300 MHz, CDC13) 8 7.55-7.52 (m, 6H), 7.38-7.25 (m, 9H), 5.92 (dd, J= 15.7, 6.0 Hz, 1H), 5.62 (dt, J= 15.7, 5.5 Hz, 1H), 5.52 (dd, J= 11.1, 9.3 Hz, 1H), 5.3 5(t, J= 10.5 Hz, 1H), 4.63 (m, 1H), 3.97 (m, 1H), 3.63 (d, J= 5.4 Hz, 2H), 3.51-3.36 (m, 2H), 3.18 (m, 1H), 2.68 (m, 1H), 2.47 (m, 1H), 1.71-1.59 (m, 3H), 1.42-1.27 (m, 2H), 1.17 (m, 1H), 1.08 (d, J=
6.7 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 0.99 (s, 9H), 0.97 (s, 9H), 0.96 (s, 9H), 0.91 (d, J=
6.8 Hz, 3H), 0.84 (d, J= 6.6 Hz, 3H), 0.18 (s, 3H), 0.16 (s, 3H), 0.15 (s, 3H), 0.13 (s, 3H), 0.12 (s, 6H);
13C NMR (75 MHz, CDC13) S 144.4, 135.2, 134.1, 131.1, 128.7, 127.7, 126.8, 126.4, 86.7, 79.8, 72.8, 69.6, 66.2, 65.2, 43.0, 42.1, 35.5, 33.7, 32.8, 32.5, 26.1, 26.0, 25.9, 18.4, 18.1, 17.6, 16.8, 16.3, 14.7, -2.9, -4.0, -4.15, -4.22, -5.3; LRMS (ESI) 951.7 [M+Na]+, 823.7, 577.4, 413.3, 328.4, 243.1; HRMS (ESI) calcd for C56H92O5Si3Na 951.6150 [M+Na]+, found 951.6165; [a]20D 30.0 (c 3.6, CHC13).
[00164] ((2E,4S,5S,7S,8Z,IOS,11R,12R,14R)-5,7,11,15-tetrakis(tert-Butyldimethylsilyloxy)-4,10,12,14-tetramethylpentadeca-2,8-dienyloxy)triphenylmethane (87). The procedure for 85 was used with above 86 (3.34 g, 3.60 mol), TBSOTf (1.82 mL, 7.9 mmol) to yield 3.53 g (94 %) of the product by flash column chromatography (EtOAc/Hexane 5:95) as a colorless oil: IR (CHC13) 2956, 2928, 2856, 1471, 1462, 1361, 1254, 1088, 836, 773, 705 cm 1; 1H NMR (300 MHz, CDC13) S 7.50-7.48 (m, 6H), 7.34-7.22 (m, 9H), 5.82 (dd, J= 15.7, 6.0 Hz, 1H), 5.57 (dt, J=
15.8, 5.9 Hz, 1H), 5.48 (dd, J= 11.0, 9.9 Hz, 1H), 5.32 (dd, J= 11.0, 8.7 Hz, 1H), 4.56 (m, 1H), 3.93 (m, 1H), 3.59 (d, J= 5.5 Hz, 2H), 3.39 (dd, J= 9.6, 5.8 Hz, 111), 3.31-3.27 (m, 2H), 2.62(m, 1H), 2.40 (m, 1H), 1.58-1.50 (m, 3H), 1.35 (m, 1H), 1.20-1.09 (m, 2H), 1.02 (d, J=
7.1 Hz, 3H), 1.00 (d, J= 7.0 Hz, 3H), 0.94 (s, 9H), 0.92 (s, 9H), 0.91 (s, 9H), 0.90 (s, 9H), 0.78 (d, J= 6.8 Hz, 3H), 0.74 (d, J= 6.6 Hz, 3H), 0.13-0.05 (m, 24H); 13C NMR (75 MHz, CDC13) S 144.4, 134.5, 133.0, 131.8, 128.7, 127.7, 126.8, 126.4, 86.7, 81.2, 72.8, 69.3, 66.6, 65.3, 43.1, 42.3, 35.9, 35.1, 33.3, 29.7, 26.2, 26.1, 26.0, 19.6, 18.4, 18.3, 18.2, 16.3, 16.0, 14.6, -2.8, -3.5, -3.6, -4.0, -4.1, -5.3; LRMS (ESI) 1065.7 [M+Na]+, 953.7, 615.1, 577.3, 359.2;
HRMS (ESI) calcd for C62H1o6O5Si4Na 1065.7015 [M+Na]+, found 1065.7068; [a]20D -22.5 (c 2.0, CHC13).
[00165] (2R,4R,5R,6S,7Z,9S,I IS,12S,13E)-5,9,11-tris(tert-Butyldimethylsilyloxy)-2,4,6,12-tetramethyl-15-(trityloxy)pentadeca-7,13-dien-l-ol (88). HF-pyridine in pyridine (40 mL, prepared by slow addition of 12 mL pyridine to 3 mL HF-pyridine complex followed by dilution with 25 mL THF) was slowly added to a solution of TBS ether 87 (3.54 g, 4.10 mmol) in THF (5 mL) at 0 C. The mixture was stirred for 2 days at 0 C and quenched with sat'd NaHCO3 (100 mL). The aqueous layer was separated and extracted with Et20 (3 x 50 mL). The combined organic layers were washed with sat'd CuSO4 (3 x 50 mL), dried over MgSO4, and concentrated. Flash colunm chromatography (EtOAc/hexane 15:85) afforded 2.08 g (66 %) of the alcohol as a colorless oil: IR (CHC13) 3400, 2956, 2928, 2856, 1471, 1448, 1254, 1075, 836, 773 cm i; 1H NMR (300 MHz, CDC13) 8 7.52-7.48 (m, 6H), 7.36-7.24 (m, 9H), 5.87 (dd, J= 15.7, 5.9 Hz, 1H), 5.59 (dt, J= 15.7, 5.7 Hz, 1H), 5.55 (dd, J= 10.6, 10.4 Hz, 1H), 5.33 (dd, J= 11.0, 8.7 Hz, 1H), 4.58 (m, 1H), 3.94 (m, 1H), 3.60 (d, J= 5.5 Hz, 2H), 3.38-3.32 (m, 2H), 3.25 (m, 1H), 2.62 (m, 1H), 2.45 (m, 1H), 1.59 (m, 1H), 1.55 (m, 1H), 1.47 (m, 1H), 1.35 (m, 1H), 1.09 (m, 1H), 1.04 (d, J= 7.6 Hz, 3H), 1.01 (d, J= 7.2 Hz, 3H), 0.96 (s, 9H), 0.94 (s, 9H), 0.93 (s, 9H), 0.79 (d, J= 6.8 Hz, 3H), 0.75 (d, J= 6.6 Hz, 3H), 0.15 (s, 9H), 0.14 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H); 13C NMR
(75 MHz, CDC13) 8 144.4, 134.0, 132.7, 131.3, 128.7, 127.7, 126.8, 126.5, 86.8, 81.0, 73.0, 69.2, 66.5, 65.3, 42.6, 42.2, 36.2, 35.5, 34.6, 33.3, 26.2, 26.1, 25.9, 20.0, 18.4, 18.2, 18.1, 15.7, 15.6, 14.9, -2.8, -3.7, -3.8, -4.0, -4.1, -4.2; LRMS (ESI) 951.6 [M+Na]+, 705.1, 631.1, 557.0, 397.2, 381.2, 353.2, 243.1; HRMS (ESI) calcd for C56H92O5Si3Na 951.6150 [M+Na]+, found 951.6158; [oc]20D -33.5 (c 2.0, CHC13).
[00166] (2R,4E,6R,8R,9R,lOS,11Z,13S,15S,16S,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxy)phenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-4,11,17-trien-3-one (89). The alcohol 88 (2.04 g, 2.20 mol) in CH2C12 (30 mL) was treated with Dess-Martin periodinane (1.40 g, 3.30 gmol). After 1 h, the mixture was quenched with saturated NaHCO3 (30 mL) and Na2S2O3 (30 mL). The aqueous layer was extracted with ethyl ether (30 mL x 2) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography filtration (hexane/EtOAc 4:1) to remove the residue from the Dess-Martin reagent provided crude aldehyde as a colorless oil, which was used for the next reaction without further purification. A mixture of ketophosphonate 38 (0.85 g, 2.20 mmol) and Ba(OH)2 (0.30 g, activated by heating to 100 C for 1-2 h before use) in THF (40 mL) was stirred at room temperature for 30 min. A solution of the above aldehyde in wet THF (4 mL + 4 x 1 mL washings, 40:1 THF/H20) was then added. After stirring for 12 h, the reaction mixture was diluted with EtaO (30 mL) and washed with sat'd NaHCO3 (50 mL) and brine (50 mL). The organic solution was dried (MgSO4) and the solvent was evaporated in vacuo. The residue was chromatographed (hexane/EtOAc 9:1) to yield 89 (2.04 g, 78 % for 2 steps) as a colorless oil: IR (CHC13) 2957, 2929, 2855, 1618, 1518, 1461, 1388, 1251, 1078, 1036, 836, 773 cm l; 1H NMR (300 MHz, CDC13) 8 7.49-7.46 (m, 6H), 7.39 (m, 2H), 7.33-7.21 (m, 9H), 6.89 (m, 2H), 6.79 (dd, J= 15.7, 7.4 Hz, 1H), 6.20 (d, J= 15.6 Hz, 1H), 5.85 (dd, J= 15.7, 5.9 Hz, 1H), 5.58 (dt, J= 15.7, 4.6 Hz, 1H), 5.49 (dd, J= 11.0, 10.4 Hz, 1H), 5.46 (s, 1H), 5.34 (dd, J= 11.1, 8.6 Hz, 1H), 4.56 (m, 1H), 4.12 (dd, J= 11.3, 4.6 Hz, 1H), 3.92 (m, 2H), 3.81 (s, 3H), 3.57 (d, J= 5.6 Hz, 1 H), 3.54 (m, 1 H), 3.29 (dd, J= 5.6, 2.4 Hz, 1H), 2.93 (m, 1H), 2.61 (in, 1H), 2.43 (m, 1H), 2.18 (m, 1H), 2.01 (m, 1H), 1.59-1.46 (m, 2H), 1.43 (m, 1H), 1.35-1.29 (m, 2H), 1.25 (d, J= 7.0 Hz, 3H), 1.03 (d, J= 7.2 Hz, 3H), 1.00 (d, J= 7.0 Hz, 3H), 0.94 (s, 9H), 0.92 (s, 9H), 0.91 (s, 9H), 0.82 (d, J= 7.0 Hz, 3H), 0.79 (d, J= 6.7 Hz, 3H), 0.77 (d, J= 6.5 Hz, 3H), 0.13 (s, 3H), 0.12 (s, 3H), 0.09 (s, 3H), 0.08 (s, 3H), 0.05 (s, 3H), 0.02 (s, 3H); 13C NMR (75 MHz, CDC13) 8 200.7, 159.8, 153.3, 144.3, 134.0, 133.3, 131.1, 130.8, 128.6, 127.7, 127.2, 126.8, 126.5, 125.7, 113.4, 100.8, 86.7, 82.7, 80.4, 72.8, 66.5, 65.8, 65.2, 55.2, 47.0, 42.8, 42.1, 39.1, 35.6, 34.9, 34.0, 32.3, 26.1, 26.0, 25.9, 19.7, 18.39, 18.36, 18.1, 16.4, 15.2, 14.7, 12.4, 10.7, -2.8, -3.6, -3.7, -4.0, -4.1; LRMS
(ESI) 1209.7 [M+Na]+, 577.4, 359.2, 243.1, 165.0; HRMS (ESI) calcd for C72H110O8Si3Na 1209.7406 [M+Na]+, found 1209.7466; [a]20D - 8.6 (c 2.5, CHC13).
[00167] (2R,6S,8R,9R,lOS,112,13S,15S,16S,17E)-9,13,15-tris(tert-Sutyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-3-one (90). NiCl2=6H2O
(0.20 g, 0.84 mmol) then portionwise NaBH4 (0.17 g, 4.49 mmol) were added to a stirred solution of unsaturated ketone 89 (2.60 g, 1.72 inol) in MeOH (60 mL), THF (20 mL) at 0 C. After 1 h, the reaction mixture was evaporated and filtered with celite using Et20 as an eluent (30 mL). The organic phase was concentrated and the residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 90 (1.55 g, 76 %) as a colorless oil: IR (CHC13) 2956, 2929, 2855, 1713, 1616, 1518, 1462, 1251, 1076, 836, 773 cm"1; 1H NMR
(300 MHz, CDC13) 6 7.52-7.50 (m, 6H), 7.42-7.24 (m, 11H), 6.92-6.86 (m, 2H), 5.87 (dd, J= 15.7, 6.0 Hz, 2H), 5.60 (dt, J= 15.8, 5.9 Hz, 1H), 5.50 (m, 1H), 5.49 (s, 1H), 5.37 (dd, J= 10.9, 8.5 Hz, 1H), 4.59 (m, 1H), 4.17 (dd, J= 11.3, 4.7 Hz, 1H), 3.98 (m, 2H), 3.82 (s, 3H), 3.62-3.55 (m, 3H), 3.29 (m, 1H), 2.73 (m, 1H), 2.65 (m, 1H), 2.49 (m, 2H), 2.06 (m, 1H), 1.63-1.50 (m, 2H), 1.47-1.32 (m, 2H), 1.27 (d, J= 7.1 Hz, 3H), 1.26 (m, 1H), 1.06 (d, J= 7.3 Hz, 3H), L03 (d, J= 7.2 Hz, 3H), 0.97-0.94 (m, 27H), 0.90-0.84 (in, 2H), 0.83 (d, J= 6.7 Hz, 3H), 0.76 (d, J= 7.0 Hz, 3H), 0.69 (d, J= 5.7 Hz, 3H), 0.17-0.05 (m, 18H); 13C NMR (75 MHz, CDC13) 8 211.7, 159.8, 144.4, 134.3, 133.1, 131.4, 130.9, 128.6, 127.9, 127.6, 127.1, 126.8, 126.4, 113.4, 100.8, 86.7, 82.9, 81.0, 72.8, 66.5, 65.2, 55.2, 48.3, 43.0, 42.2, 39.8, 38.3, 35.2, 35.1, 31.9, 31.3, 29.7, 26.2, 26.0, 25.9, 19.6, 18.6, 18.4, 18.1, 16.3, 14.6, 12.1, 9.7, -2.9, -3.5, -3.6, -4.0, -4.1, -4.2; LRMS (ESI) 1211.8 [M+Na]+, 577.3, 463.3, 413.3, 359.2, 316.9, 284.3;
HRMS (ESI) calcd for C72H112O8Si3Na 1211.7563 [M+Na]+, found 1211.7629; [a]20D
-4.3 (c 1.0, CHC13).
[00168] (2S,3R,6S,8R,9R,lOS,11Z,13S,15S,16S,17E)-9,13,15-tris(tert-Sutyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-3-ol (91). NaBH4 (0.074 g, 1.96 mmol) was added to a solution of ketone 90 (1.55 g, 1.30 mmol) in MeOH (21 mL) at 0 C.
After stirring for 2 h at 0 C, the reaction mixture was evaporated and water (30 mL) was added. The reaction mixture was extracted with ether (2 x 40 mL) and washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 1.02 g of major product (3 (less polar, 62 %) and 0.60 g (more polar, 36 %) of minor product a as colorless oils: (910) IR
(CHC13) 3540, 2956, 2929, 2855, 1615, 1518, 1461, 1385, 1252, 1074, 835, 773, 706 cm 1; 'H
NMR (300 MHz, CDC13) 8 7.54-7.50 (m, 6H), 7.42 (m, 2H), 7.37-7.25 (m, 9H), 6.94-6.91 (m, 2H), 5.88 (dd, J= 15.7, 6.0 Hz, 1H), 5.61 (dt, J= 16.0, 5.7 Hz, 1H), 5.56 (s, 1H), 5.50 (m, 1H), 5.37 (dd, J= 10.8, 8.6 Hz, 1H), 4.60 (m, 1H), 4.17 (dd, J= 11.2, 4.6 Hz, 1H), 3.96 (m, 1H), 3.87 (m, 1H), 3.84 (s, 3H), 3.74 (m, 1H), 3.64-3.53 (m, 3H), 3.32 (m, 1H), 3.20 (br, 1H), 2.67 (m, 1H), 2.44 (m,1H), 2.18 (m, 1H), 1.83 (m, 1H), 1.67-1.51 (m, 2H), 1.50-1.32 (m, 3H), 1.26 (m, 1H), 1.08 (d, J= 6.8 Hz, 3H), 1.07 (m, 2H), 1.06 (d, J= 7.0 Hz, 3H), 1.04 (d, J= 7.4 Hz, 3H), 0.98-0.85 (m, 2H), 0.82 (d, J= 6.7 Hz, 3H), 0.81 (d, J= 6.7 Hz, 3H), 0.77 (d, J= 6.0 Hz, 3H), 0.18-0.09 (m, 18H); 13C NMR (75 MHz, CDC13) S 160.0, 144.5, 144.4, 134.4, 132.9, 131.6, 130.7, 128.6, 127.6, 127.2, 126.8, 126.7, 126.4, 113.6, 101.2, 89.1, 86.7, 81.1, 76.8, 73.1, 72.8, 66.5, 55.2, 43.0, 42.3, 39.9, 37.2, 35.3, 35.1, 34.7, 32.3, 30.4, 30.2, 26.2, 26.1, 25.9, 19.6, 18.8, 18.4, 18.13, 18.10, 16.3, 14.6, 11.9, 5.5, -2.8, -3.56, -3.61, -4.0, -4.1, -4.16, -4.25; LRMS (API-ES) 1213.6 [M+Na]+, 557.0, 359.2, 243.1; HRMS (ESI) calcd for C72Hi14O8Si3Na 1213.7719 [M+Na]+, found 1213.7717; [a]20D -0.68 (c 7.1, CHC13): (91a) IR (CHC13) 3531, 2956, 2929, 2855, 1615, 1518, 1462, 1383, 1252, 1075, 836, 773 cm 1; 'H
NMR (300 MHz, CDC13) S 7.53-7.49 (m, 6H), 7.44-7.41 (m, 2H), 7.36-7.24 (m, 9H), 6.94-6.91 (m, 2H), 5.86 (dd, J= 15.7, 6.0 Hz, 1H), 5.60 (dt, J= 15.7, 5.7 Hz, 1H), 5.54 (s, 1H), 5.56-5.47 (m, 1H), 5.36 (dd, J= 11.0, 8.6 Hz, 1H), 4.60 (m, 1H), 4.17 (dd, J=
11.2, 4.6 Hz, 1H), 3.97-3.91 (m, 2H), 3.84 (s, 3H), 3.62 (d, J= 4.9 Hz, 2H), 3.61-3.53 (m, 2H), 3.32 (m, 1H), 2.67 (m, 1H), 2.44 (m,1H), 2.16 (m, 1H), 1.82 (m, 1H), 1.72-1.50 (m, 4H), 1.42-1.33 (m, 2H), 1.32-1.22 (m, 2H), 1.14 (d, J= 7.1 Hz, 3H), 1.06 ((d, J= 7.0 Hz, 3H), 1.03 (d, J=
7.0 Hz, 3H), 0.97-0.92 (m, 27H), 0.90-0.85 (m, 2H), 0.81 (d, J= 6.4 Hz, 3H), 0.79 (d, J= 6.6 Hz, 3H), 0.76 (d, J= 5.7 Hz, 3H), 0.17-0.09 (m, 18H); 13C NMR (75 MHz, CDC13) 6 160.0, 144.6, 144.4, 134.4, 133.0, 131.6, 131.1, 128.7, 127.7, 127.6, 127.3, 126.8, 126.7, 126.4, 113.6, 101.0, 86.7, 82.8, 81.2, 75.1, 73.3, 72.8, 66.6, 65.2, 55.2, 43.0, 42.3, 39.9, 37.9, 35.3, 35.1, 34.6, 33.4, 30.3, 26.3, 26.1, 26.0, 19.7, 19.0, 18.4, 18.1, 16.4, 14.6, 11.9, 11.1, -2.8, -3.5, -4.0, -4.07, -4.13; LRMS (ESI) 1213.8 [M+Na]+, 633.2, 359.2; HRMS (ESI) calcd for C72H114O8Si3Na 1213.7719 [M+Na]+, found 1213.7766; [a]20D -1.4 (c 4.7, CHC13).
[00169] (4S,5S)-4-((2R,3R,6S,8R,9R,l OS,11Z,13S,15S,16S,17E)-3,9,13,15-tetrakis(tert-Butyldimethylsilyloxy)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-2-yl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxane (92). TBSOTf (0.30 mL, 2.57 nunol) was added to a stirred solution of alcohol 91(3 (1.02 g, 0.86 mmol) and 2,6-lutidine (0.20 mL, 1.71 mmol) in CH2C12 (17 mL) at 0 C and the reaction mixture was stirred for 1 h at ambient teinperature. The reaction mixture was quenched by the addition of water (50 mL).
The reaction mixture was extracted by CH2C12 and dried over MgSO4 followed by the evaporation of the solution under reduced pressure. The residue was purified by short column chromatography (hexane/EtOAc 9:1) to yield product (0.97 g, 86 %) as a colorless oil: IR
(CHC13) 2955, 2928, 2856, 1615, 1518, 1471, 1462, 1387, 1251, 1074, 1038, 835, 773 cm 1;
1H NMR (300 MHz, CDC13) 8 7.52-7.46 (m, 6H), 7.45-7.42 (m, 2H), 7.35-7.22 (m, 9H), 6.92-6.89 (m, 2H), 5.86 (dd, J= 15.7, 6.0 Hz, 1H), 5.59 (dt, J= 15.7, 4.9 Hz, 1H), 5.48 (m, 1H), 5.47 (s, 1H), 5.36 (dd, J= 11.1, 8.6 Hz, 1H), 4.58 (m, 1H), 4.15 (dd, J=
11.2, 4.6 Hz, 1H), 3.96 (m, 1H), 3.81 (s, 3H), 3.73-3.66 (m, 2H), 3.60 (d, J= 5.6 Hz, 2H), 3.55 (m, 1H), 3.19 (m, 1H), 2.65 (m 1H), 2.42 (m, 1H), 2.07 (m, 1H), 1.91 (m, 1H), 1.57 (m, 2H), 1.40-1.21 (m, 3H), 1.14 (m, 1H), 1.06 (d, J= 6.7 Hz, 3H), 1.04 (d, J= 5.9 Hz, 3H), 1.02 (d, J= 6.9 Hz, 3H), 0.96-0.92 (m, 36H), 0.88-0.84 (m, 3H), 0.80 (m, 1H), 0.77 (d, J= 6.5 Hz, 3H), 0.76 (d, J= 6.4 Hz, 3H), 0.71 (d, J= 5.1 Hz, 3H), 0.16-0.03 (m, 24H); 13C NMR (75 MHz, CDC13) 8 159.7, 144.6, 144.4, 134.4, 133.2, 131.7, 131.4, 128.7, 127.7, 127.2, 126.8, 126.4, 113.4, 100.4, 86.7, 81.8, 81.4, 75.0, 73.3, 72.8, 66.5, 65.2, 55.2, 43.1, 42.3, 39.7, 38.9, 35.3, 35.0, 34.0, 31.2, 30.7, 30.6, 26.2, 26.1, 26.00, 25.95, 19.5, 19.1, 18.4, 18.13, 18.10, 16.5, 14.5, 12.4, 10.6, -2.8, -3.4, -3.95, -3.98, -4.2, -4.3; LRMS (ESI) 1327.8 [M+Na]+, 977.8, 739.6;
HRMS (ESI) calcd for C7gH128OgSi4Na 1327.8584 [M+Na]+, found 1327.8534; [a]20D
+6.7 (c 0.65, CHC13).
[00170] (2S,3S,4R,5R,8S,l OR,11R,12S,13Z,15S,17S,18S,19E)-3-(4-Methoxybenzyloxy)-5,11,15,17-tetrakis(tert-butyldimethylsilyloxy)-2,4,8,10,12,18-hexamethyl-21-(trityloxy)henicosa-13,19-dien-l-ol (93). DIBAL (1.0 M in hexane, 7.4 mL, 7.4 mmol) was added to a stirred solution of TBS protected acetal 92 (0.97 g, 0.74 mmol) in anhydrous CH2C12 (3 mL), under an atmosphere of N2 at 0 C dropwise.
After stirring for additional 30 min at 0 C, the reaction mixture was quenched by the careful addition of aqueous sat'd potassium sodium tartrate solution (30 mL) and stirred for 3 h at room temperature. The organic layer was separated, and the aqueous layer was extracted with CHZC12 (20 mL). The combined organic layers were washed with brine and dried over MgSO4 followed by the evaporation of the organic solution under reduced pressure. The residue was purified by column chromatography (EtOAc/hexane 1:9) to obtain 93 (0.94 g, 97 %) as a colorless oil: IR (CHC13) 3501, 2956, 2929, 2856, 1613, 1514, 1471, 1462, 1251, 1075, 835, 773, 705 crn 1; 'H NMR (300 MHz, CDC13) 6 7.55-7.51 (m, 6H), 7.37-7.25 (m, 11H), 6.94-6.92 (m, 2H), 5.90 (dd, J= 15.7, 5.9 Hz, 1H), 5.62 (dt, J= 15.6, 5.6 Hz, 1H), 5.56-5.48 (m, 1H), 5.40 (dd, J= 11.2, 8.5 Hz, 1H), 4.61 (m, 1H), 4.60 (s, 2H), 3.99 (m, 1H), 3.90 (m, 1H), 3.83 (s, 3H), 3.69 (m, 1H), 3.64 (d, J= 5.3 Hz, 1H), 3.53 (m, 1H), 3.31 (m, 1H), 2.99 (m 1H), 2.70 (m, 1H), 2.47 (m, 1H), 2.00 (m, 2H), 1.65-1.52 (m, 3H), 1.45-1.37 (m, 1H), 1.33 (m, 1H), 1.30 (m, 1H), 1.20 (d, J= 6.9 Hz, 3H), 1.10 (d, J= 6.6 Hz, 3H), 1.09 (d, J= 6.9 Hz, 3H), 1.05 (d, J= 7.0 Hz, 3H), 1.00-0.96 (m, 36H), 0.92-0.86 (m, 2H), 0.82 (d, J= 6.6 Hz, 3H), 0.76 (d, J= 5.5 Hz, 3H), 0.19-0.11 (m, 24H); 13C NMR (75 MHz, CDC13) S
159.2, 144.5, 144.4, 134.3, 133.1, 131.5, 130.5, 129.2, 128.6, 127.6, 126.8, 126.4, 113.8, 86.7, 86.0, 81.1, 75.3, 73.6, 72.8, 66.5, 65.1, 65.0, 55.1, 43.0, 42.3, 40.5, 40.0, 36.8, 35.2, 35.1, 34.0, 32.1, 30.4, 26.2, 26.1, 26.0, 25.9, 19.6, 18.9, 18.4, 18.1, 16.5, 15.8, 14.6, 9.9, -2.8, -3.4, -3.5, -3.8,'-4.0, -4.2, -4.4; LRMS (ESI) 1329.8 [M+Na]+, 1087.7, 801.5, 669.4, 537.3, 480.2, 359.2, 243.1; HRMS (ESI) calcd for C78H130O8Si4Na 1329.8741 [M+Na]+, found 1329.8778; [a]20D -9.9 (c 0.36, CHC13).
[00171] ((2E,4S,5S,7S,8Z,l OS,11R,12R,14S,17R,18R,19S,20S,21z)-19-(4-Methoxyb enzyloxy)-7,11,17-tris(tert-butyldimethylsilyloxy)-5-(tert-butyldimethylsilyloxy))-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraenyloxy)triphenylmethane (94). The alcohol 93 (0.94 g, 0.72 mol) in CH2C12 (20 mL) was treated with Dess-Martin periodinane (0.46 g, 1.08 mol). After 1 h, the mixture was quenched with saturated NaHCO3 (20 mL) and Na2S2O3 (20 mL). The aqueous layer was extracted with ethyl ether (20 mL x 2) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 9:1) to remove Dess-Martin residue provided crude aldehyde as a colorless oil, which was used for the next reaction without further purification. To a stirred solution of the above crude aldehyde and 1-bromoallyl trimethylsilane (0.89 g) in anhydrous THF (18 mL) under an atmosphere of N2 at room temperature was added CrC12 (0.73 g, 5.94 mmol), and the mixture was stirred for additional 14 h at ambient temperature. The reaction mixture was diluted with hexane followed by filtration through celite. After the evaporation of the solvent under reduced pressure, the residue was purified by short silica gel column chromatography using EtOAc/hexane (1:9) as an eluent. The foregoing product in THF (40 mL) was cooled to 0 C and NaH (95 % w/w, 0.36 g, 14.4 mmol) was added in one portion.
The ice bath was removed after 15 min and the mixture was stirred for 2 h at ambient temperature. The reaction mixture was cooled to 0 C, quenched with H20 (5 mL), extracted with ethyl ether (20 mL x 2). The combined organic layers were washed with brine and dried over MgSO4 followed by the evaporation of the organic solution under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 98:2) to obtain 94 (0.81 g, 85 % for 3 steps) as a colorless oil: IR (CHC13) 2955, 2928, 2856, 1614, 1514, 1471, 1462, 1249, 1076, 835, 772, 705 cm 1; 'H NMR (300 MHz, CDC13) 8 7.60-7.56 (m, 6H), 7.43-7.27 (m, 11H), 6.99-6.96 (m, 1H), 6.71 (ddd, J= 16.9, 10.6, 10.5 Hz, 1H), 6.14 (t, J= 11.0 Hz, 1H), 5.97 (dd, J= 15.7, 5.9 Hz, 1H), 5.82-5.77 (m, 1H), 5.74-5.70 (m, 1H), 5.68-5.62 (m, 1H), 5.61-5.56 (m, 1H), 5.46 (dd, J= 11.1, 8.6 Hz, 1H), 5.28 (d, J= 16.9 Hz, 1H), 5.20 (d, J
= 10.3 Hz, 1H), 4.66 (m, 3H), 4.05 (m, 1H), 3.86 (s, 3H), 3.76 (m, 1H), 3.69 (d, J= 5.2 Hz, 1H), 3.48 (m, 1H), 3.35 (m, 1H), 3.15 (m, 1H), 2.76 (m, 1H), 2.53 (m, 1H), 2.34 (m, 1H), 1.82 (m, 1H), 1.70-1.57 (m, 3H), 1.56-1.32 (m, 3H), 1.25 (d, J= 6.8 Hz, 3H), 1.14 (d, J= 7.1 Hz, 3H), 1.12 (m, 2H), 1.11 (d, J= 7.1 Hz, 3H), 1.08-1.03 (m, 36H), 0.98-0.90 (m, 2H), 0.86 (d, J = 6.6 Hz, 3H), 0.76 (d, J = 5.1 Hz, 3H), 0.25-0.13 (m, 24H); 13C NMR (75 MHz, CDC13) 8 159.0, 146.2, 144.6, 144.4, 134.5, 134.3, 133.2, 132.4, 131.4, 130.2, 129.0, 128.7, 127.7, 126.8, 126.5, 117.2, 113.7, 86.7, 84.5, 81.3, 75.1, 72.9, 66.6, 65.2, 55.1, 43.0, 42.3, 40.6, 40.2, 35.6, 35.25, 35.19, 33.9, 32.6, 30.3, 26.3, 26.1, 26.04, 25.99, 19.6, 18.9, 18.4, 18.2, 16.6, 14.7, 9.2, -2.8, -3.36, -3.4, -3.5, -3.9, -4.1, -4.4; LRMS (ESI) 1351.8 [M+Na]+, 837.1, 763.1, 689. 541.0; HRMS (ESI) calcd for C81H132O7Si4Na 1351.8948 [M+Na]+, found 1351.8973; [a]20D +0.4 (c 0.51, CHC13).
[00172] (2E,4S,5S,7S,8Z,l OS,11R,12R,14S,17R,18R,19S,20S,21Z)-19-(4-Methoxybenzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraen-l-ol (95). ZnBr2 solution (0.42 g in 5 mL CH2Clz and 0.8 mL of MeOH) was added to a stirred solution of trityl ether 94 (0.50 g, 0.38 mol) in MeOH (3 mL), CHZC12 (18 mL) at 0 C dropwise for 30 min. After 4 h, the reaction mixture was quenched with saturated NaHCO3 solution (20 mL) and extracted with EtzO
(10 mL x 2).
The organic phase was separated, dried with MgSO4 and concentrated. The residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 0.34 g of product 95 (83 %) as a colorless oil: IR (CHC13) 3410, 2956, 2929, 2856, 1613, 1514, 1471, 1251, 1076, 836, 773 crri 1; 'H NMR (300 MHz, CDC13) S 7.31-7.29 (m, 2H), 6.90-6.87 (m, 211), 6.60 (ddd, J =
16.8, 10.6, 10.5 Hz, 111), 6.02 (t, J= 11.0 Hz, 1 H), 5.79 (dd, J= 15.6, 5.8 Hz, 111), 5.62 (d, J
= 9.3 Hz, 1 H), 5.60 (m, 111), 5.47 (t, J= 10.3 Hz, 1 H), 5.32 (dd, J= 10.7, 8.9 Hz, 111), 5.18 (d, J= 16.8 Hz, 1H), 5.10 (d, J= 10.2 Hz, 1H), 4.54 (m, 3H), 4.07 (d, J= 5.9 Hz, 2H), 3.89 (m, 1H), 3.81 (s, 311), 3.64 (m, 1H), 3.35 (m, 111), 3.24 (br, 1H), 3.00 (m, 1H), 2.61 (m, 1H), 2.40 (m, 1H), 1.68 (m, 1H), 1.55-1.42 (m, 3H), 1.38-1.21 (m, 311), 1.12 (d, J=
6.7 Hz, 3H), 1.02-0.99 (m, 3H), 0.98 (d, J= 7.0 Hz, 3H), 0.94-0.89 (m, 40H), 0.79 (d, J=
6.9 Hz, 3H), 0.76 (d, J= 6.3 Hz, 3H), 0.11-0.06 (m, 24H); 13C NMR (75 MHz, CDC13) 6 159.0, 134.9, 134.5, 133.1, 132.4, 131.5, 131.4, 129.1, 128.9, 128.7, 117.2, 113.7, 84.5, 81.3, 75.1, 72.7, 66.4, 64.1, 55.3, 42.7, 42.0, 40.5, 40.4, 35.5, 35.23, 35.20, 33.9, 32.6, 30.5, 26.3, 26.03, 26.00, 25.96, 19.7, 18.9, 18.8, 18.5, 18.2, 18.1, 16.6, 14.7, 9.2, -2.8, -3.47, -3.53, -4.03, -4.05, -4.2, -4.5, -4.7; LRMS (ESI) 1109.7 [M+Na]+, 945.3, 797.3, 723.2, 577.4, 499.2, 413.3, 359.3; HRMS (ESI) calcd for C62H118O7Si4Na 1109.7852 [M+Na]+, found 1109.7898;
[a]20D -2.0 (c 2.6, CHC13).
[00173] (2Z,4E,6S,7S,9S,10Z,12S,13R,14IZ,16S,19R,20R,21S,22S,23Z)-Methyl-21-(4-methoxybenzyloxy)-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (96). The alcoho195 (0.34 g, 0.31 mol) in CH2C12 (20 mL) was treated with Dess-Martin periodinane (0.20 g, 0.47 gmol).
After 1 h, the mixture was quenched with saturated NaHCO3 (5 mL) and Na2S2O3 (5 mL). The aqueous layer was extracted with ethyl ether (10 mL x 2) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 9:1) to remove the Dess-Martin residue provided the crude aldehyde as a colorless oil, which was used for the next reaction without further purification.
To a stirred solution of bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl) phosphate (0.080 mL, 0.37 mol), 18-crown-6 (0.41 g, 1.55 mmol) in THF (6 mL) cooled to -78 C
was added dropwise potassium bis(trimethylsilyl)amide (0.75 mL, 0.37 mo1, 0.5M solution in toluene).
Thereafter the above aldehyde in THF (1 mL) was added and the solution was stirred for 4 h at -78 C. The reaction mixture was quenched by addition of a sat'd NH4C1 solution (5 mL) and diluted with diethyl ether (20 mL). The layers were separated and organic phase was washed with brine (30 mL) and dried with MgSO4, filtered, and concentrated.
The residue was purified by flash chromatography (EtOAc/hexane 5:95) to obtain (E,Z)-doubly unsaturated ester 96 (0.32 g, 90 % for 2 steps) as a colorless oil: IR (CHC13) 2956, 2929, 2885, 1722, 1641, 1514, 1471, 1250, 1174, 1075, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.34 (dd, J= 15.5, 11.2 Hz, 1H), 7.29-7.26 (m, 2H), 6.87-6.84 (m, 2H), 6.56 (ddd, J= 17.0, 10.6, 10.5 Hz, 1H), 6.52 (t, J= 11.4 Hz, 1 H), 6.19 (dd, J= 15.5, 6.4 Hz, 1 H), 5.99 (t, J=11.0 Hz, 1H), 5.57 (t, J= 10.5 Hz, 1H), 5.54 (d, J= 11.3 Hz, 1H), 5.42 (m, 1H), 5.30 (m, 1H), 5.15 (d, J= 16.8 Hz, 1H), 5.07 (d, J= 10.1 Hz, 1H), 4.51 (m, 3H), 3.92 (m, 1H), 3.78 (s, 3H), 3.70 (s, 3H), 3.61 (in, 1H), 3.32 (dd, J= 7.9, 2.8 Hz, 1H), 3.20 (m, 1H), 2.97 (m, 211), 2.57 (in, 2H), 1.65 (m, 1H), 1.56-1.39 (m, 3H), 1.29-1.16 (m, 3H), 1.10 (d, J= 6.8 Hz, 3H), 1.03 (d, J= 6.9 Hz, 3H), 0.98 (d, J= 7.0 Hz, 3H), 0.94 (d, J= 6.9 Hz, 3H), 0.93-0.83 (m, 39H), 0.77 (m, 1H), 0.91 (s, 9H), 0.87 (s, 9H), 0.83 (d, J= 6.4 Hz, 3H), 0.82 (d, J=
6.0 Hz, 3H), 0.13 (s, 3H), 0.76 (d, J= 6.6 Hz, 3H), 0.71 (d, J= 5.9 Hz, 3H), 0.10-0.02 (m, 24H); 13C NMR
(75 MHz, CDC13) 6 166.8, 159.0, 147.2, 145.6, 134.5, 133.1, 132.4, 131.5, 131.4, 129.0, 128.9, 126.4, 117.1, 115.1, 113.7, 84.4, 81.3, 75.0, 72.8, 72.7, 66.4, 55.2, 50.9, 42.9, 42.6, 40.5, 40.2, 35.3, 35.2, 33.8, 32.6, 30.5, 26.3, 26.0, 25.9, 19.6, 18.9, 18.8, 18.4, 18.2, 18.1, 16.7, 14.5, 9.2, -2.8, -3.4, -3.5, -3.6, -4.07, -4.14, -4.24, -4.49; LRMS
(ESI) 1163.8 [M+Na]+, 1107.9, 782.5; HRMS (ESI) calcd for C65H12oO$Si4Na 1163.7958 [M+Na]+, found 1163.8004; [a]20D -27.3 (c 5.0, CHC13).
[00174] (2Z,4E,6S,7S,9S,10Z,12S,13R,14R,16S,19R,20R,21S,22S,23Z)-Methyl-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (97). The ester 96 (0.15 g, 0.14 mol) was added to CH2C12 (5 mL) and H20 (0.2 mL) and DDQ (34 mg, 0.15 mol) was added at 0 C.
After 1 h of stirring at 0 C, the reaction mixture was quenched by adding sat'd NaHCO3 (5 mL). The organic phase was washed by sat'd NaHCO3 solution (3 x 10 mL) and brine, dried over MgSO4 and concentrated. Purification by flash column chromatography (EtOAc/hexane 1:9) furnished 97 (0.12 g, 90 %) as a colorless oil: IR (CHC13) 3540, 2956, 2929, 2856, 1641, 1601, 1471, 1462, 1407, 1379, 1361, 1255, 1174, 1089, 1004, 836, 773 cm 1; 1H
NMR (300 MHz, CDC13) S 7.33 (dd, J= 15.5, 11.2 Hz, 1H), 6.61 (ddd, J= 16.9, 10.5, 10.4 Hz, 1H), 6.51 (t, J= 11.4 Hz, 1 H), 6.17 (dd, J= 15.5, 5.9 Hz, 1H), 6.07 (t, J= 11.0 Hz, 1H), 5.54 (d, J
= 11.3 Hz, 1H), 5.45-5.37 (m, 2H), 5.28 (m, 1H), 5.18 (d, J= 16.8 Hz, 1H), 5.09 (d, J= 10.1 Hz, 1H), 4.51 (m, 1H), 3.91 (m, 1H), 3.74 (m, 1H), 3.69 (s, 3H), 3.45 (m, 1H), 3.23 (m, 1H), 3.76 (m, 1H), 2.56 (m, 2H), 2.29 (br, 1H), 1.68 (m, 1H), 1.56-1.41 (m, 3H), 1.34-1.17 (m, 3H), 1.02 (d, J= 6.9 Hz, 3H), 0.97 (d, J= 6.9 Hz, 3H), 0.94 (d, J= 6.8 Hz, 3H), 0.90-0.84 (m, 40H), 0.81 (d, J= 5.8 Hz, 3H), 0.77 (d, J= 6.5 Hz, 3H), 0.76 (d, J= 6.2 Hz, 3H), 0.08-0.01 (m, 24H); 13C NMR (75 MHz, CDC13) S 166.8, 147.3, 145.5, 135.3, 133.0, 132.3, 131.5, 129.9, 126.4, 117.6, 115.2, 81.3, 77.5, 76.7, 72.7, 66.4, 50.9, 42.9, 42.6, 40.1, 37.9, 36.1, 35.4, 35.2, 33.8, 32.2, 30.6, 26.2, 26.0, 25.9, 19.6, 19.0, 18.4, 18.10, 18.05, 17.7, 16.6, 14.4, 6.9, -2.8, -3.5, -3.6, -3.7, -4.1, -4.15, -4.21, -4.4; LRMS (ESI) 1043.7 [M+Na]+, 889.8, 757.6, 625.5, 544.3, 364.4; HRMS (ESI) calcd for C57H112O7Si4Na 1043.7383 [M+Na]+, found 1043.7433; [a] 20D -40.3 (c 2.1, CHC13).
[00175] (2Z,4E,6S,7S,9S,10Z,12S,13R,14R,16S,19R,20R,21S,22S,23Z)-7,9,13,19-tetrakis(tert-Butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoic acid (98). 1N aqueous KOH solution (1.2 mL) was added to a stirried solution of the above 97 (0.12 g, 0.12 mol) in EtOH (12 mL), THF (1 mL) and the mixture was refluxed gently until the ester disappeared (about 5 h) as determined by TLC
analysis. The ethanolic solution was concentrated and then diluted with ether (4 mL). After the solution was acidified to pH3 with 1N HC1 solution, organic phase was separated and aqueous phase was extracted with Et20 (2 x 5 mL). The combined organic phases were dried with MgSO4, concentrated and used without further purification: IR (CHC13) 2957, 2929, 2857, 1692, 1471, 1462, 1254, 1089, 836, 773 cm'1; 'H NMR (300 MHz, CDC13) 8 7.34 (dd, J= 15.1, 11.4 Hz, 1H), 6.64 (ddd, J= 16.0, 10.8, 10.5 Hz, 1H), 6.61 (t, J=
11.2 Hz, 1H), 6.22 (dd, J=15.4, 6.0 Hz, 1H), 6.09 (t, J= 11.0 Hz, 1H), 5.58 (d, J=11.3 Hz, 1H), 5.49-5.39 (m, 2H), 5.34-5.28 (m, 1H), 5.20 (d, J= 16.7 Hz, 1H), 5.11 (d, J= 10.2 Hz, 1H), 4.55 (m, 1H), 3.95 (m, 1H), 3.76 (m, 1H), 3.50 (m, 1H), 3.27 (m, 1H), 2.81 (m, 1H), 2.58 (m, 2H), 1.71 (m, 1H), 1.57-1.50 (m, 3H), 1.44-1.31 (m, 3H), 1.25 (d, J= 7.3 Hz, 3H), 1.21 (d, J= 6.1 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 0.99 (d, J= 7.0 Hz, 3H), 0.96-0.89 (m, 40H), 0.81 (d, J=
6.2 Hz, 3H), 0.79 (d, J = 5.9 Hz, 3H), 0.11-0.05 (m, 24H); 13C NMR (75 MHz, CDC13) 6 171.1, 148.1, 147.3, 135.2, 132.8, 132.3, 131.6, 129.9, 126.6, 117.6, 115.0, 81.3, 77.6, 72.7, 66.4, 58.3, 43.0, 42.6, 40.1, 37.9, 36.0, 35.4, 35.2, 33.8, 32.2, 30.6, 26.3, 26.0, 25.9, 25.2, 19.6, 19.0, 18.4, 18.09, 18.05, 17.7, 16.6, 14.5, 7.0, -2.8, -3.45, -3.54, -3.7, -4.1, -4.2, -4.4;
LRMS (ESI) 1029.7 [M+Na]+, 915.7, 897.7; HRMS (ESI) calcd for C56H11oO7Si4Na 1029.7226 [M+Na]+, found 1029.7257; [a]20D -41.7 (c 1.4, CHC13).
[00176] 8(,S),10(S),14(R),20(R)-tetrakis(tert-Sutyldimethylsilyloxy)-7(S),13 (S),15 (R),17(S),21(S)-p entamethyl-22 (S')-(1(S')-methylp enta-2,4-dienyl)oxacyclodocosa-3,5,11-trien-2-one (99). A solution of above acid 98 in THF (2 mL) was treated at 0 C with Et3N (0.10 mL, 0.72 mol) and 2,4,6-trichlorobenzoyl chloride (0.095 mL, 0.60 mol). The reaction mixture was stirred at 0 C for 30 min and then added to 4-DMAP (60 mL, 0.02 M solution in toluene) at 25 C and stirred overnight. The reaction mixture was concentrated, Et20 (10 mL) was added and the crude was washed with 0.5 N
HC1 (2 x 10 mL), dried over MgSO4. Purification by flash colunm chromatography (EtOAc/hexane 2:98) furnished macrolactone 99 (93 mg, 78 % for 2 steps) as a colorless oil:
IR (CHC13) 2957, 2929, 2856, 1745, 1715, 1581, 1471, 1369, 1270, 1117, 1082, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.11 (dd, J= 15.3, 10.5 Hz, 1H), 6.59 (ddd, J=
16.8, 10.7, 10.5 Hz, 1H), 6.22 (dd, J= 15.4, 6.0 Hz, 1H), 6.07 (dd, J= 15.4, 10.6 Hz, 1H), 5.92 (t, J
10.9 Hz, 1H), 5.70 (d, J= 15.4 Hz, 1H), 5.46 (t, J= 10.5 Hz, 1H), 5.35-5.27 (m, 2H), 5.20 (d, J= 8.4 Hz, 1 H), 5.12 (d, J= 16.8 Hz, 1 H), 5.04 (d, J= 10.3 Hz, 1H), 4.53 (m, 1H), 3.91 (in, 1H), 3.41 (m, 1H), 3.19 (m, 1H), 2.94 (m, 1H), 2.55 (m, 2H), 1.94 (m, 1H), 1.40-1.29 (m, 3H), 1.26-1.15 (m, 3H), 1.00-0.85 (m, 52H), 0.74 (d, J= 6.7 Hz, 3H), 0.63 (d, J= 6.2 Hz, 3H), 0.08-0.00 (m, 24H); 13C NMR (75 MHz, CDC13) 8 166.9, 144.93, 144.88, 136.0, 135.0, 133.5, 132.4, 130.7, 129.3, 120.2, 117.2, 80.3, 75.7, 73.9, 72.7, 66.3, 42.4, 41.0, 40.6, 39.3, 36.5, 35.8, 35.1, 34.5, 31.9, 29.7, 26.2, 26.0, 25.9, 21.6, 19.8, 19.7, 18.4, 18.11, 18.07, 17.9, 14.9, 11.3, -2.6, -3.6, -3.8, -4.2, -4.5, -4.6; LRMS (ESI) 1011.8 [M+Na]+, 857.7, 725.6, 633.2, 413.3, 375.3; HRMS (ESI) calcd for C56Hi08O6Si4Na 1011.7121 [M+Na]+, found 1011.7148; [a]20D -16.9 (c 1.24, CHC13).
[00177] 8(S),10(S),14(R),20(R)-Tetrahydroxy-7(S),13(S),15(R),17(S),21(S)-pentamethyl-22(S)-(1(S)-methyl-penta-2,4-dienyl)-oxa-cyclodocosa-3(E),5(E),11(Z)-trien-2-one (100, YSS665-2). 3 N HCl (10 mL, prepared by adding 2.5 mL of conc. HCl to 7.5 mL MeOH) was added to a stirred solution of the above macrolactone 99 (61 mg, 6.17 mol) in THF (3 mL) at 0 C. After 24 h at room temperature, the reaction mixture was diluted with EtOAc (4 mL) and HZO (4 mL) and the organic phase was separated and aqueous phase was extracted with EtOAc (2 x 4 mL). The combined organic phases were washed with sat'd NaHCO3 (10 mL), dried with MgSO4, concentrated and the residue was purified by flash chromatography (EtOAc/hexane 3:2) to yield the product 100 (8.2 mg, 25%) as a colorless oil: IR (CHC13) 3404, 2962, 2916, 1692, 1639, 1455, 1244, 1061, 1001 cni 1;1H
NMR (600 MHz, CD3OD) 8 7.15 (dd, J= 15.3, 10.5 Hz, 1 H), 6.64 (ddd, J= 16.8, 10.6, 10.3 Hz, 1H), 6.29 (dd, J= 15.4, 6.3 Hz, 1H), 6.22 (dd, J= 15.5, 10.5 Hz, 1H), 5.92 (t, J= 10.9 Hz, 1H), 5.72 (d, J= 15.3 Hz, 1H), 5.44-5.37 (m, 2H), 5.25 (t, J= 10.3 Hz, 1 H), 5.13 (dd, J=
16.8, 1.8 Hz, 1H), 5.06 (d, J= 10.8 Hz, 1H), 5.04 (dd, J= 9.1, 1.8 Hz, 1H), 4.68 (ddd, J=
9.9, 7.2, 2.4 Hz, iH), 3.82 (ddd, J= 9.2, 6.2, 2.7 Hz, 1H), 3.40 (ddd, J=
10.2, 6.2, 2.3 Hz, 1H), 3.06 (m, 1H), 2.99 (dd, J= 8.0, 3.3 Hz, 1H), 2.62 (m, 1H), 2.58 (m, 1H), 1.88 (m, 1H), 1.62 (m, 1H), 1.55 (ddd, J= 14.0, 10.5, 2.7 Hz, 1H), 1.38 (ddd, J= 12.3, 9.6, 2.7 Hz, 1H), 1.34-1.23 (m, 4H), 1.12 (d, J= 7.0 Hz, 3H), 1.06 (d, .I = 6.9 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 1.00 (d, J= 6.7 Hz, 3H), 0.95-0.88 (m, 2H), 0.87-0.82 (m, 1H), 0.79 (d, J= 5.3 Hz, 3H), 0.68 (d, J= 6.7 Hz, 3H); 13C N1VIR (150 MHz, CD3OD) 8 168.5, 147.7, 147.4, 135.7, 134.4, 133.6, 131.7, 130.8, 129.1, 120.7, 118.0, 80.7, 76.9, 74.2, 72.8, 65.9, 44.0, 42.5, 40.9, 39.5, 36.5, 36.3, 36.1, 35.5, 31.7, 31.2, 21.1, 19.0, 17.9, 17.7, 15.7, 11.3;
LRMS (ES1) 555.6 [M+Na]+, 541.4; HRMS (ESI) calcd for C32H$206 555.3662 [M+Na]+, found 555.3684;
[a] 20D -6.5 (c 0.17, MeOH).
[00178] (4S,5S)-4-((2R,3S,6S,8R,9R,l OS,11Z,13S,15S,16S,17E)-3,9,13,15-tetrakis(tert-Butyldimethylsilyloxy)-6,8,10,16-tetramethyl-19-(trityloxy)non adeca-11,17-dien-2-yl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxane (101). The same procedure for 92 was used with above 91a (0.60 g, 0.50 mol), TBSOTf (0.17 mL, 0.75 mmol) and 2,6-lutidine (0.12 mL, 1.0 mmol) to yield 0.61 g (93 %) of the product by flash colunm chromatography (EtOAc/Hexane 1:9) as a colorless oil: IR (CHC13) 2956, 2928, 2856, 1518, 1471, 1462, 1251, 1075, 835, 773 cm"1; 'H NMR (300 MHz, CDC13) S 7.56-7.48 (m, 8H), 7.38-7.26 (m, 9H), 6.97-6.94 (m, 1H), 5.91 (dd, J= 15.6, 5.9 Hz, 1H), 5.63 (dt, J= 15.7, 5.3 Hz, 1H), 5.58-5.50 (m, 1H), 5.52 (s, 1H), 5.41 (dd, J= 10.8, 8.6 Hz, 1H), 4.65 (m, 1H), 4.19 (dd, J= 11.1, 4.5 Hz, 1H), 4.01 (m, 1H), 3.90 (m, 1H), 3.84 (s, 3H), 3.66 (d, J= 5.0 Hz, 2H), 3.5 6(t, J= 11.1 Hz, 111), 3.3 6(m, 1 H), 2.71 (m 1H), 2.48 (m, 1 H), 2.12 (m, 1H), 1. 8 8(m, 1H), 1.76-1.56 (m, 3H), 1.52-1.42 (m, 2H), 1.40-1.31 (m, 2H), 1.09 (d, J= 7.7 Hz, 3H), 1.07 (d, J= 7.5 Hz, 3H), 1.05-0.94 (m, 42H), 0.93-0.90 (m, 2H), 0.86 (d, J= 6.6 Hz, 3H), 0.81 (d, J= 6.3 Hz, 3I-1), 0.21-0.13 (m, 24H); 13C NMR (75 MHz, CDC13) 8 159.7, 144.6, 144.4, 134.4, 133.0, 131.9, 131.8, 128.7, 127.7, 127.3, 126.8, 126.4, 113.4, 100.8, 86.7, 81.6, 81.3, 73.4, 72.8, 72.0, 66.6, 65.2, 55.1, 43.1, 42.3, 39.7, 38.2, 35.4, 35.3, 31.3, 30.8, 30.7, 30.3, 26.2, 26.1, 26.04, 25.97, 19.5, 18.8, 18.4, 18.1, 16.6, 14.6, 12.2, 9.1, -2.8, -3.4, -3.6, -3.9, -4.0, -4.1, -4.3; LRMS (ESI) 1327.9 [M+Na]+, 1037.9, 803.6, 647.6, 619.6, 413.3, 359.2, 229.1; HRMS (ESI) calcd for C78H128O8Si4Na 1327.8584 [M+Na]+, found 1327.8622;
[a]20D
+5.9 (c 0.3, CHC13).
[00179] (2S,3S,4R,5S,8S,10R,11R,12S,13Z,15S,17S,18S,19E)-3-(4-Methoxybenzyloxy)-5,11,15,17-tetrakis(tert-butyldimethylsilyloxy)-2,4,8,10,12,18-hexamethyl-21-(trityloxy)henicosa-13,19-dien-l-ol (102). The procedure for 93 was used with 101 (0.61 g, 0.47 mol), DIBAL (4.6 mL, 4.6 mmol) to yield 0.53 g (87 %) of the product by flash colunm chromatography (EtOAc/Hexane 0.5:9.5) as a colorless oil: IR
(CHC13) 3453, 2956, 2929, 1514, 1471, 1251, 1075, 835, 773 cm 1; 'H NMR (300 MHz, CDC13) 8 7.56-7.52 (m, 6H), 7.38-7.26 (m, 11H), 6.96-6.93 (m, 2H), 5.91 (dd, J= 15.7, 6.0 Hz, 1H), 5.64 (dt, J= 15.4, 5.5 Hz, 1H), 5.55-5.50 (m, 1H), 5.42 (dd, J= 11.1, 8.4 Hz, 1H), 4.70-4.58 (m, 3H), 4.01 (m, 1H), 3.83 (s, 3H), 3.79 (m, 2H), 3.67-3.61 (m, 3H), 3.35 (m, 1H), 3.30 (m 1H), 2.72 (m, 1H), 2.48 (m, 1H), 1.93 (m, 2H), 1.76-1.55 (m, 3H), 1.51-1.26 (m, 1H), 1.10 (d, J= 6.6 Hz, 3H), 1.09 (d, J= 6.6 Hz, 3H), 1.07 (d, J= 6.7 Hz, 3H), 1.01-0:98 (m, 39H), 0.93-0.89 (m, 2H), 0.86 (d, J= 6.6 Hz, 3H), 0.78 (d, J= 4.6 Hz, 3H), 0.21-0.13 (m, 24H); 13C NMR (75 MHz, CDC13) 6 159.2, 144.5, 144.4, 134.3, 133.1, 131.7, 130.6, 129.1, 128.6, 127.6, 126.8, 126.7, 126.4, 113.8, 86.7, 85.1, 81.3, 74.9, 74.4, 72.8, 66.5, 65.9, 65.1, 55.1, 43.0, 42.3, 41.8, 40.1, 38.4, 35.3, 35.1, 32.8, 30.7, 30.5, 26.2, 26.1, 26.0, 25.9, 19.5, 18.6, 18.4, 18.13, 18.10, 16.5, 15.4, 14.6, 10.5, -2.8, -3.4, -3.6, -3.9, -4.0, -4.2, -4.4; LRMS
(ESI) 1329.8 [M+Na]+, 801.6, 659.3, 637.3, 437.2, 243.1; HRMS (ESI) calcd for C78H130O8Si4Na 1329.8741 [M+Na]+, found 1329.8788; [a]a0D -9.8 (c 2.6, CHC13).
[00180] ((2E,4S,5S,7S,8Z,10S,11R,12R,14S,17S,18R,19S,20S,21Z)-19-(4-Methoxyb enzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraenyloxy)triphenylmethane (103). The procedure for 94 was used with 102 (0.52 g, 0.40 mol), Dess-Martin reagent (0.25 g, 0.59 mmol) and 1-bromoallyl trimethylsilane (0.49 g, 2.0 mmol), CrC12 (0.41 g, 3.32 mmol) and NaH (0.20 g, 8.0 mmol) to yield 0.46 g (88 %) of the product by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2956, 2856, 1614, 1514, 1471, 1249, 1074, 835, 773 cm 1; 1H NMR (300 MHz, CDC13) S 7.59-7.56 (m, 6H), 7.41-7.27 (m, 11H), 6.98-6.95 (m, 2H), 6.71 (ddd, J= 16.7, 10.6, 10.5 Hz, 1H), 6.14 (t, J= 11.0 Hz, 1H), 5.94 (dd, J= 15.6, 5.6 Hz, 1H), 5.80-5.67 (m, 2H), 5.64-5.55 (m, IH), 5.46 (dd, J=
11.0, 8.5 Hz, 1H), 5.31 (d, J= 16.8 Hz, 1H), 5.21 (d, J= 10.2 Hz, 1H), 4.70-4.62 (m, 3H), 4.04 (m, 1H), 3.86 (s, 3H), 3.69 (d, J= 4.7 Hz, 1H), 3.34 (m, 2H), 2.96 (m, 1H), 2.77 (m, 1H), 2.51 (m, 1H), 1.93 (m, 1H), 1.78 (m, IH), 1.75-1.63 (m, 3H), 1.57-1.31 (m, 5H), 1.21 (d, J= 6.7 Hz, 3H), 1.15 (d, J= 6.1 Hz, 3H), 1.12 (d, J= 6.7 Hz, 3H), 1.00 (d, J = 7.3 Hz, 3H), 1.05-1.01 (m, 36H), 0.96-0.93 (m, 2H), 0.89 (d, J= 6.7 Hz, 3H), 0.81 (d, J= 5.3 Hz, 3H), 0.25-0.11 (m, 24H); 13C NMR (75 MHz, CDC13) S 159.1, 146.2, 144.6, 144.4, 134.4, 134.3, 132.2, 131.3, 130.2, 129.0, 128.7, 127.7, 126.8, 126.5, 117.5, 113.7, 86.7, 84.9, 81.4, 74.9, 73.1, 72.9, 66.6, 65.2, 55.1, 43.1, 42.9, 42.3, 40.4, 35.9, 35.6, 35.3, 35.1, 34.5, 30.2, 29.4, 26.3, 26.1, 26.0, 19.6, 18.8, 18.6, 18.5, 18.2, 18.14, 18.11, 16.5, 14.7, 10.5, -1.1, -2.8, -3.0, -3.3, -3.5, -3.9, -4.2, -4.3; LRMS (ESI) 1351.8 [M+Na]+, 911.1, 837.1, 763.1, 689.1, 541.1, 413.2; HRMS
(ESI) calcd for C81H132O7Si4Na 1351.8948 [M+Na]+, found 1351.8998; [a]20D -9.3 (c 1.5, CHC13).
[00181] (2E,4S,5S,7S,8Z,l OS,11R,12R,14S,17S,18R,19S,20S,21Z)-19-(4-Methoxyb enzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraen-l-ol (104). The procedure for 95 was used with 103 (0.33 g, 0.25 mol) and ZnBr (0.28 g, 1.25 mmol) to yield 0.18 g (65 %) of the product by flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 3417, 2956, 2856, 1613, 1514, 1471, 1250, 1074, 836, 773 crn 1; 1H NMR (300 MHz, CDC13) S
7.31-7.27 (m, 2H), 6.90-6.87 (m, 2H), 6.60 (ddd, J= 16.9,10.6,10.5 Hz, 1H), 6.04 (t, J=
11.0 Hz, 1H), 5.81 (dd, J= 15.7, 5.9 Hz, 1H), 5.67-5.60 (m, 2H), 5.51-5.44 (m, 1H), 5.34 (dd, J= 11.2, 8.7 Hz, 1H), 5.21 (d, J= 16.8 Hz, 1H), 5.12 (d, J= 10.2 Hz, 1H), 4.60-4.52 (m, 3H), 4.10 (d, J=
5.7 Hz, 1H), 3.91 (m, 1H), 3.81 (s, 3H), 3.59 (m, 1H), 3.31-3.23 (m, 2H), 2.86 (m, 1H), 2.65 (m, 1H), 2.40 (m, 1H), 1.82 (m, 1H), 1.66-1.42 (m, 5H), 1.36-1.20 (m, 3H), 1.11 (d, J= 6.8 Hz, 3H), 1.03 (d, J= 7.3 Hz, 3H), 1.01 (d, J= 6.6 Hz, 3H), 0.99 (d, J= 5.8 Hz, 3H), 0.94-0.89 (m, 38H), 0.84 (d, J= 7.2 Hz, 3H), 0.82 (d, J= 6.4 Hz, 3H), 0.13-0.00 (m, 24H); 13C
NMR (75 MHz, CDC13) 6 159.0, 135.0, 134.5, 133.2, 132.2, 131.5, 131.4, 129.1, 129.0, 128.7, 117.4, 113.7, 84.8, 81.4, 74.8, 73.1, 72.7, 66.5, 64.1, 55.2, 42.8, 42.7, 42.0, 40.4, 35.9, 35.4, 35.2, 34.4, 30.3, 29.4, 26.3, 26.03, 26.97, 25.95, 19.6, 18.7, 18.6, 18.5, 18.1, 16.6, 14.7, 10.5, -2.8, -3.4, -3.5, -4.0, -4.1, -4.2, -4.3, -4.4; LRMS (ESI) 1109.8 [M+Na]+, 707.2, 633.2, 541.1, 429.1, 355.1; HRMS (ESI) calcd for C62H118O7Si4Na 1109.7852 [M+Na]+, found 1109.7874; [a]20D -15.0 (c 0.94, CHC13).
[00182] (2Z,4E,6S,7S,9S,l OZ,12S,13R,14R,16S,19S,20R,21S,22S,23Z)-Methy1-21-(4-methoxybenzyloxy)-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (105). The procedure for 96 was used with 104 (0.18 g, 0.16 mol), Dess-Martin reagent (0.10 g, 0.24 mmol) and bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl) phosphate (0.041 mL, 0.19 mol), 18-crown-6 (0.21 g, 0.19 mmol) and KHMDS (0.39 mL, 0.19 mmol) to yield 0.16 g (84 %) of the product by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR
(CHC13) 2956, 2929, 2856, 1721, 1514, 1462, 1250, 1174, 1074, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 6 7.38 (dd, J= 15.4, 11.2 Hz, 1H), 7.32-7.29 (m, 2H), 6.91-6.86 (m, 2H), 6.60 (ddd, J=17.0, 10.6, 10.5 Hz, 1H), 6.56 (t, J= 11.3 Hz, 1H), 6.23 (dd, J= 15.5, 5.9 Hz, 1H), 6.05 (t, J= 11.0 Hz, 1H), 5.68-5.56 (m, 2H), 5.50-5.43 (m, 1H), 5.38-5.31 (m, 1H), 5.23 (d, J=
16.8 Hz, 1H), 5.12 (d, J= 10.2 Hz, 1H), 4.61-4.52 (m, 3H), 3.98 (m, 1H), 3.81 (s, 3H), 3.73 (s, 3H), 3.59 (m, 1H), 3.29-3.23 (m, 2H), 2.86 (m, 1H), 2.68-2.59 (m, 2H), 1.83 (m, 1H), 1.63-1.51 (m, 2H), 1.49-1.35 (in, 3H), 1.34-1.22 (m, 2H), 1.12 (d, J= 6.8 Hz, 3H), 1.07 (d, J= 6.9 Hz, 3H), 1.03 (d, J= 5.0 Hz, 3H), 1.01 (d, J= 6.7 Hz, 3H), 0.94-0.89 (m, 38H), 0.84 (d, J= 6.6 Hz, 3H), 0.80 (d, J= 6.1 Hz, 3H), 0.14-0.00 (m, 24H); 13C NMR (75 MHz, CDC13) S
166.8, 159.1, 147.2, 145.7, 134.4, 133.2, 132.2, 131.6, 131.4, 129.2, 129.0, 126.4, 117.5, 115.2, 113.7, 84.7, 81.5, 74.9, 73.0, 72.7, 66.4, 55.2, 50.9, 42.9, 42.8, 42.6, 40.3, 35.9, 35.4, 35.2, 34.4, 30.4, 29.5, 26.3, 26.03, 25.98, 19.6, 18.8, 18.7, 18.5, 18.1, 16.7, 14.5, 10.5, -2.8, -3.3, -3.5, -4.0, -4.1, -4.17, -4.22, -4.4; LRMS (ESI) 1163.8 [M+Na]+, 1009.7, 877.6, 513.4;
HRMS (ESI) calcd for C65H12oO8Si4Na 1163.7958 [M+Na]+, found 1163.7981; [a]20o -45.3 (c 0.36, CHC13).
[00183] (2Z,4E,6S,7S,9S,l OZ,12S,13R,14R,16S,19S,20R,21S,22S,23Z)-Methyl-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (106). The procedure for 97 was used with 105 (0.16 g, 0.14 mol) and DDQ (0.034 g, 0.15 mmol) to yield 0.13 g (90 %) of the product by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR
(CHC13) 3512, 2956, 2929, 2857, 1772, 1639, 1471, 1462, 1255, 1193, 1076, 836, 773 cm l; 'H
NMR (300 MHz, CDC13) S 7.35 (dd, J= 15.4, 11.2 Hz, 1H), 6.61 (ddd, J= 16.9, 10.6, 10.5 Hz, 1H), 6.53 (t, J= 11.3 Hz, 1 H), 6.19 (dd, J= 15.6, 6.0 Hz, 1 H), 6.09 (t, J= 11.0 Hz, 1H), 5.56 (d, J
= 11.3 Hz, 1H), 5.44 (t, J= 11.0 Hz, 1H), 5.31 (dd, J= 11.0, 8.4 Hz, 1H), 5.19 (d, J= 16.8 Hz, 1H), 5.10 (d, J= 10.1 Hz, 1H), 4.55 (m, 1H), 3.94 (m, 1H), 3.71 (s, 3H), 3.25 (m, 2H), 2.75 (m, 1H), 2.58 (m, 2H), 1.72 (m, 1H), 1.67-1.60 (m, 1H), 1.59-1.49 (m, 2H), 1.40 (m, 1H), 1.32-1.25 (m, 2H), 1.22-1.13 (m, 2H), 1.04 (d, J= 7.0 Hz, 3H), 1.01 (d, J= 7.1 Hz, 3H), 0.99 (d, J= 6.8 Hz, 3H), 0.91-0.86 (m, 41H), 0.81 (d, J= 6.5 Hz, 3H), 0.79 (d, J= 6.0 Hz, 3H), 0.11-0.05 (m, 24H); 13C NMR (75 MHz, CDC13) 8 166.8, 147.2, 145.6, 136.4, 133.2, 132.6, 131.5, 129.5, 126.4, 117.3, 115.2, 81.3, 78.6, 74.3, 72.7, 66.4, 50.9, 42.9, 42.6, 39.7, 36.2, 35.8, 35.4, 35.3, 34.1, 32.4, 30.6, 26.3, 26.0, 25.9, 19.6, 19.2, 18.5, 18.1, 18.0, 17.4, 16.7, 14.5, 10.9, -2.8, -3.4, -3.5, -4.06, -4.11, -4.2, -4.3, -4.4; LRMS
(ESI) 1043.7 [M+Na]+; HRMS (ESI) calcd for C57H112O7Si4Na 1043.7383 [M+Na]+, found 1043.7424;
[a]20D -37.8 (c 1.4, CHC13).
[00184] (2Z,4E,6S,7S,9S,10Z,12S,13R,14R,16S,19S,20R,21S,22S,23Z)-7,9,13,19-tetrakis(tert-Butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoic acid (107). The procedure for 99 was used with 106 (0.13 g, 0.13 mol) and 1N KOH (1.2 mL, 1.3 mmol), 2,4,6-trichlorobenzoyl chloride (0.094 mL, 0.60 mol) and Et3N (0.10 mL, 0.78 mmol), 4-DMAP (60 mL, 1.3 mmol) to yield 0.054 g (45 %
for 2 steps) of the product by flash colunm chromatography (EtOAc/hexane 1:19) as a colorless oil: (seco acid) IR (CHC13) 2956, 2857, 1692, 1634, 1471, 1462, 1254, 1076, 836, 773 cm 1; 'H NMR (300 MHz, CDC13) S 7.34 (dd, J = 15.2, 11.3 Hz, 1H), 6.66 (ddd, J =
16.8, 10.8, 10.6 Hz, 1H), 6.62 (t, J= 11.3 Hz, 1H), 6.23 (dd, J= 15.3, 6.0 Hz, 1H), 6.09 (t, J
= 11.0 Hz, 1H), 5.57 (d, J= 11.2 Hz, 1H), 5.48-5.42 (m, 1H), 5.35-5.28 (m, 1H), 5.20 (d, J=
16.8 Hz, 1 H), 5.10 (d, J= 10.2 Hz, 1H), 4. 5 5(m, 1 H), 3.95 (m, 1H), 3.74 (m, 1H), 3.26 (m, 1H), 2.78 (m, 1H), 2.58 (m, 2H), 1.75-1.64 (m, 2H), 1.62-1.49 (m, 3H), 1.44-1.37 (m, 1H), 1.32-1.19 (m, 3H), 1.04 (d, J= 7.0 Hz, 3H), 1.01 (d, J= 7.0 Hz, 3H), 1.00 (d, J= 6.4 Hz, 3H), 0.95-0.86 (m, 41H), 0.82 (d, J= 7.1 Hz, 3H), 0.81 (d, J= 6.4 Hz, 3H), 0.12-0.05 (m, 24H); 13C NMR (75 MHz, CDC13) S 171.5, 148.3, 147.4, 136.4, 133.1, 132.6, 131.5, 129.5, 126.6, 117.3, 115.0, 81.3, 78.6, 74.3, 72.7, 66.4, 43.0, 42.7, 39.7, 36.2, 35.8, 35.5, 35.3, 34.1, 32.4, 30.6, 26.3, 26.0, 25.94, 25.92, 19.6, 19.2, 18.5, 18.1, 18.0, 17.4, 16.7, 14.5, 11.0, -2.8, -3.4, -3.5, -4.1, -4.25, -4.32, -4.7; LRMS (ESI) 1029.7 [M+Na]+, 915.8; HRMS
(ESI) calcd for C56H11oO7Si4Na 1029.7226 [M+Na]+, found 1029.7252; [a]20D -32.7 (c 0.51, CHC13).
[00185] 8(S),10(S),14(R),20(S)-Tetrahydroxy-7(S),13(S),15(R),17(S),21(S')-pentamethyl-22(S')-(1(,S')-methyl-penta-2,4-dienyl)oxacyclodocosa-3(Z),5(E),11(Z)-trien-2-one (194, YSS675-1) and 8(S),10(S),14(R),20(S)-Tetrahydroxy-7(S),13(S),15(R),17(S),21(,S)-pentamethyl-22(S)-(1(,S)-methyl-penta-2,4-dienyl)oxacyclodocosa-3(E),5(E),11(Z)-trien-2-one (108, YSS675-2). The procedure for 100 was used with 107 (0.054 g, 0.054 mol) in 3N HCl (5 mL) and THF (2 mL) to yield 13 mg (45 %) of 108 and 4.5 mg (15 %) of the 109 by flash column chromatography (EtOAc/hexane 7:3) as a colorless oil: (108) IR (CHC13) 3416, 2961, 2927, 2873, 1692, 1635, 1455, 1421, 1379, 1190, 1086, 998 cm ;1H NMR (600 MHz, CD3OD) 8 7.26 (dd, J=
15.2, 11.3 Hz, 1H), 6.65 (ddd, J= 16.8, 10.6, 10.3 Hz, 1H), 6.56 (t, J= 11.3 Hz, 1H), 5.97 (t, J=
10.9 Hz, 1 H), 5.91 (dd, J= 15.2, 9.3 Hz, 1 H), 5.49 (d, J= 10.7 Hz, 1 H), 5.42 (t, J= 8.6 Hz, 1H), 5.20 (t, J= 10.4 Hz, 1H), 5.15 (dd, J=16.9, 1.3 Hz, 1H), 5.08 (d, J=10.1 Hz, 1H), 5.05 (dd, J= 9.6, 1.3 Hz, 1H), 4.62 (ddd, J= 11.5, 7.7, 4.3 Hz, 1H), 3.65 (ddd, J=
10.0, 7.3, 3.1 Hz, 1 H), 3.07 (dd, J= 6.7, 4.0 Hz, 1 H), 3.01 (m, 1H), 2.66 (m, 1H), 2.26 (m, 1H), 1.90 (m, 1H), 1.66 (ddd, J= 11.5, 8.4, 3.4 Hz, 1H), 1.49 (ddd, J= 14.1, 10.0, 4.0 Hz, 1H), 1.45 (m, 1H), 1.3 8(m, 1H), 1.3 2(in, 1 H), 1.27 (m, 1H), 1.11 (d, J= 6.7 Hz, 3H), 1.06 (m, 1H), 1.03 (ddd, J= 11.3, 7.2, 4.4 Hz, 3H), 1.01 (d, J= 6.9 Hz, 3H), 0.99 (d, J= 6.7 Hz, 3H), 0.96 (d, J
= 7.0 Hz, 3H), 0.93 (in, 1H), 0.89 (m, 1H), 0.85 (d, J= 6.7 Hz, 3H), 0.75 (d, J= 5.9 Hz, 3H);
13C NMR (150 MHz, CD3OD) S 168.1, 148.7, 146.6, 135.7, 134.0, 133.7, 132.9, 131.1, 128.2, 118.0, 117.0, 80.9, 78.4, 74.4, 72.4, 66.3, 46.4, 43.4, 42.5, 40.9, 36.3, 35.90, 35.88, 35.7, 31.8, 31.5, 19.9, 19.3, 18.3, 17.5, 8.5; LRMS (ESI) 555.3 [M+Na]+, 537.4; HRMS
(ESI) calcd for C32H5206 555.3662 [M+Na]+, found 555.3680; [a]20D +76.5 (c 0.52, MeOH):
(109) IR (CHC13) 3428, 2962, 2928, 1690, 1635, 1380, 1243, 1145, 1064, 1000 cm"1; 'H
NMR (600 MHz, CD3OD) S 7.20 (dd, J= 15.2, 10.8 Hz, 1 H), 6.65 (ddd, J= 17.0, 10.6, 10.5 Hz, 1H), 6.38 (dd, J= 15.5, 5.4 Hz, 1H), 6.23 (dd, J= 14.4, 10.9 Hz, 1H), 5.95 (t, J= 11.0 Hz, 1H), 5.77 (d, J= 15.3 Hz, 1 H), 5.40-5.3 9(m, 2H), 5.23 (t, J= 10.5 Hz, 1H), 5.13 (d, J=
18.1 Hz, 1H), 5.12 (dd, J= 8.2, 1.5 Hz, 1H), 5.07 (d, J= 10.2 Hz, 1H), 4.66 (m, 1H), 3.90 (ddd, J= 7.6, 5. l, 2.5 Hz, 1H), 3.22 (dd, J= 9.8, 7.9 Hz, 1H), 3.04 (m, 1H), 2.95 (dd, J= 9.7, 2.1 Hz, 1H), 2.72 (m, 1H), 2.65 (m, 1H), 1.83 (m, 1H), 1.58 (m, 1H), 1.46 (m, 1H), 1.35-1.23 (m, 4H), 1.05 (d, J= 6.8 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 0.98 (d, J= 6.8 Hz, 3H), 0.97 (d, J= 7.0 Hz, 3H), 0.94 (m, 2H), 0.78 (m, 1H), 0.71 (d, J= 6.4 Hz, 3H), 0.68 (d, J= 6.5 Hz, 3H); 13C NMR (150 MHz, CD3OD) 8 169.4, 147.5, 147.4, 135.9, 134.3, 133.7, 131.0, 128.9, 120.0, 118.0, 80.5, 78.5, 72.6, 72.0, 65.2, 43.6, 42.6, 42.1, 39.3, 36.3, 35.8, 35.6, 35.3, 31.4, 29.7, 19.3, 18.5, 17.4, 17.1, 14.8, 9.0; LRMS (ESI) 555.5 [M+Na]+; HRMS (ESI) calcd for C32H5206 555.3662 [M+Na]+, found 555.3687; [a]20D -17.3 (c 0.15, MeOH).
Biology [00186] Tubulin polymerization assay. Tubulin assembly was monitored turbidimetrically in Gilford 250 spectrophotometers equipped with electronic temperature controllers as described previously (ter Haar et al., 1996). The reaction mixtures without the compounds consisted of tubulin (1 mg/ml), heat-treated MAPs (0.75 mg/ml, if present), GTP
(100 M, if present), and 0.1M (4-morpholinyl)ethane sulfonate (MeS).
Baselines were established after addition of all reaction components except the compounds to the cuvettes held at 0 C. Compounds, at 10 M or 40 M final concentration, were then added and each reaction mixture (0.25mL final volume) was subjected to the indicated temperature changes.
[00187] Antiproliferative Assay. The effects of dictyostati and its analogs on growth inhibition of parental (A549) and paclitaxel-resistant (lA9/Ptx10 and Ptx22) ovarian adenocarcinoma cell lines were evaluated following the antiproliferative assay protocol as described earlier (Minguez et al., 2003; Choy et al., 2003; Lazo et al., 2001). Cells were maintained in RPMI medium with 10% FBS in it, plated in tissue culture plates, and allowed to grow for 48-72h before transferring them into 96-well plates. Cells were allowed to attach and grow for 48 h in 96-well plates after which they were treated with either control (DMSO) or drug in triplicate/quadruplicate. Cells were incubated with the compounds for 72h. Cells were treated with MTS reagent before reading the plate in a Dynamax plate 'reader for detennining the cell number. The fifty percent growth inhibition values (GI50 values) were calculated for the compounds against all the three cell lines.
[00188] Pelleting Assay (determination of EC50): The assay was performed under three different reaction conditions following the procedure reported earlier (Gapud et al., 2004).
Reaction condition 1 included 0.2 M monosodium glutamate (MSG), 10 M tubulin, 5%
DMSO and varying concentrations of test agents. Reaction condition 2 included 0.8 M MSG, 400 M GTP, 10 M tubulin, 5% DMSO, and varying concentrations of test agents.
Reaction condition 3 had 0.6 M MSG, 200 M GTP, and 10 M tubulin, and 5%
DMSO, and varying concentrations of the test agents. The experimental protocol for all the three reaction conditions was the following. The reaction mixtures were incubated at room temperature (20-22 C) for 15 min and spun for 10 min at 14,000 rpm in an Eppendorf microtube centrifuge. Aliquots of the supernatants were removed and assayed for protein content by the method of Lowry. The EC50 was defined as drug concentration required to polymerize 50%
of tubulin compared to the pellet found in the DMSO control reaction determined for each test system. On average 5.5 4.0% of the tubulin pelleted in the DMSO
control.
[001891 MultiparameteY fluorescence microscopy high information content cell-based fluorescence screening: HeLa cells growing at log phase were trypsinized and plated in 40 L at a density of 7,000-8,000 cells per well in calf skin collagen I-coated 384-well plates (Falcon #3962; Fisher Scientific). Cells were exposed to test agents or 0.5%
DMSO within 2-8 h of plating. Concentrated DMSO stock solutions of all test agents were diluted into solutions of HBSS medium plus 10% FBS and added to the microplate wells (10 L
per well), using an automated liquid handling system (Biomek 2000; Beckman-Coulter, Inc.) to provide a serial 2-fold dilution of each test agent. The cells were incubated in the presence of test agents for 24 h. At the end of the incubation, the medium was removed and replaced with HBSS containing 4% formaldehyde and 10 g/mL Hoechst 33342 (25 L/we11) to fix the cells and fluorescently label their chromatin. After incubation at room temperature for 20-30 min, the solution was removed from each well and replaced with HBSS (100 L/well).
Further reagent additions were made to the microplates using the Biomek 2000.
After removing the HBSS from each well, cells were permeabilized for 5 min at room temperature with 0.5% (w/w) Triton X-100 in HBSS (10 L/well). This step extracts a fraction of the soluble cellular components, including soluble tubulin. The wells were washed with HBSS
(100 L/well), followed by addition of a primary antibody solution containing mouse anti-a-tubulin (1:3000) and rabbit anti-phosphohistone H3 (1:500) in HBSS (10 L/well). After 1 h at room temperature, the wells were washed with HBSS as above, followed by the addition of a secondary antibody solution containing fluorescein-5-isothiocyanate (FITC)-labeled donkey anti-mouse (1:300) and Cy3-labeled donkey anti-rabbit (1:300) antibodies diluted in HBSS
(10 L/we11). After 1 h at room temperature, the wells were washed as above, and HBSS was added (100 L/well). The plates were placed in an ArrayScan HCS Reader with the Target Activation BioApplication Software coupled to Cellomics Store and the vHCSTM
Discovery Toolbox (Cellomics, Inc.) to analyze images. Briefly, the instrument was used to scan multiple optical fields, each with multiparameter fluorescence, within a subset of the wells of the 384-well microplate. The BioApplication software produced multiple numerical feature values, such as subcellular object intensities, shapes, and location for each cell within an optical field. Data were acquired from a minimum of 1,000 cells per well, except in cases where added test agents reduced the attachment of cells to the substrate. A
nuclear mask was generated from Hoechst 33342-stained nuclei, and object identification thresholds and shape parameters were set such that the algorithm identified over 90% of the nuclei in each field.
Objects that touched each other or the edge of the image were excluded from the analysis.
Tubulin mass was defined as the average green (FITC) pixel intensity in an area defined by the Hoechst-defined nuclear mask. This cytoplasmic area around the nucleus contains cytoskeletal components is a region from which sensitive measurements of cytoplasmic characteristics can be made. The percentage of phospho-histone H3 positive cells was defined as the number of cells whose average red (Cy3) staining intensity exceeded the average Cy3 intensity plus two standard deviations of vehicle-treated cells, divided by the total number of cells.
[00190] Radiolabeled ligand binding assays: [3H]Paclitaxel, [3H]discodermolide and [14C]epothilone B solutions were prepared as 125 M stock solutions in 50%
DMSO.
Radiolabeled compound (final concentration, 4.0 M) and test agents at final concentrations noted in the text and tables were mixed in 50 L of 4:1 (v/v) 0.75 M aqueous MSG/DMSO
and warmed to 37 C. Meanwhile, a reaction mixture containing 0.75 M MSG, 2.5 M
tubulin, and 25 M ddGTP was prepared and incubated at 37 C for 30 min to form microtubuless. A 200 L aliquot of the microtubule mixture was added to the drug mixtures, and incubation continued for 30 min at 37 C. Reaction mixtures were centrifuged in an Eppendorf 5417C centrifuge at 14,000 rpm for 20 min at room temperature.
Radiolabel in the supematants (100 L) was determined by scintillation spectrometry. Bound radiolabeled compound was calculated from the total radiolabel added to each reaction mixture minus the amount of radiolabel found in the supematant.
[00191] The foregoing description and accompanying drawings set forth the preferred embodiments of the invention at the present time. Various modifications, additions and alternative designs will, of course, become apparent to those skilled in the art in light of the foregoing teachings without departing from the scope of the invention. The scope of the invention is indicated by the following claims rather than by the foregoing description. All changes and variations that fall within the meaning and range of equivalency of the claims are to be embraced within their scope.
group to give 35. Selective deprotection of the primary TBS group with HF-pyridine in buffered pyridine at 0 C gave 36. The aldehyde formed by Dess-Martin oxidation was reacted with the phosphonate 38 (prepared from 37) under Horner-Wadsworth-Enunons conditions to give the conjugated alkene 39 in good yield. Selective reduction with nickel boride gave the ketone 40, which was reduced in a purposefully unselective manner with NaBH4 to give a 2.4:1 mixture of C19 epimers of 41, with the (3 isomer, necessary for preparation of (-)-dictyostatin, predominating. The isomers of 41 were readily separated by silica gel chromatography. A ratio favoring 41(3 (5:1) was obtained by use of the bulkier reducing agent LiAl(O-t-Bu)3H, whereas a 1:1 ratio of the a and (3 isomers was obtained when L-Selectride was employed.
[0071] Alcohol 410 was protected with a TBS group to give 42, whose PMP acetal was cleaved with DIBAL-H to give alcohol 43 (Figure 4). Oxidation to the aldehyde followed by Nozaki-Hiyama addition and Peterson-type elimination installed the (E,Z)-diene to give 44 in high yield. The allylic trityl group was removed with ZnBr2 to give alcoho145.
Dess-Martin oxidation to the aldehyde and Still-Gennari reaction gave the (E,Z)-conjugated ester 46. The PMB group was removed with DDQ to give 47 and saponification with aqueous KOH in EtOH-THF to give acid 48. Yamaguchi macrolactonization gave 49 in good yield. Global deprotection with 3N HC1 in MeOH-THF gave (-)-dictyostatin 1. The sample exhibited spectral data identical to the natural product and the optical rotation matched well. Thus, the previously proposed structures of dictyostatin are incorrect.
[0072] Also shown in Figure 4 are the synthetic steps leading to two representative analogs, the open-chain methyl ester 50 and C19-epi-dictyostatin 59. Ester 50 was prepared by global removal of the TBS groups from 48 in 36% yield. The C19-epi analog 59 was prepared from alcoho141a, as made in Figure 3, by the same methods used for preparation of 1.
[0073] Synthesis of C16-desmethyl dictyostatin 79, another exemplary analog, is shown in Figure 5. The synthesis proceeded from ester 23 in a mamler similar to the existing route to 1, but with omission of the C16-methyl group. Thus, a considerably simpler-to-make middle fragment 64 lacking the awkward C16 stereocenter was used for construction of 79.
Intermediate 23 was elongated to ester 60 by Homer-Wadsorth-Emmons reaction.
Nickel boride then DIBAL-H reduction of the ester gave alcohol 61 in 76% yield. The primary hydroxy group was protected with TBSCI to give 62 quantitatively, then the PMB
group was removed to give alcohol 63 in 90% yield. Oxidation of 63 to the aldehyde by using Parikh-Doering conditions, followed by Corey-Fuchs reaction, afforded the middle fragment alkyne 64.
[0074] The remainder of the synthesis from 64 to C16-desmethyldictyostatin 79 was then completed by using the same synthetic pathway described above for 1.
Interestingly, reduction of ketone 70 (not shown, the desmethyl homologue of 40) with 3 equivalents of LiAl(O-t-Bu)3H gave the desired 71(3 in 95% yield, with only 5% of the a-isomer.
[0075] The synthesis of yet other representative analogs are shown in Figure 6-8.
These are epimers of dictyostatin at C6, C14 and/or C19. The alkyne 80 was added to bottom fragment 81 to give alkyne 82 in 98% yield (Figure 8). When this alkynyl ketone was subjected to Noyori reduction conditions, one major isomer 83 was formed in 87% yield.
Also in this case, about 20 mol% of the (S,S)-Noyori catalyst was preferred.
The Noyori product 83 was reduced by using Lindlar catalyst to give the cis-alkene 84 in 90% yield.
When the reaction time was extended (- 1 day), partial over-reduction of other multiple bonds occurred.
[0076] In order to assign the configuration of the newly generated stereocenter at C9, 84 was treated with TBAF to remove both TBS groups. The resulting triol was reacted with excess 2,2-dimethoxypropane (3.0 equiv) to form the acetal, whose HMQC (500 MHz) NMR
spectrum showed the two methyl groups of the acetonide at similar chemical shifts (24.5 ppm and 25.1 ppm) and the tertiary carbon at 100.4 ppm. These data show an anti-relationship between the C7 and C9 hydroxy groups based on the Rychnovsky method. The C9 hydroxy group in 84 was protected with a TBS group to give 85 in quantitative yield.
The PMB group was then removed with DDQ to give 86 in 84% yield. The resulting secondary hydroxy group was protected again by a TBS group, giving 87 in 94% yield. Selective deprotection of the primary TBS group was accomplished in 66% yield by treatment with HF-pyridine complex in buffered pyridine at 0 C for 2 days to give 88 along with other deprotected byproducts. After the successful coupling of the middle and bottom fragments, 88 was oxidized to the aldehyde, which then was subjected to Horner-Emmons reaction with the phosphonate 38, yielding 89 in 78% yield.
[0077] The alkene in a,(3-unsaturated ketone 89 was reduced with nickel boride giving 90 in 76% yield. As a side reaction, some over-reduction of the C4-C5 alkene in the bottom fragment was also observed. The C19 ketone was reduced by NaBH4 yielding a 1.7:1 ratio of diastereomers of 91, with the (3 isomer as the major (62%), less polar product and the a isomer as the minor (36%), more polar product. These two diastereomers could be separated by silica gel column chromatography. The newly generated C19 hydroxy group in 910 was protected by a TBS group to give 92 in 86% yield, then the PMB acetal was cleaved with DIBAL-H to give the primary alcohol 93 in 97% yield. Oxidation to the aldehyde and subsequent Nozaki-Hiyama and Peterson syn-elimination reactions gave the diene 94 in 85%
yield.
[0078] Removal of the trityl group in 94 with ZnBr2 in CH2C12-MeOH gave 95 in 83% yield. This was oxidized to the aldehyde and the (E,Z)-diene was installed by Still-Gennari reaction in 90% yield (Figure 7). The PMB group in 96 was removed by DDQ to give 97 in 90% yield, and the resulting methyl ester was hydrolyzed with 1N
aqueous KOH
in EtOH-THF. Macrolactonization by the Yamaguchi method gave, surprisingly, mainly the C2E,C4E macrolactone 99 in 78% yield. Final global TBS deprotection yielded 100 in 25%
yield.
[0079] The C19 epimer of 100 was prepared from 91a using similar reaction pathways (Figure 8). After Yamaguchi lactonization, and global TBS
deprotection, the (E,Z)-isomer 108 (less polar, 45%) could be isolated along with the isomerized (E,E)-isoiner 109 (more polar, 15%) in a 3:1 ratio.
[0080] The methods outlined in Figures 1-8 are only exemplary of many possible variants. For example, analogs containing a C15-C16 Z-alkene can be prepared by the methods outlined in US Patent Application Serial No. 10/655,916. Analogs lacking the C9 oxygen atom (C9-deoxy analogs) can likewise be prepared by methods shown in that application. See, for example, Figures 8 and 11, among others.
[0081] The preferred method for forming the macrolactones (often called macrocyclic lactones or macrolides) is the Yainaguchi lactonization. See, for example, Inanaga, J.;
Kuniko, H.; Hiroko, S.; Katsuki, T.; Yamaguchi, M. Bull. Cheyn. Soc. Jpn.
1979, 52, 1989.
An example of the Yamaguchi lactonization is the conversion of hydroxy acid 48 to lactone 49 in Figure 4. Many other commons conditions suitable to effect macrolactone formation from hydroxy acids are well laiown to those skilled in the art, and these can also be used.
See, for example, Kirst, H. A. Macrolides. Large Ring Molecules; Wiley: NY;
1996; pp 345-375, and Boeclcman, R. K., Jr; Goldstein, S. W. The Total Synthesis of Macrocyclic Lactones. The Total Synthesis ofNatural Products; Wiley: New York, 1988; p 1.
[0082] The steps of semi-reduction of the C 10-C 11 alkyne, asymmetric reduction of the C9 ketone and (optionally) protection of the resulting alcohol can be conducted under and assortment of different reaction conditions. For one example, see the conversion of alkynyl ketone 32 to alkynyl alcohol 33, to alkenyl alcohol 34, to silyl ether 35 in Figure 3. The preferred conditions for reduction of the ketone involve use of the Noyori reagent, see K.
Matsumura, S. Hashiguchi, T. Ikariya, R. Noyori, J. Am. Chem. Soc. 1997, 119, 8738-39.
However, many other common ketone reducing agents, both chiral and achiral, can also be used. See, for example, Itsuno, S. Enantioselective Reduction of Ketones. Org.
React. (N..Y.) 1998, 52, 395-576. In cases were two epimers of the alcohol are formed, chromatographic separation is used to isolate the individual epimers (see, for example, separation of 41 in Figure 3). The Lindlar reduction is the preferred method of semi-reduction of the alkyne to the Z-alkene, but other methods can also be used. See for example, Siegel, S.
Heterogeneous Catalytic Hydrogenation of C=C and Alkynes. Comprehensive Organic Synthesis;
Pergamon Press: Oxford, 1991; pp 417, and Takaya, H. Homogeneous Catalytic Hydrogenation of C=C
and Alkynes. Coinprehensive Organic Synthesis; Pergamon Press: Oxford, 1991;
pp 443.
[0083] The reactions in this sequence of steps can also be conducted in several orders.
The preferred order is semi-reduction of the C10-C11 alkyne, followed by asymmetric reduction of the C9 ketone followed by (optionally) protection of the resulting alcohol.
Other orders of reactions are asymmetric reduction of the ketone, protection of the alcohol and semi-reduction of the alkyne, or asymmetric reductiori of the ketone, semi-reduction of the alkyne and protection of the alcohol.
[0084] The preceding steps of coupling of an alkynyl anion with an activated carboxylic acid, see for example conversion of 15 and 29 to 32 in Figure 3, also can be conducted under different sets of conditions. A preferred method is the deprotonation of the alkyne with a strong base, for example BuLi, followed by addition of a carboxylic acid derivative that is activated with a suitable leaving group. Preferred activated carboxylic acids for acylation (acylating agents) are Weinreb amides where the leaving group is the N-methoxy-N-methyl amide group. Many other agents such as esters, acid halides, acid imidazolides, etc. can also be used. These have standard leaving groups such as alkoxide, imidazole and halide. The alkynyl anion can also be generated in situ from a silylalkyne by desilylation or from a geminal-haloalkene by treatment with two or more equivalents of a lithiating agent like BuLi.
[0085] In an alternative route, the alkynyl anion can be reacted with an aldehyde instead of an activated carboxylic acid to produce a C9 alcohol directly after workup. This route is more direct, but mixtures of epimers at C9 may result and chromatographic separation of the epimers may be required. One epimer of a C9 (or other) alcohol can be converted to the other by a Mitsu.nobu reaction.
[0086] Lactam analogs of dictyostatin are important as anticancer agents because of their increased hydrolytic stability compared to the lactones, both in vivo and in vitro. These analogs are readily made by starting with intermediates of the current invention, as exemplified in Figure 9. Standard oxidation of the free C21 alcohol of 110 to a ketone followed by reductive amination provides 111. If desired, the C21 amine stereoisomers can be separated by chromatography. Hydrolysis of the ester to the acid followed by macrolactamization provides lactam 112. The specific example of dictyostatin macrolactam 115, made for example by the sequence 113 -> 114 -> 115, is exemplary of a lactam analog of this invention.
[0087] The steps in the sequence can be conducted in different orders and also on different intermediates. When the C21 nitrogen atom is installed earlier in the synthesis, it is optionally protected with a standard nitrogen protecting group for the subsequent steps prior to macrolactamization. In another approach, this iiitrogen can be installed by a Mitsunobu reaction of a suitably acidic nitrogen nucleophile (for example, azide) with a C21 alcohol.
This reaction occurs with inversion, so the configuration of C23 is chosen accordingly.
[0088] For exemplary methods and conditions of reductive amination, see Baxter, E.
W.; Reitz, A. B. Reductive aminations of carbonyl compounds with borohydride and borane reducing agents. Org. React. (N.Y.) 2002, 59, 1-714. Methods of synthesizing macrolactams (macrocyclic lactams) are related to those for macrolactones. For exemplary methods and conditions, see Nubbemeyer, U. Top. Curr. Chein. 2001, 216, 125-196. For exemplary methods and conditions for Mitsunobu reactions, see Hughes, D. L. Org. Prep.
Proced. Int.
1996, 28, 127-164:
Biology [0089] Tubulin polymerization. The abilities of the new compounds to cause tubulin polymerization were determined under reaction conditions consisting of purified bovine brain tubulin (1 mg/mL) in the presence or absence of microtubule-associated proteins (MAPs, 0.75 mg/mL) and GTP (100 M). Test agents were initially screened at 10 and 40 M. In these experiments, test agent-induced assembly of soluble tubulin into polymer, with respect to the presence and absence of cofactors and at different temperatures, was monitored in a multi-cuvette, temperature-controlled spectrophotometer via development of turbidity in the solution. The initial temperature was closely controlled at 0 C, then rapidly raised to 10 C, to 20 C, then finally to 30 C to determine both the temperature at which a test agent induced assembly as well as the extent of agent-induced assembly. The temperature increases were followed by a rapid decrease in temperature back to 0 C to determine the cold-stability of polymer formed. The effects of dictyostatin 1 and discodermolide 2 were similar and far more potent than those of paclitaxel.
[0090] The C16-desmethyl compound 79 is especially potent among the analogs.
Figure 10 shows the simplest of its turbidity profiles in comparison to that of dictyostatin 1 in a tubulin-only (no MAPs, no GTP, asseinbly supported by monosodium glutamate) assay wherein initial temperature was 0 C for 2 min, followed by rapid rise in temperature to 30 C
for 20 min, then rapid decrease to 0 C. Turbidity profiles showed that analogs 50 and 59 also caused tubulin assembly at temperatures lower than 30 C. The results showed that all of the compounds had effects on the isolated target, tubulin, but with a range of potencies.
[0091] Antiproliferative activity. Representative analogs were examined for their antiproliferative activities against human ovarian carcinoma 1A9 cells and their paclitaxel-resistant mutants, lA9/Ptx10 and 1A9/Ptx22. Each of these resistant lines contains single inutations in the major [3-tubulin gene that confer to the cells, which do not express drug efflux pumps, appreciable tolerance to paclitaxel. Paclitaxel had subnanomolar potency against the parental 1A9 cells, but the mutant cells showed ca. 90- and 70-fold resistance to the drug (Table 1). Analogs 50 and 59 gave G150 values in the mid-nanomolar range. C6-epi,C14-epi-Cl9-epi-dictyostatin 108 and its C2E-diene derivative 109 were antiproliferative agents, giving mid micromolar GI50 values. Even though 100 also had three stereo/geometric alterations (C2E,C6-epi,C14-epi), it was a more potent antiproliferative agent than 108 and 109, showing high nanomolar G150 values. WitlZ one notable exception (vide infra), the fold-resistance values for 1 and its analogs against 1A9/Ptx10 and lA9/Ptx22 cell lines were much lower than that observed for paclitaxel. The one exception was compound 79, which appeared to be essentially equipotent to 1 against the parental 1A9 cells and the A1a364->Thr (3-tubulin mutant lA9/Ptx22 cells, but experienced resistance from the Phe270->Val (3-tubulin mutant lA9/PtxlO cells. Because these mutant cells are not clinically relevant, the result of reduced potency is primarily of mechanistic importance.
Table 1. Antiproliferative potencies of dictyostatin (1) and analogs as compared to discodermolide (2) and paclitaxel against human ovarian carcinoma cells (lA9) and their paclitaxel-resistant, (3-tubulin mutant clones (lA9/Ptx10 and lA9/Ptx22).
G150 S.D., nM (fold-resistance) Compound 1A9 lA9/Ptx10 1A9/Ptx22 (Phe270->Val) (A1a364->Thr) dictyostatin-1 (1) 0.69 :L 0.80 3.2 2.4 (4.6) 1.3 1.0 (1.9) discodermolide (2) 1.7 1.2 6.2 3.6 (3.6) 7.0 8.4 (4.1) paclitaxel 0.71 0.11 64 8 (90) 51 9 (72) 50 56 + 16 79 zL 13 (1.4) 85 2(1.5) 59 21 14 120 + 60 (5.7) 43 12 (2.0) 79 0.41 ::L 0.52 470 70 (1146) 5.6 4.7 (14) 107 >500 >500 (-) >500 (-) 100 310 +_ 40 780 + 200 (2.5) 790 + 560 (2.5) 108 28 :L 1 M 26 O M (0.9) 30 1 M (1.1) 109 25 + 2 M 25 1 M (1) 30 + 1 M (1.2) [0092] Pelleting Assay (EC50 determination). Dictyostatin and representative analogs were evaluated in a quantitative assay for their ability to promote tubulin polymerization. The EC50 value (defined as test agent concentration required to polyinerize 50% of tubulin compared to control) observed for dictyostatin 1 under these conditions was 3.1 0.2 M, similar to that obtained for discodermolide 2(3.6+0.4 M). Both were far superior to paclitaxel, wliich gave an EC50 value of 25+3 M. The C16-desmethyl analog 79 yielded an EC50 of 14+7 M. When the percent polymer formed was determined in the reactions, a comparison of the activities of all the analogs could be made.
Compounds 50 and 59 showed moderate activity. These EC50 data correlated well with the relative antiproliferative potencies of the analogs.
Table 2. Tubulin Assembly EC50 determinations.a Compound EC50 ( M) SD (1V) % Tubulin polymerized by 50 gM test agent dictyostatin (1) 3.1 + 0.2 (3) 99 + 4 discodermolide (2) 3.6 + 0.4 (3) 98 + 5 paclitaxel 25 3 (3) 89 + 6 50 > 50 (2) 39 7 59 > 50 (2) 30 2 79 14 7(3) 91 6 100 >50(2) 1 1 108 >50(2) 5 1 109 > 50 (2) 5 4 aBovine brain tubulin (10 M) in 0.2 M MSG, 15 min at 20 oC, centrifugation and Lowry determination of remaining soluble tubulin [0093] Radiolabeled Ligand Binding Assays. The abilities of test agents to inhibit the binding of radiolabeled forms of the microtubule stabilizers paclitaxel, discodermolide and epothilone B from tubulin polymer were determined. Dictyostatin 1 was equipotent to discodermolide in inhibition of the binding of radiolabeled paclitaxel and epothilone B to microtubules. These two compounds were the most potent of all agents tested.
The open chain methyl ester 50 and the 16-desmethyl analog 79 were ca. 60% as potent as 1 in inhibiting the binding of radiolabeled paclitaxel to microtubules.
Table 4. Percent inhibition of radiolabel from microtubules ( SD (N, number of independent determinations)).
Test Agent (4 pM) [3H]Paclitaxel [3H]Discodermolide [14C]Epothilone B
dictyostatin (1) 75 + 5(3) 40 + 3(3) 88 + 1(3) discodermolide (2) 76 6 (4) nd 90 1 (3) paclitaxel nd 6+ 5(3) 26 + 1(3) 50 42 1(3) nd nd 59 7 2(3) nd nd 79 48 3(3) nd nd 100 0 1 nd nd 108 0 1 nd nd 109 0 1 nd nd epothilone B nd 14 + 3 nd docetaxel 63 8(4) 8+ 6(3) 36 + 1(3) epothilone A 53 + 4(4) 6+ 6(3) 25 + 3 (3) [0094] Multiparameter Fluorescence Analysis of Cellular Effects. HeLa cells were plated on collagen-coated 384-well microtiter plates, allowed to attach, then treated for 24 h with test agents. Test agent concentrations began at 1 M, and two-fold dilutions were made to levels below 1 nM. After the treatment period, the cells were fixed with formalin and their chromatin stained with Hoechst 33342. Cells were permeablilized and treated with primary antibodies for a-tubulin and phosphohistone H3, and then with fluorophore-labeled secondary antibodies. The three fluorescent channels were then examined on an ArrayScan II, wliich gives quantitative pixel distribution and density information in each channel on a per cell basis. Dictyostatin 1 was the most potent of all compounds tested, followed by paclitaxel, discodermolide and the 16-desmethyl analog 79.
Table 5. Minimum detectable cellular changes determined by multiparameter fluorescence high information content analysis.
Compound Nuclear Phosphohistone Tubulin polymer intensity condensation H3 dictyostatin (1) 32.7 11.7 (3) 9.6 ~ 2.4 (4) 7.4 ~ 2.5 (4) 50 479 182 (4) 149 ~ 23.6 (4) 219 ~ 36 (4) 59 363 146 (2) 261 ~ 91 (4) 284 +108 (4) 79 71.5 18.0 (4) 34.4 ~ 10.5 (4) 26.9 2.9 (4) 100 > 5000 (4) > 5000 (4) > 5000 (4) 108 > 5000 (4) > 5000 (4) > 5000 (4) 109 > 5000 (4) > 5000 (4) > 5000 (4) discodermolide (2) 62.5 (1) 38.4 ~ 21.9 (2) 64.6 ~ 0.0 (2) Paclitaxel 40.2 13.9 (4) 17.5 ~ 6.8 (4) 8.0 ~ 2.9 (4) EXAMPLES
Chemistry [0095] Ethyl (4R,5S,2E)-5,7-bis(tert-butyldimethylsilyloxy)-4-methylhept-2-enoate (10). A solution of triethyl phosphonoacetate (3.5 inL, 17.6 mmol) was added to a cooled (0 C) stirred suspension of NaH (0.43 g, 17.0 rnmol, 95% dispersion in inineral oil) in THF (46 mL) dropwise over a 10 min period. The mixture was brought to room temperature with a water bath (30 min) and then cooled back to -78 C and the aldehyde (2.73 g, 7.58 mmol) in THF (5 mL) was added. The resulting mixture was stirred for 1 h at 0 C then pH7 phosphate buffer solution (10 mL) and Et20 (50 mL) were added. The mixture was allowed to warm to room temperature and the phases were separated. The organic phase was washed with sat'd NH4Cl solution (30 mL) and brine (30 mL), dried with MgSO4, filtered and concentrated to give oily crude product. Purification by flash chromatography (EtOAc/hexane 1:9) afforded pure ester 10 (2.92 g, 59% for 2 steps) as a colorless oil: IR
(CHC13) 2956, 2930, 2857, 1724, 1651, 1472, 1463, 1367, 1256, 1180, 1098, 1036, 836, 775 cm 1; 'H NMR (300 MHz, CDCl3) b6.88 (dd, J= 15.8, 7.6 Hz, 1H), 5.74 (d, J=
15.8 Hz, 1H), 4.19 (q, J= 7.IHz, 2H), 3.79 (ddd, J= 6.7, 4.7, 4.4 Hz, 1H), 3.59 (m, 2H), 2.43 (m, 1H), 1.53 (m, 3H), 1.22 (t, J= 7.1 Hz, 3H), 1.01 (d, J= 6.8 Hz, 3H), 0.83 (s, 18H), 0.02 (m, 12H);
13C NMR (75 MHz, CDC13) 8 166.4, 150.9, 121.3, 71.8, 59.9, 59.5, 42.0, 36.8, 25.82, 25.78, 26.1, 18.1, 18.0, 14.4, 14.2, -4.6, -4.7, -5.4; LRMS (El) 415 (M - CH3), 373, 303, 147;
HRMS (EI) calcd for C21H43O4Si 415.2710 (M - CH3), found 415.2712; [a]20D +3.8 (c 0.21, CHC13).
[0096] (4R,5S,2E)-5,7-bis(tert-Butyldimethylsilyloxy)-4-methylhept-2-en-l-ol (11). DIBAL-H (26.5 mL, 26.5 mmol, 1.0 M solution in hexane) was added to the ester 10 (3.14 g. 7.30 mol) in CH2C12 (35 mL) at -78 C dropwise and stirred for 1 h.
The reaction mixture was quenched by EtOAc (5 mL) and sat'd sodium potassium tartrate solution (20 mL) followed by vigorous stirring for 4 h. The aqueous phase was extracted with CHZCIZ (3 x 30 mL) and the combined organic layers were washed with brine (10 mL). After drying over MgSO4 and evaporation under vacuum, flash column chromatography (hexane/EtOAc 4:1) provided 2.75 g of alcohol 11 (97%) as a colorless oil: IR (CHC13) 3349, 2956, 2928, 2857, 1471, 1462, 1255, 1099, 836, 774 cm 1; 'H NMR (300 MHz, CDC13) b5.57 (m, 2H), 4.03 (m, 2H), 3.70 (ddd, J= 9.7, 6.0, 3.8 Hz, 1H), 3.59 (m, 2H), 2.27 (m, 1H), 2.00 (s, 1H), 1.53 (q, J
= 6.5 Hz, 2H), 0.96 (d, J= 6.9 Hz, 3H), 0.85 (s, 9H), 0.84 (s, 9H), 0.00 (m, 12H);13C NMR
(75 MHz, CDC13) S 134.7, 129.2, 72.4, 63.6, 60.1, 41.8, 36.3, 25.9, 18.2, 18.0, 15.1, 10.7, -4.6, -5.4; LRMS (EI) 370 (M - H20), 303, 171, 147; HRMS (EI) calcd for C20H42O2Si2 370.2723 (M - H20), found 370.2725; [a]20D -3.0 (c 0.57, CHC13).
[0097] ((4R,5S,2E)-5,7-bis(tert-Butyldimethylsilyloxy)-4-methylhept-2-enyloxy)triphenylmethane (12). Trityl chloride (4.1 g, 14.7 inmol) and DMAP
(1.8 g, 14.7 mmol) were added to a solution of alcohol 11 (2.75 g, 7.1 mmol) in pyridine (71 mL). The mixture was heated to reflux for 18 h, cooled to ambient temperature and added to a solution of sat'd CuSO4 (200 mL). The mixture was extracted with Et20 (2 x 20 mL) and the combined organic extracts were washed sat'd CuSO4 (2 x 20 mL). The organic layer was separated, dried (MgS04), filtered, and concentrated in vacuo. Flash column chromatography (EtOAc/hexane 1:19) provided 12 (4.46 g, quantitative) as a pale yellow oil:
IR (CHC13) 2954, 2856, 1471, 1448, 1254, 1095, 835, 773, 705 cm 1;111 NMR (300 MHz, CDC13) b7.56 (m, 6H), 7.32 (m, 9H), 5.79 (dd, J= 15.6, 6.7 Hz, 1H), 5.65 (dd, J= 15.7, 5.0 Hz, 1H), 3.85 (m, 1H), 3.74 (m, 1H), 3.66 (d, J= 4.9 Hz, IH), 2.43 (m, 1H), 1.70 (q, J= 6.5 Hz, 2H), 1.21 (d, J= 6.9 Hz, 3H), 0.99 (s, 9H), 0.97 (s, 9H), 0.154 (s, 3H), 0.150 (s, 3H), 0.13 (s, 3H), 0.12 (s, 3H); 13C NMR (75 MHz, CDC13) 8 144.4, 134.2, 128.7, 127.7, 126.9, 126.8, 86.8, 72.6, 65.1, 60.2, 42.1, 36.6, 26.0, 18.3, 18.1, 15.3, -4.4, -5.3; LRMS (ESI) 653.3 [M+Na]+, 422.4, 243.2; HRMS (ESI) calcd for C39H58O3Si2Na 653.3822 [M+Na]+, found 653.3851;
[a]20D -1.9 (c 0.42, CHC13).
[0098] (3S,4R,5E)-3-(tert-Butyldimethylsilyloxy)-4-methyl-7-(trityloxy)hept-5-en-1-ol (13). HF-pyridine in pyridine (40 mL, prepared by slow addition of 12 mL
pyridine to 3 mL HF-pyridine complex followed by dilution with 25 mL THF) was added to a solution of TBS ether 12 (4.46 g, 7.07 mmol) in THF (10 mL). The mixture was stirred overnight at room temperature and quenched with sat'd NaHCO3 (100 mL). The aqueous layer was separated and extracted with Et20 (3 x 50 mL). The combined organic layers were washed with sat'd CuSO4 (3 x 50 mL), dried over MgSO4, and concentrated. Flash colunui chromatography (EtOAc/hexane 1:4) afforded 3.26 g (89%) of alcohol 13 as a colorless oil:
IR (CHC13) 3407, 2955, 2928, 2856, 1490, 1471, 1448, 1254, 1058, 1031, 836, 773, 705 cm 1; 'H NMR (300 MHz, CDC13) b7.57 (m, 6H), 7.37 (m, 9H), 5.78 (dd, J= 15.6, 6.5 Hz, 1H), 5.73 (dt, J= 15.5, 4.8 Hz, 1H), 3.91 (m, 1H), 3.82 (d, J= 5.9 Hz, 2H), 3.69 (d, J= 4.4 Hz, 2H), 2.51 (m, 1H), 2.22 (br, 1H), 1.77 (m, 2H), 1.13 (d, J= 6.8 Hz, 3H), 1.03 (s, 9H), 0.21 (s, 3H), 0.19 (s, 3H); 13C NMR (75 MHz, CDC13) S 144.2, 134.1, 128.6, 127.7, 127.1, 126.9, 86.8, 74.3, 64.9, 60.4, 42.0, 34.8, 25.9, 18.0, 14.5, -4.4, -4.6; LRMS (ESI) 539.2 [M+Na]+, 243.2; HRMS (ESI) calcd for C33H44O3Si1Na 539.2957 [M+Na]+, found 539.2976;
[a]20D -2.8 (c 2.0, CHC13).
[0099] (3S,4R,5E)-3-(tert-Butyldimethylsilyloxy)-N-methoxy-N,4-dimethyl-7-(trityloxy)hept-5-enamide (15). Sulfur trioxide pyridine coinplex (3.02 g, 19.1 mmol) was added to a stirred solution of alcohol 13 (3.26 g, 6.31 mmol) and triethylamine (2.6 mL, 19.1 mmol) in anhydrous CH2C12 (6 mL) and DMSO (12 mL) at 0 C. The reaction mixture was stirred at the ambient temperature for 1 h. The mixture was diluted with Et20(100 mL) and washed with aqueous 0.5 N HCl (50 mL) and brine (10 mL). The separated organic layer was dried over MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 4:1) provided the crude aldehyde as a colorless oil, which was used without further purification. A solution of the aldehyde in THF (25 mL) and H20 (12 mL) was treated with 2-methyl-2-butene in THF (2M, 18 mL, 9.0 mmol), NaH2PO4=H20 (2.6 g, 18.8 mmol) and NaC1O2 (2.1 g, 18.6 mmol). The reaction mixture was stirred for 2 h, diluted with 1N HCl (20 mL) and extracted with CHaC12 (2 x 40 mL). The combined organic layers were dried over MgSO4, concentrated in vacuo and the crude acid was used for the next reaction without further purification. N, O-Dimethylhydroxylamine hydrochloride (0.62 g, 6.36 mmol), Et3N (0.88 mL, 6.31 mmol), DMAP (0.63 mmol) were successively added to a solution of the crude acid in CHZCIZ (10 mL). The reaction mixture was cooled to 0 C, and DCC (1.30 g, 6.30 mmol) was added. The mixture was stirred at ambient temperature for 15 h and filtered. The filtrate was washed with 0.5 N HCI, saturated aqueous NaHCO3, and brine, dried over anhydrous MgSO4 and concentrated. Purification by column chromatography over silica gel (hexane/EtOAc 4:1) gave the Weinreb amide 15 (2.65 g, 73%
for 3 steps) as a colorless oil: IR (CHC13) 2956, 2929, 2855, 1663, 1448, 1252, 1083, 1032, 836 cm'1; 'H NMR (300 MHz, CDC13) b7.58, m, 6H), 7.37 (m, 9H), 5.89 (dd, J=
15.6, 7.6 Hz, 1H), 5.72 (dt, J= 15.6, 5.2 Hz, 1H), 4.38 (ddd, J= 8.0, 5.0, 3.0 Hz, 1H), 3.74 (s, 3H), 3.70 (d, J= 5.1 Hz, 2H), 3.27 (s, 3H), 2.79 (dd, J= 15.1, 7.4 Hz, 1H), 2.52 (m, 2H), 1.20 (d, J
= 6.9 Hz, 3H), 1.02 (s, 9H), 0.22 (s, 3H), 0.16 (s, 3H);13C NMR (75 MHz, CDC13) b 172.6, 144.2, 133.3, 128.5, 127.7, 127.5, 126.8, 86.7, 72.4, 64.8, 61.2, 42.4, 36.3, 31.9, 25.8, 18.0, 15.7, -4.6, -5.0; LRMS (ESI) 596.2 [M+Na]+, 449.2, 243.0; HRMS (ESI) calcd for C35H47O4NSiNa 596.3172 [M+Na]+, found 596.3165; [a]20D -14.7 (c 0.65, CHC13).
[00100] (R)-3-((2R,3S,4S)-5-(4-Methoxybenzyloxy)-3-(tert-butyldimethylsilyloxy)-2,4-dimethylpentanoyl)-4-benzyloxazolidin-2=one (20). 2,6-Lutidine (5.14 mL, 44.2 mmol) and TBSOTf (9.36 mL, 40.8 mmol) were added to a solution of 19 (15.0 g, 33.9 mmol) in CHZCl2 (340 mL) stirred at 0 C. The mixture was stirred at 0 C for 2 h and then quenched by the addition of saturated aqueous NaHCO3. The phases were separated and the aqueous layer was extracted with CHZCl2. The combined organic phases were washed with 0.5 M
aqueous NaHSO4. The organic phase was dried over NaZSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (hexane/EtOAc 4:1) to give 20 (17.9 g, 95%) as a colorless oil: IR (film) 1781, 1696, 1513, 1383, 1248, 1209, 1110, 1042 cm'1; 'H NMR (300 MHz, CDC13) 57.35-7.28 (m, 7H), 6.85 (d, J= 8,7 Hz, 1H), 4.49 (m, 1H), 4.38 (d, J= 11.7 Hz, 1H), 4.34 (d, J= 11.7 Hz), 4.03 (m, 3H), 3.81 (m, 3H), 3.77 (s, 3H), 3.54 (dd, J= 9.2, 5.6 Hz, 1H), 3.22 (dd, J= 13.3, 3.1 Hz, 1H), 3.17 (dd, J= 9.1, 5.9 Hz, 1H), 2.72 (dd, J= 13.3, 9.6 Hz, 1H), 1.97 (m, 1H), 1.25 (d, J= 6.5 Hz, 3H), 1.02 (d, J= 7.0 Hz, 3H), 0.91 (s, 9H), 0.07 (s, 6H);13C NMR (75 MHz, CDC13) 8 176.4, 159.4, 153.1, 135.8, 131.1, 129.8, 129.3, 129.2, 127.6, 75.6, 72.9, 72.0, 66.1, 55.8, 55.6, 41.9, 39.3, 38.0, 26.4, 18.7, 15.3, 15.2, -3.5, -3.6; HRMS (ESI) calcd for C31H45NO6SiNa 578.2914 [M+Na]+, found 578.2923; [a]20D -8.1 (c 7.6, CHC13).
[00101] (2S,3R,4S)-5-(4-Methoxybenzyloxy)-3-(tert-butyldimethylsilyloxy)-2,4-dimethylpentan-l-ol (21). Dry MeOH (1.05 mL, 26.0 mmol) then LiBH4 (13 mL, 2.0 M
solution in THF, 26 mmol) were added to a stirred solution of 20 (4.79 g, 8.62 mmol) in THF
(75 mL) at 0 C. The resulting mixture was stirred at 0 C for 45 min and at room temperature for 1 h. The solution was cooled to 0 C and treated carefully with a 1.0 M
aqueous NaOH (50 mL). The phases were separated and the aqueous phase was extracted with CHZC12. The combined organic phases were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (hexane/EtOAc 7:3) to give the alcoho121 (2.98 g, 90%) as a colorless oil:
IR (film) 3425, 1613, 1513, 1463, 1249, 1091, 1037 cm 1; 1H NMR (300 MHz, CDC13) 8 7.26 (d, J= 8.5 Hz, 2H), 6.88 (d, J= 8.5 Hz, 2H), 4.47 (d, J= 11.7 Hz, 1H), 4.40 (d, J= 11.7 Hz, 1H), 3.84 (s, 3H), 3.75 (dd, J= 5.7, 2.9 Hz, 1H), 3.52 (m, 3H), 3.28 (dd, J=
9.1, 7.1 Hz, 1H), 2.10 (br, 1H), 2.05 (m, 1H), 1.93-1.81 (m, 1H), 0.97 (d, J= 7.0 Hz, 3H), 0.90 (s, 9H), 0.87 (d, J= 7.1 Hz, 3H), 0.07 (s, 3H), 0.05 (s, 3H);13C NMR (75 MHz, CDC13) 8 159.2, 130.7, 129.3, 113.8, 74.8, 72.8, 72.7, 66.3, 55.4, 39.0, 37.7, 26.2, 18.4, 15.2, 12.0, -4.1;
HRMS (ESI) calcd for C18H31O3SiNa 323.2042 [M+Na]+, found 323.2035; [a]20D -0.76 (c 2.9, CHC13).
[00102] (4S,5R,6S,2E)-Ethyl-7-(4-methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-4,6-dimethylhept-2-enoate (22). The procedure for 10 was used with the aldehyde from 21 (17.5 g, 31.6 mmol), Py-S03 (15.2 g, 95.5 mmol) and Et3N (13.3 mL, 95.5 mmol), NaH (0.90 g, 39.7 mmol) and triethylphosphonoacetate (7.2 mL, 40.3 mmol) to yield 8.96 g (63% for 3 steps) of the ester 22 by flash coluinn chromatography (EtOAc/Hexane 1:9) as a colorless oil: IR (CHC13) 2957, 2931, 2856, 1720, 1651, 1613, 1513, 1463, 1366, 1250, 1180, 1093, 1077, 837 cm"1 ; 1H NMR (300 MHz, CDC13) 57.31-7.27 (m, 2H), 7.03 (dd, J= 15.8, 7.8 Hz, 1H), 6.93-6.91 (m, 2H), 5.83 (dd, J= 15.8, 1.3 Hz, 1H), 4.48-4.40 (m, 2H), 4.23 (q, J= 7.1 Hz, 2H), 3.84 (s, 3H), 3.67 (m, 1H), 3.52 (m, 1H), 3.30 (dd, J= 9.1, 7.2 Hz, 1H), 2.59 (m, 1H), 2.00 (m, 1H), 1.33 (t, J= 7.1 Hz, 3H), 1.09 (d, J= 6.8 Hz, 3H), 1.01 (d, J= 7.0 Hz, 3H), 0.94 (s, 9H), 0.08 (m, 6H); 13C NMR (75 MHz, CDC13) 8 166.5, 159.0, 152.7, 130.6, 129.0, 120.4, 113.6, 76.8, 72.5, 71.8, 60.0, 55.1, 40.2, 38.0, 26.0, 18.2, 14.8, 14.3, 14.2, -4.0, -4.2; LRMS (ESI) 473.2 [M+Na]+; HRMS (ESI) calcd for C25H42O5SiNa 473.2699 [M+Na]+, found 473.2716; [a]20o -28.3 (c 0.41, CHC13).
[00103] (4S,5R,6S)-Ethyl-7-(4-methoxy)benzyloxy)-5-(tert-butyldimethylsilyloxy)-4,6-dimethylheptanoate (23). NiC12=6H20 (2.4 g, 10.1 mmol) then portionwise NaBH4 (1.50 g, 39.7 mmol) were added to a stirred solution of unsaturated ketone 22 (8.96 g, 19.9 mol) in MeOH (66 mL), THF (20 mL) at 0 C. After 1 h, the solvent was evaporated and filtered with Celite using Et20 as an eluent (60 mL). The organic phase was concentrated and the residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 8.76 g of 23 (97%) as a colorless oil: IR (CHC13) 2957, 2856, 1737, 1613, 1513, 1463, 1374, 1249, 1172, 1091, 1038, 836, 773 cm 1; 'H NMR (300 MHz, CDC13) 57.40-7.37 (m, 2H), 7.02-6.99 (m, 2H), 4.59-4.50 (m, 2H), 4.25 (q, J= 7.1 Hz, 2H), 3.91 (s, 3H), 3.66-3.62 (m, 2H), 3.40 (dd, J
= 8.8, 7.3 Hz, 1H), 2.52-2.33 (m, 2H), 2.13-2.02 (m, 1H), 1.90-1.82 (m, 111), 1.78-1.57 (m, 2H), 1.38 (t, J= 7.1 Hz, 3H), 1.09 (d, J= 6.9 Hz, 3H), 1.03 (s, 9H), 1.00 (d, J= 6.5 Hz, 3H), 0.19 (s, 3H), 0.18 (s, 3H); 13C NMR (75 MHz, CDC13) 8 173.6, 158.9, 130.7, 129.0, 113.5, 76.8, 72.5, 60.0, 55.0, 38.0, 35.6, 32.5, 29.9, 26.0, 18.3, 14.9, 14.1, 13.7, -3.9, -4.2; LRMS
(ESI) 475.3 [M+Na]+; HRMS (ESI) calcd for C25H44O5SiNa 475.2856 [M+Na]+, found 473.2877; [a]20D -6.0 (c 1.9, CHC13).
[00104] (4S,5R,6S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-4,6-dimethylheptanoic acid (24). Aqueous LiOH (1N, 193 mL, 0.19 mol) was added to.
a THF-H20 solution of 23 (8.76 g, 19.4 mmol). The resulting solution was warmed tQ
60 oC and stirred with heating for 6 h. Aqueous 1N HCl was added to give a neutral pH
and the mixture was extracted with CH2C12 , dried over MgSO4, filtered and evaporated to yield 8.22 g of crude acid 24, which was used without further purification: 1H NMR (300 MHz, CDC13) 6 7.24-7.22 (m, 2H), 6.86-6.83 (m, 2H), 4.39 (m, 2H), 3.77 (s, 3H), 3.69 (q, J=
7.0 Hz, 1H), 3.52 (m, 1 H), 3.47 (q, J= 7.0 Hz, 1H), 3.19 (t, J= 8.5 Hz, 114), 2.16 (m, 1H), 1.90 (m, 114), 1.65-1.51 (m, 2H), 1.21 (t, J= 7.0 Hz, 2H), 0.92-0.85 (m, 12H), 0.81 (d, J=
6.3 Hz, 3H), 0.00 (m, 6H); 13C NMR (75 MHz, CDC13) S 181.0, 158.9, 130.6, 129.1, 113.6, 72.5, 65.8, 58.0, 55.1, 37.8, 30.6, 26.1, 18.3, 18.1, 15.2, 14.0, -3.5, -4.1.
[00105] (R)-3-((4S,5R,6S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-4,6-dimethylheptanoyl)-4-benzyloxazolidin-2-one (25). A solution of the acid 24 (8.22 g, 19.4 nunol) and Et3N (5.40 mL, 38.8 mmol) in 100 mL of dry THF was cooled to -78 C and treated dropwise with pivaloyl chloride (2.86 g, 23.3 mmol), stirred in the cold for 2 h and warmed to 0 C prior to the addition of the oxazolidinone (3.5 g, 19.8 mmol) and LiCl (2.46 g, 58.8 mmol). This mixture was stirred overnight at room temperature and diluted with water (200 mL). The separated aqueous phase was extracted with ether (100 mL) and the combined organic layers were dried and evaporated to give a residue that was chromatographed to yield 7.91 g (70% for 2 steps) of imide 25 by flash colunm chromatography (EtOAc/hexane 1:4) as a colorless oil: 1H NMR (300 MHz, CDC13) S 7.41-7.23 (m, 7H), 6.94-6.91 (m, 2H), 4.71 (m, 1H), 4.51 (d, J= 11.6 Hz, 1H), 4.46 (d, J= 11.6 Hz, 1H), 4.25-4.16 (m, 2H), 3.84 (s, 3H), 3.63-3.58 (m, 2H), 3.37-3.31 (m, 2H), 3.14-3.04 (m, 1H), 2.94-2.86 (m, 1H), 2.79 (dd, J=
13.3, 9.7 Hz, 1H), 2.04 (m, 1H), 1.87-1.60 (m, 3H), 1.03 (d, J= 6.9 Hz, 3H), 0.99-0.97 (m, 12H), 0.14 (s, 3H), 0.12 (s, 3H); 13C NMR (75 MHz, CDC13) S 173.1, 158.8, 153.3, 135.2, 130.7, 129.3, 129.0, 128.8, 127.1, 113.5, 77.1, 72.5, 72.4, 65.9, 55.1, 54.9, 37.9, 37.7, 35.6, 33.7, 29.2, 26.0, 18.3, 14.9, 13.9, -3.8, -4.2.
[00106] (R)-3-((2R,4S,5R,6S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-2,4,6-trimethylheptanoyl)-4-benzyloxazolidin-2-one (26).
NaHMDS (1 M in THF, 14.9 mL, 14.9 mmol) was added dropwise over a 30 min period to a cooled (-78 C) suspension of the imide 25 (7.91 g, 13.6 mmol) in THF (45 mL).
After 15 min of stirring, the resulting cold solution was treated with Mel (2.53 mL, 40.8 mmol) and allowed to stir at -78 C for 3 h before being warmed to 25 C overnight (12 h) The reaction was quenched with H20 (100 mL), and the aqueous layer was extracted with Et20 (3 x 150 mL). The combined organic extracts were dried (MgSO4), concentrated in vacuo and chromatographed (EtOAc/hexane 1:9) to provide 5.97 g (74%) of 26 as a colorless oil: 1H
NMR (300 MHz, CDC13) 8 7.42-7.26 (m, 7H), 6.95-6.92 (m, 2H), 4.71 (m, 1H), 4.51 (m, 2H), 4.18 (m, 2H), 3.95 (m, 1H), 3.84 (s, 3H), 3.63 (dd, J= 8.9, 3.8 Hz, 1H), 3.57 (dd, J=
6.4, 2.7 Hz, 1H), 3.35 (t, J= 8.5 Hz, 1H), 3.28 (dd, J= 13.3, 3.1 Hz, 1H), 2.83 (dd, J= 13.3, 9.4 Hz, 1H), 2.10-1.95 (m, 2H), 1.68 (m, 1H), 1.38 (ddd, J= 14.1, 9.8, 4.9 Hz, 1H), 1.31 (d, J
= 6.8 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 0.98 (s, 9H), 0.95 (d, J= 6.7 Hz, 3H), 0.14 (s, 3H), 0.13 (s, 3H); 13C NMR (75 MHz, CDC13) S 176.8, 158.8, 152.8, 135.1, 130.8, 129.3, 128.9, 128.7, 127.1, 113.5, 77.6, 72.6, 72.4, 65.7, 55.0, 38.9, 38.0, 37.6, 35.3, 33.8, 26.0, 18.8, 18.3, 14.9, 13.8, -3.8, --4.2.
[00107] (2R,4S,5R,6S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-2,4,6-trimethylheptan-1-ol (27). n-BuLi (2.5 M in hexane, 17.6 mL, 44 mmol) was added to a solution of diisopropylamine (6.65 mL, 47.4 mmol) in THF (48 mL) stirred at -78 C. The solution was stirred at -78 C for 5 min and warmed to 0 C for 15 min. Borane-ammonia complex (90%, 1.55 g, 45.2 mmol) was added and the resulting mixture was stirred at 0 C
for 15 min, warmed to room temperature for 15 min and then cooled to 0 C. A
solution of amide 26 (6.62 g, 11.3 minol) in THF (35 mL) was added dropwise and the reaction was stirred at 0 C for 1 h and then at room temperature for 2 h. The mixture was cooled to 0 C
and quenched carefully with saturated aqueous NH4C1. The mixture was extracted with Et20 and the combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (step gradient of 4:1 to 7:3 hexane/EtOAc) to afford the alcohol 27 (4.57 g, 96%) as a colorless oil:
IR (film) 3410, 1612, 1513, 1249, 1067, 1038 cm 1; 'H NMR (300 MHz, CDC13) 8 7.26 (d, J
= 8.6 Hz, 2H), 6.88 (d, J= 8.6 Hz, 2H), 4.44 (d, J= 11.7 Hz, 1H), 4.39 (d, J=
11.7 Hz, 1H), 3.81 (s, 3H), 3.51 (m, 2H), 3.44 (dd, J = 5.6, 3.4 Hz, 1H), 3.37 (dd, J =
10.6, 6.5 Hz, 1H), 3.22 (dd, J= 9.0, 7.0 Hz, 1H), 2.03-1.95 (m, 1H), 1.78-1.62 (m, 2H), 1.53 (br, 1H), 1.41 (ddd, J= 13.5, 7.5, 5.8 Hz, 1H), 0.95 (d, J= 6.9 Hz, 3H), 0.94 (d, J= 6.7 Hz, 3H), 0.88 (s, 9H), 0.87 (d, J = 6.9 Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (75 MHz, CDC13) S 159.2, 130.9, 129.4, 113.9, 77.5, 72.8, 67.7, 55.4, 38.3, 38.0, 33.6, 33.2, 26.3, 18.6, 18.0, 15.6, 15.5, -3.5, -3.8; [a]20D -6.3 (c 1.7, CHC13).
[00108] (2S,3R,4S,6R)-3,7-bis(tert-Butyldimethylsilyloxy)-2,4,6-trimethylheptan-l-ol (28). TBSCI (4.16 g, 27.6 mmol) was added to a solution of alcohol 27 (5.86 g, 13.8 mmol), imidazole (2.89 g, 41.4 mmol), and DMAP (169 mg, 1.38 mmol) in CH2C12 (55 mL).
The resulting white suspension was stirred at room temperature for 2 h and the volatiles were removed under reduced pressure. The residue was dissolved in hexane and brine.
The phases were separated and the organic layer was washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (hexane/EtOAc 19:1) to afford the TBS protected alcohol (7.04 g, 95%) as a colorless oil: IR
(film) 1513, 1471, 1463, 1249, 1091, 1039 crri 1; 1H NMR (300 MHz, CDC13) b 7.30 (d, J=
8.6 Hz, 2H), 6.91 (d, J= 8.6 Hz, 2H), 4.48 (d, J= 11.9 Hz, 1H), 4.44 (d, J=
11.9 Hz, 1H), 3.82 (s, 3H), 3.60-3.49 (m, 3H), 3.39-3.28 (m, 3H), 2.05-1.95 (m, 1H), 1.80-1.66 (m, 2H), 1.49-1.40 (m, 2H), 1.02 (d, J= 6.9 Hz, 3H), 1.0-0.91 (m, 24 H), 0.10 (s, 3H), 0.09 (s, 3H), 0.08 (s, 3H); 13C NMR (75 MHz, CDC13) 8 159.2, 131.1, 129.3, 127.9, 77.3, 73.1, 72.8, 68.4, 55.3, 38.9, 38.5, 33.5, 26.4, 26.2, 18.7, 18.6, 18.1, 15.3, 15.1, -3.4, =3.8, -5.2; [a]20o -15.9 (c 0.47, CHC13). A solution of above TBS protected alcohol (5.28 g, 9.8 mmol) in CH2C12 (332 mL) and pH 7 phosphate buffer solution (33 mL) was treated with DDQ (3.34 g, 14.7 mmol).
The reaction was stirred at room temperature for 1 h and was quenched with saturated aqueous NaHCO3 solution. The phases were separated and the aqueous layer was extracted with CH2C12. The combined organic extracts were washed with water, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography (hexane/EtOAc 97:3 to 93:7) to afford 28 (4.01 g, 98%) as a colorless oil: IlZ
(film) 3353, 1472, 1463, 1388, 1360, 1255, 1091, 1030, 1005 cm 1; 1H NMR (300 MHz, CDC13) 8 3.60 (d, J= 5.3 Hz, 2H), 3.55-3.45 (m, 2H), 3.32 (dd, J= 9.7, 6.7 Hz, 1H), 2.49 (br, 1H), 1.45 (ddd, J= 13.5, 7.5, 5.3 Hz, 1H), 0.95 (d, J= 7.1 Hz, 3H), 0.92 (s, 9H), 0.89 (s, 9H), 0.93-0.87 (m, 6H), 0.11 (s, 3H), 0.09 (s, 3H), 0.04 (s, 6H); 13C NMR (75 MHz, CDC13) b 80.9, 68.0, 66.2, 38.4, 37.8, 35.4, 33.5, 26.3, 26.1, 18.5, 18.3, 16.2, 15.7, -3.6, -3.9, -5.3;
[a]20D -16.1 (c 4.4, CHC13).
[00109] (3S,4R,5S,7R)-4-(tert-Butyldimethylsilyloxy)-7-((tert-butyldimethylsilyloxy)methyl)-3,5-dimethyloct-1-yne (29). Sulfur trioxide pyridine complex (5.44 g, 34.2 mmol) was added to a solution of 28 (4.78 g, 11.4 rnmol) and triethylamine (4.77 mL, 34.2 mmol) in CH2C12 (23 mL) and DMSO (46 mL) at 0 C.
The mixture was stirred at 0 C for 1 h and then diluted with Et20. The organic phase was washed with cold 0.5 M aqueous NaHSO4 and then with brine. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by short flash chromatography (hexane/EtOAc 9:1) to afford the crude aldehyde as a golden oil which was used directly in the next reaction without further purification. Carbon tetrabromide (7.56 g, 22.8 mmol) was added to a solution of triphenylphosphine (12.3 g, 45.6 mmol) in CH2Cl2 (56 mL) at 0 C. The resulting dark-red mixture was stirred at 0 C for 10 min.
A solution of the crude aldehyde and 2,6-lutidine (2.66 mL, 22.8 mmol) in CH2C12 (45 mL) was added dropwise. The dark-brown mixture was stirred at 0 C for 1 h and then quenched with a saturated aqueous NH4C1. The layers were separated and the aqueous phase was extracted with CHZC12. The combined organic extracts were washed with HZO, dried over MgS04, filtered and concentrated under reduced pressure. The residue was purified by short flash chromatography (hexane 100%) to afford the dibromoolefin (4.76 g, 73% yield from the alcohol) as a colorless oil that was used without further purification. A
solution of the dibromoolefin (4.76 g, 8.2 nunol) in THF (40 mL) stirred at -78 C was treated with n-BuLi (1.6 M in hexane, 15.4 mL, 24.6 mmol). The solution was stirred at -78 C for 2 h and then quenched with saturated aqueous NH4C1. The mixture was allowed to reach room temperature and was diluted with Et20. The aqueous layer was extracted with Et20. The combined organic extracts were washed with brine, dried over MgS0~, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (hexane:EtOAc 97:3) to afford the pure alkyne 29 (3.26 g, 95%) as a colorless oil: IR (film) 3313, 2100, 1472, 1463, 1252, 1088, 1005 cm 1; 'H NMR (300 MHz, CDC13) 8 3.53-3.48 (m, 2H), 3.33 (d, J= 9.7, 6.8 Hz, 1H), 2.62 (ddddd, J= 7.2, 7.2, 7.2, 5.1, 2.5 Hz, 1H) 2.03 (d, J=
2.5 Hz, 1H), 1.97-1.80 (m, 1H), 1.73-1.6 (m, 1H), 1.47 (m, 1H), 1.21 (d, J=
7.1 Hz, 3H), 0.99-0.91 (m, 6H), 0.95 (s, 9H), 0.93 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H), 0.08 (s, 6H); 13C
NMR (75 MHz, CDC13) S 87.9, 77.8, 70.2, 68.5, 39.2, 33.9, 33.7, 32.3, 26.4, 26.3, 18.6, 17.9, 17.5, 15.7, -3.6, -5.1; HRMS (ESI) calcd for C22H45O2Si2Na 397.2958 [M+Na]}, found 397.2950; [a]20D -8.2 (c 3.1, CHC13).
[00110] (2R,4S,5R,6S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-N-((1S,2S)-1-hydroxy-l-phenylpropan-2-yl)N,2,4,6-tetramethylheptanamide (31).
PPh3 (7.05 g, 26.2 mmol), imidazole (1.78 g, 26.2 mmol), diisopropylethylamine (4.6 mL, 26.2 mmol) in benzene (80 mL), diethyl ether (165 mL) and acetonitrile (33 mL) were stirred at room temperature and treated with iodine (6.65 g, 26.2 mmol). The resulting mixture was vigorously stirred until the formation of a beige suspension. A solution of the alcoho121 (5.0 g, 13.1 mmol) in Et20 (20 mL) was added dropwise to the suspension and the resulting mixture was stirred at room temperature for 30 min. The reaction was quenched with saturated aqueous NaHCO3 and diluted with Et20. The aqueous phase was extracted with Et20 and the combined organic extracts were washed with brine, dried over MgSO4, filtered and concentrated under reduced pressure. The residue was triturated with hexane and the triturate was concentrated under reduced pressure. This procedure was repeated two more times to afford the iodide as a colorless oil that was used directly in the next reaction. A
solution of n-BuLi in hexane (2.5 M, 21 mL, 52.4 mmol) was added to a suspension of LiCl (7.05 g, 166.4 nunol) and diisopropylamine (7.85 mL, 56.3 mmol) in THF (40 mL) at -78 C.
The suspension was stirred at -78 C for 5 min, 0 C for 15 min and then cooled to -78 C. A
solution of (S,S)-pseudoephedrine propionamide (Meyer's auxiliary, 30) (6.09 g, 27.5 mmol) in THF (70 mL) was added dropwise. The resulting mixture was stirred at -78 C
for 1 h, at 0 C for 15 min and at room temperature for 5 min. The suspension was cooled to 0 C and the iodide was added as a solution in THF (6 mL followed by a 6 mL rinse). The reaction mixture was stirred at room temperature for 24 h and quenched with half-saturated aqueous NH4C1. The aqueous layer was extracted with EtOAc and the combined organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue which was purified by flash chromatography (hexane/EtOAc 1:1) to afford the amide 31 (6.69 g, 87%) as a colorless oil: IR (film) 3387, 1616, 1513, 1463, 1248, 1087, 1037 cm 1; HRMS
(ESI) calcd for C34H56NO5Si 586.3928, found 586.3940; [a]20D +23.2 (c 1.26, CHC13).
[00111] (4R,5S,10S,11R,12S,14R,2E)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12,14-tetramethyl-l-(trityloxy)pentadec-2-en-8-yn-7-one (32). Alkyne 29 (4.12 g, 10.0 mmol) was dissolved in THF (100 mL) and cooled to -78 C. n-BuLi (6.25 mL, 1.6 M
hexane solution) was added slowly. After 5 min, the mixture was warmed to 0 C
and stirred for 30 min. The mixture was then cooled to -78 C and amide 15 (6.47 g, 11.3 mmol) in THF
(5 mL) was added slowly. After 5 min, the solution was warmed to 0 C and stirred for 30 min. The reaction was quenched with saturated aqueous NH4C1 and the mixture was partitioned in a separatory fu.nnel. The aqueous phase was extracted with Et20 (3 x 20 mL).
The combined organic extracts were washed with brine and dried over MgSO4.
Filtration and concentration under reduced pressure, followed by flash chromatography on silica gel (hexane/EtOAc 19:1), afforded the ynone 32 (9.70 g, 93%) as a pale yellow oil:
IR (CHC13) 2955, 2928, 2856, 2209, 1676, 1471, 1462, 1252, 1085, 836, 774 cm"1; 'H NMR
(300 MHz, CDC13) 57.56, m, 6H), 7.36 (m, 9H), 5.80 (dd, J= 15.6, 7.1 Hz, 1H), 5.69 (dt, J= 15.7, 4.8 Hz, 1H), 4.37 (m, 1H), 3.69 (d, J= 4.7 Hz, 2H), 3.61 (m, 1H), 3.58 (dd, J=
9.7, 5.0 Hz, 1H), 3.43 (dd, J= 9.7, 6.5 Hz, 1H), 2.87 (m, 1H), 2.73 (m, 1H), 2.46 (m, 1H), 1.88 (m, 1H), 1.76 (m, 1 H), 1.59 (m, 1 H), 1.31 (d, J= 7.1 Hz, 3H), 1.15 (d, J= 6.8 Hz, 3H), 1.05 (m, 111), 1.00 (m, 34H), 0.194 (s, 3H), 0.190 (s, 3H), 0.17 (s, 3H), 0.15 (s, 3H), 0.14 (s, 6H);13C NMR (75 MHz, CDC13) 6 186.1, 144.2, 132.9, 128.6, 127.7, 126.9, 96.8, 86.8, 83.1, 71.5, 68.0, 64.9, 50.0, 42.3, 38.1, 34.4, 33.2, 32.1, 26.01, 25.96, 25.85, 18.3, 18.0, 17.9, 17.2, 15.5, 15.4, -3.8, -4.1, -4.6, -4.7, -5.4; LRMS (ESI) 947.5 [M+Na]+, 562:3, 243.1; HRMS (ESI) calcd for C56H$$O5Si3Na 947.5837 [M+Na]+, found 947.5875; [a]20D -12.0 (c 0.54, CHC13).
[00112] (4R,5S,7S,10S,11R,12S,14R,2E)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12,14-tetramethyl-l-(trityloxy)pentadec-2-en-8-yn-7-ol (33). Ynone 32 (5.28 g, 5.71 mmol) was taken up in i-PrOH (58 mL). The (S, S)-Noyori catalyst (0.77 g, 1.15 mmol, 20 mol%) was added in one portion and the solution was stirred overnight. The solvent was removed under vacuuin, and the crude residue was purified by flash chromatography on silica gel (hexane/EtOAc 97:3), affording propargylic alcoho133 (4.18 g, 79%) as a pale yellow oil:
IR (CHC13) 3469, 2955, 2856, 1471, 1448, 1252, 1084, 836, 774 cm"1; 1H NMR
(300 MHz, CDC13) 8 7.55 (m, 6H), 7.36 (m, 9H), 5.71 (m, 2H), 4.59 (m, 1H), 4.03 (quint, J= 3.9 Hz, 1 H), 3.65 (d, J= 3.9 Hz, 2H), 3.5 8(dd, J= 4.6, 3.2 Hz, 111), 3.55 (dd, J=
10.1, 5.1 Hz, 111), 3.38 (dd, J= 9.7, 6.8 Hz, 1H), 2.71 (m, 1H), 2.50 (m, 1H), 2.32 (d, J= 5.4 Hz, 1H), 1.88 (m, 1H), 1.80 (m, 2H), 1.55 (m, 1H), 1.23 (d, J= 7.1 Hz, 3H), 1.11 (d, J= 6.8 Hz, 3H), 0.98 (m, 34H), 0.20 (s, 3H), 0.17 (s, 3H), 0.16 (s, 3H), 0.14 (s, 3H), 0.12 (s, 6H);
13C NMR (75 MHz, CDC13) 6 144.3, 134.0, 128.6, 127.8, 127.1, 126.9, 88.1, 86.8, 83.0, 72.6, 68.3, 65.8, 65.1, 59.5, 41.9, 40.3, 38.7, 33.5, 33.2, 32.1, 26.0, 25.9, 18.4, 18.1, 17.7, 17.4, 15.7, 15.3, 14.2, -3.9, -4.0, -4.4, -4.5, -5.3; LRMS (ESI) 949.7 [M+Na]+, 413.3, 243.1; FIRMS
(ESI) calcd for C56H9oO5Si3Na 949.5994 [M+Na]+, found 949.6018; [a]20D -10.0 (c 1.2, CHC13).
[00113] (2E,4R,5S,7S,8Z,lOS,11R,12S,14R)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12,14-tetramethyl-l-(trityloxy)pentadeca-2,8-dien-7-ol (34).
A catalytic amount of Lindlar catalyst (ca. 200 mg) was added to a solution of alcohol 33 (4.18 g, 4.51 mmol) in toluene (100 mL). The flask was flushed with H2 via a balloon several times, then stirred under an atmosphere of H2 until starting material was consumed (usually 1 h) as indicated by TLC analysis. The mixture was filtered through a pad of Celite and concentrated under reduced pressure to afford the alkene 34 as a colorless oil (3.82 g, 91%):
IR (CHC13) 3436, 2954, 2926, 2855, 1461, 1378, 1252, 1061, 836, 773 cm"1; 1H
NMR (300 MHz, CDC13) S 7.56 (m, 6H), 7.34 (m, 9H), 5.73 (m, 2H), 5.60 (t, J= 10.3 Hz, 1H), 5.43 (dd, J= 10.9, 8.4 Hz, 1H), 4.73 (m, 1H), 3.98 (q, J= 5.0 Hz, 1H), 3.68 (d, J= 4.1 Hz, 1H), 3.59 (dd, J= 9.7, 4.7 Hz, 1H), 3.48 (m, 1H), 3.36 (dd, J= 9.0, 7.3 Hz, 1H), 2.79 (m, 1H), 2.58 (m, 1H), 2.23 (br, 1H), 1.78 (m, 1H), 1.71 (m, 1H), 1.66 (m, 2H), 1.50 (m, 1H), 1.11 (d, J= 6.8 Hz, 3H), 1.07 (d, J= 6.8 Hz, 3H), 1.00 (m, 34H), 0.22 (s, 3H), 0.18 (s, 3H), 0.14 (s, 6H), 0.13 (s, 6H); 13C NMR (75 MHz, CDC13) 8 144.3, 135.3, 134.6, 131.5, 128.7, 127.7, 127.0, 126.8, 86.8, 79.6, 73.0, 68.2, 65.0, 64.7, 42.0, 39.6, 38.0, 36.4, 34.9, 33.4, 26.2, 26.0, 25.9, 19.9, 18.4, 18.3, 18.1, 18.0, 15.2, 14.5, =3.4, -3.7, -4.2, -4.4, -4.5, -5.4; LRMS
(ESI) 951.7 [M+Na]+, 413.3, 243.1; HRMS (ESI) calcd for C56H92O5Si3Na 951.6150 [M+Na]+, found 951.6172; [a]20o 1.0 (c 0.62, CHC13).
[00114] ((2E,4R,5S,7S,8Z,lOS,11R,12S,14R)-5,7,11,15-tetrakis(tert-Butyldimethylsilyloxy)-4,10,12,14-tetramethylpentadeca-2,8-dienyloxy)triphenylmethane (35). TBSOTf (2.08 mL, 9.07 mmol) was added to a stirred solution of the alcohol 34 (3.82 g, 4.11 mmol) and 2,6-lutidine (1.14 mL, 9.85 mmol) in CHZC12 (14 mL) at 0 C. The reaction mixture was stirred for 1 h at 0 C. The reaction mixture was quenched by the addition of H20 (25 mL). The reaction mixture was extracted with CHZCIa wliich was dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by short colunm chromatography (hexane/EtOAc 19:1) to obtain 35 (4.27 g, 99%) as a colorless oil: IR (CHC13) 2956, 2929, 2856, 1471, 1462, 1449, 1255, 1089, 1005, 836, 773, 705 cm"1; 'H NMR (300 MHz, CDC13) S 7.60 (m, 6H), 7.39 (m, 9H), 5.77 (m, 2H), 5.56 (t, J= 10.8 Hz, 1H), 5.42 (dd, J= 11.0, 8.2 Hz, 1H), 4.69 (m, 1 H), 4.07 (m, 1 H), 3.71 (d, J= 3.8 Hz, 2H), 3.64 (dd, J= 9.8, 4.8 Hz, 1 H), 3.5 3(m, 1 H), 3.40 (dd, J= 9.6, 7.5 Hz, 1H), 2.74 (m, 1H), 2.55 (m, 1H), 1.89 (m, 3H), 1.59 (m, 3H), 1.12 (d, J= 6.2 Hz, 6H), 1.04 (m, 42H), 0.26 (s, 3H), 0.24 (s, 3H), 0.19 (s, 6H), 0.18 (s, 3H), 0.17 (s, 6H), 0.16 (s, 3H); 13C NMR (75 MHz, CDC13) 8 144.4, 134.5, 132.9, 132.6, 128.7, 127.7, 126.8, 86.8, 79.9, 72.3, 68.3, 66.5, 65.1, 64.1, 42.4, 41.6, 37.9, 36.0, 35.3, 33.6, 26.3, 26.02, 25.97, 25.7, 19.4, 18.5, 18.4, 18.20, 18.15, 18.1, 15.5, 13.3, -2.9, -3.5, -3.7, -4.1, -4.2, -4.3, -5.3; LRMS (ESI) 1065.9 [M+Na]+, 413.3, 359.3, 328.3, 243.1; HRMS (ESI) calcd for C62H106O5Si4Na 1065.7015 [M+Na]+, found 1065.7026; [a]20D -10.4 (c 0.53, CHC13).
[00115] (2R,4S,5R,6S,7Z,9S,11S,12R,13E)-5,9,11-tris(tert-Butyldimethylsilyloxy)-2,4,6,12-tetramethyl-15-(trityloxy)pentadeca-7,13-dien-l-ol (36). HF-pyridine in pyridine (40 mL, prepared by slow addition of 12 mL pyridine to 3 mL HF-pyridine complex followed by dilution with 25 mL THF) was slowly added to a solution of TBS ether 35 (4.27 g, 4.10 mmol) in THF (5 mL) at 0 C. The mixture was stirred for 21 h at 0 C and quenched with saturated aqueous NaHCO3 (100 mL). The aqueous layer was separated and extracted with Et20 (3 x 50 mL). The combined organic layers were washed with saturated aqueous CuSO4 (3 x 50 mL), dried over MgSO4, filtered and concentrated. Flash column chromatography (EtOAc/hexane 1:4) afforded 2.55 g (67%) of the alcohol 36 as a colorless oil:
IR (CHC13) 3350, 2956, 2928, 2856, 1471, 1448, 1254, 1086, 836, 773, 705 cm"1; 'H NMR
(300 MHz, CDC13) S 7.52 (m, 6H), 7.32 (m, 9H), 5.68 (m, 2H), 5.50 (t, J = 10.6 Hz, 1H), 5.35 (dd, J=
10.9, 8.5 Hz, 1H), 4.61 (t, J= 8.5 Hz, 1H), 4.00 (t, J= 8.1 Hz, 1H), 3.62 (d, J= 3.2 Hz, 2H), 3.58 (dd, J= 10.6, 4.3 Hz, 1H), 3.45 (m, 1H), 3.36 (dd, J= 9.9, 7.3 Hz, 1H), 2.66 (m, 1H), 2.48 (m, 1H), 1.70 (m, 3H), 1.49 (m, 3H), 1.04 (d, J= 6.6 Hz, 6H), 0.97 (s, 18H), 0.93 (m, 6H), 0.87 (s, 9H), 0.18 (s, 3H), 0.16 (s, 3H), 0.11 (s, 6H), 0.10 (s, 3H), 0.08 (s, 3H); 13C NMR
(75 MHz, CDC13) b 144.3, 134.4, 133.0, 132.1, 128.7, 127.7, 126.8, 86.7, 79.8, 72.3, 67.7, 66.5, 65.1, 42.4, 41.5, 37.3, 35.7, 35.5, 33.3, 26.2, 26.0, 25.9, 19.6, 18.4, 18.14, 18.06, 17.98, 15.7, 13.2, -2.9, -3.6, -3.7, -4.1, -4.2, -4.3; LRMS (ESI) 951.8 [M+Na]+, 771.6, 328.3;
HRMS (ESI) calcd for C56H92O5Si3Na 951.6150 [M+Na]+, found 951.6162; [a]20D -12.0 (c 0.71, CHC13).
[00116] (2R,4E,6R,8S,9R,10S,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-4,11,17-trien-3-one (39). The alcohol 36 (2.55 g, 2.75 mol) in CH2C12 (30 mL) was treated with Dess-Martin periodinane (1.74 g, 4.10 mol). After 1 h, the mixture was quenched with saturated aqueous NaHCO3 (30 mL) and Na2SzO3 (30 mL). The aqueous layer was extracted with Et20 (2 x 30 mL) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 4:1) provided the crude aldehyde as a colorless oil, which was used without further purification. A mixture of ketophosphonate 38 (1.06 g, 2.75 mmol) and Ba(OH)2 (0.38 g, activated by heating to 100 C for 1-2 h before use) in THF (40 mL) was stirred at room temperature for 30 min. A solution of the above aldehyde in wet THF (4 x 1 mL washings, 40:1 THF/H20) was then added. After stirring for 12 h, the reaction mixture was diluted with Et20 (30 mL) and washed with saturated aqueous NaHCO3 (50 mL) and brine (50 mL). The organic solution was dried (MgSO4), filtered and the solvent was evaporated in vacuo. The residue was chromatographed (hexane/EtOAc 9:1) to yield 39 (2.60 g, 80% for 2 steps) as a colorless oil: IR (CHC13) 2956, 2928, 2855, 1688, 1618, 1518, 1471, 1461, 1338, 1251, 1080, 1038, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) S 7.50 (m, 6H), 7.40 (m, 2H), 7.30 (m, 9H), 6.89 (m, 2H), 6.73 (dd, J= 15.6, 8.5 Hz, 1H), 6.29 (d, J= 15.6 Hz, 1H), 5.66 (m, 2H), 5.46 (t, J= 10.4 Hz, 1H), 5.46 (s, 1 H), 5.31 (dd, J=
11.0, 8.4 Hz, 1H), 4.58 (t, J= 8.1 Hz, 1H), 4.12 (dd, J= 11.3, 4.6 Hz, 1H), 3.96 (m, 1H), 3.92 (dd, J= 10.0, 4.2 Hz, 1H), 3.80 (s, 3H), 3.60 (d, J= 2.8 Hz, 2H), 3.56 (m, 1H), 3.39 (t, J=
3.3 Hz, 1H), 2.93 (m, 1H), 2.64 (m, 1H), 2.45 (m, 1H), 2.37 (m, 1H), 2.01 (m, 1H), 1.61 (m, 111), 1.54 (m, 2H), 1.50 (m, 1H), 1.44 (m, 1H), 1.27 (d, J= 7.0 Hz, 3H), 1.06 (d, J= 6.6 Hz, 3H), 1.02 (d, J= 6.5 Hz, 3H), 0.99 (d, J= 6.6 Hz, 3H), 0.95 (s, 9H), 0.94 (s, 9H), 0.88 (d, J=
6.6 Hz, 3H), 0.84 (s, 9H), 0.79 (d, J= 6.7 Hz, 3H), 0.15 (s, 3H), 0.14 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H), 0.05 (s, 3H), 0.03 (s, 3H); 13C NMR (75 MHz, CDC13) 8 200.7, 159.8, 152.3, 144.3, 134.3, 132.8, 132.1, 131.0, 128.6, 127.7, 127.1, 126.8, 126.6, 113.4, 100.8, 86.7, 82.7, 80.0, 72.8, 72.1, 66.4, 65.0, 55.2, 47.1, 42.4, 41.4, 39.3, 35.8, 34.7, 34.6, 32.2, 26.1, 25.92, 25.86, 20.8, 19.7, 18.3, 18.1, 18.0, 15.0, 13.0, 12.4, 10.8, -2.9, -3.7, -3.8, -4.18, -4.25, -4.35; LRMS (ESI) 1209.6 [M+Na]+, 828.4, 715.3, 449.2, 243.1; HRMS (ESI) calcd for C72H110O8Si3Na 1209.7406 [M+Na]+, found 1209.7474; [a]20D -6.7 (c 0.11;
CHC13).
[00117] (2R,6S,8S,9R,lOS,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-3-one (40). NiC12=6H20 (0.26 g, 1.09 mmol) then portionwise NaBH4 (0.17 g, 4.49 mmol) were added to a stirred solution of unsaturated ketone 39 (2.60 g, 2.19 mol) in 80 mL of 3:2 MeOH/THF at 0 C.
After 1 h, the reaction mixture was evaporated and filtered through Celite using Et20 (30 mL) as an eluent.
The organic phase was concentrated and the residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 1.98 g of 40 (76%) as a colorless oil: IR (CHC13) 2955, 2927, 2855, 1711, 1614, 1518, 1461, 1251, 1076, 835, 773 cni 1; 1H NMR (300 MHz, CDC13) 8 7.46 (m, 6H), 7.27 (m, 11H), 6.85 (m, 2H), 5.60 (m, 2H), 5.43 (s, 1H), 5.40 (m, 1H), 5.27 (m, 1H), 4.52 (m, 1H), 4.11 (dd, J= 11.1, 4.7 Hz, 1H), 3.91 (m, 2H), 3.78 (s, 3H), 3.55 (m 2H), 3.50 (m, 1H), 3.35 (m, 1H), 2.67 (m, 1H), 2.58 (m, 1H), 2.51 (m, 1H), 2.41 (m, 1H), 2.01 (m, 1H), 1.68 (in, 3H), 1.41 (m, 5H), 1.23 (d, J= 7.1 Hz, 3H), 0.96 (d, J= 6.7 Hz, 3H), 0.90 (s, 9H), 0.89 (s, 9H), 0.88 (m, 1H), 0.87 (m, 3H), 0.80 (s, 9H), 0.78 (m, 6H), 0.10 (s, 3H), 0.08 (s, 3H), 0.04 (s, 3H), 0.03 (s, 6H), 0.01 (s, 3H); 13C NMR (75 MHz, CDC13) b 211.9, 159.8, 144.5, 144.3, 134.4, 132.9, 132.4, 130.9, 128.6, 127.9, 127.8, 127.7, 127.1, 126.8, 113.4, 100.8, 86.7, 83.1, 79.9, 72.8, 72.2, 66.4, 65.1, 55.1, 48.3, 42.3, 41.5, 41.2, 38.1, 35.7, 35.0, 31.2, 29.8, 29.7, 26.2, 25.92, 25.87, 20.2, 19.4, 18.4, 18.1, 18.0, 15.2, 13.2, 12.1, 9.6, -3.0, -3.5, -3.7, -4.2, -4.28, -4.34; LRMS (ESI) 1211.9 (30 mL), 1031.8, 870.4, 684.3, 366.4, 243.1; HRMS (ESI) calcd for C72H112O8Si3Na 1211.7563 (30 mL), found 1211.7616;
[a]20D
+1.6 (c 0.50, CHC13).
[00118] (2S,3R,6S,8S,9R,lOS,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-3-ol (41(3). NaBH4 (0.095 g, 2.51 mmol) was added to a solution of ketone 40 (1.98 g, 1.67 mrnol) in MeOH (28 mL) at 0 C.
After stirring for 2 h at 0 C, the reaction mixture was evaporated and water (30 mL) was added. The reaction mixture was extracted with ether (2 x 40 mL) and washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield major product the title compound 410 (1.39 g, 70%, less polar) and minor product 41a (0.58 g, 28%, more polar) as a colorless oil. 41(3: IR
(CHC13) 3398, 2954, 2926, 2854, 1517, 1460, 1251, 1072, 835 cm 1; 1H NMR (300 MHz, CDC13) 8 7.50 (m, 6H), 7.39 (m, 2H), 7.33 (m, 9H), 6.89 (in, 2H), 5.66 (m, 2H), 5.54 (s, 1H), 5.46 (m, 1H), 5.32 (m, 1 H), 4. 5 8(m, 1H), 4.14 (dd, J= 11.3, 4.6 Hz, 1H), 3.95 (m, 1H), 3.87 (m, 1H), 3.80 (s, 3H), 3.72 (d, J= 9.8 Hz, 1H), 3.61 (m, 2H), 3.55 (m, 1H), 3.41 (m, 1H), 3.24 (br, 1H), 2.64 (m, 1H), 2.46 (m,1 H), 2.16 (m, 1H), 1.82 (m, 1H), 1.71 (m, 2H), 1.53 (m, 5H), 1.35 (m, 2H), 1.06 (d, J= 7.2 Hz, 3H), 1.01 (d, J= 6.6 Hz, 3H), 0.95 (s, 9H), 0.93 (s, 9H), 0.90 (m, 9H), 0.85 (s, 9H), 0.78 (d, J= 6.6 Hz, 3H), 0.14 (m, 6H), 0.09 (m, 12H); 13C
NMR (75 MHz, CDC13) 8 160.0, 144.5, 144.3, 134.4, 132.9, 132.4, 130.7, 128.7, 127.9, 127.8, 127.7, 127.6, 127.2, 127.1, 126.8, 113.6, 101.2, 89.1, 86.7, 80.0, 76.9, 73.1, 72.2, 66.5, 65.1, 42.3, 41.5, 41.4, 37.0, 36.7, 35.1, 32.5, 32.1, 30.4, 30.3, 26.2, 25.93, 25.87, 20.4, 19.4, 18.4, 18.1, 18.0, 15.4, 13.2, 11.8, 5.4, -3.0, -3.5, -3.7, -4.2, -4.27, -4.33;
LRMS (ESI) 1213.7 [M+Na]+, 1033.6, 570.9, 364.3, 243.1; HRMS (ESI) calcd for C7aH114O$Si3Na 1213.7719 [M+Na]+, found 1213.7861; [a]20D +6.5 (c 0.31, CHC13). 41a: IR
(CHC13) 3540, 2956, 2929, 2855, 1615, 1518, 1461, 1383, 1251, 1074, 835, 773 cm 1; 'H NMR
(300 MHz, CDC13) b 7.61 (m, 6H), 7.51 (m, 2H), 7.44-7.32 (m, 9H), 7.00 (m, 2H), 5.77 (m, 2H), 5.61 (s, 1H), 5.55 (m, 1H), 5.45 (m, 1H), 4.71 (m, 1H), 4.24 (dd, J= 11.1, 4.5 Hz, 1H), 4.07 (m, 111), 4.01 (m, 1H), 3.88 (s, 3H), 3.73-3.60 (m, 4H), 3.54 (m, 1H), 2.76 (m, 1H), 2.56 (m, 1H), 2.49 (m,1 H), 2.24 (m, 1H), 1.94-1.78 (m, 4H), 1.72-1.46 (m, 6H), 1.42-1.31 (m, 2H), 1.22 (d, J=
7.0 Hz, 3H), 1.13 (d, J= 5.9 Hz, 3H), 1.06 (s, 18H), 1.03 (m, 6H), 0.96 (s, 9H), 0.86 (d, J=
6.6 Hz, 3H), 0.27-0.18 (m, 18H); 13C NMR (75 MHz, CDC13) 8 159.9, 144.4, 144.3, 134.3, 132.9, 132.4, 131.0, 128.6, 127.6, 127.2, 126.8, 113.5, 101.0, 86.7, 82.8, 79.8, 74.8, 73.2, 72.2, 66.4, 65.0, 55.1, 42.3, 41.5, 37.8, 35.9, 34.9, 33.2, 32.4, 30.3, 30.2, 26.2, 25.92, 25.87, 20.4, 19.3, 18.4, 18.1, 18.0, 15.3, 13.2, 11.8, 11.0, -3.0, -3.4, -3.7, -3.9, -4.2, -4.28, -4.34;
LRMS (ESI) 1213.9 [M+Na]+, 987.7, 659.3, 437.2, 243.1; HRMS (ESI) calcd for CnH114OgSi3Na 1213.7719 [M+Na]+, found 1213.7760; [a]20D +2.3 (c 0.75, CHC13).
[00119] (4S,5S)-4-((2R,3R,6S,8S,9R,10S,11Z,13S,15S,16R,17E)-3,9,13,15-tetrakis(tert-Butyldimethylsilyloxy)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-2-yl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxane (42). TBSOTf (0.40 mL, 1.74 mmol) was added to a stirred solution of alcohol 410 (1.39 g, 1.17 mmol) and 2,6-lutidine (0.27 mL, 2.33 mmol) in CH2CI2 (23 mL) at 0 C. After stirring for 1 h at ambient temperature, the reaction mixture was quenched by the addition of water (50 mL) and extracted by CH2Cl2. After drying over MgSO4, followed by the evaporation of the solution under reduced pressure, the residue was purified by short column chromatography (hexane/EtOAc 9:1) to yield 42 (1.51 g, 99%) as a colorless oil: IR (CHC13) 2955, 2928, 2855, 1615, 1517, 1461, 1250, 1074, 1039, 835, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.59 (m, 6H), 7.52 (m, 2H), 7.41 (m, 9H), 7.01 (m, 2H), 5.74 (m, 2H), 5.57 (s, 1H), 5.50 (m, 1H), 5.43 (in, 1H), 4.67 (m, 1H), 4.25 (dd, J= 11.3, 4.6 Hz, 1H), 4.04 (m, 1H), 3.94 (s, 3H), 3.78 (m, 1H), 3.70 (m, 3H), 3.49 (m, 1H), 3.16 (m, 1H), 2.72 (m 1H), 2.54 (m, 1H), 2.18 (m, 1H), 2.01 (m, 1H), 1.82 (m, 3H), 1.54 (m, 6H), 1.14 (d, J= 6.9 Hz, 3H), 1.11 (d, J= 6.8 Hz, 3H), 1.10 (d, J= 6.5 Hz, 311), 1.05 (s, 9H), 1.03 (s, 9H), 1.02 (s, 12H), 0.98 (d, J= 6.3 Hz, 3H), 0.94 (s, 9H), 0.87 (d, J= 6.7 Hz, 3H), 0.24 (s, 3H), 0.22 (s, 3H), 0.17 (in, 18H); 13C
NMR (75 MHz, CDC13) 8 159.6, 144.5, 144.3, 134.4, 133.1, 132.6, 131.5, 128.6, 127.7, 127.6, 127.1, 126.8, 126.7, 113.3, 100.4, 86.7, 81.9, 79.8, 74.9, 73.3, 72.2, 66.4, 65.1, 55.1, 42.3, 41.5, 38.8, 35.9, 34.5, 31.3, 31.2, 30.8, 30.7, 26.3, 25.99, 25.97, 25.91, 22.6, 20.3, 19.2, 18.5, 18.10, 18.05, 15.1, 14.1, 13.1, 12.4, 10.6, ,-3.0, -3.2, -3.6, -4.2, -4.25, -4.30; LRMS
(ESI) 1327.8 [M+Na]+, 1147.7, 833.3, 631.3, 429.2, 364.3,.301.1; HRMS (ESI) calcd for C78HlZ$O8Si4Na 1327.8584 [M+Na]+, found 1327.8693; [a]20D +7.6 (c 0.17, CHC13).
[00120] (2S,3S,4R,5R,8S,l OS,11R,12S,13Z,15S,17S,18R,19E)-3-(4-Niethoxyb enzyloxy)-5,11,15,17-tets=akis(tert-butyldimethylsilyloxy)-2,4,8,10,12,18-hexamethyl-21-(trityloxy)henicosa-13,19-dien-l-ol (43). DIBAL-H (1.0 M in hexane, 11.7 mL, 11.7 mmol) was added dropwise to a stirred solution of TBS protected acetal 42 (1.53 g, 1.17 mmol) in anhydrous CHZC12 (2.3 mL) under an atmosphere of N2 at 0 C.
After stirring for additional 30 min at 0 C the reaction mixture was quenched by the careful addition of aqueous saturated aqueous potassium sodium tartrate (30 mL). The resulting mixture was stirred for 3 h at room temperature. The organic layer was separated, and the aqueous layer was extracted by CH2Cl2 (20 mL). The combined organic layers were washed with brine and dried over MgSO4 followed by the evaporation of the organic solution under reduced pressure. The residue was purified by column chromatography (EtOAc/hexane 1:9) to obtain pure 43 (1.35 g, 88%) as a colorless oil: IR (CHC13) 3464, 2956, 2929, 2856, 1613, 1514, 1471, 1252, 1087, 836, 773 cm"1; 'H NMR (300 MHz, CDC13) 8 7.46 (m, 6H), 7.28 (m, 1 1H), 6.88 (m, 2H), 5.61 (in, 2H), 5.39 (m, 1H), 5.28 (m, 1H), 4.57 (m, 1H), 4.53 (s, 2H), 3.92 (m, 2H), 3.83 (m, 1H), 3.80 (s, 3H), 3.60 (m, 2H), 3.56 (m, 2H), 3.46 (dd, J= 6.2, 4.5 Hz, 1H), 3.37 (m, 1H), 3.03 (m, 1H), 2.86 (m 1H), 2.59 (m, 1H), 2.41 (m, 1H), 1.93 (m, 1H), 1.88 (m, 1H), 1.66 (m, 3H), 1.35 (m, 5H), 1.11 (d, J= 7.0 Hz, 3H), 1.01 (d, J= 6.8 Hz, 3H), 0.97 (d, J
= 6.8 Hz, 3H), 0.92 (m, 27H), 0.85 (m, 10H), 0.81 (s, 9H), 0.11 (s, 3H), 0.09 (s, 3H), 0.07 (s, 3H), 0.06 (s, 6H), 0.05 (s, 6H), 0.04 (s, 3H); 13C NMR (75 MHz, CDC13) 6 159.2, 144.4, 144.3, 134.3, 133.0, 132.4, 130.5, 129.1, 128.6, 127.6, 126.7, 113.8, 86.7, 85.4, 79.8, 75.1, 73.8, 72.2, 66.4, 65.0, 55.0, 42.3, 41.6, 41.5, 40.5, 37.1, 35.8, 34.8, 32.0, 31.9, 30.7, 26.2, 25.94, 25.86, 20.3, 19.2, 18.4, 18.1, 18.0, 15.6, 15.2, 13.2, 10.0, -3.0, -3.4, -3.8, -3.9, --4.2, -4.28, -4.34, -4.4; LRMS (ESI) 1329.8 [M+Na]+, 707.3, 413.2, 243.1; HRMS (ESI) calcd for C78H130O8Si4Na 1329.8741 [M+Na]+, found 1329.8779; [a]20D -8.9 (c 0.46, CHC13).
[00121] ((2E,4R,5S,7S,82,1 OS,11R,12S,14S,17R,18R,19S,20S,21z)-19-(4-Methoxyb enzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraenyloxy)triphenylmethane (44). The alcoho143 (1.35 g, 1.03 mol) in CHZC12 (20 mL) was treated with Dess-Martin periodinane (0.66 g, 1.56 mol). After 1 h, the mixture was quenched with saturated aqueous NaHCO3 (20 mL) and Na2SaO3 (20 mL). The aqueous layer was extracted with EtzO (2 x 20 mL) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 9:1) provided the crude aldehyde as a colorless oil, which was used without further purification. CrC12 (1.06 g, 8.62 mmol) was added to a stirred solution of the crude aldehyde and 1-bromoallyl trimethylsilane (1.28 g, 5.20 mmol) in anhydrous THF (26 mL) under an atmosphere of N2 at room temperature and the mixture was stirred for additional 14 h at ambient temperature. The reaction mixture was diluted with hexane followed by filtration through celite. After the evaporation of the solvent under reduced pressure, the residue was purified by short silica gel column chromatography using EtOAc/hexane (1:9) as eluent. The foregoing product in THF (40 mL) was cooled to 0 C and NaH (95% w/w, 0.52 g, 20.6 mmol) was added in one portion. The ice bath was removed after 15 min and the mixture was stirred for 2 h at ambient temperature. The reaction mixture was cooled to 0 C, quenched with H20 (5 mL) and extracted with Et20 (2 x 20 mL). The coinbined organic layers were washed with brine, dried over MgSO4, filtered and the solvent removed under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 49:1) to obtain 44 (1.17 g, 85% for 3 steps) as a colorless oil:
IR (CHC13) 2956, 2928, 2856, 1614, 1514, 1471, 1462, 1249, 1088, 836, 772 cm 1; 1H NMR
(300 MHz, CDC13) S 7.46 (m, 6H), 7.27 (m, 11H), 6.86 (m, 2H), 6.58 (ddd, J= 17.0, 10.6, 10.5 Hz, 1H), 6.00 (t, J= 11.0 Hz, 1 H), 5.60 (m, 3H), 5.31 (m, 2H), 5.17 (d, J= 16.9 Hz, 1 H), 5.09 (d, J=
10.4 Hz, 1H), 4.51 (m, 3H), 3.90 (in, 2H), 3.80 (s, 3H), 3.61 (m, 1H), 3.56 (d, J= 3.7 Hz, 1H), 3.33 (m, 2H), 3.00 (m, 1H), 2.56 (m, 1H), 2.40 (m, 1H), 2.21 (m, 1H), 1.63 (m, 3H), 1.38 (m, 2H), 1.27 (m, 3H), 1.21 (m, 2H), 1.10 (d, J= 6.7 Hz, 3H), 0.96 (m, 3H), 0.93 (s, 9H), 0.91 (s, 9H), 0.89 (s, 9H), 0.86 (m, 6H), 0.82 (m, 6H), 0.80 (s, 9H), 0.79 (m, 3H), 0.08 (m, 6H), 0.05 (n1, 6H), 0.04 (m, 6H), 0.01 (m, 6H); 13C NMR (75 MHz, CDC13) S
159.0, 146.2, 144.5, 144.4, 134.6, 134.5, 133.1, 132.7, 132.3, 131.4, 129.0, 128.9, 128.7, 127.7, 126.8, 117.1, 113.7, 86.8, 84.4, 79.9, 75.0, 72.9, 72.3, 66.5, 65.1, 55.2, 42.4, 41.9, 41.6, 40.6, 36.0, 35.6, 35.3, 34.5, 32.5, 31.7, 30.5, 26.3, 26.0, 25.9, 20.2, 19.2, 18.8, 18.5, 18.2, 18.1, 15.1, 13.3, 9.3, -2.9, -3.0, -3.3, -3.6, -3.7, -4.2, -4.3, -4.4; LRMS (ESI) 1351.8 [M+Na]+, 1171.7, 1043.7, 889.6, 707.3, 536.1, 453.3, 413.2, 359.2; HRMS (ESI) calcd for C81H132O7Si4Na 1351.8948 [M+Na]+, found 1351.9012; [a]20o +1.1 (c 1.7, CHC13).
[00122] (2E,4R,5S,7S,8Z,10S,11R,12S,14S,17R,18R,19S,20S,21Z)-19-(4-Methoxybenzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraen-l-ol (45). ZnBr2 (0.41 g) in 1.2 mL of 5:1 CH2C12/MeOH was added dropwise for 30 min to a stirred solution of trityl compound 44 (0.24 g, 0.18 mol) in 1.4 mL of 6:1 CH2Cla/MeOH at 0 C. After 4 h, the reaction mixture was quenched with saturated aqueous NaHCO3 (20 mL) and extracted with Et20 (2 x 10 mL).
The organic phase were separated, dried with MgSO4, filtered and concentrated.
The residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 45 (0.15 g, 77%) as a colorless oil: IR (CHC13) 3432, 2956, 2856, 1613, 1514, 1471, 1462, 1360, 1250, 1082, 835, 773 cm 1; 1H NMR (300 MHz, CDC13) S 7.29 (m, 2H), 6.88 (m, 2H), 6.58 (ddd, J=
16.9, 10.6, 10.6 Hz, 1H), 6.00 (t, J= 11.0 Hz, 1H), 5.63 (m, 3H), 5.38 (t, J= 11.0 Hz, 1H), 5.27 (dd, J= 11.2, 8.3 Hz, 1 H), 5.17 (d, J= 16.8 Hz, 1 H), 5.10 (d, J= 10.3 Hz, 1 H), 4. 5 3(m, 3H), 4.08 (d, J= 4.4 Hz, 2H), 3.90 (m, 1H), 3.81 (s, 3H), 3.62 (m, 1H), 3.33 (m, 2H), 2.99 (ddd, J
= 10.0, 6.8, 3.2 Hz, 1H), 2.57 (m, 1H), 2.39 (m, 1H), 1.63 (m, 3H), 1.42 (m, 3H), 1.28 (m, 5H), 1.11 (d, J= 6.8 Hz, 3H), 0.97 (d, J= 6.8 Hz, 3H), 0.96 (d, J= 6.9 Hz, 3H), 0.93 (s, 9H), 0.91 (s, 18H), 0.89 (m, 3H), 0.88 (s, 9H), 0.81 (d, J= 6.7 Hz, 3H), 0.80 (d, J= 6.2 Hz, 3H), 0.10 (s, 3H), 0.09 (s, 3H), 0.08 (s, 6H), 0.06 (s, 3H), 0.05 (s, 6H), 0.03 (s, 3H); 13C NMR (75 MHz, CDC13) 8 159.0, 146.9, 135.2, 134.6, 133.0, 132.7, 132.3, 131.4, 129.2, 129.1, 128.9, 127.93, 127.90, 127.2, 84.4, 80.0, 75.0, 72.8, 72.2, 66.6, 63.9, 55.2, 42.4, 41.8, 41.7, 40.5, 35.9, 35.2, 34.6, 32.6, 31.6, 30.5, 26.3, 25.99, 25.96, 25.93, 20.2, 19.2, 18.8, 18.5, 18.2, 18.1, 15.1, 13.2, 9.2, -3.0, -3.3, -3.6, -3.7, -4.2, -4.4, -4.5; LRMS (ESI) 1109.8 [M+Na]+, 823.6, 691.5, 559.4; HRMS (ESI) calcd for C62H118O7Si4Na 1109.7852 [M+Na]+, found 1109.7897;
[a]20D +1.6 (c 0.94, CHC13).
[00123] (2Z,4E,6R;7S,9S,10Z,12S,13R,14S,16S,19R,20R,21S,22S,23Z)-Methy1-21-(4-methoxy-b enzyloxy)-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (46). The alcoho145 (127 mg, 0.117 mol) in CH2C12 (4 mL) was treated with Dess-Martin periodinane (75 mg, 0.18 mol).
After 1 h, the mixture was quenched with saturated aqueous NaHCO3 (5 mL) and Na2S2O3 (5 mL). The aqueous layer was extracted with Et20 (2 x 10 mL) and the coinbined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash colunm chromatography (hexane/EtOAc 9:1) provided the crude aldehyde as a colorless oil, which was used for the next reaction without further purification. KHIVIDS (0.28 mL, 0.14 mol, 0.5M solution in toluene) was added dropwise to a stirred solution of bis(2,2,2-trifluoroethyl)-(inethoxycarbonylmethyl) phosphate (0.030 mL, 0.14 mol) and 18-crown-6 (0.15 g, 0.57 mmol) in THF (2.3 mL) at -78 C. Thereafter, the aldehyde in THF
(0.5 mL) was added and the solution was stirred for 4 h at -78 C. The reaction mixture was quenched by addition of a saturated aqueous NH4Cl (5 mL) and diluted with EtaO (20 mL).
The organic phase was washed with brine (30 mL), dried with MgSO4, filtered and concentrated. The residue was purified by flash chromatography (EtOAc/hexane 1:19) yielding (E,Z)-doubly unsaturated ester 46 (0.12 g, 86% for 2 steps) as a colorless oil: IR (CHC13) 2955, 2929, 2856, 1722, 1514, 1471, 1462, 1250, 1174, 1085, 1041, 836, 773 cm 1; 'H NMR
(300 MHz, CDC13) 6 7.39 (dd, J= 15.4, 11.3 Hz, 1H), 7.29 (m, 2H), 6.88 (m, 2H), 6.59 (ddd, J= 16.9, 10. 8, 10. 6 Hz, 1 H), 6. 5 5(t, J= 11.3 Hz, 1 H), 6.01 (t, J= 11.0 Hz, 1H), 6.00 (dd, J= 15 . 7, 7. 0 Hz, 1H), 5.60 (d, J= 11.3 Hz, 1H), 5.59 (t, J= 10.4 Hz, 1H), 5.39 (t, J= 10.4 Hz, 1H), 5.27 (dd, J= 11.0, 8.3 Hz, 1H), 5.18 (d, J= 16.8 Hz, 1H), 5.11 (d, J= 10.3 Hz, 1H), 4.54 (m, 3H), 3.96 (m, 1H), 3.81 (s, 3H), 3.74 (s, 3H), 3.63 (m, 1H), 3.34 (m, 2H), 3.00 (m, 1H), 2.57 (in, 2H), 1.64 (m, 3H), 1.55 (m, 1H), 1.46 (t, J= 5.9 Hz, 2H), 1.26 (m, 5H), 1.11 (d, J= 6.8 Hz, 3H), 1.05 (d, J= 6.7 Hz, 3H), 0.97 (d, J= 6.9 Hz, 3H), 0.96 (d, J= 7.1 Hz, 3H), 0.94 (s, 9H), 0.92 (s, 9H), 0.91 (s, 9H), 0.87 (s, 9H), 0.83 (d, J= 6.4 Hz, 3H), 0.82 (d, J=
6.0 Hz, 3H), 0.13 (s, 3H), 0.11 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H), 0.06 (s, 3H), 0.05 (s, 6H), 0.04 (s, 3H);
13C NMR (75 MHz, CDC13) S 166.8, 159.0, 147.3, 145.5, 134.6, 132.9, 132.8, 132.4, 131.4, 129.0, 128.9, 126.9, 117.1, 115.5, 113.7, 84.4, 80.0, 75.0, 72.9, 72.1, 66.5, 55.2, 50.9, 43.5, 42.5, 41.8, 40.5, 36.0, 35.3, 34.5, 32.5, 31.6, 30.5, 26.3, 25.99, 25.96, 25.91, 20.2, 19.2, 18.8, 18.5, 18.2, 18.1, 15.0, 13.4, 9.2, -3.0, -3.2, -3.3, -3.6, -3.7, -4.1, -4.4, -4.5; LRMS (EST) 1163.9 [M+Na]+, 1009.8, 684.3, 610.2, 513.4; HRMS (ESI) calcd for C65H12oO8Si4Na 1163.7958 [M+Na]+, found 1163.7985; [oc]20D -9.3 (c 1.2, CHC13).
[00124] (2Z,4E,6R,7S,9S,l OZ,12S,13R,14S,16S,19R,20R,21S,22S,23Z)-Methyl-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (47). The ester 46 (81 mg, 71 mol) was added to CH2C12 (2 mL) and Ha0 (0.1 mL) and DDQ (20 mg, 88 mol) was added at 0 C.
After 1 h of stirring at 0 C, the reaction mixture was quenched by adding saturated aqueous NaHCO3 (5 mL). The organic phase was washed with saturated aqueous NaHCO3 (3 x mL) and brine, dried over MgSO4, filtered and concentrated. Purification by flash column chromatography (EtOAc/hexane 1:9) furnished 47 (64 mg, 88%) as a colorless oil: IR
(CHC13) 3541, 2956, 2929, 2856, 1722, 1639, 1471, 1462, 1377, 1360, 1254, 1175, 1086, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 6 7.34 (dd, J= 15.4, 11.2 Hz, 1H), 6.61 (ddd, J=
16.8, 10.7, 10.6 Hz, 1H), 6.51 (t, J= 11.3 Hz, 1H), 6.06 (t, J= 11.0 Hz, 1H), 5.96 (dd, J=
15.4, 7.1 Hz, 1 H), 5. 5 6(d, J= 11.3 Hz, 1 H), 5.3 9(t, J= 10.1 Hz, 1H), 5. 3 8(t, J= 10.3 Hz, 1H), 5.22 (dd, J= 11.0, 8.5 Hz, 1H), 5.17 (d, J= 18.7 Hz, 1H), 5.09 (d, J=
10.1 Hz, 1H), 4.50 (m, 1H), 3.92 (m, 1H), 3.71 (m, 1H), 3.70 (s, 3H), 3.44 (m, 1H), 3.32 (m, 1H), 2.74 (m, 1H), 2.52 (m, 2H), 2.31 (br, 1H), 1.61 (m, 4H), 1.39 (m, 2H), 1.31 (m, 2H), 1.26 (m, 3H), 1.00 (d, J= 6.7 Hz, 3H), 0.93 (d, J= 6.9 Hz, 3H), 0.92 (d, J= 6.7 Hz, 3H), 0.86 (m, 27H), 0.84 (m, 6H), 0.82 (m, 12H), 0.05 (s, 9H), 0.02 (s, 3H), 0.01 (s, 6H), 0.00 (s, 6H); 13C NMR
(75 MHz, CDC13) b 166.8, 147.3, 145.5, 135.3, 132.7, 132.6, 132.3, 129.9, 126.8, 117.7, 115.5, 79.9, 77.6, 76.6, 72.1, 66.5, 51.0, 43.5, 42.4, 41.5, 37.7, 36.1, 35.7, 35.0, 32.1, 31.5, 30.6, 26.3, 25.9, 25.9, 20.4, 19.4, 18.5, 18.1, 17.9, 17.7, 15.3, 13.3, 6.9, -3.0, -3.4, -3.7, -4.1, -4.2, -4.4; LRMS (ESI) 1043.6 [M+Na]}, 889.6, 757.5, 625.4, 393.3; HRMS (ESI) calcd for C57H112O7Si4Na 1043.7383 [M+Na]+, found 1043.7417; [a]20D -25.3 (c 0.61, CHC13).
[00125] (2Z,4E,6R,7S,9S,I OZ,12S,13R,14S,16S,19R,20R,21S,22S,23Z)-7,9,13,19-tetrakis(tert-Butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoic acid (48). A stirried solution of alcohol 47 (25 mg, 24 mol) in 3.4 mL of 12:5 EtOH/THF was treated with 1N aqueous KOH (0.24 mL) and the mixture was refluxed gently for 3 h. The ethanolic solution was concentrated and then diluted with Et20 (4 mL). After the solution was acidified to pH3 with 1N aqueous HC1, the organic phase was separated and aqueous phase was extracted with Et20 (2 x 5 mL). The combined organic phase was dried with MgSO4, filtered, concentrated and the residue was used without further purification: IR (CHC13) 2956, 2929, 2857, 1693, 1635, 1600, 1471, 1462, 1254, 1088, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.33 (dd, J= 15.2, 11.3 Hz, 1H), 6.61 (t, J= 11.4 Hz, 1 H), 6.61 (m, 1 H), 6.07 (t, J= 11.0 Hz, 1 H), 6.02 (dd, J= 15 . 8, 7.2 Hz, 1 H), 5.5 8 (d, J=
11.3 Hz, 1 H), 5.3 9(m, 2H), 5.23 (dd, J= 11.0, 8.2 Hz, 1 H), 5.18 (d, J= 16.8 Hz, 1 H), 5.09 (d, J= 10.2 Hz, 1H), 4.50 (m, 1H), 3.92 (m, 1H), 3.73 (m, 1H), 3.46 (dd, J=
7.3, 2.6 Hz, 1H), 3.34 (m, 1H), 2.78 (m, 1H), 2.54 (m, 2H), 1.66 (m, 4H), 1.42 (m, 4H), 1.24 (m, 3H), 1.01 (d, J= 6.8 Hz, 3H), 0.95 (d, J= 6.7 Hz, 3H), 0.94 (d, J= 6.7 Hz, 3H), 0.88 (m, 30H), 0.84 (m, 15H), 0.09 (s, 3H), 0.07 (s, 3H), 0.06 (s, 6H), 0.02 (s, 6H), 0.01 (s, 6H); 13C NMR
(75 MHz, CDC13) 8 171.2, 148.2, 147.3, 135.2, 133.2, 132.7, 132.3, 123.0, 127.0, 117.7, 115.2, 79.9, 77.6, 76.5, 72.1, 66.4, 43.5, 42.6, 41.6, 37.8, 36.0, 35.8, 34.9, 32.1, 31.5, 30.6, 26.2, 25.93, 25.87, 20.3, 19.4, 18.4, 18.10, 18.05, 17.7, 15.3, 13.6, 6.9 -3.0, -3.4, -3.7, -4.1, -4.19, -4.24, -4.4; LRMS (ES1) 1029.7 [M+Na]+, 875.6, 743.6, 611.4, 593.4, 393.3; HRMS
(ESI) calcd for C56H11oO7Si4Na 1029.7226 [M+Na]+, found 1029.7274; [a]20D -25.7 (c 0.54, CHC13).
[00126] (8S,10S,14R,20R)-tetrakis(tert-Butyldimethylsilyloxy)-(7R,13S,15S,17S,21S)-pentamethyl-(22S)-((1S)-methylpenta-2,4-dienyl)oxacyclodocosa-3,5,11-trien-2-one (49). A solution of 48 in THF (2 mL) was treated at 0 C
with Et3N (0.020 mL, 147 mol) and 2,4,6-trichlorobenzoyl chloride (0.019 mL, 122 mol). The reaction mixture was stirred at 0 C for 30 min and then added to 4-DMAP (12 mL, 0.02 M
solution in toluene) at 25 C. After stirring for 12 h, the reaction mixture was concentrated, Et20 (10 mL) was added and the crude was washed with 1N HC1 (2 x 5 mL) and dried over MgSO4.
Purification by flash colunui cliromatography (EtOAc/hexane 1:49) furnished the macrolactone (19 mg, 78% for 2 steps) as a colorless oil: IR (CHC13) 2955, 2929, 2857, 1716, 1642, 1474, 1225, 1043, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) S 6.98 (dd, J=
14.8, 11.3 Hz, 111), 6.55 (m, 1H), 6.52 (t, J= 11.2 Hz, 1H), 6.04 (t, J= 10.5 Hz, 1H), 6.01 (dd, J=
15.4, 6.4 Hz, 1H), 5.59 (d, J= 11.2 Hz, 1H), 5.58 (m, 1H), 5.38 (t, J= 10.6 Hz, 1H), 5.33 (dd, J= 11.3, 8.1 Hz, 1 H), 5.19 (d, J= 16.6 Hz, 1H), 5.11 (d, J= 10.5 Hz, 1 H), 5.06 (dd, J=
7. 6, 3.7 Hz, 1H), 4.52 (m, 1 H), 4.01 (m, 1H), 3.63 (m, 1H), 3.19 (d, J= 6.2 Hz, 1H), 3.03 (m, 1H), 2.58 (m, 1H), 2.52 (m, 2H), 1.81 (m, 4H), 1.45 (m, 3H), 1.25 (m, 3H), 1.09 (m, 3H), 1.02 (d, J= 6.8 Hz, 3H), 1.01 (d, J= 7.0 Hz, 3H), 0.97 (d, J= 6.6 Hz, 3H), 0.95 (d, J= 6.4 Hz, 3H), 0.91 (s, 9H), 0.89 (s, 9H), 0.88 (s, 9H), 0.86 (s, 9H), 0.77 (d, J=
6.4 Hz, 3H), 0.75 (d, J= 6.5 Hz, 3H), 0.10 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H), 0.04 (s, 3H), 0.033 (s, 6H), 0.026 (s, 6H); 13C NMR (75 MHz, CDC13) S 166.5, 143.1, 141.8, 133.9, 132.7, 131.8, 130.2, 129.8, 128.0, 118.4, 118.1, 81.0, 78.0, 70.4, 66.5, 62.5, 43.1, 42.3, 41.4, 39.1, 35.2, 34.8, 34.5, 31.6, 30.3, 29.7, 29.3, 26.2, 26.0, 25.94, 25.85, 20.2, 19.7, 18.5, 18.24, 18.16, 18.08, 16.2, 14.0, 9.9, -2.7, -3.4, -3.5, -3.8, -3.9, -4.2, -4.3; [a]20D -18.1 (c 0.24, CHC13).
[00127] (8S,10S,14R,20R)-Tetrahydroxy-(7R,13S,15S,17S,21S)-pentamethyl-(22S)-((1S)-methylpenta-2,4-dienyl)oxacyclodocosa-3,5,11-trien-2-one (Dictyostatin, 1). A
stirred solution of macrolactone 49 (18 mg, 18 mol) in THF (3 mL) at 0 C was treated with 3N HCl (10 mL, prepared by adding 2.5 inL of conc. HCl to 7.5 mL MeOH). After 24 h at room temperature, the reaction mixture was diluted with EtOAc (4 mL) and H20 (4 mL). The organic phase was saved and the aqueous phase was extracted with EtOAc (2 x 4 mL). The combined organic phase was washed with saturated aqueous NaHCO3 (10 mL), dried with MgSO4, filtered and concentrated. The residue was purified by flash chromatography (EtOAc/hexane 3:2) to yield 1 as a white solid (5.3 mg, 55%): IR (CHC13) 3406, 2960, 2924, 2872, 1693, 1637, 1461, 1378, 1274, 1181, 1069, 998, 738 cni 1; 1H NMR (600 MHz, CD3OD) S 7.21 (dd, J= 15.6, 11.1 Hz, 1H), 6.71 (ddd, J= 16.9, 11.0, 10.6 Hz, 1H), 6.65 (dd, J=11.3, 11.3 Hz, 111), 6.17 (dd, J= 15.6, 6.7 Hz, 1H), 6.06 (dd, J= 11.1, 11.1 Hz, 1H), 5.56 (d, J= 11.3 Hz, 1H), 5.55 (dd, J= 11.0, 11.0 Hz, 1H), 5.41 (dd, J= 11.1, 8.8 Hz, 1H), 5.34 (dd, J= 10.7, 10.6 Hz, 1 H), 5.25 (dd, J= 16.8, 1.8 Hz, 1H), 5.15 (d, J= 10.1 Hz, 1H), 5.14 (dd, J= 7.0, 5.0 Hz, 1H), 4.65 (ddd, J= 9.5, 9.5, 3.3 Hz, 1H), 4.05 (ddd, J=
10.6, 3.7, 2.8 Hz, 1H), 3.17 (ddq, J= 10.1, 6.8, 6.6 Hz, 1H), 3.10 (dd, J= 8.1, 2.9 Hz, 1H), 2.76 (m, 1H), 2.60 (m, 1H), 1.89 (m, 1H), 1.84 (dddd, J= 12.9, 11.2, 6.4, 5.4 Hz, 1H), 1.60 (m, 1H), 1.58 (m, 1H), 1.54 (m, 1H), 1.50 (ddd, J= 14.1, 10.7, 3.5 Hz, 1H), 1.42 (ddd, J=
14.0, 10.0, 2.7 Hz, 1H), 1.25 (ddd, J= 13.7, 10.6, 3.6 Hz, 1H), 1.15 (d, J= 6.9 Hz, 3H), 1.12 (d, J= 7.0 Hz, 3H), 1.10 (m, 1H), 1.07 (d, J= 6.9 Hz, 3H), 1.01 (d, J= 6.8 Hz, 3H), 0.95 (d, J= 6.5 Hz, 3H), 0.93 (d, J= 6.5 Hz, 3H). 0.90 (m, 1H), 0.71 (dddd, J= 12.9, 12.8, 8.7, 4.9 Hz, 1H); 13C
NMR (150 MHz, CD3OD) 6 168.10, 146.42, 144.90, 134.87, 134.54, 133.43, 131.32, 131.27, 128.60, 118.58, 118.04, 80.37, 78.64, 73.73, 70.41, 65.53, 44.07, 42.28, 40.84, 40.65, 35.84, 35.78, 35.33, 32.75, 32.51, 31.23, 21.81, 19.36, 18.08, 15.98, 13.80, 10.41;
LRMS (ESI) 555.3 [M+Na]+, 449.2, 243.1; HRMS (ESI) calcd for C32H52O6Na 555.3662 [M+Na]+, found 555.3665; [a]20D -22.6 (c 0.27, MeOH).
[00128] (2Z,4E,6R,7S,9S,l OZ,12S,13R,14S,16S,19R,20S,21S,22S,23Z)-Methyl-7,9,13,19,21-penta-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (50). 3N HCl (10 mL, prepared by adding 2.5 mL of conc. HCl to 7.5 mL
MeOH) was added to a stirred solution of the macrolactonization precursor 48 (23 mg, 23 mol) in THF (3 mL) at 0 C. After 24 h at room temperature, the reaction mixture was diluted with EtOAc (4 mL) and H20 (4 mL). The organic phase was retained and aqueous phase was extracted with EtOAc (2 x 4 mL). The combined organic phase was washed with saturated aqueous NaHCO3 (10 mL), dried with MgSO4, filtered and concentrated.
The residue was purified by flash chromatography (EtOAc/hexane 3:2) to yield the product 50 (4.5 mg, 36%) as a colorless oil: IR (CHC13) 3399, 2917, 2849, 1713, 1635, 1600, 1461, 1439, 1197, 1178, 970, 757 cm 1;1H NMR (600 MHz, CD3OD) S 7.36 (dd, J= 15.3, 11.2 Hz, 1H), 6.67 (ddd, J= 16.9, 11.1, 10.6 Hz, 1H), 6.63 (dd, J= 11.3, 11.3 Hz, 1H), 6.14 (dd, J=
15.4, 8.3 Hz, 1H), 6.03 (dd, J= 11.0, 11.0 Hz, 1H), 5.59 (d, J= 11.4 Hz, 1H), 5.43 (dd, J=
10.7, 10.7 Hz, 1H), 5.42 (dd, J= 10.8, 9.2 Hz, 1H), 5.32 (dd, J= 10.4, 10.4 Hz, 1H), 5.17 (dd, J= 16.8, 2.0 Hz, 1H), 5.08 (d, J= 10.2 Hz, 1H), 4.61 (ddd, J= 12.9, 8.5, 4.6 Hz, 1H), 3.80 (ddd, J= 8.9, 4.4, 4.4 Hz, 1H), 3.69 (s, 3H), 3.63 (m, 1H), 3.46 (t, J=
5.8 Hz, 1H), 3.13 (dd, J= 8.0, 3.2 Hz, 1H), 2.93 (m, 1H), 2.71 (m, 1H), 2.38 (m, 1H), 1.73 (m, 1H), 1.56-1.53 (m, 3H), 1.52-1.46 (m, 2H), 1.44-1.36 (m, 3H), 1.09 (d, J= 6.9 Hz, 3H), 0.98 (d, J= 6.8 Hz, 3H), 0.96 (d, J= 6.6 Hz, 3H), 0.95 (m, 2H), 0.94 (d, J= 6.9 Hz, 3H), 0.87 (d, J= 6.6 Hz, 3H), 0.86 (d, J= 6.8 Hz, 3H); 13C NMR (150 MHz, CD3OD) 6 168.4, 148.5, 146.9, 135.7, 135.4, 133.85, 133.82, 130.6, 128.2, 117.7, 116.2, 79.2, 78.5, 74.8, 72.4, 65.8, 51.5, 45.1, 43.2, 43.0, 41.0, 37.2, 36.5, 34.0, 33.3, 33.1, 31.0, 20.7, 18.6, 18.4, 16.7, 13.8, 7.8; LRMS
(ESI) 587.5 [M+Na]+, 559.2, 485.2, 413.3, 355.1, 212.1; HRMS (ESI) calcd for C33H5607Na 587.3924 [M+Na]+, found 587.3953; [a]20D +8.7 (c 0.30, CDC13).
(4S,5S)-4-((2R,3S,6S,8S,9R,lOS,11Z,13S,15S,16R,17E)-3,9,13,15-tetrakis(tert-Butyldimethylsilyloxy)-6,8,10,16-tetramethyl-19-trityloxynonadeca-11,17-dien-2-yl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxane (51).
[00129] The procedure for 42 was used with 41a (0.58 g, 0.49 mmol), TBSOTf (0.17 mL, 0.74 mmol) and 2,6-lutidine (0.11 mL, 0.97 mmol) to yield 0.62 g (97%) of the product by flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR
(CHC13) 2955, 2856, 1615, 1518, 1462, 1385, 1251, 1082, 835, 773, 705 cm 1; iH NMR (300 MHz, CDC13) 6 7.55 (m, 6H), 7.49 (m, 2H), 7.40-7.27 (m, 9H), 6.96 (m, 2H), 5.72 (m, 2H), 5.53 (m, 1H), 5.52 (s, 1H), 5.38 (m, 1H), 4.65 (m, 1H), 4.19 (dd, J= 11.0, 4.4 Hz, 1H), 4.03 (m, 1H), 3.95 (d, J= 8.7 Hz, 1H), 3.86 (m, 1H), 3.84 (s, 3H), 3.66 (d, J= 3.7 Hz, 2H), 3.56 (t, J= 11.1 Hz, 1H), 3.50 (m 1H), 2.71 (m, 1H), 2.52 (m, 1H), 2.12 (m, 1H), 1.90-1.79 (m, 2H), 1.75-1.68 (in, 3H), 1.61-1.37 (m, 6H), 1.08 (d, J= 6.6 Hz, 6H), 1.02-0.91 (m, 36H), 0.81 (d, J= 6.5 Hz, 3H), 0.22-0.13 (in, 24H); 13C NMR (75 MHz, CDC13) 6 159.7, 144.5, 134.4, 132.8, 132.6, 131.7, 128.7, 127.7, 127.3, 126.8, 113.4, 100.9, 86.7, 81.4, 80.1, 73.4, 72.3, 71.5, 66.5, 65.1, 55.1, 42.4, 41.5, 37.9, 35.5, 35.1, 31.3, 30.8, 30.2, 27.9, 26.3, 26.01, 25.99, 25.93, 25.7, 20.6, 19.5, 18.4, 18.11, 18.07, 15.4, 13.4, 13.3, 12.2, 9.2, -2.9, -3.5, -3.7, -3.9, -4.1, -4.2, -4.3, -4.9; LRMS (ESI) 1328.0 [M+Na]+, 782.5, 659.3, 437.2; HRMS (ESI) calcd for C78H128O8Si.4Na 1327.8584 [M+Na]+, found 1327.8624; [a]20D +6.1 (c 0.93, CHC13).
[00130] (2S,3S,4R,5S,8S,lOS,1-1R,12S,13Z,15S,17S,18R,19E)-3-(4-Methoxyb enzyloxy))-5,11,15,17-tetrakis(tert-butyldimethylsilyloxy)-2,4,8,10,12,18-hexamethyl-21-trityloxyhenicosa-13,19-dien-l-ol (52). The procedure for 43 was used with 51 (0.62 g, 0.47 mmol) and DIBAL-H (1.0 M in hexane, 4.7 mL, 4.7 mmol) to yield 0.54 g (87%) of the product after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 3479, 2955, 2928, 2856, 1613, 1514, 1471, 1251, 1084, 835, 773 cni 1; 1H
NMR (300 MHz, CDC13) 6 7.56-7.52 (in, 6H), 7.38-7.33 (m, 9H), 7.30 (m, 2H), 6.94 (m, 2H), 5.72 (m, 2H), 5.52 (m, 1H), 5.38 (m, 1H), 4.67 (d, J= 10.3 Hz, 1H), 4.65 (m, 1H), 4.60 (d, J= 10.4 Hz, 1H), 4.03 (m, 1H), 3.83 (s, 3H), 3.70 (m, 3H), 3.65 (d, J= 3.7 Hz, 2H), 3.49 (m, 1H), 3.02 (m, 1H), 2.71 (m 1H), 2.52 (m, 1H), 1.91 (m, 2H), 1.80-1.64 (m, 3H), 1.60-1.34 (m, 8H), 1.09-0.90 (m, 54H), 0.21-0.12 (m, 24H); 13C NMR (75 MHz, CDC13) S 159.2, 144.5, 144.3, 134.4, 132.8, 132.4, 130.6, 129.0, 128.6, 127.7, 126.8, 113.8, 86.7, 84.7, 80.0, 74.8, 74.5, 72.2, 66.5, 66.2, 65.1, 55.1, 42.3, 41.4, 38.7, 35.5, 35.2, 35.0, 31.5, 30.9, 30.7, 29.8, 26.2, 26.00, 25.95, 25.89, 20.5, 19.4, 18.4, 18.13, 18.08, 18.02, 15.4, 15.2, 13.2, 10.4, -3.0, -3.6, -3.7, -3.8, -4.18, -4.24, -4.3, -4.4; LRMS (ESI) 1329.8 [M+Na]+, 782.4, 413.2;
HRMS (ESI) calcd for C78H130O8Si4Na 1329.8741 [M+Na]+, found 1329.8782; [a]20D
-6.8 (c 0.66, CHC13).
[00131] ((2E,4R,5S,7S,8Z,l OS,11R,12S,14S,17S,18R,19S,20S,21Z)-19-(4-Methoxybenzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraenyloxy)triphenylmethane (53). The procedure for 44 was used with 52 (0.54 g, 0.41 mol) and Dess-Martin periodinane (0.26 g, 0.61 mol), 1-bromoallyl trimethylsilane (0.50 g, 2.60 mmol) and CrC12 (0.42 g, 3.42 mmol), NaH (95%
w/w, 0.21 g, 8.31 mmol) to yield 0.46 g (83% for 3 steps) of the product by flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 2955, 2928, 2856, 1613, 1514, 1462, 1250, 1069, 835, 773, 705 cm 1; 'H NMR (300 MHz, CDC13) S 7.58-7.54 (m, 6H), 7.40-7.35 (m, 9H), 7.33-7.30 (m, 2H), 6.96-6.93 (m, 2H), 6.69 (ddd, J=
16.8, 10.6, 10.5 Hz, 1H), 6.12 (t, J= 11.0 Hz, 1H), 5.80-5.67 (m, 3H), 5.52 (t, J= 10.4 Hz, 1H), 5.40 (m, 1H), 5.28 (d, J= 16.8 Hz, 1H), 5.19 (d, J=10.2 Hz, 1H), 4.63 (m, 3H), 4.03 (m, 1H), 3.85 (s, 3H), 3.67 (m, 2H), 3.51 (m, 1H), 3.38 (m, 1H), 2.96 (m, 1H), 2.72 (m, 1H), 2.53 (m, 1H), 1.93-1.74 (m, 2H), 1.66-1.37 (m, 7H), 1.31-1.23 (m, 3H), 1.18 (d, J= 6.8 Hz, 3H), 1.09 (m, 6H), 1.03-0.92 (m, 45H), 0.23-0.10 (m, 24H); 13C NMR (75 MHz, CDC13) 6 159.1, 144.5, 144.4, 134.7, 134.5, 133.0, 132.6, 132.2, 131.4, 129.1, 129.0, 128.7, 127.7, 126.8, 117.5, 113.7, 86.8, 84.6, 79.9, 74.7, 73.6, 72.3, 66.5, 65.1, 55.2, 42.5, 42.4, 41.6, 36.1, 35.9, 34.8, 32.0, 30.8, 29.8, 26.3, 26.02, 25.96, 20.5, 19.3, 18.6, 18.5, 18.2, 18.1, 15.4, 13.3, 10.5, -2.9, -3.4, -3.7, -4.1, -4.2, -4.3; LRMS (ESI) 1352.0 [M+Na]+, 782.5, 647.6, 619.6, 437.2;
HRMS (ESI) calcd for C81H132O7Si4Na 1351.8948 [M+Na]+, found 1351.8987; [a]20D -8.6 (c 1.6, CHC13).
[00132] (2E,4R,5S,7S,8Z,l OS,11R,12S,14S,17S,18R,19S,20S,21Z)-19-(4-Methoxyb enzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraen-l-ol (54). The procedure for 45 was used with 53 (0.46 g, 0.35 mol) and ZnBr2 (0.41 g in 5.8 mL of 24:5 CH2C12/MeOH) to yield 0.21 g (55%) of the product after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 3410, 2956, 2929, 2856, 1614, 1514, 1471, 1462, 1251, 1075, 836, 773 cm 1;
'H NMR (300 MHz, CDC13) S 7.28 (m, 2H), 6.87 (m, 2H), 6.60 (ddd, J= 16.8, 10.7, 10.6 Hz, 1H), 6.03 (t, J= 11.0 Hz, 1H), 5.67-5.57 (m, 3H), 5.41 (m, 1H), 5.29 (m, 1H), 5.20 (d, J=
18.2 Hz, 1H), 5.11 (d, J= 10.2 Hz, 1H), 4.56 (m, 3H), 4.10 (d, J= 4.4 Hz, 1H), 3.93 (m, 1H), 3.81 (s, 3H), 3.66-3.57 (m, 2H), 3.40 (dd, J= 4.6, 2.6 Hz, 1H), 3.28 (dd, J
6.2, 4.2 Hz, 1H), 2.85 (m, 1H), 2.60 (m, 1H), 2.39 (m, 1H), 1.79 (m, 1H), 1.70 (m, 1H), 1.66-1.56 (m, 2H), 1.51-1.19 (m, 8H), 1.09 (d, J= 6.8 Hz, 3H), 0.98 (d, J= 6.8 Hz, 3H), 0.97 (d, J= 6.9 Hz, 3H), 0.92-0.86 (m, 45H), 0.11-0.00 (m, 24H); 13C NMR (75 MHz, CDC13) 8 159.0, 135.2, 134.7, 132.8, 132.7, 132.3, 131.4, 129.2, 129.1, 129.0, 117.4, 113.7, 84.6, 80.0, 74.7, 73.6, 72.2, 66.6, 63.9, 63.3, 55.3, 42.4, 41.7, 36.1, 35.8, 34.8, 31.9, 30.8, 29.8, 26.3, 26.0, 25.9, 20.5, 19.4, 19.3, 18.6, 18.5, 18.1, 15.3, 13.3, 10.5, -3.0, -3.4, -3.7, -4.2, -4.3, -4.5; LRMS
(ESI) 1109.9 [M+Na]+, 947.8, 782.5, 689.2, 615.2, 541.1, 413.3, 306.3; HRMS
(ESI) calcd for C62H118O7Si4Na 1109.7856 [M+Na]+, found 1109.7902; [a]20D -12.0 (c 1.7, CHC13).
[00133] (2Z,4E,6R,7S,9S,10Z,12S,13R,14S,16S,19S,20R,21S,22S,23Z)-Methyl-21-(4-methoxyb enzyloxy)-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (55). The procedure for 46 was used with 54 (117 mg, 0.108 mol) and Dess-Martin periodinane (69 mg, 0.16 mol), bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl) phosphate (0.027 mL, 0.13 mol), 18-crown-6 (0.14 g, 0.53 mmol) and KHMDS (0.26 mL, 0.13 mol, 0.5 M solution in toluene) to yield 69 mg (56% for 2 steps) of the product after flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2956, 2929, 2856, 1722, 1640, 1514, 1471, 1462, 1250, 1174, 1080, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.44 (dd, J= 15.2, 11.3 Hz, 1H), 7.28 (m, 2H), 6.88 (m, 2H), 6.60 (ddd, J= 16.7, 10.6, 10.5 Hz, 1H), 6.56 (t, J=11.3 Hz, 1H), 6.04 (dd, J= 15.5, 7.1 Hz, 1H), 6.00 (t, J= 11.0 Hz, 1H), 5.62 (m, 2H), 5.42 (m, 1H), 5.27 (m, 1H), 5.21 (d, J=16.8 Hz, 1H), 5.11 (d, J=10.3 Hz, 1H), 4.54 (m, 3H), 3.97 (m, 1H), 3.81 (s, 3H), 3.74 (s, 3H), 3.60 (m, 111), 3.40 (m, 1H), 3.29 (m, 1H), 2.86 (m, 1H), 2.57 (m, 211), 1.80-1.67 (m, 3H), 1.55-1.41 (in, 4H), 1.40-1.20 (m, 4H), 1.09 (d, J= 6.8 Hz, 3H), 1.06 (d, J
= 6.8 Hz, 3H), 0.99 (d, J= 6.6 Hz, 3H), 0.98 (d, J= 6.7 Hz, 3H), 0.95-0.85 (m, 42H), 0.13-0.00 (m, 24H); 13C NMR (75 MHz, CDC13) S 166.8, 159.0, 147.3, 145.5, 134.7, 132.9, 132.7, 132.3, 131.4, 129.1, 129.0, 126.9, 117.4, 115.5, 113.7, 84.6, 80.0, 74.7, 73.6, 72.1, 66.5, 55.3, 51.0, 43.5, 42.4, 41.6, 36.1, 35.8, 34.8, 31.9, 30.7, 29.8, 26.3, 26.0, 25.9, 20.5, 19.3, 18.6, 18.5, 18.1, 15.3, 13.4, 10.5, -3.0, -3.3, -3.7, -4.10, -4.15, -4.19, -4.3, -4.4; LRMS (ESI) 1163.8 [M+Na]+, 1057.7, 782.4, 541.1; HRMS (ESI) calcd for C65H12oO$Si4Na 1163.7958 [M+Na]+, found 1163.8000; [a]20D -16.7 (c 0.33, CHC13).
[00134] (2Z,4E,6R,7S,9S,10Z,12S,13R,14S,16S,19S,20R,21S,22S,23Z)-Methyl-7,9,13,19-tetf=akis(tert-butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (56). The procedure for 47 was used with 55 (68 mg, 60 mol) and DDQ (15 mg, 66 mol) to yield 56 mg (92%) of the product after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 3499, 2956, 2929, 2856, 1723, 1641, 1471, 1462, 1255, 1175, 1081, 836, 773 cm 1; 1H NMR
(300 MHz, CDC13) 8 7.35 (dd, J= 15.2, 11.3 Hz, 1H), 6.64 (ddd, J= 16.9, 10.6, 10.5 Hz, 1H), 6.52 (t, J
= 11.3 Hz, 1H), 6.07 (t, J= 11.0 Hz, 1H), 5.96 (dd, J= 15.5, 7.1 Hz, 1H), 5.56 (d, J= 11.3 Hz, 1H), 5.44-5.33 (m, 2H), 5.26-5.21 (m, 1H), 5.17 (d, J= 16.7 Hz, 1H), 5.07 (d, J= 10.1 Hz, 1H), 4.49 (m, 1H), 3.92 (m, 1H), 3.73-3.67 (m, 5H), 3.34 (m, 1H), 3.25 (br, 1H), 2.73 (m, 1H), 2.52 (m, 2H), 1.82-1.50 (m, 4H), 1.44-1.16 (m, 7H), 1.01 (d, J= 6.8 Hz, 3H), 0.97 (d, J
= 7.1 Hz, 3H), 0.93 (d, J= 6.9 Hz, 3H), 0.90 (d, J= 6.9 Hz, 3H), 0.88-0.81 (m, 42H), 0.08-0.00 (m, 24H); 13C NMR (75 MHz, CDC13) 6 166.8, 147.3, 145.5, 136.5, 132.8, 132.7, 132.6, 129.6, 126.8, 117.3, 115.5, 79.8, 78.4, 74.2, 72.1, 66.5, 51.0, 43.5, 42.5, 41.4, 36.0, 35.9, 35.8, 35.0, 32.4, 31.9, 30.7, 26.3, 26.0, 25.9, 20.4, 19.4, 18.5, 18.12, 18.08, 17.98, 17.4, 15.3, 13.4, 10.8, -3.0, -3.4, -3.7, -4.1, -4.2, -4.3, -4.4, -4.8; LRMS (ESI) 1043.7 [M+Na]+, 889.6, 758.2, 684.2, 610.1; HRMS (ESI) calcd for C57H112O7Si4Na 1043.7383 [M+Na]+, found 1043.7435; [a]20D -9.4 (c 0.62, CHC13).
[00135] (2Z,4E,6R,7S,9S,10Z,12S,13R,14S,16S,19S,20R,21S,22S,23Z)-7,9,13,19-tetrakis(tert-Butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoic acid (57). The procedure for 48 was used with 56 (56 mg, 55 mol) and 1N aqueous KOH (0.54 mL) to yield 57, which was used without further purification: IR
(CHC13) 2956, 2929, 2857, 1693, 1634, 1471, 1462, 1254, 1082, 836, 773 cm 1;
'H NMR
(300 MHz, CDC13) 8 7.34 (dd, J= 15.1, 11.4 Hz, 1H), 6.64 (ddd, J= 16.5, 10.6, 10.5 Hz, 1H), 6.61 (t, J= 11.2 Hz, 1H), 6.07 (t, J= 11.0 Hz, 1H), 6.01 (dd, J= 15.5, 7.2 Hz, 1 H), 5.58 (d, J= 11.3 Hz, 1H), 5.44-5.34 (m, 2H), 5.23 (dd, J= 11.0, 8.2 Hz, 1H), 5.17 (d, J= 18.0 Hz, 1H), 5.08 (d, J= 10.1 Hz, 1H), 4.50 (m, 1H), 3.92 (m, 1H), 3.69 (m, 1H), 3.35 (m, 1H), 2.75 (m, 1H), 2.54 (m, 2H), 1.74-1.56 (m, 4H), 1.49-1.20 (m, 7H), 1.02 (d, J= 6.8 Hz, 3H), 0.98 (d, J= 7.2 Hz, 3H), 0.94 (d, J= 7.0 Hz, 3H), 0.90-0.82 (m, 45H), 0.09-0.01 (m, 24H); 13C
NMR (75 MHz, CDC13) 8 171.1, 148.2, 147.4, 136.4, 132.7, 132.6, 129.6, 127.0, 117.4, 115.1, 79.8, 78.4, 74.2, 72.1, 66.5, 43.5, 42.6, 41.5, 36.0, 35.9, 35.8, 35.0, 31.9, 30.8, 29.7, 26.3, 26.0, 25.9, 20.4, 19.3, 18.5, 18.13, 18.08, 17.97, 17.4, 15.4, 13.7, 10.8, -3.0, -3.4, -3.7, -4.1, -4.2, -4.3, -4.4, -4.8; LRMS (ESI) 1029.8 [M+Na]+, 832.3, 758.3, 684.3, 610.2, 541.2;
HRMS (ESI) calcd for C56H11oO7Si4Na 1029.7226 [M+Na]+, found 1029.7255; [a]20D
-6.5 (c 0.17, CHC13).
[00136] (8S,10S,14R,20S)-tetrakis(tert-Butyldimethylsilyloxy)-(7R,13S,15S,17S,21S)-pentamethyl-(22S)-((1S)-methylpenta-2,4-dienyl)-oxacyclodocosa-3,5,11-trien-2-one (58). The procedure for 49 was used with 57, Et3N (0.046 mL, 33 mol), 2,4,6-trichlorobenzoyl chloride (0.043 mL, 28 mol) and 4-DMAP (27 mL, 0.02 M
solution in toluene) to yield 42 mg (78% for 2 steps) of 58 after flash column chromatography (EtOAc/hexane 1:49) as a colorless oil: IR (CHC13) 2956, 2929, 2856, 1704, 1638, 1471, 1462, 1378, 1361, 1255, 1086, 1044, 1004, 835, 773 cm 1; 1H NMR (300 MHz, CDC13) 6 6.98 (dd, J= 15.3, 11.3 Hz, 1H), 6.58 (ddd, J= 16.9, 10.6, 10.5 Hz, 1H), 6.42 (t, J= 11.4 Hz, 1H), 5.94 (t, J= 9.2 Hz, 1H), 5.92 (dd, J= 9.5, 5.2 Hz, 1H), 5.55 (m, 1H), 5.42 (d, J= 11.6 Hz, 1H), 5.33-5.21 (in, 3H), 5.12 (d, J= 15.1 Hz, 1H), 4.99 (d, J= 9.7 Hz, 1H), 4.54 (m, 1H), 3.99 (m, 1H), 3.44 (m, 1H), 3.17 (m, 1H), 2.99 (m, 1H), 2.54 (m, 1H), 2.19 (m, 114), 1.99 (m, 1H), 1.61-1.42 (m, 7H), 1.37-1.18 (m, 3H), 1.10 (d, J= 6.9 Hz, 3H), 1.05 (d, J= 7.1 Hz, 3H), 1.00 (d, J= 6.3 Hz, 3H), 0.98 (d, J= 6.4 Hz, 3H), 0.98-0.82 (m, 36H), 0.79 (d, J= 6.6 Hz, 3H), 0.66 (d, J= 6.7 Hz, 3H), 0.11-0.01 (m, 24H); 13C NMR (75 MHz, CDC13) 8 166.4, 146.5, 143.9, 134.3, 132.7, 132.2, 130.8, 129.8, 127.9, 117.4, 117.1, 81.6, 78.0, 77.1, 73.0, 66.7, 46.9, 45.7, 41.2, 37.5, 35.8, 35.1, 34.5, 31.1, 29.7, 26.2, 26.1, 26.0, 25.9, 20.5, 19.5, 19.1, 18.5, 18.4, 18.2, 17.9, 17.3, 16.9, 7.9, -2.6, -3.4, -3.5, -4.3, -4.4, -4.6; LRMS (ESI) 1011.7 [M+Na]+, 803.5, 633.1, 544.2, 413.2; HRMS (ESI) calcd for C56H10sO6Si4Na 1011.7121 [M+Na]+, found 1011.7164; [a]20D -61.6 (c 2.8, CHC13).
[00137] (8S,1 OS,14R,20S)-Tetrahydroxy-(7R,13S,15S,17S,21S)-pentamethyl-(22S)-((1S)-methylpenta-2,4-dienyl)-oxacyclodocosa-3,5,11-trien-2-one (59). 3N HCl (10 mL, prepared by adding 2.5 mL of conc. HCl to 7.5 mL MeOH) was added to a stirred solution of macrolactone 58 (42 ing, 42 mol) in THF (3 mL) at 0 C. After 24 h at room temperature, the reaction mixture was diluted with EtOAc (4 mL) and H20 (4 mL). The organic phase was retained and the aqueous phase was extracted with EtOAc (2 x 4 mL). The combined organic phase was washed with saturated aqueous NaHCO3 (10 mL), dried with MgSO4, filtered and concentrated. The residue was purified by flash chromatography (EtOAc/hexane 3:2) to yield 59 (7.9 mg, 35%) as a colorless oil: IR (CHC13) 3415, 2961, 2917, 2849, 1681, 1637, 1461, 1279, 1067, 965, 758 cm 1;1H NMR (600 MHz, CD3OD) 6 7.05 (dd, J= 15.3, 11.3 Hz, 1H), 6.65 (ddd, J= 16.9, 10.2, 10.1 Hz, 1H), 6.53 (dd, J= 11.5, 11.5 Hz, 1H), 5.97 (dd, J= 15.3, 9.5 Hz, 1H), 5.94 (dd, J= 11.0, 11.0 Hz, 1H), 5.60 (dd, J= 10.8, 9.6 Hz, 1H), 5.41 (d, J=
11.5 Hz, 1H), 5.20 (dd, J= 10.5, 10.3 Hz, 1H), 5.11 (dd, J= 16.9, 2.0 Hz, 1H), 5.10 (dd, J=
9.7, 2.1 Hz, 1H), 5.01 (d, J= 10.1 Hz, 1H), 4.60 (ddd, J=10.1, 9.7, 2.7 Hz, 1H), 3.94 (ddd, J
= 11.0, 2.1, 2.0 Hz, 1 H), 3.3 8(ddd, J= 9. 8, 3.0, 2.0 Hz, 1 H), 3.09 (ddq, J= 13 .0, 7.0, 4.9 Hz, 1H), 3.01 (dd, J= 8.3, 2.7 Hz, 1H), 2.70 (m, 1H), 2.23(ddd, J= 9.3, 7.0, 2.4 Hz, 1H), 2.07 (ddd, J= 7.0, 2. 6, 2.5 Hz, 1 H), 1.67 (m, 2H), 1. 5 6(ddd, J= 14. 0, 10. 9, 2.9 Hz, 1H), 1.51 (m, 1H), 1.47 (ddd, J= 14.1, 10.5, 1.9 Hz, 1H), 1.17 (d, J= 6.9 Hz, 3H), 1.13 (m, 1H), 1.11 (d, J
= 7.1 Hz, 3H), 1.09 (d, J= 7.0 Hz, 3H), 1.02 (d, J= 6.7 Hz, 3H), 1.00 (m, 1H), 0.93 (d, J=
6.4 Hz, 311), 0.92 (m, 1H), 0.78 (m, 1H), 0.76 (d, J= 6.7 Hz, 3H). 0.74 (m, 1H); 13C NMR
(150 MHz, CD3OD) 8 168.3, 147.6, 145.3, 135.4, 134.3, 133.5, 131.3, 131.0, 130.1, 118.1, 81.2, 79.9, 77.6, 72.0, 65.1, 45.9, 44.8, 42.4, 38.7, 36.0, 35.6, 31.8, 29.8, 27.8, 22.2, 19.8, 18.4, 17.6, 16.4, 9.1; LRMS (ESI) 555.3 [M+Na]+, 443.2; HRMS (ESI) calcd for 555.3662 [M+Na]+, found 555.3655; [a]20D -76.2 (c 0.45, MeOH).
[00138] (4S,5R,6,S)-7-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-4,6-dimethylheptan-l-ol (61). DIBAL-H (19.8 mL, 19.8 mmol, 1.0 M solution in hexane) was added at -78 C dropwise to ester 60 (3.59 g. 7.94 mol) in CHaC12 (40 mL).
After stirring for 1 h, the reaction mixture was quenched by addition of EtOAc (5 mL) and saturated aqueous sodium potassium tartrate (80 mL), followed by vigorous stirring for 4 h. The aqueous phase was extracted with CHZCIz (3 x 20 mL) and the combined organic layers were washed with brine (40 mL). After drying over MgSO4, filtration and evaporation under vacuum, flash column chromatography (hexane/EtOAc 3:7) provided 60 (2.51 g, 77%) as a colorless oil: IR (CHC13) 3387, 2934, 2856, 1612, 1513, 1472, 1462, 1360, 1302, 1249, 1172, 1039, 836, 773 crri 1; 'H NMR (300 MHz, CDC13) b7.42-7.38 (m, 2H), 7.03-6.98 (m, 2H), 4.58 (d, J= 11.6 Hz, 1H), 4.53 (d, J= 11.6 Hz, 1H), 3.92 (s, 3H), 3.70 (d, J=
6.6 Hz, 2H), 3.64 (m, 2H), 3.38 (dd, J= 8.8, 7.6 Hz, 1H), 2.31 (br, 1H), 2.16-2.03 (m, 1H), 1.78-1.66 (m, 2H), 1.65-1.50 (m, 2H), 1.38-1.28 (m, 1H), 1.09 (d, J= 6.9 Hz, 3H), 1.03 (s, 9H), 1.01 (d, J=
6.9 Hz, 3H), 0.18 (s, 3H), 0.17 (s, 3H); 13C NMR (75 MHz, CDC13) b 159.0, 130.7, 129.0, 113.6, 77.4, 72.6, 72.5, 62.8, 55.1, 37.8, 36.1, 30.8, 30.4, 26.0, 18.3, 15.2, 14.5, -3.8, -4.2;
LRMS (ESI) 433.3 [M+Na]+; HRMS (ESI) calcd for C23H42O4SiNa 433.2750 [M+Na]+, found 433.2765; [a]20D -10.2 (c 1.0, CHC13).
[00139] 1-(((2S,3R,4S')-3,7-bis(tert-Butyldimethylsilyloxy)-2,4-dimethylheptyloxy)methyl)-4-methoxybenzene (62). TBSC1 (0.92 g, 6.11 mmol) was added to a solution of above alcohol 61 (2.51 g, 6.11 mmol) and imidazole (0.46 g, 6.76 mmol) in CH2C12 (20 niL). The resulting slurry was stirred for 1 h at room temperature. The organic phase was washed with water (100 mL) and brine (2 x 100 mL). After drying over MgSO4, filtration and evaporation under vacuum, the residue was used directly in next step:
IR (CHC13) 2930, 2856, 1613, 1513, 1471, 1360, 1250, 1098, 1040, 835, 773 cm"1; 1H NMR
(300 MHz, CDC13) S 7.29-7.26 (m, 2H), 6.90-6.88 (m, 2H), 4.46 (d, J= 11.6 Hz, 1H), 4.42 (d, J= 11.6 Hz, 1H), 3.81 (s, 3H), 3.62 (t, J= 6.3 Hz, 2H), 3.58-3.52 (m, 2H), 3.28 (dd, J=
8.8, 7.7 Hz, 1H), 2.02-1.94 (m, 1H), 1.66-1.54 (m, 2H), 1.52-1.39 (m, 2H), 1.28-1.18 (m, 1H), 0.99 (d, J= 6.9 Hz, 3H), 0.94 (s, 9H), 0.92 (s, 9H), 0.89 (d, J= 6.8 Hz, 3H), 0.09 (s, 6H), 0.07 (s, 3H), 0.06 (3H);13C NMR (75 MHz, CDC13) S 159.0, 130.9, 129.0, 113.6, 77.5, 72.8, 72.6, 63.4, 55.1, 38.0, 36.3, 31.1, 30.8, 26.1, 25.9, 18.4, 18.3, 15.2, 14.4, -3.8, -4.1, -5.3; LRMS (ESI) 547.4 [M+Na]+ 413.3, 212.1; HRMS (ESI) calcd for C29H56O4Si2Na 547.3615 [M+Na]+, found 547.3638; [a]20D -9.9 (c 2.5, CHC13).
[001401 (2S,3R,4S)-3,7-bis(tert-Butyldimethylsilyloxy)-2,4-dimethylheptan-l-ol (63). The PMB alcohol 62 (6.11 mmol) was added to CH2C1Z (19 mL) then H20 (1 mL) and DDQ (1.80 g, 7.93 mol) were added. After 1 h of stirring, the reaction was quenched by adding saturated aqueous NaHCO3 (100 mL). The organic phase was washed with saturated aqueous NaHCO3 (3 x 100 mL) and brine, dried over MgSO4 filtered and concentrated.
Purification by flash colunm cliromatography (EtOAc/hexane 1:9) fiuliished 63 (2.23 g, 90%) as a colorless oil: IR (CHC13) 3403, 2928, 2856, 1472, 1463, 1388, 1256, 1100, 836, 773 cm"
1; 'H NMR (300 MHz, CDC13) b3.59-3.50 (m, 4H), 3.46 (dd, J= 5.5, 3.7 Hz, 1H), 1.83-1.75 (m, 1H), 1.62-1.52 (m, 2H), 1.49-1.35 (m, 2H), 1.18-1.05 (m, 1H), 0.91 (d, J=
7.0 Hz, 3H), 0.87-0.84 (m, 21H), 0.05 (s, 3H), 0.03 (s, 3H), 0.00 (s, 6H); 13C NMR (75 MHz, CDC13) b 80.4, 65.8, 63.3, 38.1, 37.8, 31.1, 29.6, 26.0, 25.9, 18.2, 15.9, 14.9, -4.0, -4.2, -5.4; LRMS
(ESI) 427.3 [M+Na]+, 256.8, 212.1; HRMS (ESI) calcd for C21H48O3SiaNa 427.3040 [M+Na]+, found 427.3050; [a]20D -14.0 (c 0.6, CHC13).
[001411 (3S,4R,5S)-4,8-bis(tert-Butyldimethylsilyloxy)-3,5-dimethyloct-1-yne (64).
Sulfur trioxide pyridine complex (2.63 g, 16.5 mmol) was added to a stirred solution of alcoho163 (2.23 g, 5.51 mmol) and triethylamine (2.25 mL, 16.5 mmol) in anhydrous CH2C12 (12 mL) and DMSO (22 mL) at 0 C. The reaction mixture was stirred at ambient temperature for 1 h. The mixture was diluted with EtaO (100 niL) and washed with 0.5N
aqueous HC1(50 mL) and brine (10 mL). The separated organic layer was dried over MgSO4.
Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 4:1) provided the crude aldehyde as a colorless oil, which was used without further purification. A mixture of carbon tetrabromide (3.65 g, 11.0 mmol) and triphenylphosphine (5.78 g, 22.0 mmol) in CH2Cla (50 mL) was stirred at 0 C for 10 min. A
solution of the crude aldehyde and 2,6-lutidine (1.27 mL, 11.0 mmol) in CH2C12 (5 mL) was transferred via cannula to the reaction mixture. The reaction was stirred for an additional 2 h at 0 C, then quenched with a saturated aqueous NH4C1 (20 mL). The layers were separated and the aqueous layer was extracted with CH2C12 (2 x 20 mL). The combined layers were dried over MgSO4, filtered and concentrated irz vacuo. Flash column chromatography over silica gel (EtOAc/hexane 1:19) afforded the vinyl dibromide as a colorless oil. The vinyl dibromide in THF (18 mL) was cooled to -78 C and treated with n-BuLi (8.6 mL, 13.8 mmol, 1.6 M
solution in hexane). The reaction was stirred for 1 h at -78 C, warmed to 20 C and stirred an additional 1 h. Saturated aqueous NH4C1(5 mL) was added, the layers were separated and the aqueous layer was extracted with Et20. The combined organic layer was dried over MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (EtOAc/hexane 1:9) furnished 64 (1.20 g, 55% for 3 steps) as a colorless oil:
IR (CHC13) 3313, 2930, 2857, 1472, 1463, 1387, 1361, 1254, 1099, 835, 774, 627 cm 1; 1H
NMR (300 MHz, CDC13) b3.74 (m, 2H), 3.66 (dd, J= 4.7, 3.8 Hz, 1H), 2.74 (m, 1H), 2.14 (d, J= 2.5 Hz, 1H), 1.85 (m, 111), 1.74-1.56 (m, 4H), 1.31 (d, J= 7.1 Hz, 3H), 1.05-1.01 (m, 18H), 0.23 (s, 3H), 0.20 (s, 3H), 0.18 (s, 6H);13C NMR (75 MHz, CDC13) b 87.4, 77.9, 69.9, 63.4, 36.5, 31.5, 31.0, 30.7, 26.1, 26.0, 18.4, 18.3, 17.5, 15.0, -3.9, -5.3; LRMS (ESI) 421.3 [M+Na]+, 372.8, 359.3, 256.8, 212.1; HRMS (ESI) calcd for C2aH46O2Si2Na 421.2934 [M+Na]+, found 421.2942; [a]20D -5.3 (c 1.3, CHC13).
[00142] (4R,5S,10S,11R,12S,E)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12-trimethyl-l-trityloxypentadec-2-en-8-yn-7-one. The procedure for 32 was used with 15 (1.31 g, 2.28 mol), 64 (1.20 g, 3.01 mmol) and n-BuLi (1.88 mL, 1.20 mmol) to yield the ynone (1.79 g, 86%) after flash colunm chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2929, 2856, 2209, 1675, 1471, 1462, 1385, 1254, 1093, 836, 775, 705 cm 1;
1H NMR (300 MHz, CDC13) 57.56-7.53 (m, 6H), 7.38-7.25 (m, 9H), 5.79 (dd, J=
15.6, 7.2 Hz, 111), 5.67 (dt, J= 15.6, 4.9 Hz, 111), 4.3 6(m, 1 H), 3.69-3.66 (m, 4H), 3.63 (t, J= 4.1 Hz, 111), 2.86 (m, 1H), 2.72 (m, 1H), 2.45 (m, 1H), 1.76 (m, 111), 1.67-1.51 (m, 311), 1.34 (m, 1H), 1.29 (d, J= 7.1 Hz, 3H), 1.14 (d, J= 6.8 Hz, 3H), 1.00-0.97 (m, 28H), 0.18-0.13 (m, 18H); 13C NMR (75 MHz, CDC13) S 186.0, 144.2, 132.8, 128.6, 127.9, 127.7, 126.8, 96.7, 86.8, 83.1, 77.8, 71.6, 64.8, 63.2, 50.1, 42.3, 37.2, 31.7, 30.9, 30.2, 26.0, 25.9, 25.8, 18.3, 18.2, 18.0, 17.3, 15.4, 14.8, -3.9, -4.1, -4.6, -4.7, -5.3; LRMS (ESI) 933.6 [M+Na]+, 795.5, 665.2, 496.1, 413.2, 243.1; HRMS (ESI) calcd for C55H86O5Si3Na 933.5681 [M+Na]+, found 933.5692; [a]20o -9.5 (c 0.55, CHC13).
[00143] (4R,5S,7S,10S,11R,12S,2E)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12-trimethyl-l-trityloxypentadec-2-en-8-yn-7-ol (65). The procedure for 33 was used with the above ynone (1.77 g, 1.94 mol), (S,S)-Noyori catalyst (0.26 g, 20 mol%) and i-PrOH (19 mL) to yield 65 (1.69 g, 95%) after flash column chromatography (EtOAc/hexane 1:19) as a pale yellow oil: IR (CHC13) 3464, 2929, 2856, 1471, 1448, 1386, 1254, 1090, 836, 774, 705 cm 1; 'H NMR (300 MHz, CDC13) 8 7.56-7.54 (m, 6H), 7.39-7.26 (m, 9H), 5.78 (dd, J= 15.7, 6.4 Hz, 1H), 5.68 (dt, J= 15.6, 4.9 Hz, 1H), 4.57 (m, 1H), 4.06 (m, 1H), 3.71-3.67 (m, 4H), 3.62 (t, J= 4.0 Hz, 1H), 2.74 (m, 1H), 2.50 (m, 1H), 2.46 (d, J= 5.4 Hz, 1H), 1.82 (m, 3H), 1.72-1.54 (m, 3H), 1.36 (m, 1H), 1.24 (d, J= 7.1 Hz, 3H), 1.13 (d, J=
6.8 Hz, 3H), 1.04-0.94 (m, 27H), 0.21-0.14 (m, 18H); 13C NMR (75 MHz, CDC13) S 144.3, 133.8, 128.6, 127.7, 127.2, 126.8, 87.8, 86.8, 83.1, 77.7, 72.5, 65.0, 63.5, 59.4, 41.9, 40.6, 36.4, 31.7, 30.7, 26.01, 25.96, 25.9, 18.3, 18.0, 17.4, 15.2, 14.5, -4.0, -4.1, -4.4, -4.5, -5.3; LRMS (ESI) 935.4 [M+Na]+; HRMS (ESI) calcd for C55H88O5Si3Na 935.5837 [M+Na]+, found 935.5851;
[a]20D -10.5 (c 0.86, CHC13).
[00144] (2E,4R,5S,7S,8Z,l OS,11R,12S)-5,11,15-tris(tert-Butyldimethylsilyloxy)-4,10,12-trimethyl-l-(trityloxy)pentadeca-2,8-dien-7-ol (66). The procedure for 34 was used with alkyne 65 (1.69 g, 1.85 mol) and Lindlar catalyst (ca. 200 mg) to yield 66 (1.70 g, quantitative) as a pale yellow oil: IR (CHC13) 3477, 2955, 2856, 1471, 1448, 1386, 1254, 1057, 835, 773, 705 cm"1; 1H NMR (300 MHz, CDC13) 6 7.63-7.60 (m, 6H), 7.43-7.27 (m, 9H), 5.88-5.77 (m, 2H), 5.70 (t, J= 10.1 Hz, 1H), 5.49 (dd, J= 10.6, 8.4 Hz, 1H), 4.78 (m, 1H), 4.06 (m, 1H), 3.76-3.72 (m, 4H), 3.58 (t, J= 3.6 Hz, 1H), 2.89 (m, 1H), 2.63 (m, 1H), 2.20 (d, J= 2.8 Hz, 1H), 1.73-1.48 (m, 7H), 1.18 (d, J= 6.9 Hz, 3H), 1.15 (d, J= 7.0 Hz, 3H), 1.08-1.02 (m, 27H), 0.29-0.20 (m, 18H); 13C NMR (75 MHz, CDC13) 6 144.3, 134.9, 134.4, 131.5, 128.6, 127.7, 127.0, 126.8, 86.7, 79.8, 72.8, 65.0, 64.7, 63.5, 42.1, 39.7, 37.9, 35.9, 31.4, 29.9, 26.2, 26.0, 25.9, 20.1, 18.4, 18.3, 18.0, 14.9, 14.5, -3.6, -3.8, -4.5, -4.6, -5.3; LRMS (ESI) 937.5 [M+Na]+; HRMS (ESI) calcd for C55H9oO5Si3Na 937.5994 [M+Na]+, found 937.6016; [a]ZOD +2.1 (c 0.92, CHC13).
[00145] ((2E,4R,5S,7S,8Z,10S,11R,12S)-5,7,11,15-tetrakis(tert-Butyldimethylsilyloxy)-4,10,12-trimethylpentadeca-2,8-dienyloxy)triphenylmethane (67). The procedure for 35 was used with alcoho166 (1.70 g, 1.85 mol), TBSOTf (0.94 mL, 4.07 mmol) and 2,6-lutidine (0.51 mL, 4.44 mmol) to yield 67 (1.82 g, 96%) by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2956, 2856, 1471, 1448, 1254, 1092, 1004, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.77-7.75 (m, 6H), 7.57-7.47 (m, 9H), 6.02-5.87 (m, 2H), 5.76 (t, J= 10.8 Hz, 1H), 5.61 (dd, J= 10.8, 8.5 Hz, 1H), 4.88 (m, 1H), 4.24 (m, 1H), 3. 8 8(m, 4H), 3.75 (m, 1H), 2.94 (m, 1H), 2.73 (m, 1H), 1.83 (m, 2H), 1.75 (m, 2H), 1.57 (m, 1H), 1.46-1.41 (m, 2H), 1.31 (d, J = 6.8 Hz, 3H), 1.30 (d, J= 6.3 Hz, 3H), 1.24-1.13 (m, 39H), 0.44-0.34 (m, 24H); 13C NMR (75 MHz, CDC13) S 144.4, 134.4, 132.9, 132.2, 128.7, 127.7, 126.8, 86.8, 80.2, 72.3, 66.6, 65.1, 63.6, 42.4, 41.6, 38.4, 35.7, 31.6, 29.9, 26.3, 26.0, 19.6, 18.5, 18.4, 18.2, 15.1, 13.2, -2.9, -3.6, -3.7, -4.2, -5.2; LRMS
(ESI) 1051.6 [M+Na]+, 918.6, 769.5, 637.4, 413.2; HRMS (ESI) calcd for C61H1o4O5Si4Na 1051.6859 [M+Na]+, found 1051.6848 [a]20j, -8.3 (c 2.4, CHC13).
[00146] (4S,5R,6S,7Z,9S,11S,12R,13E)-5,9,11-tris(tert-Butyldimethylsilyloxy)-4,6,12-trimethyl-15-(trityloxy)pentadeca-7,13-dien-l-ol (68). The procedure for 36 was used with 67 (1.82 g, 1.77 mol) and HF-pyridine in pyridine (100 mL) to yield 68 (1.15 g, 71%) by flash column chromatography (EtOAc/Hexane 1:9) as a colorless oil: IR
(CHC13) 3349, 2956, 2929, 2856, 1471, 1448, 1254, 1060, 836, 773, 705 cm 1; 1H NMR
(300 MHz, CDC13) S 7.58-7.55 (m, 6H), 7.39-7.27 (m, 9H), 5.81-5.65 (m, 2H), 5.56 (t, J=
10.7 Hz, 1H), 5.41 (dd, J= 11.0, 8.4 Hz, 1H), 4.67 (m, 1H), 4.05 (m, 1H), 3.69-3.63 (m, 4H), 3.53 (m, 1H), 2.73 (m, 1H), 2.52 (m, 1H), 1.64 (m, 3H), 1.58-1.48 (m, 2H), 1.30-1.20 (m, 2H), 1.11 (d, J=
6.8 Hz, 3H), 1.10 (d, J= 6.6 Hz, 3H), 1.03-0.92 (m, 30H), 0.23-0.14 (m, 18H);
13C NMR (75 MHz, CDC13) 8 144.3, 134.3, 132.9, 132.0, 128.6, 127.7, 126.8, 86.7, 80.1, 72.3, 66.4, 65.0, 63.1, 42.4, 41.7, 38.2, 35.5, 31.2, 29.5, 26.2, 25.95, 25.89, 19.6, 18.4, 18.1, 18.0, 15.1, 13.3, -2.9, -3.7, -3.8, -4.17, -4.24, -4.3; LRMS (ESI) 937.6 [M+Na]+; HRMS (ESI) calcd for C55H9oO5Si3Na 937.5994 [M+Na]+, found 937.6035; [a]20D -10.8 (c 0.84, CHC13).
[00147] (2R,4E,8S,9R,10S,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-8,10,16-trimethyl-19-(trityloxy)nonadeca-4,11,17-trien-3-one (69). The procedure for 39 was used with alcohol 68 (1.15 g, 1.26 mol), Dess-Martin reagent (0.80 g, 1.89 mmol) and Ba(OH)2 (0.17 g, 1.01 mmol) and 38 (0.49 g, 1.27 mmol) to yield 69 (1.22 g, 83%) after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 2956, 2929, 2856, 1693, 1618, 1518, 1461, 1388, 1251, 1080, 836, 773 cm"1; 1H NMR (300 MHz, CDC13) S 7.70-7.68 (m, 6H), 7.60-7.57 (m, 2H), 7.52-7.39 (m, 9H), 7.11 (m, 1H), 7.07-7.04 (m, 2H), 6.54 (d, J= 15.6, Hz, 1H), 5.94-5.78 (m, 2H), 5.67 (t, J= 10.9 Hz, 1H), 5.64 (s, 1H), 5.54 (dd, J= 11.0, 8.2 Hz, 1 H), 4.80 (m, 1H), 4.28 (dd, J= 11.3, 4.6 Hz, 1H), 4.18 (m, 1H), 4.11 (dd, J= 9.8, 3.9 Hz, 1H), 3.94 (s, 3H), 3.81 (m, 2H), 3.71 (m, 1H), 3.66 (m, 1H), 3.12 (m, 1H), 2.87 (m, 1H), 2.66 (m, 1H), 2.47 (m, 1H), 2.34 (m, 1H), 2.19 (m, 1H), 1.90-1.73 (m, 3H), 1.67-1.51 (m, 2H), 1.45 (d, J= 7.0 Hz, 3H), 1.23 (d, J= 6.6 Hz, 3H), 1.22 (d, J= 6.8 Hz, 3H), 1.16-1.05 (m, 30H), 0.96 (d, J= 6.7 Hz, 3H), 0.36-0.26 (m, 18H); 13C
NMR (75 MHz, CDC13) S 200.4, 159.6, 147.2, 144.2, 134.1, 133.0, 131.9, 130.9, 128.5, 127.8, 127.6, 127.1, 126.7, 113.3, 100.6, 86.6, 82.7, 79.8, 72.7, 72.1, 66.3, 64.9, 55.0, 46.8, 42.3, 41.5, 37.9, 35.3, 32.0, 31.7, 30.8, 26.1, 25.9, 19.5, 18.3, 18.0, 17.9, 14.7, 13.1, 12.3, 10.4, -3.0, -3.7, -3.9, -4.3, -4.4; LRMS (ESI) 1195.7 [M+Na]+, 1051.8; HRMS (ESI) calcd for C71H108O8Si3Na 1195.7250 [M+Na]+ found 1195.7297; [a]20D +9.1 (c 1.2, CHC13).
[00148] (2R,8S,9R,lOS,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-8,10,16-trimethyl-19-trityloxynonadeca-11,17-dien-3-one (70). The procedure for 40 was used with 69 (1.22 g, 1.04 mol), NiC12-6H20 (0.12 g, 0.52 mmol) and NaBH4 (0.079 g, 2.08 mmol) to yield 70 (0.80 g, 65%) after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 2956, 2929, 2855, 1713, 1615, 1518, 1461, 1388, 1251, 1077, 1037, 836, 773 cm"1; 1H NMR (300 MHz, CDC13) 8 7.70-7.66 (m, 6H), 7.57-7.40 (m, 11H), 7.07-7.04 (m, 2H), 5.92-5.77 (m, 2H), 5.65 (m, 1H), 5.64 (s, 1H), 5.52 (m, 1H), 4.78 (m, 1H), 4.30 (dd, J= 11.2, 4.6 Hz, 1H), 4.14 (m, 2H), 3.94 (s, 3H), 3.79 (d, J= 3.9 Hz, 2H), 3.73 (t, J=
11.1 Hz, 1H), 3.61 (m, 1H), 2.92-2.79 (m, 2H), 2.72 (t, J= 7.4 Hz, 2H), 2.65 (m, 1H), 2.22 (m, 1H), 1.91-1.71 (m, 4H), 1.65-1.56 (m, 3H), 1.51 (m, 1H), 1.43 (d, J= 7.1 Hz, 3H), 1.35 (m, 1H), 1.20 (d, J= 6.7 Hz, 3H), 1.14-1.12 (m, 21H), 1.08 (d, J= 6.2 Hz, 3H), 1.05-1.03 (m, 9H), 0.96 (d, J = 6.7 Hz, 3H), 0.34-0.25 (m, 18H); 13C NMR (75 MHz, CDC13) S
211.5, 159.8, 144.4, 144.3, 134.3, 132.9, 132.2, 130.9, 128.6, 127.6, 127.1, 126.8, 113.4, 100.8, 86.7, 83.0, 80.1, 72.8, 72.2, 66.4, 65.0, 55.0, 48.2, 42.3, 41.6, 40.6, 38.0, 35.7, 33.5, 31.2, 27.6, 26.2, 25.91, 25.87, 23.9, 19.4, 18.4, 18.05, 17.99, 14.8, 13.2, 12.0, 9.5, -3.0, -3.6, -3.8, -4.2, -4.3, -4.4; LRMS (ESI) 1197.7 [M+Na]+, 684.2, 541.1; HRMS (ESI) calcd for C71H110O8Si3Na 1197.7406 [M+Na]+, foundll97.7411; [a]20D +4.6 (c 1.1, CHC13).
[00149] (2S,3R,8S,9R,lOS,11 Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-8,10,16-trimethyl-19-(trityloxy)nonadeca-11,17-dien-3-ol (71). LiAI(O-t-Bu)3H
(2.0 mL, 1.0 M solution in THF) was added to a solution of 70 (0.80 g, 0.68 mmol) in THF (7 mL).
After 30 min of stirring at room temperature, the reaction was quenched with saturated aqueous NH4C1 (1 mL), stirring for 1 h, dried over MgSO4, filtered, concentrated iya vacuo, and chromatographed (EtOAc/hexane 3:17) to provide the (3 isomer of 71 (0.76 g, 95%) as a colorless oil: IR (CHC13) 3538, 2929, 2855, 1615, 1518, 1461, 1385, 1251, 1072, 835, 773, 734 cm 1; 1H NMR (300 MHz, CDC13) 8 7.70-7.66 (m, 6H), 7.59-7.56 (m, 2H), 7.52-7.39 (m, 9H), 7.08-7.05 (m, 2H), 5.93-5.77 (m, 2H), 5.71 (s, 1H), 5.67 (t, J= 10.2 Hz, 1H), 5.55-5.48 (m, 1H), 4.78 (m, 1H), 4.30 (dd, J= 11.4, 4.8 Hz, 1H), 4.15 (m, 1H), 4.09 (m, 1H), 3.94 (s, 3H), 3.88 (dd, J= 10.0, 1.5 Hz, 1H), 3.79 (d, J= 3.9 Hz, 2H), 3.70 (t, J= 11.1 Hz, 1H), 3.64 (m, 1H), 3.38 (br, 1H), 2.84 (m, 1H), 2.65 (m,1H), 2.33 (m, 1H), 2.22-1.91 (m, 2H), 1.86-1.71 (m, 3H), 1.66-1.54 (m, 4H), 1.49-1.34 (m, 3H), 1.24 (d, J= 7.0 Hz, 3H), 1.21 (d, J= 6.6 Hz, 3H), 1.15-1.08 (m, 21H), 1.09 (d, J = 6.9 Hz, 3H), 1.04 (m, 9H), 0.94 (d, J= 6.7 Hz, 3H), 0.34-0.25 (m, 18H); 13C NMR (75 MHz, CDC13) b 160.0, 144.4, 144.3, 134.3, 132.8, 132.2, 130.6, 128.6, 127.6, 127.1, 126.7, 113.6, 101.1, 88.9, 86.7, 80.1, 76.2, 73.0, 72.2, 66.4, 65.0, 55.1, 42.3, 41.6, 38.2, 37.4, 35.7, 35.0, 33.6, 30.3, 28.0, 26.5, 26.1, 25.91, 25.87, 19.5, 18.4, 18.05, 17.99, 15.0, 13.2, 11.8, 5.6, -3.0, -3.7, -3.8, -4.2, -4.3; LRMS
(ESI) 1199.7 [M+Na]+, 937.6, 782.4, 413.2; HRMS (EST) calcd for C71H112O8Si3Na 1199.7563 [M+Na]+, found 1199.7538; [a]20D +8.9 (c 0.46, CHCl3).
[00150] (2S,3R,8S,9R,lOS,11Z,13S,15S,16R,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-8,10,16-trimethyl-19-(trityloxy)nonadeca-11,17-dien-3-ol (72). The procedure for 42 was used with 71 (0.76 g, 0.65 mol), TBSOTf (0.22 mL, 0.98 mmol) and 2,6-lutidine (0.15 mL, 1.30 mmol) to yield 72 (0.76 g, 92%) after flash colunm chromatography (EtOAc/Hexane 1:9) as a colorless oil: IR (CHC13) 2955, 2929, 2856, 1615, 1518, 1471, 1388, 1251, 1074, 836, 773 cm l; 'H NMR (300 MHz, CDC13) S 7.60-7.57 (m, 6H), 7.52-7.49 (m, 211), 7.41-7.27 (m, 9H), 6.99-6.96 (in, 2H), 5.83-5.67 (m, 2H), 5.56 (t, J= 9.2 Hz, 1H), 5.55 (s, 1H), 5.43 (dd, J= 10.9, 8.4 Hz, 1H), 4.69 (m, 1H), 4.21 (m, 1H), 4.06 (m, 1H), 3.84 (s, 3H), 3.81 (m, 1H), 3.76-3.70 (m, 3H), 3.60 (t, J= 11.1 Hz, 1H), 3.54 (m, 1H), 2.74 (m 1H), 2.54 (m, 111), 2.14 (m, 1H), 2.00 (t, J= 6.7 Hz, 1H), 1.68 (m, 3H), 1.58-1.40 (m, 5H), 1.34-1.20 (m, 3H), 1.13 (d, J= 6.8 Hz, 3H), 1.10 (m, 3H), 1.05-0.95 (m, 42H), 0.84 (d, J=
6.4 Hz, 3H), 0.25-0.17 (m, 24H); 13C NMR (75 MHz, CDC13) b 159.7, 144.5, 144.3, 134.3, 132.9, 132.4, 131.6, 128.7, 127.7, 127.1, 126.8, 113.4, 100.5, 86.7, 81.9, 80.2, 74.7, 73.3, 72.3, 66.5, 65.0, 55.1, 42.3, 41.6, 38.9, 38.2, 35.9, 34.0, 33.7, 30.7, 28.4, 26.2, 26.0, 25.96, 25.9, 25.7, 19.4, 18.4, 18.1, 14.8, 13.2, 12.3, 10.6, -3.0, -3.5, -3.8, -4.2, -4.3; LRMS (ESn 1313.8 [M+Na]+, 782.4, 413.2; HRMS (ESI) calcd for C77H126O$Si4Na 1313.8428 [M+Na]+, found 1313.8402;
[a]20D +9.5 (c 0.38, CHC13).
[00151] (2S,3S,4R,5R,l OS,11R,12S,13Z,15S,17S,18R,19E)-3-(4-Methoxybenzyloxy)-5,11,15,17-tetrakis(tert-butyldimethylsilyloxy)-2,4,10,12,18-pentamethyl-21-trityloxyhenicosa-13,19-dien-l-ol (73). The procedure for 43 was used with 72 (0.76 g, 0.59 mol) and DIBAL-H (5.9 mL, 5.9 mmol) to yield 73 (0.69 g, 90%) after flash column chromatography (EtOAc/Hexane 3:17) as a colorless oil: IR
(CHC13) 3484, 2928, 2856, 1613, 1514, 1471, 1360, 1251, 1037, 835, 773 crn 1; 1H NMR
(300 MHz, CDC13) S 7.62-7.58 (m, 6H), 7.47-7.34 (m, 11H), 7.02-7.00 (m, 2H), 5.82-5.68 (m, 2H), 5.55 (t, J= 10.0 Hz, 1 H), 5.46-5.41 (m, 1 H), 4.70 (m, 1 H), 4.66 (s, 2H), 4.04 (m, 1 H), 3.97 (m, 1H), 3.94 (s, 3H), 3.77 (m, 1H), 3.70 (d, J= 3.3 Hz, 2H), 3.59 (dd, J= 6.6, 4.3 Hz, 1H), 3.53 (m, 1 H), 3.00 (dd, J= 5.8, 4.4 Hz, 1H), 2.72 (m 1 H), 2. 5 5(m, 1 H), 2.10 (m, 1 H), 2.02 (m, 1H), 1.77-1.61 (m, 5H), 1.55-1.47 (m, 3H), 1.41-1.33 (m, 5H), 1.25 (d, J= 7.0 Hz, 3H), 1.14 (d, J= 6.9 Hz, 3H), 1.11 (d, J= 6.8 Hz, 3H), 1.05-0.94 (m, 42H), 0.25-0.16 (m, 24H); 13C
NMR (75 MHz, CDC13) 6 159.2, 144.3, 144.2, 134.3, 132.9, 132.2, 130.5, 129.2, 128.6, 127.6, 126.8, 113.8, 86.7, 85.6, 80.1, 75.1, 73.4, 72.2, 66.4, 65.0, 55.0, 42.3, 41.5, 40.5, 38.2, 37.0, 35.7, 34.7, 33.7, 28.3, 26.2, 25.9, 19.4, 18.4, 18.1, 15.7, 14.8, 13.1, 10.1, -3.0, -3.6, -3.8, -3.9, -4.3, -4.4; LRMS (ESI) 1315.8 [M+Na]+, 937.6; HRMS (ESI) calcd for C77H128O8Si4Na 1315.8584 [M+Na]+, found 1315.8534; [a]20D -4.2 (c 1.5, CHC13).
[00152] ((2E,4R,5S,7S,8Z,l OS,11R,12S,17R,18R,19S,20S,21Z)-19-(4-Methoxybenzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,18,20-pentamethyltetracosa-2,8,21,23-tetraenyloxy)triphenylmethane (74). The procedure for 44 was used wit11 73 (0.69 g, 0.53 mol), Dess-Martin reagent (0.34 g, 0.80 mmol) and 1-bromoallyltrimethylsilane (0.66 g, 2.65 inmol), CrC12 (0.54 g, 4.39 nimol) and NaH (0.27 g, 10.7 mmol) to yield 74 (0.58 g, 82% for 3 steps) after flash colunm chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2955, 2929, 2856, 1613, 1514, 1471, 1250, 1063, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.63-7.60 (m, 6H), 7.43-7.31 (m, 11H), 6.99-6.97 (m, 2H), 6.74 (ddd, J= 16.8, 10.6, 1055 Hz, 1H), 6.16 (t, J=
11.0 Hz, 1H), 5.86-5.71 (m, 3H), 5.58 (t, J= 9.8 Hz, 1H), 5.46 (dd, J= 11.0, 8.3 Hz, 1H), 5.31 (d, J= 16.8 Hz, 1H), 5.23 (d, J= 10.2 Hz, 1H), 4.75-4.63 (m, 3H), 4.09 (m, 1H), 3.86 (s, 3H), 3.81 (m, 1H), 3.73 (d, J= 4.0 Hz, 1H), 3.55 (m, 1H), 3.49 (m, 1H), 3.18 (m, 1H), 2.77 (m, 1H), 2.57 (m, 1H), 1.91-1.78 (m, 2H), 1.73-1.50 (m, 6H), 1.49-1.35 (m, 3H), 1.26 (d, J=
6.6 Hz, 3H), 1.15 (d, J= 6.3 Hz, 3H), 1.13 (d, J= 5.9 Hz, 3H), 1.10-0.97 (m, 42H), 0.28-0.19 (m, 24H);
13C NMR (75 MHz, CDC13) 8 159.2, 144.5, 144.4, 134.6, 134.4, 133.0, 132.5, 132.4, 131.3, 129.1, 129.0, 128.7, 127.7, 126.8, 117.2, 113.7, 86.8, 84.3, 80.3, 75.0, 72.6, 72.3, 66.5, 65.1, 55.1, 42.4, 41.6, 40.7, 38.0, 36.0, 35.3, 35.2, 34.0, 28.2, 26.3, 26.03, 26.00, 25.97, 25.7, 19.4, 18.8, 18.5, 18.2, 18.14, 18.09, 14.8, 13.3, 9.4, -2.9, -3.5, -3.6, -3.8, -4.1, -4.2, -4.3, -4.4;
LRMS (ESI) 1337.8 [M+Na]+, 537.4, 243.1; HRMS (ESI) calcd for C80H130O7Si4Na 1337.8791 [M+Na]+, found 1337.8785; [a]20D +5.1 (c 0.37, CHC13).
[00153] (2E,4R,5S,7S,8Z,l OS,11R,12S,17R,18R,19S,20S,21Z)-19-(4-Methoxybenzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,18,20-pentamethyltetracosa-2,8,21,23-tetraen-l-ol (75). The procedure for 45 was used with 74 (0.58 g, 0.22 mol), ZnBr (0.25 g, 1.11 mmol) to yield 75 (0.42 g, 89%) after flash colunm chromatography (EtOAc/hexane 3:17) as a colorless oil: IR (CHC13) 3402, 2956, 2929, 2856, 1614, 1514, 1471, 1251, 1085, 836, 773 cm 1; 'H NMR (300 MHz, CDC13) S 7.47-7.44 (m, 2H), 7.04-7.01 (m, 2H), 6.76 (ddd, J= 16.8, 10.6, 10.5 Hz, 1H), 6.19 (t, J=
11.0 Hz, 1H), 5.87-5.72 (m, 3H), 5.59 (t, J= 10.0 Hz, 1H), 5.45 (dd, J= 10.9, 8.3 Hz, 1H), 5.35 (d, J= 16.8 Hz, 1H), 5.27 (d, J= 10.2 Hz, 1H), 4.75-4.65 (m, 3H), 4.22 (d, J= 4.5 Hz, 2H), 4.09 (m, 1H), 3.94 (s, 3H), 3.83 (m, 1H), 3.56 (in, 1H), 3.51 (m, 1H), 3.17 (m, 1H), 2.77 (m, 1H), 2.57 (m, 1H), 1.95 (m, 1H), 1.85 (m, 1H), 1.78-1.55 (m, 8H), 1.53-1.40 (m, 3H), 1.29 (d, J= 6.7 Hz, 3H), 1.56-1.06 (m, 45H), 1.01 (d, J= 6.7 Hz, 3H), 0.29-0.22 (m, 24H); 13C NMR
(75 MHz, CDC13) 6 158.9, 134.8, 134.5, 132.8, 132.4, 132.3, 131.2, 129.2, 129.1, 128.9, 117.1, 113.6, 84.3, 80.2, 75.0, 72.4, 72.2, 66.5, 63.6, 55.1, 42.3, 41.5, 40.5, 37.9, 35.7, 35.2, 33.8, 28.1, 26.2, 25.9, 25.6, 19.3, 18.8, 18.4, 18.2, 18.0, 14.6, 13.0, 9.2, -3.0, -3.5, -3.7, -3.9, -4.3, -4.4, -4.5; LRMS (ESI) 1095.7 [M+Na]+, 809.6, 677.5, 537.4, 413.2; HRMS (ESI) calcd for C61H116O7Si4Na 1095.7696 [M+Na]+, found 1095.7712; [a]20D +4.8 (c 1.7, CHC13).
[00154] (2Z,4E,6R,7S,9S,10Z,12S,13R,14S,19R,20R,21S,22S,23Z)-Methyl-21-(4-methoxybenzyloxy)-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-6,12,14,20,22-pentamethylhexacosa-2,4,10,23,25-pentaenoate (76). The procedure for 46 was used with 75 (0.42 g, 0.39 mol), Dess-Martin reagent (0.25 g, 0.59 mmol) and bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl) phosphate (0.10 mL, 0.47 mol), 18-crown-6 (0.52 g, 1.97 mmol) and KHMDS (0.94 mL, 0.47 mmol) to yield 76 (0.38 g, 86% for 2 steps) by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2955, 2856, 1722, 1640, 1514, 1462, 1250, 1174, 1084, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.44 (dd, J=15.3, 11.3 Hz, 1H), 7.31-7.29 (m, 2H), 6.90-6.87 (m, 2H), 6.04 (t, J= 11.0 Hz, 1H), 6.02 (m, 1H), 5.66-5.60 (m, 2H), 5.44 (t, J= 10.0 Hz, 1H), 5.30 (dd, J=
11.1, 8.3 Hz, 1H), 5.20 (d, J= 16.8 Hz, 1H), 5.12 (d, J= 10.2 Hz, 1H), 4.61-4.51 (m, 3H), 3.98 (m, 1H), 3.80 (s, 3H), 3.73 (s, 3H), 3.68 (m, 1H), 3.42 (m, 1H), 3.37 (dd, J= 7.6, 3.1 Hz, 1H), 3.03 (m, 1H), 2.60 (m, 2H), 1.72 (m, 2H), 1.61-1.41 (m, 1H), 1.38-1.27 (m, 3H), 1.20-1.15 (m, 2H), 1.14 (d, J= 6.7 Hz, 3H), 1.08 (d, J= 6.8 Hz, 3H), 1.01 (d, J= 6.6 Hz, 3H), 1.00 (d, J= 6.7 Hz, 3H), 0.99-0.87 (m, 39H), 0.16-0.07 (m, 24H); 13C NMR (75 MHz, CDC13) S
166.7, 159.0, 147.1, 145.4, 134.5, 132.6, 132.3, 131.3, 129.0, 128.9, 126.8, 117.1, 115.4, 113.6, 84.3, 80.2, 75.0, 72.5, 72.1, 66.4, 55.1, 50.8, 43.4, 42.4, 40.6, 37.9, 35.9, 35.2, 33.9, 28.1, 26.2, 26.0, 25.90, 25.87, 25.6, 19.3, 18.8, 18.4, 18.1, 18.05, 18.04, 14.6, 13.3, 9.3, -3.0, -3.5, -3.7, -3.8, -4.2, -4.3, -4.4, -4.5; LRMS (ESI) 1149.7 [M+Na]+, 995.7, 436.2;
HRMS (ESI) calcd for C64H118O$Si4Na 1149.7802 [M+Na]+, found 1149.7813; [a]20D -3.8 (c 0.85, CHC13).
[00155] (2Z,4E,6R,7S,9S,102,12S,13R,14S,19R,20R,21S,22S,232)-Methyl-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-21-hydroxy-6,12,14,20,22-pentamethylhexacosa-2,4,10,23,25-pentaenoate (77). The procedure for 47 was used with 76 (0.38 g, 0.34 mol) and DDQ (0.084 g, 0.37 mmol) to yield 77 (0.28 g, 82%) after flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 3542, 2956, 2856, 1722, 1640, 1462, 1254, 1175, 1086, 1004, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.39 (dd, J= 15.2, 11.2 Hz, 1H), 6.63 (ddd, J= 16.9, 10.5, 10.4 Hz, 1H), 6.53 (t, J= 11.3 Hz, 1H), 6.09 (t, J= 11.0 Hz, 1H), 5.98 (dd, J= 8.3, 7.1 Hz, 1H), 5.58 (d, J=
11.3 Hz, 1H), 5.45-5.39 (m, 2H), 5.26 (dd, J= 10.8, 8.4 Hz, 1H), 5.20 (d, J= 16.9 Hz, 1H), 5.11 (d, J=
10.1 Hz, 1H), 4.53 (m, 1H), 3.95 (m, 1H), 3.76 (m, 111), 3.71 (s, 3H), 3.47 (m, 1H), 3.40 (m, 1H), 2.82 (m, 1H), 2.55 (m, 1H), 2.20 (br, 111), 1.72 (m, 2H), 1.60-1.35 (m, 5H), 1.32-1.10 (m, 5H), 1.04 (d, J= 6.8 Hz, 3H), 0.99-0.83 (m, 48H), 0.12-0.03 (m, 24H); 13C
NMR (75 MHz, CDC13) 8 166.7, 147.1, 145.4, 135.2, 132.6, 132.5, 132.3, 130.0, 126.8, 117.7, 115.5, 80.2, 77.3, 76.2, 72.1, 66.5, 50.9, 43.4, 42.5, 38.3, 38.1, 36.1, 35.8, 34.7, 33.7, 28.3, 26.2, 25.94, 25.89, 25.5, 19.5, 18.4, 18.1, 17.7, 14.9, 13.3, 7.2, -3.0, -3.6, -3.8, -4.18, -4.20, -4.37, -4.41; LRMS (ESI) 1029.7 [M+Na]+, 875.6, 379.3; HRMS (ESI) calcd for C56H11oO7Si4Na 1029.7226 [M+Na]+, found 1029.7244; [a]20D -18.7 (c 0.62, CHC13).
[00156] (8S,lOS,14R,20R)-tetrakis(tert-Butyldimethylsilyloxy)-(7R,13S,15S,21S)-tetramethyl-(22S)-((1S)-methylpenta-2,4-dienyl)-oxacyclodocosa-3,5,11-trien-2-one (78).
The procedure for 48 was used with 77 (0.28 g, 0.28 mol) and 1N KOH (2.8 mL, 2.8 mmol) to yield the acid (0.27 g, quantitative) as a pale yellow oil, which was used directly in next step: IR (CHC13) 2930, 1693, 1635, 1462, 1387, 1255, 1089, 838, 773 cm 1; 1H
NMR (300 MHz, CDC13) S 7.36 (dd, J= 15.0, 11.4 Hz, 1H), 6.6-6.57 (m, 2H), 6.08 (t, J=
10.9 Hz, 1H), 6.02 (dd, J= 15.7, 7.0 Hz, 1H), 5.59 (d, J= 11.3 Hz, 1H), 5.45-5.39 (m, 2H), 5.26 (m, 1H), 5.20 (d, J= 17.8 Hz, 1H), 5.11 (d, J= 10.2 Hz, 1H), 4.55 (in, 111), 3.95 (m, 1H), 3.76 (m, 1H), 3.49 (m, 1H), 3.41 (m, 1H), 2.82 (m, 1H), 2.57 (m, 2H), 1.70 (m, 2H), 1.57-1.41 (m, 5H), 1.31-1.12 (m, 5H), 1.04 (d, J= 6.7 Hz, 3H), 0.99-0.84 (m, 48H), 0.12-0.04 (m, 24H);
13C NMR (75 MHz, CDC13) S 170.9, 147.7, 146.8, 134.9, 132.5, 132.4, 132.2, 130.0, 126.9, 117.6, 115.5, 80.1, 75.7, 72.0, 66.4, 58.1, 43.4, 42.5, 38.3, 38.1, 35.9, 35.6, 34.7, 33.5, 28.3, 26.2, 25.90, 25.85, 25.5, 25.1, 19.5, 18.4, 18.1, 18.0, 17.7, 14.9, 13.3, 7.3, -3.1, -3.7, -3.8, -3.9, -4.2, -4.3, -4.4, -4.5; LRMS (ESI) 1015.7 [M+Na]+, 861.6, 729.5, 651.4;
HRMS (ESI) calcd for CssHi0sO7Si4Na 1015.7070 [M+Na]+, found 1015.7091; [a]20p -14.6 (c 1.4, CHC13). The procedure for 49 was used with the acid (0.26 g, 0.26 mol), 2,4,6-trichlorobenzoyl chloride (0.21 mL, 1.30 mmol), Et3N (0.22 mL, 1.56 inmol) and (130 mL, 2.6 mmol) to yield 78 (0.19 g, 76% for 2 steps) by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2956, 2929, 2856, 1714, 1640, 1471, 1255, 1088, 836, 773 cm 1; iH NMR (300 MHz, CDC13) 8 7.16 (dd, J= 15.6, 11.2 Hz, 1H), 6.61 (ddd, J= 16.8, 10.6, 10.5 Hz, 1H), 6.52 (t, J= 11.3 Hz, 1H), 6.03 (d, J=
9.6, 5.9 Hz, I H), 6.00 (t, J= 10.6 Hz, I H), 5.62 (t, J= 10.5 Hz, 1 H), 5.5 6(d, J= 11.3 Hz, 1 H), 5.3 9(t, J
= 10.5 Hz, 1H), 5.28 (dd, J= 11.2, 8.0 Hz, 1H), 5.20-5.14 (m, 2H), 5.09 (d, J=10.3 Hz, 1H), 4.59 (m, 1H), 4.01 (m, IH), 3.53 (in, 1H), 3.43 (m, IH), 3.06 (m, 1H), 2.56 (m, 1H), 2.45 (m, 1H), 1.90 (m, 1H), 1.55-1.35 (m, 6H), 1.28 (m, 1H), 1.24-1.12 (m, 4H), 1.08 (d, J= 6.7 Hz, 3H), 1.02 (d, J= 5.9 Hz, 3H), 1.01 (d, J= 6.0 Hz, 3H), 0.93-0.88 (m, 39H), 0.81 (d, J= 6.9 Hz, 3H), 0.14-0.05 (m, 24H); 13C NMR (75 MHz, CDCI,) b 166.2, 144.1, 142.6, 133.9, 132.1, 131.5, 129.7, 128.0, 127.5, 117.8, 117.6, 80.3, 74.0, 71.2, 66.5, 62.4, 43.7, 39.8, 39.3, 34.9, 34.0, 33.0, 31.8, 27.8, 26.1, 26.05, 25.98, 20.1, 18.33, 18.28, 18.14, 18.11, 17.8, 16.1, 14.0, 10.7, -2.7, -3.8, -4.0, -4.1, -4.2, -4.3; LRMS (ESI) 997.7 [M+Na]+, 843.6, 711.5, 579.4; HRMS (ESI) calcd for C5sH106O6Si4Na 997.6964 [M+Na]+, found 997.6989;
[a]20D -26.4 (c 0.59, CHC13).
[00157] (8S,10S,14R,20R)-Tetrahydroxy-(7R,13S,15S,21S)-tetramethyl-(22S)-((LS)-methylpenta-2,4-dienyl)-oxacyclodocosa-3,5,11-trien-2-one (79). The procedure for 1 was used with 78 (0.19 g, 0.19 mol), 3N HCl in 15 ml of 2:1 MeOH/THF to yield 79 (25 mg, 24%) after flash coluinn chromatography (EtOAc/hexane 3:7) as a colorless oil: IR
(CHC13) 3414, 2965, 2930, 1708, 1637, 1454, 1375, 1273, 1182, 1046, 968 cnf 1;
(600 MHz, CD3OD) S 7.22 (dd, J= 15.4, 11.2 Hz, 1H), 6.67 (ddd, J= 17.3, 11.0, 10.5 Hz, 1H), 6.64 (dd, J= 11.4, 11.4 Hz, 1 H), 6.07 (dd, J= 15.4, 7.7 Hz, 1H), 6.02 (dd, J= 10.9, 10.9 Hz, 1H), 5.55 (t, J= 10.6 Hz, 1H), 5.52 (d, J=11.4 Hz, 1H), 5.43 (dd, J= 10.9, 9.0 Hz, 1H), 5.3 5(dd, J= 10.7, 10.6 Hz, 1 H), 5.20 (d, J= 16.7 Hz, 1 H), 5.12 (d, J= 10.2 Hz, 1 H), 5.08 (dd, J= 5.9, 5.9 Hz, 1H), 4.64 (m, 1H), 3.86 (ddd, J= 8.4, 4.7, 4.5 Hz, 1H), 3.43 (m, 1H), 3.16 (m, 1H), 3.14 (dd, J= 8.1, 2.6 Hz, 1H), 2.73 (m, 1H), 2.37 (m, 1H), 1.84 (m, 1H), 1.68 (m, 1H), 1.51-1.45 (m, 3H), 1.31 (m, 1H), 1.20 (m, 1H), 1.14-1.11 (m, 1H), 1.08 (d, J= 6.9 Hz, 6H), 1.07-1.01 (in, 2H), 0.99 (d, J= 6.8 Hz, 3H), 0.98 (d, J= 6.7 Hz, 3H), 0.95 (m, 1H), 0.92 (d, J= 6.6 Hz, 3H); 13C NMR (150 MHz, CD3OD) 8 168.2, 146.6, 144.8, 134.3, 133.8, 133.4, 132.2, 131.3, 129.1, 118.5, 118.0, 79.9, 79.3, 72.4, 71.0, 65.5, 44.9, 41.7, 40.7, 37.9, 36.0, 35.4, 35.2, 33.9, 27.4, 27.2, 19.5, 18.3, 16.4, 15.1, 10.1; LRMS (ES1) 541.3 [M+Na]}, 483.3; HRMS (ESI) calcd for C31H50O6Na 541.3505 [M+Na]+, found 541.3521;
[a]20D -34.4 (c 0.18, MeOH).
[00158] (3S,4S,E)-3-(tert-Butyldimethylsilyloxy)-N-methoxy 1V,4-dimethyl-7-(trityloxy)hept-5-enamide (81). (3S,4S,E)-3-(tert-Butyldimethylsilyloxy)-4-methyl-7-trityloxyhept-5-en-l-ol (0.34 g, 0.66 mmol) in CHZC12 (10 mL) was treated with Dess-Martin periodinane (0.41 g, 0.99 mmol). After 1 h, the mixture was quenched with saturated NaHCO3 (10 mL). The aqueous layer was extracted with ethyl ether (10 mL x 2) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 8:2) to remove the Dess-Martin residue provided the aldehyde as a colorless oil, which was used for the next reaction without further purification. A solution of the above aldehyde in THF (10 mL) and H20 (5 mL) was treated with a 2 M solution of 2-methyl-2-butene (1.9 mL, 0.95 mmol) in THF, NaHZPO4=H20 (0.27 g, 1.96 mmol) and NaC1O2 (0.22 g, 1.96 mmol). The reaction mixture was stirred for 2 h, diluted with 1N HCI (20 mL) and extracted with CH2C12 (2 x 40 mL). The combined organic layers were dried over MgSO4, concentrated in vacuo and the crude was used for the next reaction without further purification. To a solution of acid in CH2C12, N, 0-dimethylhydroxylamine hydrochloride (0.064 g, 0.65 mmol), Et3N (0.09 mL, 0.65 mmol), DMAP (8 mg, 0.065 mmol) were successively added. The reaction mixture was cooled to 0 C, DCC (0.14 g, 0.65 mmol) was added. The mixture was stirred at ambient temperature for 15 h and filtered. The filtrate was washed with 0.5 N HCI, saturated aqueous NaHCO3, and brine, dried over anllydrous MgSO4 and concentrated. Purification by column chromatography over silica gel (hexane/EtOAc 4:1) gave the Weinreb amide 81 (0.37 g, 81 % for 3 steps) as a colorless oil: IR (CHC13) 2956, 2929, 2855, 1661, 1448, 1385, 1251, 1089, 1054, 1003, 836, 775, 706 cm 1; 1H NMR (300 MHz, CDC13) 57.64-7.61, m, 6H), 7.45-7.33 (m, 9H), 6.09 (dd, J= 15.7, 6.6 Hz, 1H), 5.75 (dt, J= 15.7, 5.2 Hz, 1H), 4.42 (m, 1H), 3.76 (s, 3H), 3.70 (m, 2H), 3.29 (s, 3H), 2.88 (m, 1H), 2.55 (m, 2H), 1.18 (d, J=
6.8 Hz, 3H), 1.06 (s, 9H), 0.27 (s, 3H), 0.20 (s, 3H) ; 13C NMR (75 MHz, CDC13) S 172.5, 144.2, 133.5, 128.5, 127.6, 126.8, 86.5, 72.8, 64.6, 61.1, 42.2, 36.0, 31.9, 25.8, 18.0, 14.8, -4.7, -4.8; LRMS (EI) 573, 558, 516, 246, 165; HRMS (EI) calcd for C35H47O4N1Si1 573.3290, found 573.3290;
[a]20D -40.1 (c 1.2, CHC13).
[00159] (4S,5S,10S,11R,12R,14R,E)-11-(4-Methoxybenzyloxy)-5,15-bis(tert-butyldimethylsilyloxy)-4,10,12,14-tetramethyl-l-(trityloxy)pentadec-2-en-8-yn-7-one (82).
Alkyne 80 (7.75 g, 18.5 mmol) was taken up in THF (185 mL) and cooled to -78 C. n-BuLi (11.6 mL, 1.6 M solution in hexane) was added slowly. After 5 min, the mixture was warmed to 0 C and stirred for 30 min. The mixture was then cooled to -78 C and amide 81 (5.31 g, 9.26 mmol) in THF (15 mL) was added slowly. After 5 min the solution was warmed to 0 C
and stirred for 1 h. The reaction was quenched with aq NH4Cl and the mixture was partitioned in a separatory funnel. The aqueous phase was extracted with ether (50 mL x 3) and combined organic extracts were washed with brine and dried over MgSO4.
Filtration and concentration under reduced pressure, followed by flash chromatography on silica gel (hexane/EtOAc 95:5) afforded ynone (8.45 g, 98 %) as a pale yellow oil: IR
(CHC13) 2955, 2929, 2856, 2208, 1674, 1514, 1470, 1249, 1092, 836, 775, 706 cm 1; 1H NMR
(300 MHz, CDC13) 57.50-7.47, m, 6H), 7.35-7.22 (m, 11H), 6.88-6.84 (m, 2H), 5.81 (dd, J=
15.6, 6.7 Hz, 1H), 5. 5 8(dt, .I = 15.6, 5.2 Hz, 1H), 4.64 (d, J= 10.8 Hz, 1 H), 4.54 (d, J= 10.8 Hz, 1H), 4.27 (m, 1H), 3.80 (s, 3H), 3.59 (d, J= 5.2 Hz, 2H), 3.44-3.34 (m, 2H), 3.18 (t, J= 5.4 Hz, 1H), 2.94 (m, 1H), 2.62 (m, 1H), 2.38 (m, 1H), 1.89 (m, 1H), 1.68 (m, 1H), 1.26 (d, J= 7.0 Hz, 3H), 1.24 (m, 1 H), 0.99 (d, J= 6.9 Hz, 3H), 0.97 (d, J= 6.9 Hz, 3H), 0.92 (s, 9H), 0.91 (m, 1H), 0.89 (s, 9H), 0.84 (d, J = 6.7 Hz, 3H), 0.09-0.05 (m, 12H); 13C NMR
(75 MHz, CDC13) S 186.4, 159.1, 144.3, 133.5, 130.7, 129.2, 128.7, 127.7, 127.3, 126.9, 113.7, 96.8, 86.8, 86.2, 82.6, 74.0, 72.3, 69.2, 64.9, 55.2, 50.5, 42.3, 34.9, 33.2, 33.0, 29.5, 26.0, 25.9, 18.3, 18.1, 17.2, 16.3, 15.9, 14.8, -4.50, -4.55, -5.3; LRMS (ESI) 953.6 [M+Na]+, 855.4, 797.4, 577.5, 413.4, 359.3, 328.4; HRMS (ESI) calcd for C58H82O6Si2Na 953.5548 [M+Na]+, found 953.5552; [a]20D -9.5 (c 2.8, CHC13).
[00160] (4S,5S,7.S,10S,11R,12R,14R,E)-11-(4-Methoxybenzyloxy)-5,15-bis(tert-butyldimethylsilyloxy)-4,10,12,14-tetramethyl-l-(trityloxy)pentadec-2-en-8-yn-7-ol (83).
Ynone 82 (7.06 g, 7.59 mmol) was taken up in i-PrOH (100 mL). Noyori catalyst (1.02 g, 1.52 mmol, 20 mol%) was added in one portion and the solution was stirred for 12 h. The solvent was removed under vacuum, and the crude residue was purified by flash chromatography on silica gel (hexane/EtOAc 9:1), affording propargylic alcohol 83 (6.16 g, 87 %) as a pale yellow oil: IR (CHC13) 3434, 2955, 2928, 2855, 1613, 1513, 1462, 1250, 1091, 836, 775 cm 1; 'H NMR (300 MHz, CDC13) S 7.59-7.57 (m, 6H), 7.42-7.30 (m, 11H), 6.96-6.93 (m, 2H), 5.96 (dd, J= 15.7, 6.4 Hz, 1H), 5.68 (dt, J= 15.2, 5.3 Hz, 1H), 4.79 (d, J
= 10.8 Hz, 1H), 4.67 (m, 1H), 4.63 (d, J= 10.9 Hz, 1H), 4.07 (m, 1H), 3.86 (s, 3H), 3.69 (d, J
= 4.7 Hz, 2H), 3.49 (m, 2H), 3.22 (t, J= 5.5 Hz, 1H), 2.91 (m, 1 H), 2.67 (d, J= 5.3 Hz, 1 H), 2.56 (m, 1H), 1.98 (m, 1H), 1.86 (m, 2H), 1.77 (m, 1H), 1.36 (m, 1H), 1.31 (d, J= 7.0 Hz, 3H), 1.09 (d, J= 7.1 Hz, 3H), 1.06 (d, J= 7.1 Hz, 3H), 1.03 (s, 9H), 1.02 (s, 9H), 0.94 (d, J=
6.6 Hz, 3H), 0.24 (s, 3H), 0.22 (s, 3H), 0.15 (s, 6H); 13C NMR (75 1VIHz, CDC13) S 158.9, 144.3, 133.2, 131.0, 129.1, 128.6, 127.7, 127.0, 126.8, 113.5, 87.5, 86.79, 86.74, 82.6, 74.0, 73.3, 69.3, 65.0, 59.6, 55.1, 41.4, 40.2, 34.5, 33.1, 32.7, 29.1, 25.9, 18.3, 18.0, 17.9, 16.6, 15.8, 15.3, -4.3, -4.5, -5.4; LRMS (ESI) 955.6 [M+Na]+, 707.3, 633.3, 559.2, 413.3; HRMS
(ESI) calcd for C58H84O6Si2Na 955.5704 [M+Na]+, found 955.5734; [a]20D -8.5 (c 1.5, CHC13).
[00161] (2E,4S,5S,7S,8Z,10S,11R,12R,14R)-11-(4-Methoxybenzyloxy)-5-(tert-butyldimethylsilyloxy)-15-(tert-butyldimethylsilyloxy))-4,10,12,14-tetramethyl-(trityloxy)pentadeca-2,8-dien-7-ol (84). A catalytic amount of Lindlar catalyst (ca. 200 mg) was added to a solution of alcoho183 (3.11 g, 3.33 mmol) in toluene (100 mL).
The flask was fitted with a Ha balloon, and stirred under an atmosphere of H2 until starting material was consumed (usually 1 h), as indicated by TLC analysis. The mixture was filtered through a pad of celite and concentrated under reduced pressure to afford the olefin 84 as a colorless oil (2.81 g, 90 %): IR (CHC13) 3434, 2956, 2928, 2856, 1613, 1514, 1471, 1249, 1062, 836, 774 cm i; 1H NMR (300 MHz, CDC13) 6 7.58-7.55 (m, 6H), 7.4-7.29 (m, 1H), 6.93 (m, 2H), 5.90 (dd, J= 15.6, 6.6 Hz, 1H), 5.68 (dt, J= 15.7, 5.4 Hz, 1H), 5.60 (dd, J= 11.1, 8.9 Hz, 1H), 5.51 (dd, J= 11.2, 7.3 Hz, 1H), 4.66 (m, 1H), 4.58 (d, J= 10.9 Hz, 1H), 4.55 (d, J= 10.9 Hz, 1H), 3.95 (m, 1H), 3.86 (s, 3H), 3.66 (dd, J= 4.9 Hz, 1H), 3.52-3.38 (m, 2H), 3.01 (m, 2H), 2.89 (br, 1H), 2.55 (m, 1H), 1.79 (m, 1H), 1.70 (m, 1H), 1.62 (m, 2H), 1.33-1.29 (m, 2H), 1.12 (d, J= 5.8 Hz, 3H), 1.10 (d, J= 6.7 Hz, 3H), 1.02 (s, 9H), 1.01 (s, 9H), 0.89 (d, J= 6.1 Hz, 314), 0.87 (d, J= 6.3 Hz, 3H), 0.19 (s, 6H), 0.14 (s, 6H); 13C NMR (75 MHz, CDC13) 8 158.9, 144.3, 134.1, 133.5, 132.6, 131.0, 129.0, 128.6, 127.7, 126.8, 126.7, 113.5, 88.4, 86.7, 74.9, 73.5, 69.4, 65.2, 65.1, 55.1, 41.8, 40.2, 35.0, 34.6, 33.1, 25.9, 19.1, 18.3, 18.0, 16.6, 15.8, 15.6, -4.4, -4.5, -5.3; LRMS (ESI) 957.6 [M+Na]+, 781.4, 707.3, 559.3, 485.2, 413.4;
HRMS (ESI) calcd for C58H86O6SiaNa 957.5861 [M+Na]+, found 957.5900; [a]20D
+2.0 (c 1.2, CHC13).
[00162] ((2E,4S,5S,7S,8Z,10S,11R,12R,14R)-11-(4-Methoxybenzyloxy)-5,7,15-tf=is(tert-butyldimethylsilyloxy)-4,10,12,14-tetramethylpentadeca-2,8-dienyloxy)triphenylmethane (85). TBSOTf (1.05 mL, 4.57 mmol) was added to a stirred solution of the alcohol 84 (3.89 g, 4.16 mmol) and 2,6-lutidine (0.58 mL, 5.01 mmol) in CH2C12 (14 mL) at 0 C. After stirring for 1 h at 0 C, the reaction mixture was quenched by the addition of water (25 mL), and extracted by CHZC12 and dried over MgSO4, followed by the evaporation of the solvent under reduced pressure. The residue was purified by short column chromatography (hexane/EtOAc 9:1) to obtain the product 85 (4.36 g, quantitative) as a colorless oil: IR (CHC13) 2956, 2928, 2856, 1613, 1514, 1471, 1462, 1250, 1088, 836, 773, 705 cm 1; 1H NMR (300 MHz, CDC13) S 7.61-7.58 (m, 6H), 7.43-7.31 (m, 11H), 6.97-6.94 (m, 2H), 5.95 (dd, J= 15.7, 6.0 Hz, 1H), 5.67 (dt, J= 15.7, 5.6 Hz, 1H), 5.62-5.46 (m, 2H), 4.71 (m, 1H), 4.62 (m, 2H), 4.05 (m, 1H), 3.87 (s, 3H), 3.69 (d, J= 5.3 Hz, 2H), 3.53-3.40 (m, 2H), 3.08 (m, 1H), 2.91 (m, 1H), 2.51 (m, 1H), 1.76 (m, 1H), 1.66 (m, 2H), 1.50-1.40 (m, 2H), 1.32 (m, 1H), 1.22 (d, J= 6.8 Hz, 6H), 1.09 (d, J= 6.9 Hz, 3H), 1.06-0.96 (m, 27H), 0.91 (d, J= 6.6 Hz, 3H), 0.83 (d, J= 6.5 Hz, 3H), 0.25-0.17 (m, 18H);
13C NMR (75 MHz, CDC13) 6 158.9, 144.4, 134.3, 133.7, 131.4, 129.4, 129.0, 128.6, 127.7, 126.8, 126.4, 113.5, 88.8, 86.7, 74.8, 72.8, 69.5, 66.3, 65.1, 55.1, 43.0, 42.3, 35.4, 35.1, 33.4, 33.1, 26.1, 26.0, 18.8, 18.3, 18.1, 16.7, 15.7, 14.6, -2.8, -3.9, -4.1, -4.2, -5.3; LRMS
(ESI) 1071.9 [M+Na]+, 413.4, 359.3, 243.2; HRMS (ESl) calcd for C64H100O6Si3Na 1071.6725 [M+Na]+, found 1071.6779; [a]20D -9.5 (c 3.0, CHC13).
[00163] (2R,4R,5R,6S,7Z,9S,11S,12S,13E)-1,9,11-tris(tert-Butyldimethylsilyloxy)-2,4,6,12-tetramethy1-15-(trityloxy)pentadeca-7,13-dien-5-ol (86). The above PMB alcohol 85 (2.90 g, 2.77 mmol) was added to CH2C12 (25 mL) and H20 (1 mL), and DDQ
(0.94 g, 4.15 mol) was added. After 1 h of stirring, the reaction mixture was quenched by adding sat'd NaHCO3 (200 mL). The organic phase was washed by sat'd NaHCO3 solution (3 x 100 mL) and brine, dried over MgSO4 and concentrated. Purification by flash column chromatography (EtOAc/hexane 5:95) furnished 86 (2.16 g, 84 %) as a colorless oil: IR
(CHC13) 3477, 2956, 2928, 2856, 1471, 1386, 1254, 1088, 836, 774 cm 1; 1H NMR
(300 MHz, CDC13) 8 7.55-7.52 (m, 6H), 7.38-7.25 (m, 9H), 5.92 (dd, J= 15.7, 6.0 Hz, 1H), 5.62 (dt, J= 15.7, 5.5 Hz, 1H), 5.52 (dd, J= 11.1, 9.3 Hz, 1H), 5.3 5(t, J= 10.5 Hz, 1H), 4.63 (m, 1H), 3.97 (m, 1H), 3.63 (d, J= 5.4 Hz, 2H), 3.51-3.36 (m, 2H), 3.18 (m, 1H), 2.68 (m, 1H), 2.47 (m, 1H), 1.71-1.59 (m, 3H), 1.42-1.27 (m, 2H), 1.17 (m, 1H), 1.08 (d, J=
6.7 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 0.99 (s, 9H), 0.97 (s, 9H), 0.96 (s, 9H), 0.91 (d, J=
6.8 Hz, 3H), 0.84 (d, J= 6.6 Hz, 3H), 0.18 (s, 3H), 0.16 (s, 3H), 0.15 (s, 3H), 0.13 (s, 3H), 0.12 (s, 6H);
13C NMR (75 MHz, CDC13) S 144.4, 135.2, 134.1, 131.1, 128.7, 127.7, 126.8, 126.4, 86.7, 79.8, 72.8, 69.6, 66.2, 65.2, 43.0, 42.1, 35.5, 33.7, 32.8, 32.5, 26.1, 26.0, 25.9, 18.4, 18.1, 17.6, 16.8, 16.3, 14.7, -2.9, -4.0, -4.15, -4.22, -5.3; LRMS (ESI) 951.7 [M+Na]+, 823.7, 577.4, 413.3, 328.4, 243.1; HRMS (ESI) calcd for C56H92O5Si3Na 951.6150 [M+Na]+, found 951.6165; [a]20D 30.0 (c 3.6, CHC13).
[00164] ((2E,4S,5S,7S,8Z,IOS,11R,12R,14R)-5,7,11,15-tetrakis(tert-Butyldimethylsilyloxy)-4,10,12,14-tetramethylpentadeca-2,8-dienyloxy)triphenylmethane (87). The procedure for 85 was used with above 86 (3.34 g, 3.60 mol), TBSOTf (1.82 mL, 7.9 mmol) to yield 3.53 g (94 %) of the product by flash column chromatography (EtOAc/Hexane 5:95) as a colorless oil: IR (CHC13) 2956, 2928, 2856, 1471, 1462, 1361, 1254, 1088, 836, 773, 705 cm 1; 1H NMR (300 MHz, CDC13) S 7.50-7.48 (m, 6H), 7.34-7.22 (m, 9H), 5.82 (dd, J= 15.7, 6.0 Hz, 1H), 5.57 (dt, J=
15.8, 5.9 Hz, 1H), 5.48 (dd, J= 11.0, 9.9 Hz, 1H), 5.32 (dd, J= 11.0, 8.7 Hz, 1H), 4.56 (m, 1H), 3.93 (m, 1H), 3.59 (d, J= 5.5 Hz, 2H), 3.39 (dd, J= 9.6, 5.8 Hz, 111), 3.31-3.27 (m, 2H), 2.62(m, 1H), 2.40 (m, 1H), 1.58-1.50 (m, 3H), 1.35 (m, 1H), 1.20-1.09 (m, 2H), 1.02 (d, J=
7.1 Hz, 3H), 1.00 (d, J= 7.0 Hz, 3H), 0.94 (s, 9H), 0.92 (s, 9H), 0.91 (s, 9H), 0.90 (s, 9H), 0.78 (d, J= 6.8 Hz, 3H), 0.74 (d, J= 6.6 Hz, 3H), 0.13-0.05 (m, 24H); 13C NMR (75 MHz, CDC13) S 144.4, 134.5, 133.0, 131.8, 128.7, 127.7, 126.8, 126.4, 86.7, 81.2, 72.8, 69.3, 66.6, 65.3, 43.1, 42.3, 35.9, 35.1, 33.3, 29.7, 26.2, 26.1, 26.0, 19.6, 18.4, 18.3, 18.2, 16.3, 16.0, 14.6, -2.8, -3.5, -3.6, -4.0, -4.1, -5.3; LRMS (ESI) 1065.7 [M+Na]+, 953.7, 615.1, 577.3, 359.2;
HRMS (ESI) calcd for C62H1o6O5Si4Na 1065.7015 [M+Na]+, found 1065.7068; [a]20D -22.5 (c 2.0, CHC13).
[00165] (2R,4R,5R,6S,7Z,9S,I IS,12S,13E)-5,9,11-tris(tert-Butyldimethylsilyloxy)-2,4,6,12-tetramethyl-15-(trityloxy)pentadeca-7,13-dien-l-ol (88). HF-pyridine in pyridine (40 mL, prepared by slow addition of 12 mL pyridine to 3 mL HF-pyridine complex followed by dilution with 25 mL THF) was slowly added to a solution of TBS ether 87 (3.54 g, 4.10 mmol) in THF (5 mL) at 0 C. The mixture was stirred for 2 days at 0 C and quenched with sat'd NaHCO3 (100 mL). The aqueous layer was separated and extracted with Et20 (3 x 50 mL). The combined organic layers were washed with sat'd CuSO4 (3 x 50 mL), dried over MgSO4, and concentrated. Flash colunm chromatography (EtOAc/hexane 15:85) afforded 2.08 g (66 %) of the alcohol as a colorless oil: IR (CHC13) 3400, 2956, 2928, 2856, 1471, 1448, 1254, 1075, 836, 773 cm i; 1H NMR (300 MHz, CDC13) 8 7.52-7.48 (m, 6H), 7.36-7.24 (m, 9H), 5.87 (dd, J= 15.7, 5.9 Hz, 1H), 5.59 (dt, J= 15.7, 5.7 Hz, 1H), 5.55 (dd, J= 10.6, 10.4 Hz, 1H), 5.33 (dd, J= 11.0, 8.7 Hz, 1H), 4.58 (m, 1H), 3.94 (m, 1H), 3.60 (d, J= 5.5 Hz, 2H), 3.38-3.32 (m, 2H), 3.25 (m, 1H), 2.62 (m, 1H), 2.45 (m, 1H), 1.59 (m, 1H), 1.55 (m, 1H), 1.47 (m, 1H), 1.35 (m, 1H), 1.09 (m, 1H), 1.04 (d, J= 7.6 Hz, 3H), 1.01 (d, J= 7.2 Hz, 3H), 0.96 (s, 9H), 0.94 (s, 9H), 0.93 (s, 9H), 0.79 (d, J= 6.8 Hz, 3H), 0.75 (d, J= 6.6 Hz, 3H), 0.15 (s, 9H), 0.14 (s, 3H), 0.10 (s, 3H), 0.09 (s, 3H), 0.08 (s, 3H), 0.07 (s, 3H); 13C NMR
(75 MHz, CDC13) 8 144.4, 134.0, 132.7, 131.3, 128.7, 127.7, 126.8, 126.5, 86.8, 81.0, 73.0, 69.2, 66.5, 65.3, 42.6, 42.2, 36.2, 35.5, 34.6, 33.3, 26.2, 26.1, 25.9, 20.0, 18.4, 18.2, 18.1, 15.7, 15.6, 14.9, -2.8, -3.7, -3.8, -4.0, -4.1, -4.2; LRMS (ESI) 951.6 [M+Na]+, 705.1, 631.1, 557.0, 397.2, 381.2, 353.2, 243.1; HRMS (ESI) calcd for C56H92O5Si3Na 951.6150 [M+Na]+, found 951.6158; [oc]20D -33.5 (c 2.0, CHC13).
[00166] (2R,4E,6R,8R,9R,lOS,11Z,13S,15S,16S,17E)-9,13,15-tris(tert-Butyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxy)phenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-4,11,17-trien-3-one (89). The alcohol 88 (2.04 g, 2.20 mol) in CH2C12 (30 mL) was treated with Dess-Martin periodinane (1.40 g, 3.30 gmol). After 1 h, the mixture was quenched with saturated NaHCO3 (30 mL) and Na2S2O3 (30 mL). The aqueous layer was extracted with ethyl ether (30 mL x 2) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography filtration (hexane/EtOAc 4:1) to remove the residue from the Dess-Martin reagent provided crude aldehyde as a colorless oil, which was used for the next reaction without further purification. A mixture of ketophosphonate 38 (0.85 g, 2.20 mmol) and Ba(OH)2 (0.30 g, activated by heating to 100 C for 1-2 h before use) in THF (40 mL) was stirred at room temperature for 30 min. A solution of the above aldehyde in wet THF (4 mL + 4 x 1 mL washings, 40:1 THF/H20) was then added. After stirring for 12 h, the reaction mixture was diluted with EtaO (30 mL) and washed with sat'd NaHCO3 (50 mL) and brine (50 mL). The organic solution was dried (MgSO4) and the solvent was evaporated in vacuo. The residue was chromatographed (hexane/EtOAc 9:1) to yield 89 (2.04 g, 78 % for 2 steps) as a colorless oil: IR (CHC13) 2957, 2929, 2855, 1618, 1518, 1461, 1388, 1251, 1078, 1036, 836, 773 cm l; 1H NMR (300 MHz, CDC13) 8 7.49-7.46 (m, 6H), 7.39 (m, 2H), 7.33-7.21 (m, 9H), 6.89 (m, 2H), 6.79 (dd, J= 15.7, 7.4 Hz, 1H), 6.20 (d, J= 15.6 Hz, 1H), 5.85 (dd, J= 15.7, 5.9 Hz, 1H), 5.58 (dt, J= 15.7, 4.6 Hz, 1H), 5.49 (dd, J= 11.0, 10.4 Hz, 1H), 5.46 (s, 1H), 5.34 (dd, J= 11.1, 8.6 Hz, 1H), 4.56 (m, 1H), 4.12 (dd, J= 11.3, 4.6 Hz, 1H), 3.92 (m, 2H), 3.81 (s, 3H), 3.57 (d, J= 5.6 Hz, 1 H), 3.54 (m, 1 H), 3.29 (dd, J= 5.6, 2.4 Hz, 1H), 2.93 (m, 1H), 2.61 (in, 1H), 2.43 (m, 1H), 2.18 (m, 1H), 2.01 (m, 1H), 1.59-1.46 (m, 2H), 1.43 (m, 1H), 1.35-1.29 (m, 2H), 1.25 (d, J= 7.0 Hz, 3H), 1.03 (d, J= 7.2 Hz, 3H), 1.00 (d, J= 7.0 Hz, 3H), 0.94 (s, 9H), 0.92 (s, 9H), 0.91 (s, 9H), 0.82 (d, J= 7.0 Hz, 3H), 0.79 (d, J= 6.7 Hz, 3H), 0.77 (d, J= 6.5 Hz, 3H), 0.13 (s, 3H), 0.12 (s, 3H), 0.09 (s, 3H), 0.08 (s, 3H), 0.05 (s, 3H), 0.02 (s, 3H); 13C NMR (75 MHz, CDC13) 8 200.7, 159.8, 153.3, 144.3, 134.0, 133.3, 131.1, 130.8, 128.6, 127.7, 127.2, 126.8, 126.5, 125.7, 113.4, 100.8, 86.7, 82.7, 80.4, 72.8, 66.5, 65.8, 65.2, 55.2, 47.0, 42.8, 42.1, 39.1, 35.6, 34.9, 34.0, 32.3, 26.1, 26.0, 25.9, 19.7, 18.39, 18.36, 18.1, 16.4, 15.2, 14.7, 12.4, 10.7, -2.8, -3.6, -3.7, -4.0, -4.1; LRMS
(ESI) 1209.7 [M+Na]+, 577.4, 359.2, 243.1, 165.0; HRMS (ESI) calcd for C72H110O8Si3Na 1209.7406 [M+Na]+, found 1209.7466; [a]20D - 8.6 (c 2.5, CHC13).
[00167] (2R,6S,8R,9R,lOS,112,13S,15S,16S,17E)-9,13,15-tris(tert-Sutyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-3-one (90). NiCl2=6H2O
(0.20 g, 0.84 mmol) then portionwise NaBH4 (0.17 g, 4.49 mmol) were added to a stirred solution of unsaturated ketone 89 (2.60 g, 1.72 inol) in MeOH (60 mL), THF (20 mL) at 0 C. After 1 h, the reaction mixture was evaporated and filtered with celite using Et20 as an eluent (30 mL). The organic phase was concentrated and the residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 90 (1.55 g, 76 %) as a colorless oil: IR (CHC13) 2956, 2929, 2855, 1713, 1616, 1518, 1462, 1251, 1076, 836, 773 cm"1; 1H NMR
(300 MHz, CDC13) 6 7.52-7.50 (m, 6H), 7.42-7.24 (m, 11H), 6.92-6.86 (m, 2H), 5.87 (dd, J= 15.7, 6.0 Hz, 2H), 5.60 (dt, J= 15.8, 5.9 Hz, 1H), 5.50 (m, 1H), 5.49 (s, 1H), 5.37 (dd, J= 10.9, 8.5 Hz, 1H), 4.59 (m, 1H), 4.17 (dd, J= 11.3, 4.7 Hz, 1H), 3.98 (m, 2H), 3.82 (s, 3H), 3.62-3.55 (m, 3H), 3.29 (m, 1H), 2.73 (m, 1H), 2.65 (m, 1H), 2.49 (m, 2H), 2.06 (m, 1H), 1.63-1.50 (m, 2H), 1.47-1.32 (m, 2H), 1.27 (d, J= 7.1 Hz, 3H), 1.26 (m, 1H), 1.06 (d, J= 7.3 Hz, 3H), L03 (d, J= 7.2 Hz, 3H), 0.97-0.94 (m, 27H), 0.90-0.84 (in, 2H), 0.83 (d, J= 6.7 Hz, 3H), 0.76 (d, J= 7.0 Hz, 3H), 0.69 (d, J= 5.7 Hz, 3H), 0.17-0.05 (m, 18H); 13C NMR (75 MHz, CDC13) 8 211.7, 159.8, 144.4, 134.3, 133.1, 131.4, 130.9, 128.6, 127.9, 127.6, 127.1, 126.8, 126.4, 113.4, 100.8, 86.7, 82.9, 81.0, 72.8, 66.5, 65.2, 55.2, 48.3, 43.0, 42.2, 39.8, 38.3, 35.2, 35.1, 31.9, 31.3, 29.7, 26.2, 26.0, 25.9, 19.6, 18.6, 18.4, 18.1, 16.3, 14.6, 12.1, 9.7, -2.9, -3.5, -3.6, -4.0, -4.1, -4.2; LRMS (ESI) 1211.8 [M+Na]+, 577.3, 463.3, 413.3, 359.2, 316.9, 284.3;
HRMS (ESI) calcd for C72H112O8Si3Na 1211.7563 [M+Na]+, found 1211.7629; [a]20D
-4.3 (c 1.0, CHC13).
[00168] (2S,3R,6S,8R,9R,lOS,11Z,13S,15S,16S,17E)-9,13,15-tris(tert-Sutyldimethylsilyloxy)-2-((4S,5S)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxan-4-yl)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-3-ol (91). NaBH4 (0.074 g, 1.96 mmol) was added to a solution of ketone 90 (1.55 g, 1.30 mmol) in MeOH (21 mL) at 0 C.
After stirring for 2 h at 0 C, the reaction mixture was evaporated and water (30 mL) was added. The reaction mixture was extracted with ether (2 x 40 mL) and washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 1.02 g of major product (3 (less polar, 62 %) and 0.60 g (more polar, 36 %) of minor product a as colorless oils: (910) IR
(CHC13) 3540, 2956, 2929, 2855, 1615, 1518, 1461, 1385, 1252, 1074, 835, 773, 706 cm 1; 'H
NMR (300 MHz, CDC13) 8 7.54-7.50 (m, 6H), 7.42 (m, 2H), 7.37-7.25 (m, 9H), 6.94-6.91 (m, 2H), 5.88 (dd, J= 15.7, 6.0 Hz, 1H), 5.61 (dt, J= 16.0, 5.7 Hz, 1H), 5.56 (s, 1H), 5.50 (m, 1H), 5.37 (dd, J= 10.8, 8.6 Hz, 1H), 4.60 (m, 1H), 4.17 (dd, J= 11.2, 4.6 Hz, 1H), 3.96 (m, 1H), 3.87 (m, 1H), 3.84 (s, 3H), 3.74 (m, 1H), 3.64-3.53 (m, 3H), 3.32 (m, 1H), 3.20 (br, 1H), 2.67 (m, 1H), 2.44 (m,1H), 2.18 (m, 1H), 1.83 (m, 1H), 1.67-1.51 (m, 2H), 1.50-1.32 (m, 3H), 1.26 (m, 1H), 1.08 (d, J= 6.8 Hz, 3H), 1.07 (m, 2H), 1.06 (d, J= 7.0 Hz, 3H), 1.04 (d, J= 7.4 Hz, 3H), 0.98-0.85 (m, 2H), 0.82 (d, J= 6.7 Hz, 3H), 0.81 (d, J= 6.7 Hz, 3H), 0.77 (d, J= 6.0 Hz, 3H), 0.18-0.09 (m, 18H); 13C NMR (75 MHz, CDC13) S 160.0, 144.5, 144.4, 134.4, 132.9, 131.6, 130.7, 128.6, 127.6, 127.2, 126.8, 126.7, 126.4, 113.6, 101.2, 89.1, 86.7, 81.1, 76.8, 73.1, 72.8, 66.5, 55.2, 43.0, 42.3, 39.9, 37.2, 35.3, 35.1, 34.7, 32.3, 30.4, 30.2, 26.2, 26.1, 25.9, 19.6, 18.8, 18.4, 18.13, 18.10, 16.3, 14.6, 11.9, 5.5, -2.8, -3.56, -3.61, -4.0, -4.1, -4.16, -4.25; LRMS (API-ES) 1213.6 [M+Na]+, 557.0, 359.2, 243.1; HRMS (ESI) calcd for C72Hi14O8Si3Na 1213.7719 [M+Na]+, found 1213.7717; [a]20D -0.68 (c 7.1, CHC13): (91a) IR (CHC13) 3531, 2956, 2929, 2855, 1615, 1518, 1462, 1383, 1252, 1075, 836, 773 cm 1; 'H
NMR (300 MHz, CDC13) S 7.53-7.49 (m, 6H), 7.44-7.41 (m, 2H), 7.36-7.24 (m, 9H), 6.94-6.91 (m, 2H), 5.86 (dd, J= 15.7, 6.0 Hz, 1H), 5.60 (dt, J= 15.7, 5.7 Hz, 1H), 5.54 (s, 1H), 5.56-5.47 (m, 1H), 5.36 (dd, J= 11.0, 8.6 Hz, 1H), 4.60 (m, 1H), 4.17 (dd, J=
11.2, 4.6 Hz, 1H), 3.97-3.91 (m, 2H), 3.84 (s, 3H), 3.62 (d, J= 4.9 Hz, 2H), 3.61-3.53 (m, 2H), 3.32 (m, 1H), 2.67 (m, 1H), 2.44 (m,1H), 2.16 (m, 1H), 1.82 (m, 1H), 1.72-1.50 (m, 4H), 1.42-1.33 (m, 2H), 1.32-1.22 (m, 2H), 1.14 (d, J= 7.1 Hz, 3H), 1.06 ((d, J= 7.0 Hz, 3H), 1.03 (d, J=
7.0 Hz, 3H), 0.97-0.92 (m, 27H), 0.90-0.85 (m, 2H), 0.81 (d, J= 6.4 Hz, 3H), 0.79 (d, J= 6.6 Hz, 3H), 0.76 (d, J= 5.7 Hz, 3H), 0.17-0.09 (m, 18H); 13C NMR (75 MHz, CDC13) 6 160.0, 144.6, 144.4, 134.4, 133.0, 131.6, 131.1, 128.7, 127.7, 127.6, 127.3, 126.8, 126.7, 126.4, 113.6, 101.0, 86.7, 82.8, 81.2, 75.1, 73.3, 72.8, 66.6, 65.2, 55.2, 43.0, 42.3, 39.9, 37.9, 35.3, 35.1, 34.6, 33.4, 30.3, 26.3, 26.1, 26.0, 19.7, 19.0, 18.4, 18.1, 16.4, 14.6, 11.9, 11.1, -2.8, -3.5, -4.0, -4.07, -4.13; LRMS (ESI) 1213.8 [M+Na]+, 633.2, 359.2; HRMS (ESI) calcd for C72H114O8Si3Na 1213.7719 [M+Na]+, found 1213.7766; [a]20D -1.4 (c 4.7, CHC13).
[00169] (4S,5S)-4-((2R,3R,6S,8R,9R,l OS,11Z,13S,15S,16S,17E)-3,9,13,15-tetrakis(tert-Butyldimethylsilyloxy)-6,8,10,16-tetramethyl-19-(trityloxy)nonadeca-11,17-dien-2-yl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxane (92). TBSOTf (0.30 mL, 2.57 nunol) was added to a stirred solution of alcohol 91(3 (1.02 g, 0.86 mmol) and 2,6-lutidine (0.20 mL, 1.71 mmol) in CH2C12 (17 mL) at 0 C and the reaction mixture was stirred for 1 h at ambient teinperature. The reaction mixture was quenched by the addition of water (50 mL).
The reaction mixture was extracted by CH2C12 and dried over MgSO4 followed by the evaporation of the solution under reduced pressure. The residue was purified by short column chromatography (hexane/EtOAc 9:1) to yield product (0.97 g, 86 %) as a colorless oil: IR
(CHC13) 2955, 2928, 2856, 1615, 1518, 1471, 1462, 1387, 1251, 1074, 1038, 835, 773 cm 1;
1H NMR (300 MHz, CDC13) 8 7.52-7.46 (m, 6H), 7.45-7.42 (m, 2H), 7.35-7.22 (m, 9H), 6.92-6.89 (m, 2H), 5.86 (dd, J= 15.7, 6.0 Hz, 1H), 5.59 (dt, J= 15.7, 4.9 Hz, 1H), 5.48 (m, 1H), 5.47 (s, 1H), 5.36 (dd, J= 11.1, 8.6 Hz, 1H), 4.58 (m, 1H), 4.15 (dd, J=
11.2, 4.6 Hz, 1H), 3.96 (m, 1H), 3.81 (s, 3H), 3.73-3.66 (m, 2H), 3.60 (d, J= 5.6 Hz, 2H), 3.55 (m, 1H), 3.19 (m, 1H), 2.65 (m 1H), 2.42 (m, 1H), 2.07 (m, 1H), 1.91 (m, 1H), 1.57 (m, 2H), 1.40-1.21 (m, 3H), 1.14 (m, 1H), 1.06 (d, J= 6.7 Hz, 3H), 1.04 (d, J= 5.9 Hz, 3H), 1.02 (d, J= 6.9 Hz, 3H), 0.96-0.92 (m, 36H), 0.88-0.84 (m, 3H), 0.80 (m, 1H), 0.77 (d, J= 6.5 Hz, 3H), 0.76 (d, J= 6.4 Hz, 3H), 0.71 (d, J= 5.1 Hz, 3H), 0.16-0.03 (m, 24H); 13C NMR (75 MHz, CDC13) 8 159.7, 144.6, 144.4, 134.4, 133.2, 131.7, 131.4, 128.7, 127.7, 127.2, 126.8, 126.4, 113.4, 100.4, 86.7, 81.8, 81.4, 75.0, 73.3, 72.8, 66.5, 65.2, 55.2, 43.1, 42.3, 39.7, 38.9, 35.3, 35.0, 34.0, 31.2, 30.7, 30.6, 26.2, 26.1, 26.00, 25.95, 19.5, 19.1, 18.4, 18.13, 18.10, 16.5, 14.5, 12.4, 10.6, -2.8, -3.4, -3.95, -3.98, -4.2, -4.3; LRMS (ESI) 1327.8 [M+Na]+, 977.8, 739.6;
HRMS (ESI) calcd for C7gH128OgSi4Na 1327.8584 [M+Na]+, found 1327.8534; [a]20D
+6.7 (c 0.65, CHC13).
[00170] (2S,3S,4R,5R,8S,l OR,11R,12S,13Z,15S,17S,18S,19E)-3-(4-Methoxybenzyloxy)-5,11,15,17-tetrakis(tert-butyldimethylsilyloxy)-2,4,8,10,12,18-hexamethyl-21-(trityloxy)henicosa-13,19-dien-l-ol (93). DIBAL (1.0 M in hexane, 7.4 mL, 7.4 mmol) was added to a stirred solution of TBS protected acetal 92 (0.97 g, 0.74 mmol) in anhydrous CH2C12 (3 mL), under an atmosphere of N2 at 0 C dropwise.
After stirring for additional 30 min at 0 C, the reaction mixture was quenched by the careful addition of aqueous sat'd potassium sodium tartrate solution (30 mL) and stirred for 3 h at room temperature. The organic layer was separated, and the aqueous layer was extracted with CHZC12 (20 mL). The combined organic layers were washed with brine and dried over MgSO4 followed by the evaporation of the organic solution under reduced pressure. The residue was purified by column chromatography (EtOAc/hexane 1:9) to obtain 93 (0.94 g, 97 %) as a colorless oil: IR (CHC13) 3501, 2956, 2929, 2856, 1613, 1514, 1471, 1462, 1251, 1075, 835, 773, 705 crn 1; 'H NMR (300 MHz, CDC13) 6 7.55-7.51 (m, 6H), 7.37-7.25 (m, 11H), 6.94-6.92 (m, 2H), 5.90 (dd, J= 15.7, 5.9 Hz, 1H), 5.62 (dt, J= 15.6, 5.6 Hz, 1H), 5.56-5.48 (m, 1H), 5.40 (dd, J= 11.2, 8.5 Hz, 1H), 4.61 (m, 1H), 4.60 (s, 2H), 3.99 (m, 1H), 3.90 (m, 1H), 3.83 (s, 3H), 3.69 (m, 1H), 3.64 (d, J= 5.3 Hz, 1H), 3.53 (m, 1H), 3.31 (m, 1H), 2.99 (m 1H), 2.70 (m, 1H), 2.47 (m, 1H), 2.00 (m, 2H), 1.65-1.52 (m, 3H), 1.45-1.37 (m, 1H), 1.33 (m, 1H), 1.30 (m, 1H), 1.20 (d, J= 6.9 Hz, 3H), 1.10 (d, J= 6.6 Hz, 3H), 1.09 (d, J= 6.9 Hz, 3H), 1.05 (d, J= 7.0 Hz, 3H), 1.00-0.96 (m, 36H), 0.92-0.86 (m, 2H), 0.82 (d, J= 6.6 Hz, 3H), 0.76 (d, J= 5.5 Hz, 3H), 0.19-0.11 (m, 24H); 13C NMR (75 MHz, CDC13) S
159.2, 144.5, 144.4, 134.3, 133.1, 131.5, 130.5, 129.2, 128.6, 127.6, 126.8, 126.4, 113.8, 86.7, 86.0, 81.1, 75.3, 73.6, 72.8, 66.5, 65.1, 65.0, 55.1, 43.0, 42.3, 40.5, 40.0, 36.8, 35.2, 35.1, 34.0, 32.1, 30.4, 26.2, 26.1, 26.0, 25.9, 19.6, 18.9, 18.4, 18.1, 16.5, 15.8, 14.6, 9.9, -2.8, -3.4, -3.5, -3.8,'-4.0, -4.2, -4.4; LRMS (ESI) 1329.8 [M+Na]+, 1087.7, 801.5, 669.4, 537.3, 480.2, 359.2, 243.1; HRMS (ESI) calcd for C78H130O8Si4Na 1329.8741 [M+Na]+, found 1329.8778; [a]20D -9.9 (c 0.36, CHC13).
[00171] ((2E,4S,5S,7S,8Z,l OS,11R,12R,14S,17R,18R,19S,20S,21z)-19-(4-Methoxyb enzyloxy)-7,11,17-tris(tert-butyldimethylsilyloxy)-5-(tert-butyldimethylsilyloxy))-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraenyloxy)triphenylmethane (94). The alcohol 93 (0.94 g, 0.72 mol) in CH2C12 (20 mL) was treated with Dess-Martin periodinane (0.46 g, 1.08 mol). After 1 h, the mixture was quenched with saturated NaHCO3 (20 mL) and Na2S2O3 (20 mL). The aqueous layer was extracted with ethyl ether (20 mL x 2) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 9:1) to remove Dess-Martin residue provided crude aldehyde as a colorless oil, which was used for the next reaction without further purification. To a stirred solution of the above crude aldehyde and 1-bromoallyl trimethylsilane (0.89 g) in anhydrous THF (18 mL) under an atmosphere of N2 at room temperature was added CrC12 (0.73 g, 5.94 mmol), and the mixture was stirred for additional 14 h at ambient temperature. The reaction mixture was diluted with hexane followed by filtration through celite. After the evaporation of the solvent under reduced pressure, the residue was purified by short silica gel column chromatography using EtOAc/hexane (1:9) as an eluent. The foregoing product in THF (40 mL) was cooled to 0 C and NaH (95 % w/w, 0.36 g, 14.4 mmol) was added in one portion.
The ice bath was removed after 15 min and the mixture was stirred for 2 h at ambient temperature. The reaction mixture was cooled to 0 C, quenched with H20 (5 mL), extracted with ethyl ether (20 mL x 2). The combined organic layers were washed with brine and dried over MgSO4 followed by the evaporation of the organic solution under reduced pressure. The residue was purified by column chromatography (hexane/EtOAc 98:2) to obtain 94 (0.81 g, 85 % for 3 steps) as a colorless oil: IR (CHC13) 2955, 2928, 2856, 1614, 1514, 1471, 1462, 1249, 1076, 835, 772, 705 cm 1; 'H NMR (300 MHz, CDC13) 8 7.60-7.56 (m, 6H), 7.43-7.27 (m, 11H), 6.99-6.96 (m, 1H), 6.71 (ddd, J= 16.9, 10.6, 10.5 Hz, 1H), 6.14 (t, J= 11.0 Hz, 1H), 5.97 (dd, J= 15.7, 5.9 Hz, 1H), 5.82-5.77 (m, 1H), 5.74-5.70 (m, 1H), 5.68-5.62 (m, 1H), 5.61-5.56 (m, 1H), 5.46 (dd, J= 11.1, 8.6 Hz, 1H), 5.28 (d, J= 16.9 Hz, 1H), 5.20 (d, J
= 10.3 Hz, 1H), 4.66 (m, 3H), 4.05 (m, 1H), 3.86 (s, 3H), 3.76 (m, 1H), 3.69 (d, J= 5.2 Hz, 1H), 3.48 (m, 1H), 3.35 (m, 1H), 3.15 (m, 1H), 2.76 (m, 1H), 2.53 (m, 1H), 2.34 (m, 1H), 1.82 (m, 1H), 1.70-1.57 (m, 3H), 1.56-1.32 (m, 3H), 1.25 (d, J= 6.8 Hz, 3H), 1.14 (d, J= 7.1 Hz, 3H), 1.12 (m, 2H), 1.11 (d, J= 7.1 Hz, 3H), 1.08-1.03 (m, 36H), 0.98-0.90 (m, 2H), 0.86 (d, J = 6.6 Hz, 3H), 0.76 (d, J = 5.1 Hz, 3H), 0.25-0.13 (m, 24H); 13C NMR (75 MHz, CDC13) 8 159.0, 146.2, 144.6, 144.4, 134.5, 134.3, 133.2, 132.4, 131.4, 130.2, 129.0, 128.7, 127.7, 126.8, 126.5, 117.2, 113.7, 86.7, 84.5, 81.3, 75.1, 72.9, 66.6, 65.2, 55.1, 43.0, 42.3, 40.6, 40.2, 35.6, 35.25, 35.19, 33.9, 32.6, 30.3, 26.3, 26.1, 26.04, 25.99, 19.6, 18.9, 18.4, 18.2, 16.6, 14.7, 9.2, -2.8, -3.36, -3.4, -3.5, -3.9, -4.1, -4.4; LRMS (ESI) 1351.8 [M+Na]+, 837.1, 763.1, 689. 541.0; HRMS (ESI) calcd for C81H132O7Si4Na 1351.8948 [M+Na]+, found 1351.8973; [a]20D +0.4 (c 0.51, CHC13).
[00172] (2E,4S,5S,7S,8Z,l OS,11R,12R,14S,17R,18R,19S,20S,21Z)-19-(4-Methoxybenzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraen-l-ol (95). ZnBr2 solution (0.42 g in 5 mL CH2Clz and 0.8 mL of MeOH) was added to a stirred solution of trityl ether 94 (0.50 g, 0.38 mol) in MeOH (3 mL), CHZC12 (18 mL) at 0 C dropwise for 30 min. After 4 h, the reaction mixture was quenched with saturated NaHCO3 solution (20 mL) and extracted with EtzO
(10 mL x 2).
The organic phase was separated, dried with MgSO4 and concentrated. The residue was purified by flash chromatography (EtOAc/hexane 1:9) to yield 0.34 g of product 95 (83 %) as a colorless oil: IR (CHC13) 3410, 2956, 2929, 2856, 1613, 1514, 1471, 1251, 1076, 836, 773 crri 1; 'H NMR (300 MHz, CDC13) S 7.31-7.29 (m, 2H), 6.90-6.87 (m, 211), 6.60 (ddd, J =
16.8, 10.6, 10.5 Hz, 111), 6.02 (t, J= 11.0 Hz, 1 H), 5.79 (dd, J= 15.6, 5.8 Hz, 111), 5.62 (d, J
= 9.3 Hz, 1 H), 5.60 (m, 111), 5.47 (t, J= 10.3 Hz, 1 H), 5.32 (dd, J= 10.7, 8.9 Hz, 111), 5.18 (d, J= 16.8 Hz, 1H), 5.10 (d, J= 10.2 Hz, 1H), 4.54 (m, 3H), 4.07 (d, J= 5.9 Hz, 2H), 3.89 (m, 1H), 3.81 (s, 311), 3.64 (m, 1H), 3.35 (m, 111), 3.24 (br, 1H), 3.00 (m, 1H), 2.61 (m, 1H), 2.40 (m, 1H), 1.68 (m, 1H), 1.55-1.42 (m, 3H), 1.38-1.21 (m, 311), 1.12 (d, J=
6.7 Hz, 3H), 1.02-0.99 (m, 3H), 0.98 (d, J= 7.0 Hz, 3H), 0.94-0.89 (m, 40H), 0.79 (d, J=
6.9 Hz, 3H), 0.76 (d, J= 6.3 Hz, 3H), 0.11-0.06 (m, 24H); 13C NMR (75 MHz, CDC13) 6 159.0, 134.9, 134.5, 133.1, 132.4, 131.5, 131.4, 129.1, 128.9, 128.7, 117.2, 113.7, 84.5, 81.3, 75.1, 72.7, 66.4, 64.1, 55.3, 42.7, 42.0, 40.5, 40.4, 35.5, 35.23, 35.20, 33.9, 32.6, 30.5, 26.3, 26.03, 26.00, 25.96, 19.7, 18.9, 18.8, 18.5, 18.2, 18.1, 16.6, 14.7, 9.2, -2.8, -3.47, -3.53, -4.03, -4.05, -4.2, -4.5, -4.7; LRMS (ESI) 1109.7 [M+Na]+, 945.3, 797.3, 723.2, 577.4, 499.2, 413.3, 359.3; HRMS (ESI) calcd for C62H118O7Si4Na 1109.7852 [M+Na]+, found 1109.7898;
[a]20D -2.0 (c 2.6, CHC13).
[00173] (2Z,4E,6S,7S,9S,10Z,12S,13R,14IZ,16S,19R,20R,21S,22S,23Z)-Methyl-21-(4-methoxybenzyloxy)-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (96). The alcoho195 (0.34 g, 0.31 mol) in CH2C12 (20 mL) was treated with Dess-Martin periodinane (0.20 g, 0.47 gmol).
After 1 h, the mixture was quenched with saturated NaHCO3 (5 mL) and Na2S2O3 (5 mL). The aqueous layer was extracted with ethyl ether (10 mL x 2) and the combined extracts were dried over anhydrous MgSO4. Filtration and concentration followed by short flash column chromatography (hexane/EtOAc 9:1) to remove the Dess-Martin residue provided the crude aldehyde as a colorless oil, which was used for the next reaction without further purification.
To a stirred solution of bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl) phosphate (0.080 mL, 0.37 mol), 18-crown-6 (0.41 g, 1.55 mmol) in THF (6 mL) cooled to -78 C
was added dropwise potassium bis(trimethylsilyl)amide (0.75 mL, 0.37 mo1, 0.5M solution in toluene).
Thereafter the above aldehyde in THF (1 mL) was added and the solution was stirred for 4 h at -78 C. The reaction mixture was quenched by addition of a sat'd NH4C1 solution (5 mL) and diluted with diethyl ether (20 mL). The layers were separated and organic phase was washed with brine (30 mL) and dried with MgSO4, filtered, and concentrated.
The residue was purified by flash chromatography (EtOAc/hexane 5:95) to obtain (E,Z)-doubly unsaturated ester 96 (0.32 g, 90 % for 2 steps) as a colorless oil: IR (CHC13) 2956, 2929, 2885, 1722, 1641, 1514, 1471, 1250, 1174, 1075, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.34 (dd, J= 15.5, 11.2 Hz, 1H), 7.29-7.26 (m, 2H), 6.87-6.84 (m, 2H), 6.56 (ddd, J= 17.0, 10.6, 10.5 Hz, 1H), 6.52 (t, J= 11.4 Hz, 1 H), 6.19 (dd, J= 15.5, 6.4 Hz, 1 H), 5.99 (t, J=11.0 Hz, 1H), 5.57 (t, J= 10.5 Hz, 1H), 5.54 (d, J= 11.3 Hz, 1H), 5.42 (m, 1H), 5.30 (m, 1H), 5.15 (d, J= 16.8 Hz, 1H), 5.07 (d, J= 10.1 Hz, 1H), 4.51 (m, 3H), 3.92 (m, 1H), 3.78 (s, 3H), 3.70 (s, 3H), 3.61 (in, 1H), 3.32 (dd, J= 7.9, 2.8 Hz, 1H), 3.20 (m, 1H), 2.97 (m, 211), 2.57 (in, 2H), 1.65 (m, 1H), 1.56-1.39 (m, 3H), 1.29-1.16 (m, 3H), 1.10 (d, J= 6.8 Hz, 3H), 1.03 (d, J= 6.9 Hz, 3H), 0.98 (d, J= 7.0 Hz, 3H), 0.94 (d, J= 6.9 Hz, 3H), 0.93-0.83 (m, 39H), 0.77 (m, 1H), 0.91 (s, 9H), 0.87 (s, 9H), 0.83 (d, J= 6.4 Hz, 3H), 0.82 (d, J=
6.0 Hz, 3H), 0.13 (s, 3H), 0.76 (d, J= 6.6 Hz, 3H), 0.71 (d, J= 5.9 Hz, 3H), 0.10-0.02 (m, 24H); 13C NMR
(75 MHz, CDC13) 6 166.8, 159.0, 147.2, 145.6, 134.5, 133.1, 132.4, 131.5, 131.4, 129.0, 128.9, 126.4, 117.1, 115.1, 113.7, 84.4, 81.3, 75.0, 72.8, 72.7, 66.4, 55.2, 50.9, 42.9, 42.6, 40.5, 40.2, 35.3, 35.2, 33.8, 32.6, 30.5, 26.3, 26.0, 25.9, 19.6, 18.9, 18.8, 18.4, 18.2, 18.1, 16.7, 14.5, 9.2, -2.8, -3.4, -3.5, -3.6, -4.07, -4.14, -4.24, -4.49; LRMS
(ESI) 1163.8 [M+Na]+, 1107.9, 782.5; HRMS (ESI) calcd for C65H12oO$Si4Na 1163.7958 [M+Na]+, found 1163.8004; [a]20D -27.3 (c 5.0, CHC13).
[00174] (2Z,4E,6S,7S,9S,10Z,12S,13R,14R,16S,19R,20R,21S,22S,23Z)-Methyl-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (97). The ester 96 (0.15 g, 0.14 mol) was added to CH2C12 (5 mL) and H20 (0.2 mL) and DDQ (34 mg, 0.15 mol) was added at 0 C.
After 1 h of stirring at 0 C, the reaction mixture was quenched by adding sat'd NaHCO3 (5 mL). The organic phase was washed by sat'd NaHCO3 solution (3 x 10 mL) and brine, dried over MgSO4 and concentrated. Purification by flash column chromatography (EtOAc/hexane 1:9) furnished 97 (0.12 g, 90 %) as a colorless oil: IR (CHC13) 3540, 2956, 2929, 2856, 1641, 1601, 1471, 1462, 1407, 1379, 1361, 1255, 1174, 1089, 1004, 836, 773 cm 1; 1H
NMR (300 MHz, CDC13) S 7.33 (dd, J= 15.5, 11.2 Hz, 1H), 6.61 (ddd, J= 16.9, 10.5, 10.4 Hz, 1H), 6.51 (t, J= 11.4 Hz, 1 H), 6.17 (dd, J= 15.5, 5.9 Hz, 1H), 6.07 (t, J= 11.0 Hz, 1H), 5.54 (d, J
= 11.3 Hz, 1H), 5.45-5.37 (m, 2H), 5.28 (m, 1H), 5.18 (d, J= 16.8 Hz, 1H), 5.09 (d, J= 10.1 Hz, 1H), 4.51 (m, 1H), 3.91 (m, 1H), 3.74 (m, 1H), 3.69 (s, 3H), 3.45 (m, 1H), 3.23 (m, 1H), 3.76 (m, 1H), 2.56 (m, 2H), 2.29 (br, 1H), 1.68 (m, 1H), 1.56-1.41 (m, 3H), 1.34-1.17 (m, 3H), 1.02 (d, J= 6.9 Hz, 3H), 0.97 (d, J= 6.9 Hz, 3H), 0.94 (d, J= 6.8 Hz, 3H), 0.90-0.84 (m, 40H), 0.81 (d, J= 5.8 Hz, 3H), 0.77 (d, J= 6.5 Hz, 3H), 0.76 (d, J= 6.2 Hz, 3H), 0.08-0.01 (m, 24H); 13C NMR (75 MHz, CDC13) S 166.8, 147.3, 145.5, 135.3, 133.0, 132.3, 131.5, 129.9, 126.4, 117.6, 115.2, 81.3, 77.5, 76.7, 72.7, 66.4, 50.9, 42.9, 42.6, 40.1, 37.9, 36.1, 35.4, 35.2, 33.8, 32.2, 30.6, 26.2, 26.0, 25.9, 19.6, 19.0, 18.4, 18.10, 18.05, 17.7, 16.6, 14.4, 6.9, -2.8, -3.5, -3.6, -3.7, -4.1, -4.15, -4.21, -4.4; LRMS (ESI) 1043.7 [M+Na]+, 889.8, 757.6, 625.5, 544.3, 364.4; HRMS (ESI) calcd for C57H112O7Si4Na 1043.7383 [M+Na]+, found 1043.7433; [a] 20D -40.3 (c 2.1, CHC13).
[00175] (2Z,4E,6S,7S,9S,10Z,12S,13R,14R,16S,19R,20R,21S,22S,23Z)-7,9,13,19-tetrakis(tert-Butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoic acid (98). 1N aqueous KOH solution (1.2 mL) was added to a stirried solution of the above 97 (0.12 g, 0.12 mol) in EtOH (12 mL), THF (1 mL) and the mixture was refluxed gently until the ester disappeared (about 5 h) as determined by TLC
analysis. The ethanolic solution was concentrated and then diluted with ether (4 mL). After the solution was acidified to pH3 with 1N HC1 solution, organic phase was separated and aqueous phase was extracted with Et20 (2 x 5 mL). The combined organic phases were dried with MgSO4, concentrated and used without further purification: IR (CHC13) 2957, 2929, 2857, 1692, 1471, 1462, 1254, 1089, 836, 773 cm'1; 'H NMR (300 MHz, CDC13) 8 7.34 (dd, J= 15.1, 11.4 Hz, 1H), 6.64 (ddd, J= 16.0, 10.8, 10.5 Hz, 1H), 6.61 (t, J=
11.2 Hz, 1H), 6.22 (dd, J=15.4, 6.0 Hz, 1H), 6.09 (t, J= 11.0 Hz, 1H), 5.58 (d, J=11.3 Hz, 1H), 5.49-5.39 (m, 2H), 5.34-5.28 (m, 1H), 5.20 (d, J= 16.7 Hz, 1H), 5.11 (d, J= 10.2 Hz, 1H), 4.55 (m, 1H), 3.95 (m, 1H), 3.76 (m, 1H), 3.50 (m, 1H), 3.27 (m, 1H), 2.81 (m, 1H), 2.58 (m, 2H), 1.71 (m, 1H), 1.57-1.50 (m, 3H), 1.44-1.31 (m, 3H), 1.25 (d, J= 7.3 Hz, 3H), 1.21 (d, J= 6.1 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 0.99 (d, J= 7.0 Hz, 3H), 0.96-0.89 (m, 40H), 0.81 (d, J=
6.2 Hz, 3H), 0.79 (d, J = 5.9 Hz, 3H), 0.11-0.05 (m, 24H); 13C NMR (75 MHz, CDC13) 6 171.1, 148.1, 147.3, 135.2, 132.8, 132.3, 131.6, 129.9, 126.6, 117.6, 115.0, 81.3, 77.6, 72.7, 66.4, 58.3, 43.0, 42.6, 40.1, 37.9, 36.0, 35.4, 35.2, 33.8, 32.2, 30.6, 26.3, 26.0, 25.9, 25.2, 19.6, 19.0, 18.4, 18.09, 18.05, 17.7, 16.6, 14.5, 7.0, -2.8, -3.45, -3.54, -3.7, -4.1, -4.2, -4.4;
LRMS (ESI) 1029.7 [M+Na]+, 915.7, 897.7; HRMS (ESI) calcd for C56H11oO7Si4Na 1029.7226 [M+Na]+, found 1029.7257; [a]20D -41.7 (c 1.4, CHC13).
[00176] 8(,S),10(S),14(R),20(R)-tetrakis(tert-Sutyldimethylsilyloxy)-7(S),13 (S),15 (R),17(S),21(S)-p entamethyl-22 (S')-(1(S')-methylp enta-2,4-dienyl)oxacyclodocosa-3,5,11-trien-2-one (99). A solution of above acid 98 in THF (2 mL) was treated at 0 C with Et3N (0.10 mL, 0.72 mol) and 2,4,6-trichlorobenzoyl chloride (0.095 mL, 0.60 mol). The reaction mixture was stirred at 0 C for 30 min and then added to 4-DMAP (60 mL, 0.02 M solution in toluene) at 25 C and stirred overnight. The reaction mixture was concentrated, Et20 (10 mL) was added and the crude was washed with 0.5 N
HC1 (2 x 10 mL), dried over MgSO4. Purification by flash colunm chromatography (EtOAc/hexane 2:98) furnished macrolactone 99 (93 mg, 78 % for 2 steps) as a colorless oil:
IR (CHC13) 2957, 2929, 2856, 1745, 1715, 1581, 1471, 1369, 1270, 1117, 1082, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 8 7.11 (dd, J= 15.3, 10.5 Hz, 1H), 6.59 (ddd, J=
16.8, 10.7, 10.5 Hz, 1H), 6.22 (dd, J= 15.4, 6.0 Hz, 1H), 6.07 (dd, J= 15.4, 10.6 Hz, 1H), 5.92 (t, J
10.9 Hz, 1H), 5.70 (d, J= 15.4 Hz, 1H), 5.46 (t, J= 10.5 Hz, 1H), 5.35-5.27 (m, 2H), 5.20 (d, J= 8.4 Hz, 1 H), 5.12 (d, J= 16.8 Hz, 1 H), 5.04 (d, J= 10.3 Hz, 1H), 4.53 (m, 1H), 3.91 (in, 1H), 3.41 (m, 1H), 3.19 (m, 1H), 2.94 (m, 1H), 2.55 (m, 2H), 1.94 (m, 1H), 1.40-1.29 (m, 3H), 1.26-1.15 (m, 3H), 1.00-0.85 (m, 52H), 0.74 (d, J= 6.7 Hz, 3H), 0.63 (d, J= 6.2 Hz, 3H), 0.08-0.00 (m, 24H); 13C NMR (75 MHz, CDC13) 8 166.9, 144.93, 144.88, 136.0, 135.0, 133.5, 132.4, 130.7, 129.3, 120.2, 117.2, 80.3, 75.7, 73.9, 72.7, 66.3, 42.4, 41.0, 40.6, 39.3, 36.5, 35.8, 35.1, 34.5, 31.9, 29.7, 26.2, 26.0, 25.9, 21.6, 19.8, 19.7, 18.4, 18.11, 18.07, 17.9, 14.9, 11.3, -2.6, -3.6, -3.8, -4.2, -4.5, -4.6; LRMS (ESI) 1011.8 [M+Na]+, 857.7, 725.6, 633.2, 413.3, 375.3; HRMS (ESI) calcd for C56Hi08O6Si4Na 1011.7121 [M+Na]+, found 1011.7148; [a]20D -16.9 (c 1.24, CHC13).
[00177] 8(S),10(S),14(R),20(R)-Tetrahydroxy-7(S),13(S),15(R),17(S),21(S)-pentamethyl-22(S)-(1(S)-methyl-penta-2,4-dienyl)-oxa-cyclodocosa-3(E),5(E),11(Z)-trien-2-one (100, YSS665-2). 3 N HCl (10 mL, prepared by adding 2.5 mL of conc. HCl to 7.5 mL MeOH) was added to a stirred solution of the above macrolactone 99 (61 mg, 6.17 mol) in THF (3 mL) at 0 C. After 24 h at room temperature, the reaction mixture was diluted with EtOAc (4 mL) and HZO (4 mL) and the organic phase was separated and aqueous phase was extracted with EtOAc (2 x 4 mL). The combined organic phases were washed with sat'd NaHCO3 (10 mL), dried with MgSO4, concentrated and the residue was purified by flash chromatography (EtOAc/hexane 3:2) to yield the product 100 (8.2 mg, 25%) as a colorless oil: IR (CHC13) 3404, 2962, 2916, 1692, 1639, 1455, 1244, 1061, 1001 cni 1;1H
NMR (600 MHz, CD3OD) 8 7.15 (dd, J= 15.3, 10.5 Hz, 1 H), 6.64 (ddd, J= 16.8, 10.6, 10.3 Hz, 1H), 6.29 (dd, J= 15.4, 6.3 Hz, 1H), 6.22 (dd, J= 15.5, 10.5 Hz, 1H), 5.92 (t, J= 10.9 Hz, 1H), 5.72 (d, J= 15.3 Hz, 1H), 5.44-5.37 (m, 2H), 5.25 (t, J= 10.3 Hz, 1 H), 5.13 (dd, J=
16.8, 1.8 Hz, 1H), 5.06 (d, J= 10.8 Hz, 1H), 5.04 (dd, J= 9.1, 1.8 Hz, 1H), 4.68 (ddd, J=
9.9, 7.2, 2.4 Hz, iH), 3.82 (ddd, J= 9.2, 6.2, 2.7 Hz, 1H), 3.40 (ddd, J=
10.2, 6.2, 2.3 Hz, 1H), 3.06 (m, 1H), 2.99 (dd, J= 8.0, 3.3 Hz, 1H), 2.62 (m, 1H), 2.58 (m, 1H), 1.88 (m, 1H), 1.62 (m, 1H), 1.55 (ddd, J= 14.0, 10.5, 2.7 Hz, 1H), 1.38 (ddd, J= 12.3, 9.6, 2.7 Hz, 1H), 1.34-1.23 (m, 4H), 1.12 (d, J= 7.0 Hz, 3H), 1.06 (d, .I = 6.9 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 1.00 (d, J= 6.7 Hz, 3H), 0.95-0.88 (m, 2H), 0.87-0.82 (m, 1H), 0.79 (d, J= 5.3 Hz, 3H), 0.68 (d, J= 6.7 Hz, 3H); 13C N1VIR (150 MHz, CD3OD) 8 168.5, 147.7, 147.4, 135.7, 134.4, 133.6, 131.7, 130.8, 129.1, 120.7, 118.0, 80.7, 76.9, 74.2, 72.8, 65.9, 44.0, 42.5, 40.9, 39.5, 36.5, 36.3, 36.1, 35.5, 31.7, 31.2, 21.1, 19.0, 17.9, 17.7, 15.7, 11.3;
LRMS (ES1) 555.6 [M+Na]+, 541.4; HRMS (ESI) calcd for C32H$206 555.3662 [M+Na]+, found 555.3684;
[a] 20D -6.5 (c 0.17, MeOH).
[00178] (4S,5S)-4-((2R,3S,6S,8R,9R,l OS,11Z,13S,15S,16S,17E)-3,9,13,15-tetrakis(tert-Butyldimethylsilyloxy)-6,8,10,16-tetramethyl-19-(trityloxy)non adeca-11,17-dien-2-yl)-2-(4-methoxyphenyl)-5-methyl-1,3-dioxane (101). The same procedure for 92 was used with above 91a (0.60 g, 0.50 mol), TBSOTf (0.17 mL, 0.75 mmol) and 2,6-lutidine (0.12 mL, 1.0 mmol) to yield 0.61 g (93 %) of the product by flash colunm chromatography (EtOAc/Hexane 1:9) as a colorless oil: IR (CHC13) 2956, 2928, 2856, 1518, 1471, 1462, 1251, 1075, 835, 773 cm"1; 'H NMR (300 MHz, CDC13) S 7.56-7.48 (m, 8H), 7.38-7.26 (m, 9H), 6.97-6.94 (m, 1H), 5.91 (dd, J= 15.6, 5.9 Hz, 1H), 5.63 (dt, J= 15.7, 5.3 Hz, 1H), 5.58-5.50 (m, 1H), 5.52 (s, 1H), 5.41 (dd, J= 10.8, 8.6 Hz, 1H), 4.65 (m, 1H), 4.19 (dd, J= 11.1, 4.5 Hz, 1H), 4.01 (m, 1H), 3.90 (m, 1H), 3.84 (s, 3H), 3.66 (d, J= 5.0 Hz, 2H), 3.5 6(t, J= 11.1 Hz, 111), 3.3 6(m, 1 H), 2.71 (m 1H), 2.48 (m, 1 H), 2.12 (m, 1H), 1. 8 8(m, 1H), 1.76-1.56 (m, 3H), 1.52-1.42 (m, 2H), 1.40-1.31 (m, 2H), 1.09 (d, J= 7.7 Hz, 3H), 1.07 (d, J= 7.5 Hz, 3H), 1.05-0.94 (m, 42H), 0.93-0.90 (m, 2H), 0.86 (d, J= 6.6 Hz, 3H), 0.81 (d, J= 6.3 Hz, 3I-1), 0.21-0.13 (m, 24H); 13C NMR (75 MHz, CDC13) 8 159.7, 144.6, 144.4, 134.4, 133.0, 131.9, 131.8, 128.7, 127.7, 127.3, 126.8, 126.4, 113.4, 100.8, 86.7, 81.6, 81.3, 73.4, 72.8, 72.0, 66.6, 65.2, 55.1, 43.1, 42.3, 39.7, 38.2, 35.4, 35.3, 31.3, 30.8, 30.7, 30.3, 26.2, 26.1, 26.04, 25.97, 19.5, 18.8, 18.4, 18.1, 16.6, 14.6, 12.2, 9.1, -2.8, -3.4, -3.6, -3.9, -4.0, -4.1, -4.3; LRMS (ESI) 1327.9 [M+Na]+, 1037.9, 803.6, 647.6, 619.6, 413.3, 359.2, 229.1; HRMS (ESI) calcd for C78H128O8Si4Na 1327.8584 [M+Na]+, found 1327.8622;
[a]20D
+5.9 (c 0.3, CHC13).
[00179] (2S,3S,4R,5S,8S,10R,11R,12S,13Z,15S,17S,18S,19E)-3-(4-Methoxybenzyloxy)-5,11,15,17-tetrakis(tert-butyldimethylsilyloxy)-2,4,8,10,12,18-hexamethyl-21-(trityloxy)henicosa-13,19-dien-l-ol (102). The procedure for 93 was used with 101 (0.61 g, 0.47 mol), DIBAL (4.6 mL, 4.6 mmol) to yield 0.53 g (87 %) of the product by flash colunm chromatography (EtOAc/Hexane 0.5:9.5) as a colorless oil: IR
(CHC13) 3453, 2956, 2929, 1514, 1471, 1251, 1075, 835, 773 cm 1; 'H NMR (300 MHz, CDC13) 8 7.56-7.52 (m, 6H), 7.38-7.26 (m, 11H), 6.96-6.93 (m, 2H), 5.91 (dd, J= 15.7, 6.0 Hz, 1H), 5.64 (dt, J= 15.4, 5.5 Hz, 1H), 5.55-5.50 (m, 1H), 5.42 (dd, J= 11.1, 8.4 Hz, 1H), 4.70-4.58 (m, 3H), 4.01 (m, 1H), 3.83 (s, 3H), 3.79 (m, 2H), 3.67-3.61 (m, 3H), 3.35 (m, 1H), 3.30 (m 1H), 2.72 (m, 1H), 2.48 (m, 1H), 1.93 (m, 2H), 1.76-1.55 (m, 3H), 1.51-1.26 (m, 1H), 1.10 (d, J= 6.6 Hz, 3H), 1.09 (d, J= 6.6 Hz, 3H), 1.07 (d, J= 6.7 Hz, 3H), 1.01-0:98 (m, 39H), 0.93-0.89 (m, 2H), 0.86 (d, J= 6.6 Hz, 3H), 0.78 (d, J= 4.6 Hz, 3H), 0.21-0.13 (m, 24H); 13C NMR (75 MHz, CDC13) 6 159.2, 144.5, 144.4, 134.3, 133.1, 131.7, 130.6, 129.1, 128.6, 127.6, 126.8, 126.7, 126.4, 113.8, 86.7, 85.1, 81.3, 74.9, 74.4, 72.8, 66.5, 65.9, 65.1, 55.1, 43.0, 42.3, 41.8, 40.1, 38.4, 35.3, 35.1, 32.8, 30.7, 30.5, 26.2, 26.1, 26.0, 25.9, 19.5, 18.6, 18.4, 18.13, 18.10, 16.5, 15.4, 14.6, 10.5, -2.8, -3.4, -3.6, -3.9, -4.0, -4.2, -4.4; LRMS
(ESI) 1329.8 [M+Na]+, 801.6, 659.3, 637.3, 437.2, 243.1; HRMS (ESI) calcd for C78H130O8Si4Na 1329.8741 [M+Na]+, found 1329.8788; [a]a0D -9.8 (c 2.6, CHC13).
[00180] ((2E,4S,5S,7S,8Z,10S,11R,12R,14S,17S,18R,19S,20S,21Z)-19-(4-Methoxyb enzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraenyloxy)triphenylmethane (103). The procedure for 94 was used with 102 (0.52 g, 0.40 mol), Dess-Martin reagent (0.25 g, 0.59 mmol) and 1-bromoallyl trimethylsilane (0.49 g, 2.0 mmol), CrC12 (0.41 g, 3.32 mmol) and NaH (0.20 g, 8.0 mmol) to yield 0.46 g (88 %) of the product by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR (CHC13) 2956, 2856, 1614, 1514, 1471, 1249, 1074, 835, 773 cm 1; 1H NMR (300 MHz, CDC13) S 7.59-7.56 (m, 6H), 7.41-7.27 (m, 11H), 6.98-6.95 (m, 2H), 6.71 (ddd, J= 16.7, 10.6, 10.5 Hz, 1H), 6.14 (t, J= 11.0 Hz, 1H), 5.94 (dd, J= 15.6, 5.6 Hz, 1H), 5.80-5.67 (m, 2H), 5.64-5.55 (m, IH), 5.46 (dd, J=
11.0, 8.5 Hz, 1H), 5.31 (d, J= 16.8 Hz, 1H), 5.21 (d, J= 10.2 Hz, 1H), 4.70-4.62 (m, 3H), 4.04 (m, 1H), 3.86 (s, 3H), 3.69 (d, J= 4.7 Hz, 1H), 3.34 (m, 2H), 2.96 (m, 1H), 2.77 (m, 1H), 2.51 (m, 1H), 1.93 (m, 1H), 1.78 (m, IH), 1.75-1.63 (m, 3H), 1.57-1.31 (m, 5H), 1.21 (d, J= 6.7 Hz, 3H), 1.15 (d, J= 6.1 Hz, 3H), 1.12 (d, J= 6.7 Hz, 3H), 1.00 (d, J = 7.3 Hz, 3H), 1.05-1.01 (m, 36H), 0.96-0.93 (m, 2H), 0.89 (d, J= 6.7 Hz, 3H), 0.81 (d, J= 5.3 Hz, 3H), 0.25-0.11 (m, 24H); 13C NMR (75 MHz, CDC13) S 159.1, 146.2, 144.6, 144.4, 134.4, 134.3, 132.2, 131.3, 130.2, 129.0, 128.7, 127.7, 126.8, 126.5, 117.5, 113.7, 86.7, 84.9, 81.4, 74.9, 73.1, 72.9, 66.6, 65.2, 55.1, 43.1, 42.9, 42.3, 40.4, 35.9, 35.6, 35.3, 35.1, 34.5, 30.2, 29.4, 26.3, 26.1, 26.0, 19.6, 18.8, 18.6, 18.5, 18.2, 18.14, 18.11, 16.5, 14.7, 10.5, -1.1, -2.8, -3.0, -3.3, -3.5, -3.9, -4.2, -4.3; LRMS (ESI) 1351.8 [M+Na]+, 911.1, 837.1, 763.1, 689.1, 541.1, 413.2; HRMS
(ESI) calcd for C81H132O7Si4Na 1351.8948 [M+Na]+, found 1351.8998; [a]20D -9.3 (c 1.5, CHC13).
[00181] (2E,4S,5S,7S,8Z,l OS,11R,12R,14S,17S,18R,19S,20S,21Z)-19-(4-Methoxyb enzyloxy)-5,7,11,17-tetrakis(tert-butyldimethylsilyloxy)-4,10,12,14,18,20-hexamethyltetracosa-2,8,21,23-tetraen-l-ol (104). The procedure for 95 was used with 103 (0.33 g, 0.25 mol) and ZnBr (0.28 g, 1.25 mmol) to yield 0.18 g (65 %) of the product by flash column chromatography (EtOAc/hexane 1:9) as a colorless oil: IR (CHC13) 3417, 2956, 2856, 1613, 1514, 1471, 1250, 1074, 836, 773 crn 1; 1H NMR (300 MHz, CDC13) S
7.31-7.27 (m, 2H), 6.90-6.87 (m, 2H), 6.60 (ddd, J= 16.9,10.6,10.5 Hz, 1H), 6.04 (t, J=
11.0 Hz, 1H), 5.81 (dd, J= 15.7, 5.9 Hz, 1H), 5.67-5.60 (m, 2H), 5.51-5.44 (m, 1H), 5.34 (dd, J= 11.2, 8.7 Hz, 1H), 5.21 (d, J= 16.8 Hz, 1H), 5.12 (d, J= 10.2 Hz, 1H), 4.60-4.52 (m, 3H), 4.10 (d, J=
5.7 Hz, 1H), 3.91 (m, 1H), 3.81 (s, 3H), 3.59 (m, 1H), 3.31-3.23 (m, 2H), 2.86 (m, 1H), 2.65 (m, 1H), 2.40 (m, 1H), 1.82 (m, 1H), 1.66-1.42 (m, 5H), 1.36-1.20 (m, 3H), 1.11 (d, J= 6.8 Hz, 3H), 1.03 (d, J= 7.3 Hz, 3H), 1.01 (d, J= 6.6 Hz, 3H), 0.99 (d, J= 5.8 Hz, 3H), 0.94-0.89 (m, 38H), 0.84 (d, J= 7.2 Hz, 3H), 0.82 (d, J= 6.4 Hz, 3H), 0.13-0.00 (m, 24H); 13C
NMR (75 MHz, CDC13) 6 159.0, 135.0, 134.5, 133.2, 132.2, 131.5, 131.4, 129.1, 129.0, 128.7, 117.4, 113.7, 84.8, 81.4, 74.8, 73.1, 72.7, 66.5, 64.1, 55.2, 42.8, 42.7, 42.0, 40.4, 35.9, 35.4, 35.2, 34.4, 30.3, 29.4, 26.3, 26.03, 26.97, 25.95, 19.6, 18.7, 18.6, 18.5, 18.1, 16.6, 14.7, 10.5, -2.8, -3.4, -3.5, -4.0, -4.1, -4.2, -4.3, -4.4; LRMS (ESI) 1109.8 [M+Na]+, 707.2, 633.2, 541.1, 429.1, 355.1; HRMS (ESI) calcd for C62H118O7Si4Na 1109.7852 [M+Na]+, found 1109.7874; [a]20D -15.0 (c 0.94, CHC13).
[00182] (2Z,4E,6S,7S,9S,l OZ,12S,13R,14R,16S,19S,20R,21S,22S,23Z)-Methy1-21-(4-methoxybenzyloxy)-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (105). The procedure for 96 was used with 104 (0.18 g, 0.16 mol), Dess-Martin reagent (0.10 g, 0.24 mmol) and bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl) phosphate (0.041 mL, 0.19 mol), 18-crown-6 (0.21 g, 0.19 mmol) and KHMDS (0.39 mL, 0.19 mmol) to yield 0.16 g (84 %) of the product by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR
(CHC13) 2956, 2929, 2856, 1721, 1514, 1462, 1250, 1174, 1074, 836, 773 cm 1; 1H NMR (300 MHz, CDC13) 6 7.38 (dd, J= 15.4, 11.2 Hz, 1H), 7.32-7.29 (m, 2H), 6.91-6.86 (m, 2H), 6.60 (ddd, J=17.0, 10.6, 10.5 Hz, 1H), 6.56 (t, J= 11.3 Hz, 1H), 6.23 (dd, J= 15.5, 5.9 Hz, 1H), 6.05 (t, J= 11.0 Hz, 1H), 5.68-5.56 (m, 2H), 5.50-5.43 (m, 1H), 5.38-5.31 (m, 1H), 5.23 (d, J=
16.8 Hz, 1H), 5.12 (d, J= 10.2 Hz, 1H), 4.61-4.52 (m, 3H), 3.98 (m, 1H), 3.81 (s, 3H), 3.73 (s, 3H), 3.59 (m, 1H), 3.29-3.23 (m, 2H), 2.86 (m, 1H), 2.68-2.59 (m, 2H), 1.83 (m, 1H), 1.63-1.51 (m, 2H), 1.49-1.35 (in, 3H), 1.34-1.22 (m, 2H), 1.12 (d, J= 6.8 Hz, 3H), 1.07 (d, J= 6.9 Hz, 3H), 1.03 (d, J= 5.0 Hz, 3H), 1.01 (d, J= 6.7 Hz, 3H), 0.94-0.89 (m, 38H), 0.84 (d, J= 6.6 Hz, 3H), 0.80 (d, J= 6.1 Hz, 3H), 0.14-0.00 (m, 24H); 13C NMR (75 MHz, CDC13) S
166.8, 159.1, 147.2, 145.7, 134.4, 133.2, 132.2, 131.6, 131.4, 129.2, 129.0, 126.4, 117.5, 115.2, 113.7, 84.7, 81.5, 74.9, 73.0, 72.7, 66.4, 55.2, 50.9, 42.9, 42.8, 42.6, 40.3, 35.9, 35.4, 35.2, 34.4, 30.4, 29.5, 26.3, 26.03, 25.98, 19.6, 18.8, 18.7, 18.5, 18.1, 16.7, 14.5, 10.5, -2.8, -3.3, -3.5, -4.0, -4.1, -4.17, -4.22, -4.4; LRMS (ESI) 1163.8 [M+Na]+, 1009.7, 877.6, 513.4;
HRMS (ESI) calcd for C65H12oO8Si4Na 1163.7958 [M+Na]+, found 1163.7981; [a]20o -45.3 (c 0.36, CHC13).
[00183] (2Z,4E,6S,7S,9S,l OZ,12S,13R,14R,16S,19S,20R,21S,22S,23Z)-Methyl-7,9,13,19-tetrakis(tert-butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoate (106). The procedure for 97 was used with 105 (0.16 g, 0.14 mol) and DDQ (0.034 g, 0.15 mmol) to yield 0.13 g (90 %) of the product by flash column chromatography (EtOAc/hexane 1:19) as a colorless oil: IR
(CHC13) 3512, 2956, 2929, 2857, 1772, 1639, 1471, 1462, 1255, 1193, 1076, 836, 773 cm l; 'H
NMR (300 MHz, CDC13) S 7.35 (dd, J= 15.4, 11.2 Hz, 1H), 6.61 (ddd, J= 16.9, 10.6, 10.5 Hz, 1H), 6.53 (t, J= 11.3 Hz, 1 H), 6.19 (dd, J= 15.6, 6.0 Hz, 1 H), 6.09 (t, J= 11.0 Hz, 1H), 5.56 (d, J
= 11.3 Hz, 1H), 5.44 (t, J= 11.0 Hz, 1H), 5.31 (dd, J= 11.0, 8.4 Hz, 1H), 5.19 (d, J= 16.8 Hz, 1H), 5.10 (d, J= 10.1 Hz, 1H), 4.55 (m, 1H), 3.94 (m, 1H), 3.71 (s, 3H), 3.25 (m, 2H), 2.75 (m, 1H), 2.58 (m, 2H), 1.72 (m, 1H), 1.67-1.60 (m, 1H), 1.59-1.49 (m, 2H), 1.40 (m, 1H), 1.32-1.25 (m, 2H), 1.22-1.13 (m, 2H), 1.04 (d, J= 7.0 Hz, 3H), 1.01 (d, J= 7.1 Hz, 3H), 0.99 (d, J= 6.8 Hz, 3H), 0.91-0.86 (m, 41H), 0.81 (d, J= 6.5 Hz, 3H), 0.79 (d, J= 6.0 Hz, 3H), 0.11-0.05 (m, 24H); 13C NMR (75 MHz, CDC13) 8 166.8, 147.2, 145.6, 136.4, 133.2, 132.6, 131.5, 129.5, 126.4, 117.3, 115.2, 81.3, 78.6, 74.3, 72.7, 66.4, 50.9, 42.9, 42.6, 39.7, 36.2, 35.8, 35.4, 35.3, 34.1, 32.4, 30.6, 26.3, 26.0, 25.9, 19.6, 19.2, 18.5, 18.1, 18.0, 17.4, 16.7, 14.5, 10.9, -2.8, -3.4, -3.5, -4.06, -4.11, -4.2, -4.3, -4.4; LRMS
(ESI) 1043.7 [M+Na]+; HRMS (ESI) calcd for C57H112O7Si4Na 1043.7383 [M+Na]+, found 1043.7424;
[a]20D -37.8 (c 1.4, CHC13).
[00184] (2Z,4E,6S,7S,9S,10Z,12S,13R,14R,16S,19S,20R,21S,22S,23Z)-7,9,13,19-tetrakis(tert-Butyldimethylsilyloxy)-21-hydroxy-6,12,14,16,20,22-hexamethylhexacosa-2,4,10,23,25-pentaenoic acid (107). The procedure for 99 was used with 106 (0.13 g, 0.13 mol) and 1N KOH (1.2 mL, 1.3 mmol), 2,4,6-trichlorobenzoyl chloride (0.094 mL, 0.60 mol) and Et3N (0.10 mL, 0.78 mmol), 4-DMAP (60 mL, 1.3 mmol) to yield 0.054 g (45 %
for 2 steps) of the product by flash colunm chromatography (EtOAc/hexane 1:19) as a colorless oil: (seco acid) IR (CHC13) 2956, 2857, 1692, 1634, 1471, 1462, 1254, 1076, 836, 773 cm 1; 'H NMR (300 MHz, CDC13) S 7.34 (dd, J = 15.2, 11.3 Hz, 1H), 6.66 (ddd, J =
16.8, 10.8, 10.6 Hz, 1H), 6.62 (t, J= 11.3 Hz, 1H), 6.23 (dd, J= 15.3, 6.0 Hz, 1H), 6.09 (t, J
= 11.0 Hz, 1H), 5.57 (d, J= 11.2 Hz, 1H), 5.48-5.42 (m, 1H), 5.35-5.28 (m, 1H), 5.20 (d, J=
16.8 Hz, 1 H), 5.10 (d, J= 10.2 Hz, 1H), 4. 5 5(m, 1 H), 3.95 (m, 1H), 3.74 (m, 1H), 3.26 (m, 1H), 2.78 (m, 1H), 2.58 (m, 2H), 1.75-1.64 (m, 2H), 1.62-1.49 (m, 3H), 1.44-1.37 (m, 1H), 1.32-1.19 (m, 3H), 1.04 (d, J= 7.0 Hz, 3H), 1.01 (d, J= 7.0 Hz, 3H), 1.00 (d, J= 6.4 Hz, 3H), 0.95-0.86 (m, 41H), 0.82 (d, J= 7.1 Hz, 3H), 0.81 (d, J= 6.4 Hz, 3H), 0.12-0.05 (m, 24H); 13C NMR (75 MHz, CDC13) S 171.5, 148.3, 147.4, 136.4, 133.1, 132.6, 131.5, 129.5, 126.6, 117.3, 115.0, 81.3, 78.6, 74.3, 72.7, 66.4, 43.0, 42.7, 39.7, 36.2, 35.8, 35.5, 35.3, 34.1, 32.4, 30.6, 26.3, 26.0, 25.94, 25.92, 19.6, 19.2, 18.5, 18.1, 18.0, 17.4, 16.7, 14.5, 11.0, -2.8, -3.4, -3.5, -4.1, -4.25, -4.32, -4.7; LRMS (ESI) 1029.7 [M+Na]+, 915.8; HRMS
(ESI) calcd for C56H11oO7Si4Na 1029.7226 [M+Na]+, found 1029.7252; [a]20D -32.7 (c 0.51, CHC13).
[00185] 8(S),10(S),14(R),20(S)-Tetrahydroxy-7(S),13(S),15(R),17(S),21(S')-pentamethyl-22(S')-(1(,S')-methyl-penta-2,4-dienyl)oxacyclodocosa-3(Z),5(E),11(Z)-trien-2-one (194, YSS675-1) and 8(S),10(S),14(R),20(S)-Tetrahydroxy-7(S),13(S),15(R),17(S),21(,S)-pentamethyl-22(S)-(1(,S)-methyl-penta-2,4-dienyl)oxacyclodocosa-3(E),5(E),11(Z)-trien-2-one (108, YSS675-2). The procedure for 100 was used with 107 (0.054 g, 0.054 mol) in 3N HCl (5 mL) and THF (2 mL) to yield 13 mg (45 %) of 108 and 4.5 mg (15 %) of the 109 by flash column chromatography (EtOAc/hexane 7:3) as a colorless oil: (108) IR (CHC13) 3416, 2961, 2927, 2873, 1692, 1635, 1455, 1421, 1379, 1190, 1086, 998 cm ;1H NMR (600 MHz, CD3OD) 8 7.26 (dd, J=
15.2, 11.3 Hz, 1H), 6.65 (ddd, J= 16.8, 10.6, 10.3 Hz, 1H), 6.56 (t, J= 11.3 Hz, 1H), 5.97 (t, J=
10.9 Hz, 1 H), 5.91 (dd, J= 15.2, 9.3 Hz, 1 H), 5.49 (d, J= 10.7 Hz, 1 H), 5.42 (t, J= 8.6 Hz, 1H), 5.20 (t, J= 10.4 Hz, 1H), 5.15 (dd, J=16.9, 1.3 Hz, 1H), 5.08 (d, J=10.1 Hz, 1H), 5.05 (dd, J= 9.6, 1.3 Hz, 1H), 4.62 (ddd, J= 11.5, 7.7, 4.3 Hz, 1H), 3.65 (ddd, J=
10.0, 7.3, 3.1 Hz, 1 H), 3.07 (dd, J= 6.7, 4.0 Hz, 1 H), 3.01 (m, 1H), 2.66 (m, 1H), 2.26 (m, 1H), 1.90 (m, 1H), 1.66 (ddd, J= 11.5, 8.4, 3.4 Hz, 1H), 1.49 (ddd, J= 14.1, 10.0, 4.0 Hz, 1H), 1.45 (m, 1H), 1.3 8(m, 1H), 1.3 2(in, 1 H), 1.27 (m, 1H), 1.11 (d, J= 6.7 Hz, 3H), 1.06 (m, 1H), 1.03 (ddd, J= 11.3, 7.2, 4.4 Hz, 3H), 1.01 (d, J= 6.9 Hz, 3H), 0.99 (d, J= 6.7 Hz, 3H), 0.96 (d, J
= 7.0 Hz, 3H), 0.93 (in, 1H), 0.89 (m, 1H), 0.85 (d, J= 6.7 Hz, 3H), 0.75 (d, J= 5.9 Hz, 3H);
13C NMR (150 MHz, CD3OD) S 168.1, 148.7, 146.6, 135.7, 134.0, 133.7, 132.9, 131.1, 128.2, 118.0, 117.0, 80.9, 78.4, 74.4, 72.4, 66.3, 46.4, 43.4, 42.5, 40.9, 36.3, 35.90, 35.88, 35.7, 31.8, 31.5, 19.9, 19.3, 18.3, 17.5, 8.5; LRMS (ESI) 555.3 [M+Na]+, 537.4; HRMS
(ESI) calcd for C32H5206 555.3662 [M+Na]+, found 555.3680; [a]20D +76.5 (c 0.52, MeOH):
(109) IR (CHC13) 3428, 2962, 2928, 1690, 1635, 1380, 1243, 1145, 1064, 1000 cm"1; 'H
NMR (600 MHz, CD3OD) S 7.20 (dd, J= 15.2, 10.8 Hz, 1 H), 6.65 (ddd, J= 17.0, 10.6, 10.5 Hz, 1H), 6.38 (dd, J= 15.5, 5.4 Hz, 1H), 6.23 (dd, J= 14.4, 10.9 Hz, 1H), 5.95 (t, J= 11.0 Hz, 1H), 5.77 (d, J= 15.3 Hz, 1 H), 5.40-5.3 9(m, 2H), 5.23 (t, J= 10.5 Hz, 1H), 5.13 (d, J=
18.1 Hz, 1H), 5.12 (dd, J= 8.2, 1.5 Hz, 1H), 5.07 (d, J= 10.2 Hz, 1H), 4.66 (m, 1H), 3.90 (ddd, J= 7.6, 5. l, 2.5 Hz, 1H), 3.22 (dd, J= 9.8, 7.9 Hz, 1H), 3.04 (m, 1H), 2.95 (dd, J= 9.7, 2.1 Hz, 1H), 2.72 (m, 1H), 2.65 (m, 1H), 1.83 (m, 1H), 1.58 (m, 1H), 1.46 (m, 1H), 1.35-1.23 (m, 4H), 1.05 (d, J= 6.8 Hz, 3H), 1.04 (d, J= 6.9 Hz, 3H), 0.98 (d, J= 6.8 Hz, 3H), 0.97 (d, J= 7.0 Hz, 3H), 0.94 (m, 2H), 0.78 (m, 1H), 0.71 (d, J= 6.4 Hz, 3H), 0.68 (d, J= 6.5 Hz, 3H); 13C NMR (150 MHz, CD3OD) 8 169.4, 147.5, 147.4, 135.9, 134.3, 133.7, 131.0, 128.9, 120.0, 118.0, 80.5, 78.5, 72.6, 72.0, 65.2, 43.6, 42.6, 42.1, 39.3, 36.3, 35.8, 35.6, 35.3, 31.4, 29.7, 19.3, 18.5, 17.4, 17.1, 14.8, 9.0; LRMS (ESI) 555.5 [M+Na]+; HRMS (ESI) calcd for C32H5206 555.3662 [M+Na]+, found 555.3687; [a]20D -17.3 (c 0.15, MeOH).
Biology [00186] Tubulin polymerization assay. Tubulin assembly was monitored turbidimetrically in Gilford 250 spectrophotometers equipped with electronic temperature controllers as described previously (ter Haar et al., 1996). The reaction mixtures without the compounds consisted of tubulin (1 mg/ml), heat-treated MAPs (0.75 mg/ml, if present), GTP
(100 M, if present), and 0.1M (4-morpholinyl)ethane sulfonate (MeS).
Baselines were established after addition of all reaction components except the compounds to the cuvettes held at 0 C. Compounds, at 10 M or 40 M final concentration, were then added and each reaction mixture (0.25mL final volume) was subjected to the indicated temperature changes.
[00187] Antiproliferative Assay. The effects of dictyostati and its analogs on growth inhibition of parental (A549) and paclitaxel-resistant (lA9/Ptx10 and Ptx22) ovarian adenocarcinoma cell lines were evaluated following the antiproliferative assay protocol as described earlier (Minguez et al., 2003; Choy et al., 2003; Lazo et al., 2001). Cells were maintained in RPMI medium with 10% FBS in it, plated in tissue culture plates, and allowed to grow for 48-72h before transferring them into 96-well plates. Cells were allowed to attach and grow for 48 h in 96-well plates after which they were treated with either control (DMSO) or drug in triplicate/quadruplicate. Cells were incubated with the compounds for 72h. Cells were treated with MTS reagent before reading the plate in a Dynamax plate 'reader for detennining the cell number. The fifty percent growth inhibition values (GI50 values) were calculated for the compounds against all the three cell lines.
[00188] Pelleting Assay (determination of EC50): The assay was performed under three different reaction conditions following the procedure reported earlier (Gapud et al., 2004).
Reaction condition 1 included 0.2 M monosodium glutamate (MSG), 10 M tubulin, 5%
DMSO and varying concentrations of test agents. Reaction condition 2 included 0.8 M MSG, 400 M GTP, 10 M tubulin, 5% DMSO, and varying concentrations of test agents.
Reaction condition 3 had 0.6 M MSG, 200 M GTP, and 10 M tubulin, and 5%
DMSO, and varying concentrations of the test agents. The experimental protocol for all the three reaction conditions was the following. The reaction mixtures were incubated at room temperature (20-22 C) for 15 min and spun for 10 min at 14,000 rpm in an Eppendorf microtube centrifuge. Aliquots of the supernatants were removed and assayed for protein content by the method of Lowry. The EC50 was defined as drug concentration required to polymerize 50%
of tubulin compared to the pellet found in the DMSO control reaction determined for each test system. On average 5.5 4.0% of the tubulin pelleted in the DMSO
control.
[001891 MultiparameteY fluorescence microscopy high information content cell-based fluorescence screening: HeLa cells growing at log phase were trypsinized and plated in 40 L at a density of 7,000-8,000 cells per well in calf skin collagen I-coated 384-well plates (Falcon #3962; Fisher Scientific). Cells were exposed to test agents or 0.5%
DMSO within 2-8 h of plating. Concentrated DMSO stock solutions of all test agents were diluted into solutions of HBSS medium plus 10% FBS and added to the microplate wells (10 L
per well), using an automated liquid handling system (Biomek 2000; Beckman-Coulter, Inc.) to provide a serial 2-fold dilution of each test agent. The cells were incubated in the presence of test agents for 24 h. At the end of the incubation, the medium was removed and replaced with HBSS containing 4% formaldehyde and 10 g/mL Hoechst 33342 (25 L/we11) to fix the cells and fluorescently label their chromatin. After incubation at room temperature for 20-30 min, the solution was removed from each well and replaced with HBSS (100 L/well).
Further reagent additions were made to the microplates using the Biomek 2000.
After removing the HBSS from each well, cells were permeabilized for 5 min at room temperature with 0.5% (w/w) Triton X-100 in HBSS (10 L/well). This step extracts a fraction of the soluble cellular components, including soluble tubulin. The wells were washed with HBSS
(100 L/well), followed by addition of a primary antibody solution containing mouse anti-a-tubulin (1:3000) and rabbit anti-phosphohistone H3 (1:500) in HBSS (10 L/well). After 1 h at room temperature, the wells were washed with HBSS as above, followed by the addition of a secondary antibody solution containing fluorescein-5-isothiocyanate (FITC)-labeled donkey anti-mouse (1:300) and Cy3-labeled donkey anti-rabbit (1:300) antibodies diluted in HBSS
(10 L/we11). After 1 h at room temperature, the wells were washed as above, and HBSS was added (100 L/well). The plates were placed in an ArrayScan HCS Reader with the Target Activation BioApplication Software coupled to Cellomics Store and the vHCSTM
Discovery Toolbox (Cellomics, Inc.) to analyze images. Briefly, the instrument was used to scan multiple optical fields, each with multiparameter fluorescence, within a subset of the wells of the 384-well microplate. The BioApplication software produced multiple numerical feature values, such as subcellular object intensities, shapes, and location for each cell within an optical field. Data were acquired from a minimum of 1,000 cells per well, except in cases where added test agents reduced the attachment of cells to the substrate. A
nuclear mask was generated from Hoechst 33342-stained nuclei, and object identification thresholds and shape parameters were set such that the algorithm identified over 90% of the nuclei in each field.
Objects that touched each other or the edge of the image were excluded from the analysis.
Tubulin mass was defined as the average green (FITC) pixel intensity in an area defined by the Hoechst-defined nuclear mask. This cytoplasmic area around the nucleus contains cytoskeletal components is a region from which sensitive measurements of cytoplasmic characteristics can be made. The percentage of phospho-histone H3 positive cells was defined as the number of cells whose average red (Cy3) staining intensity exceeded the average Cy3 intensity plus two standard deviations of vehicle-treated cells, divided by the total number of cells.
[00190] Radiolabeled ligand binding assays: [3H]Paclitaxel, [3H]discodermolide and [14C]epothilone B solutions were prepared as 125 M stock solutions in 50%
DMSO.
Radiolabeled compound (final concentration, 4.0 M) and test agents at final concentrations noted in the text and tables were mixed in 50 L of 4:1 (v/v) 0.75 M aqueous MSG/DMSO
and warmed to 37 C. Meanwhile, a reaction mixture containing 0.75 M MSG, 2.5 M
tubulin, and 25 M ddGTP was prepared and incubated at 37 C for 30 min to form microtubuless. A 200 L aliquot of the microtubule mixture was added to the drug mixtures, and incubation continued for 30 min at 37 C. Reaction mixtures were centrifuged in an Eppendorf 5417C centrifuge at 14,000 rpm for 20 min at room temperature.
Radiolabel in the supematants (100 L) was determined by scintillation spectrometry. Bound radiolabeled compound was calculated from the total radiolabel added to each reaction mixture minus the amount of radiolabel found in the supematant.
[00191] The foregoing description and accompanying drawings set forth the preferred embodiments of the invention at the present time. Various modifications, additions and alternative designs will, of course, become apparent to those skilled in the art in light of the foregoing teachings without departing from the scope of the invention. The scope of the invention is indicated by the following claims rather than by the foregoing description. All changes and variations that fall within the meaning and range of equivalency of the claims are to be embraced within their scope.
Claims (27)
1. A compound of the following structure or its enantiomer wherein R1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2)n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C.ident.C-;
R4 is wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, or R23a and R23b together form a portion of six-membered acetal ring incorporating CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group; and R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e; provided that the compound is not dictyostatin 1.
R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2)n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C.ident.C-;
R4 is wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, or R23a and R23b together form a portion of six-membered acetal ring incorporating CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group; and R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e; provided that the compound is not dictyostatin 1.
2. The compound of claim 1 with the following stereostructure, or its enantiomer wherein R1 is alkenyl; R2 is H; R3 is -CH2CH(CH3), CH2CH2CH=CH, or -CH=C(CH3).
3. The compound of claim 2 wherein the compound is 16-desmethyldictyostatin and wherein R3 is CH2CH2, R5 is OH, R1 is CH=CH2 and R23a, R23b are H.
4. The compound of claim 2 wherein R5 is OH or OSiR a R b R c.
5. The compound of claim 1 wherein the compound is the C2-C3 E-stereoisomer or its enantioner.
6. The compound of claim 2 wherein the compound is the C2-C3 E-stereoisomer or its enantioner.
7. A compound having the following formula, or its enantiomer R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2)n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C.ident.C-;
R11a and R11b are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e, or R11a and R11b together form a portion of six-membered acetal ring containing CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R12 is a halogen atom, CH2OR2c, CHO, CO2R10O, CH=CHCH2OR2c, CH=CHCHO or CH=CHCO2R10, wherein R2c is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl; and R14a and R14b are independently H, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e, or R14a and R14b together form a six-membered ring containing CR v R w, wherein R v and R w are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2)n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C.ident.C-;
R11a and R11b are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e, or R11a and R11b together form a portion of six-membered acetal ring containing CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R12 is a halogen atom, CH2OR2c, CHO, CO2R10O, CH=CHCH2OR2c, CH=CHCHO or CH=CHCO2R10, wherein R2c is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl; and R14a and R14b are independently H, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e, or R14a and R14b together form a six-membered ring containing CR v R w, wherein R v and R w are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
8. The compound of claim 7 with the following stereostructure, or its enantiomer wherein R3 is CH2CH(CH3)CH2CH2, CH=CH, or CH=C(CH3); and R11a and R11b are H
or together form a portion of a six-membered acetal ring containing C(H)(p-C6H4OCH3) or C(CH3)2.
or together form a portion of a six-membered acetal ring containing C(H)(p-C6H4OCH3) or C(CH3)2.
9. A compound having the following formula, or its enantiomer wherein R2 is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein R g and R h are independently H, an alkyl group or an aryl group;
R11 is a protecting group, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R12 is a halogen atom, CH2OR2c, CHO, CO2R10, CH=CHCH2OR2c, CH=CHCHO or CH=CHCO2R10, wherein R2c is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl;
R16 is H or alkyl;
R17 is CH2OR2f, CHO, CO2R10, wherein R2f is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e; and R24 is C.ident.C, cis or trans CH=CH, or CH2CH2.
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NRgRh, wherein R g and R h are independently H, an alkyl group or an aryl group;
R11 is a protecting group, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R12 is a halogen atom, CH2OR2c, CHO, CO2R10, CH=CHCH2OR2c, CH=CHCHO or CH=CHCO2R10, wherein R2c is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl;
R16 is H or alkyl;
R17 is CH2OR2f, CHO, CO2R10, wherein R2f is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e; and R24 is C.ident.C, cis or trans CH=CH, or CH2CH2.
10. The compound of claim 9 with the following stereostructure, or its enantiomer wherein R a is H, an alkyl group, a benzyl group, a trityl group, -SiR a R b R
c, CH2OR d, or COR e;
and R24 is C.ident.C or cis CH=CH.
c, CH2OR d, or COR e;
and R24 is C.ident.C or cis CH=CH.
11. A compound having the following formula, or its enantiomer wherein X is H, NCH3(OCH3), or a leaving group;
R11 is H, a protecting group, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, R t and R u are independently H, an alkyl group or an aryl group;
R12 is a halogen atom, CH2OR2c, CHO, CO2R10, CH=CHCH2OR2c, CH=CHCHO or CH=CHCO2R10, wherein R2c is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl.
R11 is H, a protecting group, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, R t and R u are independently H, an alkyl group or an aryl group;
R12 is a halogen atom, CH2OR2c, CHO, CO2R10, CH=CHCH2OR2c, CH=CHCHO or CH=CHCO2R10, wherein R2c is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl.
12. A compound having the following formula, or its enantiomer wherein R11a and R11b are independently H, a protecting group, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e, or R11a and R11b together form a portion of six-membered acetal ring containing CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R12 is a halogen atom, CH2OR2c, CHO, CO2R10, CH=CHCH2OR2c, CH=CHCHO or CH=CHCO2R10, wherein R2c is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl.
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R12 is a halogen atom, CH2OR2c, CHO, CO2R10, CH=CHCH2OR2c, CH=CHCHO or CH=CHCO2R10, wherein R2c is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl.
13. A process of conversion of a compound with the following formula, or its enantiomer wherein R2 a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R11b' is an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR
a R b R c, CH2OR d, COR e;
R12 is a halogen atom, CH2OR2c, CO2R10, CH=CHCH2OR2c, or CH=CHCO2R10, wherein R2a is a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl;
R16 is H or alkyl; and R17 is CH2OR2f, CO2R10, wherein R2f is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e; and R24 is C.ident.C to a compound of the following formula, or its enantiomer wherein R11a is H, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2OR d, COR e and R11b is an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e, or R11a and R11b together form a portion of six-membered acetal ring containing CR t R u;
R t and R u are independently H, an alkyl group or an aryl group; and R24 is cis CH=CH, comprising at least the steps of semi-reduction of the alkyne and asymmetric reduction of the ketone, or asymmetric reduction of the ketone and semihydrogentation of the alkyne.
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R11b' is an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR
a R b R c, CH2OR d, COR e;
R12 is a halogen atom, CH2OR2c, CO2R10, CH=CHCH2OR2c, or CH=CHCO2R10, wherein R2a is a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl;
R16 is H or alkyl; and R17 is CH2OR2f, CO2R10, wherein R2f is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e; and R24 is C.ident.C to a compound of the following formula, or its enantiomer wherein R11a is H, an alkyl group, and aryl group, a benzyl group, a trityl group, -SiRaRbR , CH2OR d, COR e and R11b is an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e, or R11a and R11b together form a portion of six-membered acetal ring containing CR t R u;
R t and R u are independently H, an alkyl group or an aryl group; and R24 is cis CH=CH, comprising at least the steps of semi-reduction of the alkyne and asymmetric reduction of the ketone, or asymmetric reduction of the ketone and semihydrogentation of the alkyne.
14. The process of claim 13 comprisng at least the steps of semi-reduction of the alkyne, asymmetric reduction of the ketone and protection of a resulting alcohol, or asymmetric reduction of the ketone, protection of a resulting alcohol and semihydrogentation of the alkyne, or asymmetric reduction of the ketone, semi-hydrogentation of the alkyne and protection of a resulting alcohol.
15. A compound of the following formula, or its enantiomer wherein R2 is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R16 is H or alkyl; and R17 is CH2OR2f, CHO, CONHCH(CH3)CH(OH)Ph, CO2R10, wherein R2f is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R
b R c, CH2OR d, or COR e;
R25 is CO2R10, CHO, CH=CBr2, C.ident.CH, or C.ident.C SiR a R b R c; and R10 is H or an alkyl group.
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R16 is H or alkyl; and R17 is CH2OR2f, CHO, CONHCH(CH3)CH(OH)Ph, CO2R10, wherein R2f is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R
b R c, CH2OR d, or COR e;
R25 is CO2R10, CHO, CH=CBr2, C.ident.CH, or C.ident.C SiR a R b R c; and R10 is H or an alkyl group.
16. A process for reacting a first compound of the following formula, or its enantiomer wherein R2 a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R16 is H or alkyl; and R17 is CH2OR21 , CHO, CO2R v, wherein R2f is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R25 CH=CX2, C=CH or C.ident.CSiR a R b R;
X is Cl, Br or I with a second compound of the following formula, or its enantiomer wherein X is NCH3(OCH3), or a leaving group;
R11 an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e;
R12 is a halogen atom, CH2OR2 c, CO2R v, CH=CHCH2OR2c or CH=CHCO2R v, wherein R2c is an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R v is alkyl, comprising metalation of the first compound and addition of the second compound to produce a compound of the following formula, or its enantiomer wherein R24 is C.ident.C.
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i SiR a R b R
c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R16 is H or alkyl; and R17 is CH2OR21 , CHO, CO2R v, wherein R2f is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R25 CH=CX2, C=CH or C.ident.CSiR a R b R;
X is Cl, Br or I with a second compound of the following formula, or its enantiomer wherein X is NCH3(OCH3), or a leaving group;
R11 an alkyl group, and aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e;
R12 is a halogen atom, CH2OR2 c, CO2R v, CH=CHCH2OR2c or CH=CHCO2R v, wherein R2c is an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R v is alkyl, comprising metalation of the first compound and addition of the second compound to produce a compound of the following formula, or its enantiomer wherein R24 is C.ident.C.
17. A process for reacting a first compound of the following formula, or its enantiomer wherein R2 a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R16 is H or alkyl;
R17 is CH2OR2 ; CHO, C02R10, wherein R 2f is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R25 CH=CX2, C=CH or C=CS i R a R b R;
with a second compound of the following formula, or its enantiomer wherein X is H;
R11 an alkyl group, and aryl group, a benzyl group, a trityl group, -S i R a R
b R c, CH2OR d, COR e;
R12 is a halogen atom, CH2OR2c, C02R10, CH=CHCH2OR2c or CH=CHCO2R10, wherein R2c is an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, and R10 is alkyl, comprising metalation of the first compound and addition of the second compound to produce a compound of the following formula, or its enantiomer wherein R24 is C=C.
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R16 is H or alkyl;
R17 is CH2OR2 ; CHO, C02R10, wherein R 2f is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R25 CH=CX2, C=CH or C=CS i R a R b R;
with a second compound of the following formula, or its enantiomer wherein X is H;
R11 an alkyl group, and aryl group, a benzyl group, a trityl group, -S i R a R
b R c, CH2OR d, COR e;
R12 is a halogen atom, CH2OR2c, C02R10, CH=CHCH2OR2c or CH=CHCO2R10, wherein R2c is an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, and R10 is alkyl, comprising metalation of the first compound and addition of the second compound to produce a compound of the following formula, or its enantiomer wherein R24 is C=C.
18. A compound of the following structure wherein R1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2) n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2) p where p is an integer in the range of 4 to 12, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)CH(R s3)CH(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)CH(R s3)CH(R s4)--, wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, R k1,R k2, R k3, R k4 and R k5 are independently H, CH3, or OR2a, and R s1, R s2, R s3, and R s4 are independently H or CH3, wherein R2a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or CORe; and R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R26 is H, a protecting group, an alkyl group, an aryl group, -S i R a R b R c, or COR e;
R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2) n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2) p where p is an integer in the range of 4 to 12, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)CH(R s3)CH(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)CH(R s3)CH(R s4)--, wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, R k1,R k2, R k3, R k4 and R k5 are independently H, CH3, or OR2a, and R s1, R s2, R s3, and R s4 are independently H or CH3, wherein R2a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or CORe; and R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R26 is H, a protecting group, an alkyl group, an aryl group, -S i R a R b R c, or COR e;
19. The compound of claim 18 with the following stereostructure, or its enantiomer wherein R1 is alkenyl; R3 is - CH2CH2, -CH=CH, -CH2CH(CH3) or -CH=C(CH3); and R4 is wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, or R23 a and R23 b together form a portion of six-membered acetal ring incorporating CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group.
20. A compound of the following structure wherein R 1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2) n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2) p where p is an integer in the range of 4 to 12, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)CH(R s3)CH(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)CH(R s3)CH(R s4)-, wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, R k1, R
k2, R k3, R k4 and R k5 are independently H, CH3, or OR2a, and R s1, R s2, R s3, and R s4 are independently H or CH3, wherein R2a is H, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R26 is H, a protecting group, an alkyl group, an aryl group, -S i R a R b R c, or COR e;
R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2) n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2) p where p is an integer in the range of 4 to 12, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)CH(R s3)CH(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)CH(R s3)CH(R s4)-, wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, R k1, R
k2, R k3, R k4 and R k5 are independently H, CH3, or OR2a, and R s1, R s2, R s3, and R s4 are independently H or CH3, wherein R2a is H, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R26 is H, a protecting group, an alkyl group, an aryl group, -S i R a R b R c, or COR e;
21. The compound of claim 20 with the following stereostructure, or its enantiomer wherein R1 is alkenyl; R3 is -CH2CH2, -CH=CH, -CH2CH(CH3) or -CH=C(CH3); and R4 is wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, R23 b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, or R23a and R23b together form a portion of six-membered acetal ring incorporating CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group
22. A process for synthesizing a compound having the following structure wherein R1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2) n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2) p where p is an integer in the range of 4 to 12, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1 )=C (R s2) C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)CH(R s3)CH(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)CH(R s3)CH(R s4)-, wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, R k1, R
k2, R k3, R k4 and R k5 are independently H, CH3, or OR2a, and R s1, R s2, R s3, and R s4 are independently H or CH3, wherein R2a is H, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R5 is H or OR2b, wherein R2b is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R26 is H, a protecting group, an alkyl group, a aryl group, -S i R a R b R c, or COR e;
comprising the step of reacting a starting compound having the formula:
wherein R10 is H, under conditions suitable to form the macrolactam ring.
R2 is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2) n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2) p where p is an integer in the range of 4 to 12, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1 )=C (R s2) C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)CH(R s3)CH(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)CH(R s3)CH(R s4)-, wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, R k1, R
k2, R k3, R k4 and R k5 are independently H, CH3, or OR2a, and R s1, R s2, R s3, and R s4 are independently H or CH3, wherein R2a is H, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R5 is H or OR2b, wherein R2b is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R26 is H, a protecting group, an alkyl group, a aryl group, -S i R a R b R c, or COR e;
comprising the step of reacting a starting compound having the formula:
wherein R10 is H, under conditions suitable to form the macrolactam ring.
23. The process of claim 22 where the starting compound has the following structure, or its enantiomer wherein R1 is alkenyl; R3 is -CH2CH(CH3) or -CH=C(CH3); and R4 is wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, or R 23a and R23b together form a portion of six-membered acetal ring incorporating CR t R c;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group and the product compound has the following structure, or its enantiomer
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group and the product compound has the following structure, or its enantiomer
24. A process for converting a starting compound of the following structure wherein R1 is H, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 and R2d are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
Ra , R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2) p where p is an integer in the range of 4 to 12, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)C(R s3)=C(R s4) -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5C(R S1)=C(R
s2)CH(R s3)CH(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)CH(R s3)CH(R s4)-, wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, R k1, R
k2, R k3, R k4 and R k5 are independently H, -CH3, or OR2a, and R s1, R s2, R s3, and R s4 are independently H or CH3, wherein R2a is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R5 is H or OR2b, wherein R2b is H, a protecting groupan alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R10 is H or alkyl to a compound of the following structure where R26 is H, a protecting group, an alkyl group, a aryl group, -S i R a R b R c, or COR e, comprising at least the steps of alcohol oxidation and reductive amination.
R2 and R2d are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
Ra , R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is (CH2) p where p is an integer in the range of 4 to 12, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 C(R s1)=C(R
s2)C(R s3)=C(R s4) -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)C(R s3)=C(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5C(R S1)=C(R
s2)CH(R s3)CH(R s4)-, -(CHR k1) y1 (CHR k2) y2 (CHR k3) y3 (CHR k4) y4 (CHR k5) y5 CH(R s1)CH(R
s2)CH(R s3)CH(R s4)-, wherein y1 and y2 are 1 and y3, y4 and y5 are independently 0 or 1, R k1, R
k2, R k3, R k4 and R k5 are independently H, -CH3, or OR2a, and R s1, R s2, R s3, and R s4 are independently H or CH3, wherein R2a is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R5 is H or OR2b, wherein R2b is H, a protecting groupan alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e; and R10 is H or alkyl to a compound of the following structure where R26 is H, a protecting group, an alkyl group, a aryl group, -S i R a R b R c, or COR e, comprising at least the steps of alcohol oxidation and reductive amination.
25. The process of claim 24 where the starting compound has the following structure, or its enantiomer wherein R1 is alkenyl; R3 is -CH2CH(CH3) or -CH=C(CH3); and R4 is wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, or R23a and R23b together form a portion of six-membered acetal ring incorporating CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group and the product compound has the following structure, or its enantiomer
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group and the product compound has the following structure, or its enantiomer
26. A compound of the following structure or its enantiomer wherein R1 is H, a protecting group, an alkyl group, an aryl group, an alkenyl group, an alkynyl group, or a halogen atom;
R2 and Rad are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, or R23a and R23b together form a portion of six-membered acetal ring incorporating CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R10 is H or alkyl; and R27 is CH=CHC(O), CH=CHCH(OH), or CH2CH2C(O).
R2 and Rad are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2)õ where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R4 is wherein R23a is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, R23b is H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e, or R23a and R23b together form a portion of six-membered acetal ring incorporating CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R5 is H or OR2b, wherein R2b is H, a protecting group, an alkyl group, an aryl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R10 is H or alkyl; and R27 is CH=CHC(O), CH=CHCH(OH), or CH2CH2C(O).
27. A compound of the following structure or its enantiomer wherein R1 is H, a protecting group, an alkyl group, an aryl group, an alkenyl group, al alkynyl group, or a halogen atom;
R2 and R2d are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2) n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R5 is H or OR2b, wherein R2b is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R11a and R11b are independently H, a portecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e, or R11a and R11b together form a portion of six-membered acetal ring incorporating CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R12 is a halogen atom, CH2OR2c, CHO, CO2R10, CH=CHCH20R2c, CH=CHCHO, wherein R20 is H, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl; and R27 is CH=CHC(O), CH=CHCH(OH), or CH2CH2C(O).
R2 and R2d are independently H, a protecting group, an alkyl group, a benzyl group, a trityl group, -S i R a R b R c, CH2OR d, or COR e;
R a, R b and R c are independently an alkyl group or an aryl group;
R d is an alkyl group, an aryl group, an alkoxylalkyl group, -R i S i R a R b R c or a benzyl group, wherein R i is an alkylene group;
R e is an alkyl group, an allyl group, a benzyl group, an aryl group, an alkoxy group, or -NR g R h, wherein R g and R h are independently H, an alkyl group or an aryl group;
R3 is (CH2) n where n is and integer in the range of 0 to 5, -CH2CH(CH3)-, -CH=CH-, -CH=C(CH3)-, or -C=C-;
R5 is H or OR2b, wherein R2b is H, an alkyl group, an aryl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e;
R11a and R11b are independently H, a portecting group, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, COR e, or R11a and R11b together form a portion of six-membered acetal ring incorporating CR t R u;
R t and R u are independently H, an alkyl group, an aryl group or an alkoxyaryl group;
R12 is a halogen atom, CH2OR2c, CHO, CO2R10, CH=CHCH20R2c, CH=CHCHO, wherein R20 is H, an alkyl group, a benzyl group, a trityl group, -SiR a R b R c, CH2OR d, or COR e, and R10 is H or alkyl; and R27 is CH=CHC(O), CH=CHCH(OH), or CH2CH2C(O).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57485804P | 2004-05-27 | 2004-05-27 | |
US60/574,858 | 2004-05-27 | ||
PCT/US2005/018767 WO2005117588A2 (en) | 2004-05-27 | 2005-05-27 | Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2568221A1 true CA2568221A1 (en) | 2005-12-15 |
Family
ID=35463276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002568221A Abandoned CA2568221A1 (en) | 2004-05-27 | 2005-05-27 | Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1765073A4 (en) |
JP (1) | JP2008500370A (en) |
AU (1) | AU2005249480A1 (en) |
CA (1) | CA2568221A1 (en) |
WO (1) | WO2005117588A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7321046B2 (en) | 2002-09-06 | 2008-01-22 | University Of Pittsburgh | Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5430053A (en) * | 1994-04-19 | 1995-07-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structure of dictyostatin 1 |
WO2004022552A1 (en) * | 2002-09-06 | 2004-03-18 | University Of Pittsburgh | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof |
WO2005068451A2 (en) * | 2003-12-31 | 2005-07-28 | Cambridge University Technical Services Limited | Methods for the synthesis of dictyostatin and derivatives and analogues thereof, stereochemical characterisation, novel dictyostatin compounds and uses thereof and synthetic intermediates |
-
2005
- 2005-05-27 EP EP05767747A patent/EP1765073A4/en not_active Withdrawn
- 2005-05-27 AU AU2005249480A patent/AU2005249480A1/en not_active Abandoned
- 2005-05-27 WO PCT/US2005/018767 patent/WO2005117588A2/en active Application Filing
- 2005-05-27 JP JP2007515395A patent/JP2008500370A/en active Pending
- 2005-05-27 CA CA002568221A patent/CA2568221A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1765073A2 (en) | 2007-03-28 |
EP1765073A4 (en) | 2009-07-15 |
AU2005249480A1 (en) | 2005-12-15 |
JP2008500370A (en) | 2008-01-10 |
WO2005117588A3 (en) | 2007-03-15 |
WO2005117588A2 (en) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020091269A1 (en) | Synthesis of epothilones and related analogs | |
AU9340998A (en) | New epothilone derivatives, method for producing same and their pharmaceutical use | |
Shin et al. | Synthesis and biological evaluation of (−)-dictyostatin and stereoisomers | |
CA2857385A1 (en) | Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene | |
Mı́nguez et al. | Synthesis and biological assessment of simplified analogues of the potent microtubule stabilizer (+)-discodermolide | |
Drouet et al. | Stereoselective Total Synthesis of Reveromycin B and C19‐epi‐Reveromycin B | |
EP3406604B1 (en) | Method for preparing 3-((2s,5s)-4-methylene-5-(3-oxopropyl)tetrahydrofurane-2-yl) propanol derivative, and intermediate therefor | |
PL212658B1 (en) | Method for obtaining the derivatives of 13,14-dihydro-PGF₂α | |
Anderson et al. | Applications of crotyldiisopinocampheylboranes in synthesis: a formal total synthesis of (+)-calyculin A | |
Sinz et al. | Total synthesis of the polyene macrolide dermostatin A | |
Montaña et al. | Asymmetry induction on the [4C (4π)+ 3C (2π)] cycloaddition reaction of C2-functionalized furans: influence of the chiral auxiliary nature | |
CZ305964B6 (en) | Process for preparing prostaglandin | |
Jaegel et al. | Formal total synthesis of palmerolide A | |
CA2568221A1 (en) | Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof | |
Show et al. | Stereoselective synthesis of ophiocerins A and C | |
US7321046B2 (en) | Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof | |
Panek et al. | Synthesis, resolution and absolute stereochemical assignment of C1-oxygenated allylsilanes and C3-oxygenated vinylsilanes | |
Jiang et al. | Synthesis of hept-6-en-2, 4, 5-triols and hept-6-en-2, 3, 5-triols | |
Habrant et al. | Towards the total synthesis of Calyculin C: preparation of the C13–C25 spirocyclic core | |
Hu et al. | Stereoselective synthesis of (+)-boronolide and its 8-epimer | |
Chakraborty et al. | A radical mediated approach to the stereoselective formal total synthesis of (+)-Sch 642305 | |
Valeev et al. | Building blocks for (C 15− C 3)-modified epothilone D analogs | |
JP2001500484A (en) | Method for producing pharmaceutical compounds | |
WO2003080567A2 (en) | Intermediates for the synthesis of discodermolide and related analogues and methods for their preparation | |
JP2008538368A (en) | Method for preparing 9,10-dehydro-12,13-desoxyepothilone derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |